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I 
I. Abstract 
Persistent infection with high-risk types of human papillomavirus (HPV) can cause several 
malignancies, in particular oropharyngeal and anogenital cancers. HPV16 has been identified as the 
most prevalent high-risk type, being related to 60% of cervical cancers, 75% of oropharyngeal cancers, 
71% of anal cancers and the majority of precancerous lesions. As standard of care treatment is 
invasive, and harbors risks and side effects, there is a need for new approaches. For rationally 
designing a therapeutic vaccine against HPV-induced malignancies, it is essential to identify suitable 
target epitopes, which are presented on the surface of an HPV-transformed cell and induce immune 
responses that eventually mediate target cell death. The HPV16 oncoproteins E6 and E7 represent 
ideal targets for immunotherapy as they mediate the transforming potential of the virus and are 
constitutively expressed in all malignant cells. 
In order to define HPV16 target epitopes, in this thesis several algorithms were used to predict 
potential HPV16 E6- and E7-derived binders of human leukocyte antigen (HLA) class I in silico. 
Predicted peptides were synthesized and HLA binding capacity was validated in competition-based 
cellular binding assays. To ensure broad population coverage, predictions and validations were 
performed for seven frequent HLA alleles: A*01:01, A*02:01, A*03:01, A*11:01, A*24:02, B*07:02 
and B*15:01. Including peptides derived from HPV16 E6/E7 variants containing amino acid changes, 
271 peptides were experimentally assessed and 69 binders were identified. Combined with previous 
results, the total HPV16 E6/E7 dataset comprised 779 peptide-HLA measurements. 
The HPV16 E6/E7 dataset was used to evaluate the performance of employed predictors. No single 
algorithm was outperforming other methods, but different predictors were found to be best for 
different settings, depending on investigated HLA type and peptide length. As applying commonly 
used decision threshold yielded only low sensitivity, criteria for optimal decision thresholds were 
defined and optimal thresholds were calculated for individual predictors, HLA-types and peptide 
lengths. Comparing threshold-dependent performance of predictors showed that using criteria-based 
thresholds allowed more sensitive prediction of HLA-binding peptides without a strong negative 
influence on prediction accuracy. 
To identify T cell epitopes among the HPV16 E6- and E7-derived HLA ligands, their capacity to 
induce immune responses was investigated. To this end, peripheral blood mononuclear cells of healthy 
donors were HLA-typed and stimulated with respective peptides to generate epitope-specific T cell 
lines. By assessing interferon-γ-secretion of these T cells, 31 immunogenic peptides were identified. 
Further characterizing the functionality of epitopes in cytotoxicity assays, five of ten immunogenic 
HLA-A*02:01-peptides mediated specific killing of HPV16
+
 target cells by CD8
+
 T cells. 
In conclusion, several immunogenic HPV16 E6-and E7-derived epitopes were identified, which are 
the basis for rational design of a therapeutic HPV vaccine. Additionally, this thesis provides an 
evaluation of peptide–HLA class-I binding prediction method and recommendations to increase 
prediction sensitivity to extend the number of potential epitopes as targets for immunotherapy. 
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II 
II. Zusammenfassung 
Anhaltende Infektionen mit Hoch-Risiko-Typen von humanen Papillomviren (HPVs) können diverse 
maligne Erkrankungen auslösen, insbesondere Krebs des Oropharyngeal-, Anal- und Genitaltrakts. 
HPV16 wurde als häufigster Hoch-Risiko-Typ identifiziert, verantwortlich für 60% aller Zervix-, 75% 
der Oropharynx- und 71% der Analkarzinome sowie die Mehrheit prä-kanzeröser Läsionen. Da 
Standardbehandlungen invasiv und mit Nebenwirkungen wie auch Risiken verbunden sind, werden 
neue Therapiemöglichkeiten benötigt. Um einen Impfstoff gegen HPV-induzierte Krankheiten zu 
entwickeln, ist es essentiell geeignete Ziel-Epitope zu identifizieren, die auf der Oberfläche von HPV-
transformierten Zellen präsentiert werden und Immunantworten auslösen, die zum Zielzelltod führen. 
Die HPV16 Onkoproteine E6 und E7 sind ideale Zielstrukturen für Immuntherapien, da sie dem Virus 
sein Transformations-Potenzial verleihen und konstitutiv in allen malignen Zellen exprimiert werden. 
Um potenzielle HPV16 E6 und E7 Peptide mit Bindungskapazität zu humanen Leukozyten-Antigenen 
(HLA) Klasse I Molekülen in silico vorherzubestimmen, wurden verschiedene Algorithmen benutzt. 
Die Peptide wurden synthetisiert und ihre HLA-Bindung in kompetitiven Bindungstests validiert. Um 
einen Großteil der Bevölkerung abdecken zu können, wurden diese Experimente für sieben häufige 
HLA-Allele durchgeführt, A*01:01, A*02:01, A*03:01, A*11:01, A*24:02, B*07:02 und B*15:01. 
Inklusive von Peptiden, die von HPV16 E6/E7 Varianten mit Aminosäureaustausch stammen, wurden 
271 experimentell validiert und 69 Binder identifiziert. Gemeinsam mit vorherigen Resultaten umfasst 
der HPV16 E6/E7 Datensatz 779 Peptid-HLA-Messungen. 
Mithilfe des HPV16 E6/E7 Datensatzes wurde die Leistung der verwendeten Vorhersagemethoden 
evaluiert. Kein Algorithmus übertraf alle anderen, sondern verschiedene Methoden waren, abhängig 
von untersuchten HLA-Typen und Peptidlängen, die leistungsstärksten. Weil die Verwendung 
gebräuchlicher Grenzwerte in geringer Sensitivität resultierte, wurden Kriterien für optimale 
Grenzwerte definiert und optimale Grenzwerte individuell für Algorithmen, HLA-Typen und 
Peptidlängen berechnet. Im Vergleich mit gebräuchlichen Grenzwerten erreichte die Verwendung 
optimaler Grenzwerte eine höhere Sensitivität ohne starken negativen Einfluss auf die Genauigkeit. 
Um T-Zell-Epitope unter den HLA-bindenden HPV16 E6/E7 Peptiden zu identifizieren, wurde deren 
Fähigkeit zur Induktion von Immunantworten ermittelt. Dazu wurden mononukleäre Zellen des 
peripheren Blutes gesunder Spender HLA-typisiert und mit entsprechenden Peptiden stimuliert, um 
Epitop-spezifische T-Zelllinien zu generieren. Durch Untersuchung der Interferon-γ-Sekretion von re-
stimulierten T-Zelllinien wurden 31 immunogene Peptide identifiziert. In Zytotoxizitäts-Studien zur 
weiteren Charakterisierung der Funktionalität der Epitopevermittelten 5 von 10 immunogenen HLA-
A*02:01-Peptiden den spezifischen Tod HPV16
+
 Zielzellen durch CD8
+
 T-Zellen. 
Zusammenfassend wurden mehrere HPV16 E6/E7 Epitope identifiziert, die die Basis für die Entwick-
lung eines therapeutischen HPV-Impfstoffs bilden. Zusätzlich legt diese Arbeit die Evaluierung von 
Peptid-HLA Klasse I Bindungs-Vorhersagemethoden vor, sowie Empfehlungen um deren Sensitivität 
und die Anzahl potenzieller Epitope als Zielstrukturen für Immuntherapien zu erhöhen. 
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1 Introduction 
1.1 Cancer and human papillomavirus infection 
The term “cancer” describes a group of diseases characterized by uncontrolled growth of abnormal 
cells beyond their original boundaries and by invasion or spreading (metastasis) into different tissues 
and organs. Cancer encompasses malignant tumors, also called neoplasms, which can develop from 
premalignant dysplasia. It was the cause of 9.6 million deaths in 2018 and thus is globally the 2
nd
 
leading cause of death (WHO, 2019). As cancer cells represent altered cells of the own body, for 
therapeutic approaches it is crucial to distinguish cancerous from healthy cells. 
Cancer cells acquired specific capabilities during their malignant transformation, which were 
described 2000 by Hanahan and Weinberg as the hallmarks of cancer (Hanahan and Weinberg, 2000). 
These are - next to tissue invasion and metastasis, as mentioned above - evasion of apoptosis, self-
sufficiency in growth signals, insensitivity to anti-growth signals, limitless replicative potential and 
sustained angiogenesis. In 2011, two emerging hallmarks, deregulation of cellular energetics and 
avoiding immune destruction, and two enabling characteristics, genome instability and mutation and 
tumor-promoting inflammation, were added (Hanahan and Weinberg, 2011). Cancer causing factors 
are multifaceted and comprise inherited genetic predispositions and environmental factors such as diet, 
alcohol drinking, tobacco smoking, exposition to ultraviolet (UV)-light and infection with pathogens 
(Wu et al., 2016). 
Pathogens are relevant cancer causing agents (Figure 1 A) and comprise for example the bacterium 
Helicobacter pylori in ~75-89% of non-cardia gastric cancer cases, hepatitis B and C viruses (HBV 
and HCV) accounting for ~76% of liver cancer cases, Epstein-Barr virus (EBV) related to lymphoid 
malignancies and nasopharyngeal tumors, and high-risk types of human papillomavirus (HPV) 
(Plummer et al., 2015; Maucort-Boulch et al., 2018; Maeda et al., 2009). Infections with HPVs are 
frequent in all world populations (Figure 1 B) and attributable to all cervical, 88% of anal, 50% of 
penile and ~31% of oropharyngeal cancer cases (de Martel et al., 2017). In 2012, 630,000 cancer cases 
were attributed to HPV infection (Figure 1 C), which represents 8.6% of all cancer cases in women 
and 0.8% in men (de Martel et al., 2017). Of all cancer cases attributable to pathogens, HPV is the 
cause of 5.6% in men and more than half (53.6%) in women (Figure 1 E and D). HPVs are associated 
with virtually all cervical carcinomas, which explains the pronounced difference in numbers between 
males and females (Plummer et al., 2016). In terms of incidence (~570,000) and mortality (~311,000) 
cervical cancer was the fourth most common cancer entity in women worldwide in 2018 (Figure 1 F) 
(Ferlay et al., 2019). In 2012, it was the second most common cancer and the third most frequent cause 
of cancer death in less developed regions (Ferlay et al., 2015). The prevalence of all HPV-attributable 
cancers is highest in these regions, but HPV represents a worldwide health problem (Figure 1 G). 
Papillomaviruses are highly species-specific and infect epithelium of not only humans but also other 
mammals, birds and reptiles (Bravo et al., 2010). The connection between human PV infection and 
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cervical cancer was postulated and proven by groundbreaking research of Harald zur Hausen and his 
team (Gissmann et al., 1977). Since they isolated and sequenced the first HPV DNA of type 16 
(HPV16) from cervical carcinoma samples in 1983, more than 220 HPV types were identified (Eklund 
and Dillner, 2019; Dürst et al., 1983). These were divided into low- and high-risk types according to 
their carcinogenic potential. Low-risk types mainly cause benign warts of skin and anogenital regions, 
whereas high-risk types can induce malignant transformation into anogenital (cervical, vaginal, vulvar, 
anal and penile) and head and neck (oropharyngeal, oral cavity, laryngeal) cancers and their precursor 
lesions (Chow et al., 2010). Other sites of infections are the conjunctiva of the eyes, ear canals and 
nasal sinuses. 
So far, 12 high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) and 12 types which are 
probably carcinogenic (26, 30, 34, 53, 66, 67, 68, 69, 70, 73, 82 and 97) were defined (ICO/IARC 
HPV Information Centre, 2019). The majority of HPV-associated cancer cases are caused by HPV16 
and HPV18 (de Martel et al., 2017). Together they contribute to 70.8% of cervical, 84.9% of head and 
neck and even 87% of anal cancers. HPV16 is the most prevalent genotype in all world regions 
accounting for 60.5% cervical, 75.2% oropharyngeal, and 71.4% anal cancer cases and the majority of 
precancerous lesions (Serrano et al., 2018; Castellsagué et al., 2016). 
In the affected tissues, the virus infects the epithelia of cutaneous and mucosal surfaces. Infections at 
the transformation zones between squamous and columnar epithelium are at especially high risk for 
malignant transformation (Egawa et al., 2015). Epithelial cells get infected during sexual intercourse 
as primary route of transmission (ICO/IARC HPV Information Centre, 2019). This explains a peak in 
HPV incidence in people at the age of first sexual activity (Figure 2 A). Infections are typically 
asymptomatic and unnoticed HPV spreads rapidly in sexually active males and females. Fewer new 
sexual contacts with increasing age result in HPV incidence drops. Sexual behavior is also expected to 
influence the highly variable HPV prevalence by geographical region (Schiffman et al., 2016). 
Persisting HPV infection with a high-risk type is referred to as intraepithelial neoplasia grade 1, named 
after the infection site: CIN1 (cervical), VIN1 (vulval), VAIN1 (vaginal) or AIN1 (anal). In >90% of 
the infected individuals, HPV infection is cleared within less than 2 years. If not cleared by the 
immune system these lesions might progress into precancerous moderate (e.g. CIN2) or severe (CIN3) 
dysplasia and eventually into cancer (Figure 2 B) (Schiffman et al., 2016). The slow transformation 
process leaves time for intervention. 
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Figure 1. Cancer cases attributable to pathogens in 2012. (A) Bar graphs show the number of cancer cases 
per population among both sexes attributable to pathogens. (B) Contribution of major agents to pathogen-caused 
cancers. (C) Numbers of worldwide cancer cases per infectious agent for both sexes, (D) and (E) Frequencies of 
pathogen-related cancers in 1.1 million total cases for males and females, respectively. (F) Estimated worldwide 
incidence and death numbers (in thousands) in 2018 (GLOBCAN2018) of ten major cancer entities in women of 
all ages. (G) The proportion of cancer cases attributable to human papillomavirus infection among both sexes 
shown by country. Graphs were produced using tools provided by the Global Cancer Observatory and the 
International Agency for Research on Cancer (Plummer et al., 2016; Ferlay et al., 2019). 
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Preventive measures against HPV infection and associated diseases comprise prophylactic vaccination 
and cancer screening programs. Three prophylactic vaccines have been developed and represent the 
most effective long-term intervention for controlling high-risk infections (see section “Prophylactic 
vaccination”). National vaccination programs were introduced by 65 mostly high- and middle-income 
countries (by 2016) and typically target adolescent girls and, increasingly, boys. As most countries did 
not yet start vaccination programs, secondary prevention still plays a major role. Screening aims at 
detecting pre- and early stage cancers to minimize overtreatment. Methods comprise the screen, e.g. 
by Papanicolau (Pap) testing or HPV DNA detection, triage, colposcopy and biopsy for histological 
examination (Schiffman et al., 2016). 
 
Figure 2. HPV infection stages and population prevalence at different ages. (A) Without clearance, 
persisting HPV infection can progress to precancerous lesions and, upon invasion, to a final cancer state. HPV 
prevalence peaks with beginning sexual activity in youth. Several years later the prevalence of precancer peaks. 
A plateau for invasive cancer is seen many years later starting from the age of 40. (B) The progressing 
transformation by HPV infection can be divided into different grades of severity according to cytological 
abnormalities found by histology and cytology. Figure adapted from (Schiffman et al., 2016). 
Current treatment options for severe dysplasia and cancers involve surgery, radiotherapy and 
chemotherapy (mainly cisplatin-based), depending on the stage of the disease. As gold standard, 
cervical precancerous lesions are treated by invasive excisional procedures with a risk for subsequent 
obstetrical complications. Less invasive ablative technologies exist but do not provide tissue for 
subsequent histopathology. Especially surgery can damage surrounding tissue and carry the risk for 
losing fertility as a consequence of radical hysterectomy. Treatments of invasive cancers show the 
expected post-treatment morbidity (Schiffman et al., 2016). This highlights the need of new non-
invasive interventions, which could be achieved by immunotherapy approaches such as therapeutic 
HPV vaccination (see section “HPV-specific immunotherapies”). 
1.1.1 The organization of the HPV genome  
HPVs are non-enveloped double-stranded DNA (dsDNA) viruses with a circular genome of a size 
between 7kb and 8kb with eight or nine open reading frames (ORFs) (McBride and Warburton, 2017; 
Doorbar et al., 2015). In order to fit the genome into the relatively small size of about 8kb, genes 
partially overlap, resulting in polycistronic transcripts that are separated by splicing of mRNA. 
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In case of HPV16, 7908bp contain six early genes (E1, E2, E4, E5, E6 and E7) and two late genes (L1 
and L2) differentiated by their time of expression during the viral life cycle (see section ”HPV life 
cycle and protein expression”). Figure 3 A shows the genomic organization of the early and late genes. 
A noncoding upstream regulatory region (URR) contains promoter and enhancer elements as well as 
the viral origin of replication (Stanley, 2012). A large region contains early genes which have 
functions at the level of viral replication and transcription and contain the transforming proteins E6 
and E7 (see section “The early proteins E1, E2, E4, E5 and the oncoproteins E6 and E7”). The late 
gene region encodes for the major (L1) and minor (L2) capsid proteins (see section “The late proteins 
L1 and L2”). Together, these two proteins form 72 capsomers that build the icosahedral capsid 
structure (Figure 3 B), which is able to self-assemble and measures 55nm in diameter (Doorbar et al., 
2015; Hagensee et al., 1993). 
HPV gene products can further be divided into highly conserved core proteins (E1, E2, L1 and L2) 
that are directly involved in viral genome replication and into accessory proteins (E4, E5, E6 and E7) 
which show greater functional variability across HPV types (Schiffman et al., 2016). 
 
Figure 3. HPV and the organization of its genome. (A) The genomic organization of HPVs is representatively 
shown for HPV16. Arrowheads mark the early (P97) and late (P670) promoters. The genome is organized in 
three main regions. The non-coding upstream regulatory region (URR) contains promoter and enhancer 
elements, the origin (ORI) of viral replication and binding sites for the E1 and E2 proteins and SP1 transcription 
factor. The early gene region contains open reading frames (ORFs) for E1, E2, E4 and E7 (blue) and the 
transforming oncogenes E6 and E7 (red). The late gene region is comprised of the ORFs for L1 and L2, the 
major and minor capsid protein, respectively. Core viral proteins (*) are required for genome replication, viral 
assembly and release whereas accessory proteins (‡) provide functions of cell cycle entry and immune evasion. 
(B) Negatively stained transmission electron micrograph shows HPV particles. Figure and legend were adapted 
from (Schiffman et al., 2016). 
1.1.2 HPV life cycle and protein expression 
Infection with HPV occurs if virus particles access the epithelial basal layer through wounds or 
epithelial trauma. In order to become established, they infect basal keratinocytes with a stem cell-like 
phenotype (Egawa et al., 2015). As the virus is dependent on the host’s replication machinery, it 
requires infecting an actively dividing cell (as in wound healing). In epithelia only basal cells are 
actively dividing and thus infected by HPV (Hoffmann et al., 2006; Pyeon et al., 2009). 
Internalization, in contrast to other viruses, takes several hours and is initiated by L1 binding to the 
basement membrane (Horvath et al., 2010). This triggers conformational changes of both capsid 
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proteins as a prerequisite for cellular uptake. Endocytosis of HPV16 happens via a clathrin-dependent 
pathway (Day et al., 2003). L2, on the other hand, is complexed to the viral DNA and is responsible 
for intracellular transport and nuclear accumulation (Campos, 2017). A recent study showed that 
virions remain largely intact during nuclear entry which is in contrast to a previous concept of 
dissembling capsids (Day et al., 2019). 
An initial phase of viral genome replication is separate from the cell cycle but dependent on the 
cellular DNA synthesis machinery supported by the viral replication proteins E1 and E2 (Chiang et al., 
1992). The viral copy number is amplified to 50-100 copies per cell (Egawa et al., 2012). Upon host 
cell division, the resulting episomes are distributed to daughter cells. The low episomal copy numbers 
are maintained as dividing cells transit the parabasal layers of the epithelium until they eventually 
enter suprabasal layers and undergo differentiation. Viral gene expression and DNA replication then is 
upregulated and increases the viral copy numbers to thousands per cell. This is achieved by expression 
of E5 and, primarily-y, the E6 and E7 proteins, which play an essential role in viral genome 
amplification, mainly by driving S-phase re-entry (Egawa et al., 2015). Pathological characteristics of 
E6 and E7, in addition to increased cell division are a lower sensitivity of the infected cells to cellular 
contact inhibition and inhibition of the normal cellular differentiation program (Schiffman et al., 
2016). In high-risk types, persistent overexpression of these two oncogenes severely affects the 
integrity of the host cell by various mechanisms (see section “The early proteins E1, E2, E4, E5 and 
the oncoproteins E6 and E7”). 
In the upper suprabasal layers of the epithelium, E4 and the late genes L1 and L2 are expressed 
(Doorbar et al., 2015). The E2 protein recruits the minor capsid protein L2 to regions of replication 
where amplified viral genomes get packed when L2 and the major capsid protein L1 self-assemble and 
form virions (Day et al., 1998). The virus finally matures in the superficial terminally differentiated 
keratinocytes, which undergo natural shedding. It is thought that E4 contributes to virion release, but it 
definitely plays a role in disrupting keratin structure and compromising the normal assembly of the 
cornified envelope by forming amyloid fibrils (Doorbar et al., 1991; Brown et al., 2006; McIntosh et 
al., 2008). Released virions can now infect further basal keratinocytes in compromised epithelium or 
can be transmitted to another host organism.  
The whole viral lifecycle from infection to virus release takes a comparatively long time, ranging from 
3 weeks to months (Stanley, 2012). In this time, the virus remains exclusively intraepithelial as it is 
dependent on and tailored to the complete keratinocyte differentiation. In high-risk types, productive 
infection can turn into abortive infection (Figure 4) if ordered expression of gene products is prevented 
by cell cycle deregulation mediated by E6 and E7. This can lead to the integration of the viral genome 
into the host cell’s DNA. The thus induced instability of the host genome characterizes progressing 
dysplasia and, if persisting for several years, accumulation of genetic changes eventually leads to 
invasive cancer (Doorbar et al., 2015). 
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Figure 4. Productive and non-productive HPV infection. In virion-producing productive infection, E6 and E7 
are expressed at low levels and do not stimulate excessive cell cycle entry in parabasal layers (absence of red cell 
cycle marker in first immunofluorescence image). E4 and late L1 and L2 gene products can be extensive (green 
on fluorescence images). Such lesions are labeled cervical intraepithelial neoplasia grade 1 (CIN1). Higher grade 
lesions (CIN2 to CIN3) are regarded to be abortive (non-productive) infections, where E6 and E7 activity is 
increased and late gene expression restricted. Progression to cancer can take several years, as the HPV genome 
integrates into the host genome and genetic changes accumulate in the host cell promoted by deregulated E6 and 
E7 expression. More severe disease grades are located in the transformation zone and endocervix rather than in 
the ectocervix. Figure and legend adapted from (Schiffman et al., 2016). 
1.1.2.1 The early proteins E1, E2, E4, E5 and the oncoproteins E6 and E7 
As outlined above, the expression of the early proteins is spatiotemporally regulated, which is 
reflected by their specific roles in the viral life cycle. After infection of a basal keratinocyte, the DNA 
helicase E1 and the transcription factor E2 are regulating early transcription of the viral episome. E2 
initiates viral replication by binding to the non-coding URR, thereby recruiting E1 to the viral origin 
of replication (Dell et al., 2003; Abbate et al., 2004). E2 regulates E6 and E7 expression, as low E2 
levels enhance and high E2 levels repress and transcription (Doorbar et al., 2015). Overexpression of 
E2 induces expression of the late genes in the course of keratinocyte differentiation (Johansson et al., 
2012). The E2 protein furthermore anchors the viral episomes to cellular chromosomes and also plays 
a role in virus assembly as it recruits the L2 protein to replication sites (You, 2010; Day et al., 1998). 
Viral DNA integration into the host genome often disrupts the E1 and E2 genes which alleviates 
transcriptional repression of the E6 and E7 oncogenes (McBride and Warburton, 2017). 
The early protein E4 is expressed as a splicing product in the upper epithelial layers where 
keratinocytes terminally differentiate (Doorbar, 2013). Its functions reflect adaption of the HPVs to 
the keratinocytes, as it is known to disrupt the keratin cytoskeleton and to modify the cornified cell 
envelope, which is believed to support release of virions (Doorbar et al., 1991; Brown et al., 2006). 
Viral replication is supported by the E5 transmembrane protein. It is mostly found in the 
endoplasmatic reticulum (ER) where it interferes with endosomal trafficking, which leads to recycling 
of epidermal growth factor (EGF) receptors to the cell surface (Suprynowicz et al., 2010). This way, 
E5 enhances the activity of EGF receptors, promoting cellular replication. 
Due to their potential in driving malignant transformation of host cells, the proteins E6 and E7 were 
designated as oncoproteins. In high-risk types these proteins are involved in immortalization and 
transformation of the host cell, whereas in low-risk types they simply stimulate replication (zur 
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Hausen, 1996; Egawa et al., 2015). To keep the host cell dividing, E6 and E7 reactivate cellular DNA 
synthesis, inhibit apoptosis and delay differentiation. Overexpression can lead to uncontrolled cell 
growth and the development of dysplasia and invasive cancer (Figure 5 A). 
In HPV16, the E7 protein has a size of 98 amino acids (aa) and a molecular weight of 11kDa. Its 
multiple functions on the host cell cycle were thoroughly reviewed (Roman and Munger, 2013; Vande 
Pol and Klingelhutz, 2013; Moody and Laimins, 2010). It binds to the retinoblastoma protein (pRB) 
and thereby in turn inhibits pRB binding to the transcription factor E2F (Figure 5 B). The free E2F 
induces activation of S-phase promoting genes such as cyclin A and E. Further, E2F mediates 
transcription of p16
INK4A
, a surrogate marker for HPV infection, and p14
Arf
,
 
which increase the levels 
of cyclin kinases and p53, respectively (Klaes et al., 2001). The pRB-dependent actions are further 
promoted by E7 supporting the proteasome-mediated degradation of pRB (Schiffman et al., 2016). 
Additionally, E7 interferes with epigenetic pathways, cell cycle checkpoints and centrosome synthesis, 
promoting instability of the host genome (Moody and Laimins, 2010). 
The E6 protein of HPV16 consists of 158aa with a molecular weight of 19kDa. E6 complements the 
function of E7 as it interacts with p53, levels of which are increased in response to E7 expression 
(Figure 5 C) (Vande Pol and Klingelhutz, 2013) . Specifically, it binds to the ubiquitin-protein ligase 
E3A, also called E6 associated protein, thereby directing p53 poly-ubiquitination, which marks p53 for 
proteasomal degradation (Werness et al., 1990). The reduced presence of the p53 tumor suppressor 
prevents apoptosis of the host cell in response to E7-mediated cell cycle activation (Schiffman et al., 
2016). Further, E6 upregulates expression of the reverse transcriptase component of telomerase 
(TERT) and thus activates telomerase (Klingelhutz et al., 1996; Veldman et al., 2001). This decreases 
telomere shortening and prevents the cells from becoming senescent. 
 
 
Figure 5. Simplified synergistic mechanisms of the E6 and E7 oncoproteins in driving transformation. (A) 
E7 and E6 together drive viral genome replication and host cell instability. (B) E7 achieves this by binding pRB, 
which leads to a release of the E2F transcription factor and transcriptional activation of many cell cycle 
activators, but also the tumor suppressor protein p53. (C) E6 binds to the ubiquitin ligase E3A, which 
ubiquitinizes p53 and marks it for proteasomal degradation. Figure is modified from (Moody and Laimins, 2010; 
Yim and Park, 2005). 
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1.1.2.2 The late proteins L1 and L2 
The late gene products L1 and L2 represent the major and minor capsid proteins, respectively. Both 
are expressed in the late stage of the viral life cycle, when differentiated keratinocytes reach outer 
epithelial layers. The major capsid protein L1 has a weight of ~55kDa and forms pentamers, of which 
72 can self-assemble in a non-covalent complex with up to 72 L2 proteins to build-d the capsid 
structure (Buck et al., 2013). The minor capsid protein has a weight of 55-78kDa and its role has been 
reviewed (Wang and Roden, 2013). It remains controversial whether either capsid protein interacts 
specifically with encapsulated viral DNA, but the current hypothesis is that L2 co-localizes with L1, 
E2 and the viral genome at the replication site before virions assemble. Additionally, L1 is involved in 
the infectious entry of the virion into the host cell, whereas L2 is supposed to have a role in 
intracellular and nuclear trafficking. 
As the outer surface of the capsid is mainly comprised of L1, it represents the major antigen presented 
to the immune system. Thus, classification of different HPV types is mainly based on the L1 gene 
sequence (see section “Classification of HPV”). In contrast, it is still controversial if L2 is exposed on 
the virion surface. As the capsid proteins do not require viral DNA in order to self-assemble, empty 
non-infectious virus-like particles (VLPs) can be produced from purified L1 for immunization 
purposes (see section “Prophylactic vaccination”). 
1.1.3 Prophylactic vaccination 
Since HPV infection was first associated with cervical cancer, the development of preventive vaccines 
was actively investigated. The finding that the L1 protein can self-assemble into VLPs was exploited 
for vaccine design. Injected intramuscularly, VLPs traffic to the lymph nodes where they are taken up 
by antigen presenting cells (APCs) (Lenz et al., 2003). This leads to activation of APCs and 
subsequent initiation of an immune cascade that eventually leads to T cell-dependent B cell responses 
and high levels of L1-specific neutralizing antibodies (Deschuyteneer et al., 2010). 
To date, three HPV type-specific prophylactic vaccines have been licensed by US Food and Drug 
Administration (FDA) and European Medicines Agency (EMA) (de Oliveira et al., 2019). The first 
was the quadrivalent vaccine Gardasil, developed by Merck in 2006, which contains VLPs of the most 
prevalent high-risk types HPV16 and HPV18, thus protecting against ~70% of cervical cancer. It 
additionally contains VLPs of the low-risk types HPV6 and HPV11 which are associated with close to 
100% of all genital warts (Lacey et al., 2006). The second vaccine was the bivalent Cervarix 
developed by GlaxoSmithKline in 2007. Cervarix contains VLPs of HPV16 and HPV18. Both 
vaccines induce antibody-titers that are considerably higher than after natural infection, which is 
required in order to scavenge virions before they infect a host cell (Arbyn et al., 2018). The third and 
most recent vaccine, the nonavalent Gardasil9, was brought onto the market in 2014. In contrast to 
Gardasil, it additionally contains VLPs of HPV31, 33, 45, 52 and 58, and thus covering a broader 
range of high-risk HPV types, and protecting against 90% of cervical cancer (Huh et al., 2017). Other 
vaccine formulations, comprising also monovalent vaccines, are being tested in clinical trials. 
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A recent Cochrane review of 26 trials evaluated the possible harms and the protective effect of 
prophylactic HPV vaccines against cervical precancer and HPV16/18 infection in adolescent girls and 
women (Arbyn et al., 2018). The studies involved 1 monovalent, 18 bivalent and 7 quadrivalent 
vaccines and enrolled mostly women younger than 26 over a period from 6 months to 7 years. This 
period was not enough to evaluate cervical cancer outcomes, but addressed CIN2 and CIN3 lesions as 
well as adenocarcinoma-in-situ (AIS). The meta-analysis concludes that vaccination protected against 
cervical precancer with high certainty and without increased risk of serious adverse events, 
miscarriage or pregnancy termination. A higher efficacy was observed in association with HPV16/18 
and in women negative for high-risk HPVs or HPV16/18 at the time of enrolment. However, effects 
against any CIN and AIS were shown, which is in line with other reports about cross-protection 
(Folschweiller et al., 2019). The nonavalent vaccine was not assessed in the reviewed trials. However, 
safety and efficacy of the nonavalent vaccine were demonstrated in direct comparison to the 
quadrivalent vaccine in a randomized double-blind trial (Huh et al., 2017). 
Although prophylactic HPV vaccination is recommended in several countries for adolescent girls, and 
increasingly also for boys, vaccination coverage rates still greatly vary (de Oliveira et al., 2019). 
Especially in low and lower-middle income countries, access to HPV vaccines is almost non-existent 
(Bruni et al., 2016). In many cases, challenges for national HPV vaccine implementation are political 
will, vaccine costs, scarce knowledge about HPV-induced diseases and anti-vaccine movements (de 
Oliveira et al., 2019). It has been estimated that in 75 years from now, in the target population of 118 
million women worldwide, 39.7% (444,627 of 1,120,178) expected cancer cases will be prevented by 
vaccination (Bruni et al., 2016). The remaining 60.3% of cancer cases will arise in unvaccinated 
women and result from non-16/18 HPV types. This estimation highlights a continuous need for 
therapeutic treatment options. 
1.1.4 Classification of HPV 
According to the latest taxonomy release, the family of Papillomaviridae has two subfamilies, the 
First- and Secondpapillomaviridae (ICTV International Committee on Taxonomy of Viruses, 2018). 
Whereas the latter subfamily only contains Alefpapillomavirus species, Firstpapillomaviridae are 
further categorized into different genera named after greek letters (Figure 6). 
Alphapapillomaviridae have been researched extensively, as the cancer-causing high-risk types belong 
to this genus. They infect mucosal epithelia, whereas other genera primarily infect cutaneous sites. The 
α-genus is further distinguished into 15 species groups (Fehler! Verweisquelle konnte nicht 
gefunden werden.). For example, the high-risk type HPV16 belongs to the α-9 species, as do other 
types with carcinogenic potential. More than 220 different types of HPV were classified based on 
≥10% sequence difference of the L1 ORFs (Burk et al., 2013; Eklund and Dillner, 2019). Isolates of 
the same HPV type were formerly referred to as variants or subtypes when the sequence of the L1 
ORF differed by 2% to <10%. However, Burk and colleagues reviewed this terminology and 
established the terms lineages and sublineages based on complete genomic difference of 1% to <10%) 
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and 0.5% to <1%, respectively (Burk et al., 2013). For HPV16, four lineages were distinguished based 
on regional prevalence. “A” (European) is divided into four sublineages, “B” (African-1) into two, 
lineage “C” (African-2) is not yet divided further and the lineage “D” (Asian-American) has three 
sublineages. 
 
 
Figure 6. Phylogenetic tree representing 118 papillomavirus sequences. Papillomavirus sequences were 
grouped into different genera based on the L1 ORFs. Figure from (ICTV International Committee on Taxonomy 
of Viruses, 2018). 
The first HPV16 genome was sequenced 1983 from a German patient and became the reference 
genome belonging to the European A1 sublineage (Dürst et al., 1983; Seedorf et al., 1985). Nowadays, 
this genomic sequence is known to be rather uncommon (Zehbe et al., 1998). Therefore, infections 
with genetic variants of HPV16 are likely to be the rule rather than an exception. Moreover, the 
genetic variations are possibly influencing HPV persistence, progression into cancer and survival of 
patients (Xi et al., 2007; Zuna et al., 2011; Clifford et al., 2019). 
In a sublineage, HPV genomes can further differ in single nucleotide polymorphisms (SNPs). Such 
point mutations are described by the reference residue, the position in the gene and the new residue. 
For example, a nucleotide change in the E6 ORF from thymine to guanine at position 350 is 
designated as G350T. Similarly, aa changes in the protein are described. The SNP of the example 
results in an aa change from leucine to valine at position 90 of the E6 protein and is designated as 
L90V. In the scope of this thesis, this description of amino acid changes in comparison to the 
reference sequence was used to refer to HPV16 E6 and E7 proteins variants. 
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Figure 7. Schematic taxonomy of Papillomaviridae focusing on HPV16. Papillomaviridae are classified into 
families, subfamilies, genera, species and types. Types are distinguished based on a difference in the L1 ORF of 
more than 10% compared to all other types. Types are further divided into lineages and sublineages, based on 
genomic differences greater and smaller than 1%, respectively. Sublineages of HPV16 are related to regional 
prevalence which resulted in different clade names in prior phylogenetic analyses. This representation is based 
on the 2018b Taxonomy Release of the International Committee on Taxonomy of Viruses and the review by 
Burk and colleagues (Burk et al., 2013; ICTV International Committee on Taxonomy of Viruses, 2018). 
1.2 The immune system and HPV 
Constantly, the human body is contact with numerous pathogens like fungi, parasites, bacteria and 
viruses. In order to prevent and act against infections and disease organisms have developed 
multifaceted mechanisms to respond, which are summarized as the immune system. The field of 
science that aims to elucidate such responses is termed immunology. Immunology was born in 1796 as 
Edward Jenner proved his hypothesis that inoculation of healthy people with cowpox can protect from 
the deadly smallpox. This event represents the first described vaccination (from latin vaccinus – “from 
the cow”). Almost a hundred years later, Robert Koch and Louis Pasteur proved the connection 
between diseases and specific pathogens. 
The immune system comprises lymphoid organs, which are classified into primary (bone marrow and 
thymus) and secondary (spleen, lymph nodes, mucosa-associated lymphoid tissues) lymphoid organs 
and tissues, and cellular and soluble (humoral) components. Cells of the immune system mainly 
originate from hematopoietic stem cells of the bone marrow (Murphy and Weaver, 2017). 
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1.2.1 Innate and adaptive immunity 
The mechanisms of innate and adaptive immunity differ in mechanisms of pathogen recognition, 
kinetics of the immune response, involvement of cellular and soluble components and ability for 
generating immunological memory. 
Innate immunity represents the immediate but less-specific response to pathogen encounter. On the 
humoral side, pathogens can be bound by a system of plasma proteins, called the complement system. 
They promote the uptake and destruction of pathogens by phagocytes. On the cellular side, the 
identification of pathogens depends on germline-encoded pattern recognition receptors (PRR) that 
recognize regular patterns of molecular structures shared by many microorganisms. These repetitive 
structures are also called pathogen-associated molecular patterns (PAMPs). In addition to PAMPs, 
there are also receptors that recognize damage-associated molecule patterns (DAMPs), which are 
released during cellular damage or death. One group of PRRs are Toll-like receptors (TLRs) and each 
of them engages with different ligands stimulating particular pathways. For example, surface-
expressed TLR4 detects bacterial lipopolysaccharide (LPS), whereas endosomal TLR7 binds to single-
stranded RNA of internalized viruses. Most TLRs interact with adaptor molecule myeloid 
differentiation factor 88 (MyD88), which leads to activation of transcription factor NFκB. Upon 
binding of pathogen components, an immune response is instantly initiated. Such a response could be 
phagocytosis of the recognized particle, chemotaxis of immune cells to the site of infection, or 
production and release of effector molecules. These functions are performed by the innate immune 
cells such as neutrophils, natural killer (NK) cells, macrophages, monocytes and dendritic cells (DCs). 
DCs and macrophages act as a link between the innate and adaptive immune system, based on their 
ability to endocytose pathogenic components and to process and present resulting fragments to 
adaptive immune cells. 
The adaptive immune cells are T and B lymphocytes. Both express specific antigen receptors, B cell 
receptors (BCRs) and T cell receptors (TCRs), respectively. In order to recognize virtually all 
pathogenic structures, receptor diversity is generated by random recombination of receptor genes, 
which is called V(D)J-recombination. Further, random nucleotides are added at the junction site of the 
recombined genes generating up to 10
14
-10
18
 different receptor specificities. This random mechanism 
leads to the unique specificity of a clonal cell. In a process called clonal deletion, self-reactive 
receptors get depleted to induce central tolerance. 
If B and T cells encounter their specific antigen and get activated, they proliferate, expand clonally 
and differentiate into effector lymphocytes with special functionalities. The effector forms of B cells 
are plasma cells. They produce antibodies that share the antigen specificity of the BCR. Thus, these 
antibodies represent the humoral arm of the adaptive immune system. They target the pathogen that 
led to activation of the B cell. On the other hand, T cells can differentiate into one of several different 
effector T lymphocytes. They can be grouped by mediating three major functions, which are 
activation, regulation and killing. 
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Cytotoxic CD8
+
 T lymphocytes (CTLs) mediate cytolysis of target cells displaying specific antigens, 
which are cells of the body that are either infected with intracellular pathogens, such as viruses, or 
displaying mutated features of a tumor cells. CD4
+
 T helper (Th) cells recognize extracellular antigens 
displayed on APCs and orchestrate other immune cells by secretion of different signature cytokines by 
which they can be distinguished into different Th types. Their signals help activating antigen-
stimulated B cells to differentiate and they promote the functions of macrophages and CTLs. 
Regulatory T cells (Treg) control immune responses and induce tolerance by suppressing the activity of 
other lymphocytes. They play a role in preventing autoimmunity, but also downregulate anti-tumor 
immunity in the tumor microenvironment. 
Most effector lymphocytes are eliminated when their specific antigen is successfully cleared. 
However, some of the cells that encountered antigen differentiate into so-called memory cells. If they 
encounter the same antigen in a secondary infection, they rapidly divide and differentiate into effector 
cells. Thus, the adaptive immune cells are responsible for long-lasting antigen specific immunity 
(Murphy and Weaver, 2017). 
 
In the following, only the components of the immune system which are involved in antigen-specific 
and cytotoxic immune responses are described in greater detail as this work is focusing on induction of 
CTL-mediated immunity. 
1.2.2 Antigen presentation by major histocompatibility complex molecules 
Pathogen-derived peptide fragments will be recognized by T cells only if they are displayed on the cell 
surface in complex with special membrane glycoproteins. These complexes were first identified as 
determinants of histocompatibility in transplantations and are thus called major histocompatibility 
complexes (MHCs). In humans, MHC molecules are also called human leucocyte antigens (HLAs). 
There are two main types of classical MHC molecules that differ in their properties for peptide binding 
and immune cell stimulation. MHC class I molecules are found on virtually all nucleated cells and 
present mainly 8-11aa long peptides derived from cytosolic antigens. The peptide-MHC class I 
complexes are preferentially bound by CD8
+
 T cells and stimulate cytotoxic responses in order to kill 
infected or tumor cells. In contrast, MHC class II molecules are mainly expressed by professional 
APCs such as B cells, macrophages and DCs. The displayed peptides are derived from proteins in 
intracellular vesicles, such as internalized pathogenic components, and typically vary in their length 
from 9aa to 25aa. MHC class II molecule-presented peptides are recognized by CD4
+
 T cells. 
MHC class I molecules are heterodimers composed of two polypeptide chains. The membrane-
spanning α-chain folds into three domains, α1-α3 and non-covalently binds a smaller chain, β2-
microglobulin. Together, α1 and α2 fold into a closed cleft or groove, which is the site for peptide 
binding. Hydrogen bonds and ionic interactions between the MHC chains and the atoms of the free 
peptide termini stabilize peptide binding. Additionally, other residues in the peptide serve as so-called 
“anchor residues”. The binding preferences at these anchor residues are specific for MHC alleles and 
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can be used to predict the MHC binding affinity of peptides (see section “In silico epitope 
prediction”). 
As illustrated in Figure 8, the generation of peptide-MHC class I complexes starts in the cytosol where 
intracellular proteins are degraded into peptides by the proteasome. Stimulation with pro-inflammatory 
cytokines can induce expression of the immunoproteasome, which leads to a different enzymatic 
specificity and thus to changes in the presented peptide repertoire. After degradation, peptides are 
actively translocated to the ER by the transporter associated with antigen processing (TAP), a 
heterodimer that consists of TAP1 and TAP2. Translocated peptides can be subject to further trimming 
by ER-associated aminopeptidase 1 and 2 (ERAP1/ERAP2). In the ER, immature MHC class I 
molecules are part of the peptide loading complex, which additionally involves TAP, tapasin, 
calreticulin, Erp57 and calnexin. Calnexin stabilizes the MHC alpha chain until it finally assembles 
with β2-microglobulin. Calreticulin and Erp57 act as chaperones that stabilize the empty MHC 
molecule. Tapasin links the MHC molecule to TAP and facilitates peptide loading. The loaded, 
matured peptide-MHC class I complex leaves the ER and transits to the cell surface via the secretory 
pathways of the Golgi apparatus. All components involved in these processed are referred to as the 
antigen processing machinery (APM). 
 
 
Figure 8. Antigen-presentation pathways of MHC class I and MHC class II. Intracellular antigens, as e.g. 
derived from viral proteins, are processed and presented via the MHC class I pathway (left, blue arrow). The 
proteasome degrades cytosolic proteins into peptides, which are translocated to the endoplasmatic reticulum 
(ER) via the transporter associated with antigen processing (TAP). Immature MHC class I molecules form the 
peptide loading complex together with tapasin, Erp57 and calreticulin. Mature loaded MHC class I complexes 
transit through the Golgi apparatus to the surface where they present peptide to CD8
+
 T cells. In the MHC class 
II pathway (right, green arrow), extracellular proteins are internalized into endosomes and digested by proteases. 
Immature MHC class II molecules are stabilized by the invariant chain (li). li is processed into a short peptide 
(CLIP), which is replaced by the peptide to be presented. Mature MHC class II complexes reach the cell surface 
and present peptides to CD4
+
 T cells. Figure and legend were adapted from (Purcell et al., 2019). 
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Apart from this classical pathway of MHC class I presentation, it is possible that extracellular antigens 
get “cross-presented” on MHC class I if antigens escape from the endosome into the cytosol. 
However, this can only happen in APCs, which are capable of both MHC class I and class II antigen 
presentation. 
The MHC class II heterodimer consists of two transmembrane chains, α and β, with two domains each. 
The domains α1 and β1 form the binding groove that, in contrast to MHC class I, forms hydrogen 
bonds all along the peptide length and allows the peptide to emerge from both ends. This enables 
binding of longer peptides. Similarly to MHC class I, certain aa residues of the peptide serve as anchor 
residues, but as bound peptides differ in their length, anchor residues are harder to define and 
prediction of binding peptides is more difficult. 
Peptides presented by MHC class II are derived from extracellular proteins, which enter the APC 
through endocytosis (Figure 8). The resulting endosomes fuse with lysosomes containing acid 
proteases, such as cathepsins, that digest the internalized protein. Immature MHC class II molecules 
arising from the ER are stabilized by the invariant chain (li) that prevents binding of cellular peptides. 
During the transit of MHC class II in a vesicle, li gets cleaved, leaving a short class II-associated 
invariant chain peptide (CLIP) bound to the cleft. If the vesicle fuses with an endolysosome containing 
peptides from degraded proteins, CLIP is displaced by a peptide. Mature MHC class II complexes are 
delivered to the cell surface where they can be recognized by CD4
+
 T cells (Murphy and Weaver, 
2017). 
The MHC family is a large gene cluster. In humans, HLAs are encoded by >200 genes, of which the 
classical MHC genes HLA-A, -B, and -C (HLA class I) and HLA-DPA1, -DPB1, -DQA1, -DQB1,  
-DRA and -DRB1 (HLA class II) are studied best. These genes are highly polymorphic; each 
individual co-dominantly expresses two alleles for each of the MHC class I and II genes and to date 
16,200 HLA class I and 6,162 HLA class II alleles are known (Robinson et al., 2015). However, some 
alleles are more frequent than others. For example, HLA-A*02:01 is one of the most frequent alleles in 
Europe, with 38.5-53.8% of individuals expressing that allele. Despite the polymorphism, HLA class I 
molecules can be clustered into sets of molecules that share peptide binding motifs. Such clusters of 
HLA class I molecules represent so-called supertypes (Sidney et al., 2008a). The combined phenotypic 
frequencies of the supertypes A2, A3, A24, B7 and B15 provide more than 95% population coverage, 
regardless of ethnicity. This indicates that for therapeutic vaccine development as few as five HLA 
class I-restricted epitopes may be enough to elicit CTL responses in the whole population (Reche and 
Reinherz, 2007). 
1.2.3 Immune responses of T lymphocytes 
Upon recognition of PAMPS or DAMPS, APCs internalize the triggering particle, via phagocytosis or 
macropinocytosis. APCs include macrophages, B cells and DCs. Macrophages are specialized in 
taking up particulate material, whereas B cells especially perform receptor-mediated endocytosis. DCs 
ingest extracellular fluid and its components by macropinocytosis. They are especially important for 
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initiating T cell responses. Immature DCs arise from hematopoietic progenitor cells in the bone 
marrow and migrate through the blood stream into tissues where they constantly screen their 
environment. Once DCs get activated, e.g. by sensing viral double-stranded RNA via TLR3 in an 
endosome, they switch to a mature phenotype. They lose the ability of endocytosis, secrete cytokines, 
increase the expression of MHC molecules and induce expression of chemokine receptor CCR7. This 
sensitizes DCs to the chemokines CCL19 and CCL21, which direct the cells to the draining lymph 
nodes. Additionally, maturing DCs induce expression of costimulatory molecules like CD70 and 
CD80/CD86 (B7 molecules) on their surface. In the lymph node, the mature DCs are able to activate 
naïve T cells by providing three signals as illustrated in Figure 9. 
 
Figure 9. T cell priming by DCs and induction of CD8
+
 T cell responses. In the lymph node, mature DCs 
(yellow) provide three major signals to CD4
+
 (blue) and CD8
+
 T cells (green): 1) the cognate peptide-MHC 
complex recognized by the T cell receptor (TCR), 2) the costimulatory molecules CD70 and CD80/CD86 
signaling to the receptors CD27 and CD28, respectively and 3) cytokines such as interferonγ (IFNγ) and 
interleukin-2 (IL-2) that direct effector differentiation when bound to IFNγ receptor 1 (IFNGR1) and IL2 
receptor (IL2R), respectively. Additional costimulatory factors are provided by interaction between CD40 and 4-
1BBL (DCs) with CD40L and 4-1BB (T cells), respectively. Activation of T cells leads to autocrine IL-2 
signaling, driving proliferation and clonal expansion, and differentiation into effector and memory T cells. CD8
+
 
T cells turn into cytotoxic T lymphocytes (CTLs) that mediate cytotoxicity by cytokines (IFNγ and TNFα), 
cytotoxins (GrzB) and FasL interaction. Figure adapted from (Borst et al., 2018). 
First, the TCR of the T cell has to bind its cognate peptide presented by the respective MHC class I/II 
molecule on the DC in order for the T cell to get activated (signal 1). Second, the T cell is interacting 
with costimulatory molecules on the DC by their respective counterpart on the T cell surface, e.g. B7 
by CD28 and CD70 by CD27. Without the costimulatory signal 2, the T cell would undergo anergy or 
apoptosis. Third, the milieu of secreted cytokines directs the differentiation of the naïve T cell into an 
effector cell. Together, these signals induce clonal expansion of the T cell. During this interaction, the 
T cell binds transiently to the DC via adhesion molecules, such as LFA1 on the T cell side binding to 
ICAM1 and ICAM2 on DCs, forming the ‘immunological synapse’. The T cell-APC-dialog is 
supported by other costimulatory factors, such as binding between CD40L and CD40 or 4-1BB and 4-
1BBL. 
A T cell that does not encounter its cognate peptide-MHC complex remains naïve, leaves the lymph 
node and re-enters the blood flow. If a T cells gets activated by the DC interaction, the recognized 
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cognate peptide is referred to as a T cell epitope. Once the T cell received all three signals, it starts to 
secrete interleukin 2 (IL-2), an autocrine proliferation factor for T cells, clonally expands and 
differentiates into different effector types. CD4
+
 T cells differentiate into different classes 
characterized by expressing signature cytokines. Th1 cells activate macrophages and CTLs by 
producing interferon-γ (IFNγ), Th2 cells stimulate humoral immune responses by B cells via IL-4, IL-5 
and IL-13, and Th17 cells recruit neutrophils through IL-17, IL-21 and IL-22. The effector type is 
directed by the third signal; IL-12 and IFNγ induce Th1, IL-4 mediates Th2 and tumor growth factor β 
(TGFβ) and IL-6 lead to Th17 differentiation. Importantly, a lack of IL-6 in abundance of TGFβ favors 
development of adaptive Tregs expressing the forkhead box P3 (FoxP3) transcription factor. Primed 
CD8
+
 T cells differentiate into CTLs that produce IFNγ, tumor necrosis factor α (TNFα) and 
cytotoxins and express Fas ligand. The cytokines IFNγ and TNFα have antiviral, immunoregulatory 
and anti-tumor properties (Schroder et al., 2004). Cytotoxins produced by CTLs comprise perforins, 
granzymes and granulysin. They are stored in specific lysosomes called cytotoxic granules, which are 
released if a CTL engages its target. Upon degranulation, perforin induces the formation of pores in 
the target cell plasma membrane and allows granzymes to enter, which in turn activate caspases and 
trigger apoptosis. Granulysin has antimicrobial functions. The Fas ligand is a transmembrane protein 
that induces apoptosis in the target cells upon interaction with its receptor. Via these different 
mechanisms, CTLs can mediate cytotoxicity once they leave the lymph node and migrate into tissues. 
Once an infection is cleared, T cells start to express regulatory receptors. Examples for such 
coinhibitory interactions are cytotoxic T lymphocyte antigen 4 (CTLA4) and programmed cell death 
protein 1 (PD1). They can bind to B7 and PD1-ligand expressed on DCs, which induces anergy and 
apoptosis. Such immune checkpoint mechanisms are important to regulate T cell proliferation, 
maintain self-tolerance and prevent excessive immune responses after clearing an infection. T cell 
responses are ended either by activation-induced cell death or T lymphocyte exhaustion. Only a 
minority of specific effector T cells remains and constitutes memory T cells. They show a distinct 
phenotype. Whereas naïve T cells express chemokine receptor 7 (CCR7), the lymphoid homing 
marker, and the CD45RA isoform, central memory T cells (TCM) switch to the CD45RO isoform. 
Effector memory T cells (TEM) additionally lose CCR7 expression and are found in the periphery. 
They can rapidly mature into effector T cells and secrete large amounts of IFNγ, IL-4 and IL-5 after 
stimulation. A subset of TEM re-expresses CD45RA and thus is called TEMRA. Tissue-resident memory 
cells (TRM) are another subset of memory T cells. They populate and reside in certain tissues and do 
not re-circulate. Such tissues represent primary barriers against pathogens, as for example intestinal, 
genital and respiratory mucosa or the skin (Murphy and Weaver, 2017). 
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1.2.4 Immune evasion mechanisms of HPV 
1.2.4.1 Immunoediting of tumor cells 
Tumor cells present DAMPS and antigens. Still, they can escape from detection by the immune 
system. Avoidance of immune destruction is one of the emerging hallmarks of cancer described in 
section “Cancer and human papillomavirus infection”. Tumor cells can achieve this in a process called 
immunoediting. Three phases of tumor editing are described. In the first “elimination” phase, the 
immune system recognizes target cells and eradicates them, leading to a prevention of tumor growth. 
However, if elimination is not complete, surviving tumor cells enter an “equilibrium” phase. The 
actions of the immune system are counterbalanced with immunosuppressive mechanisms. During this 
phase, the pressure of the immune system “selects” cells that have the ability to survive and remain 
undetected by immune cells – immunoediting in the strict sense. This eventually leads to the third 
phase of immune “escape” when tumors are established and progress (Murphy and Weaver, 2017). 
The three immunoediting phases can be observed for HPV infections and HPV-associated tumors as 
well. In the elimination phase, macrophages, CD4
+
 and CD8
+
 T cells infiltrate the infection site (Woo 
et al., 2008). T cell responses eliminate infected cells and neutralizing antibodies are induced after 
natural infection (Stanley et al., 2008). However, HPVs can escape immune surveillance and induce 
persistent infection, as they employ several immune evasion strategies as reviewed (Grabowska and 
Riemer, 2012; Cicchini et al., 2016; Steinbach and Riemer, 2018). 
1.2.4.2 Immune evasion mechanisms of HPV and HPV-positive tumor cells 
The life cycle of the virus allows hiding from immune detection in several ways. The virus infects 
only cell layers above the basement membrane, which are less populated with immune cells. The 
hijacked cell produces viral proteins only at a low level and does not secrete them. Only in the upper 
epithelial layers, when keratinocytes terminally differentiate, expression of viral genes is upregulated 
and virions are formed. However, at this stage, keratinocytes are naturally shed and release virions 
away from the epithelial surface. Overall, HPVs remain completely intra-epithelial, without viremia 
and cause no lysis or death of the host cell and thus do not induce inflammation. 
In order to prevent recognition HPVs actively interfere with immune recognition via the early proteins 
E5, E6 and E7. The proteins dysregulate gene expression, protein function and antigen processing. 
Major altering of gene expression is achieved by epigenetic changes. E7 associates with DNA 
methyltransferase 1 (DNMT1) (Burgers et al., 2007). The activated methyltransferase acts on different 
promoters of important immune components. For example, gene expression of CXCL14 and 
E-cadherin is downregulated, which leads to impaired attraction of Langerhans cells, the DCs of the 
skin (Laurson et al., 2010; Cicchini et al., 2016). Histone modification mediated by E7 leads to 
downregulation of TLR9, which senses viral dsDNA (Hasan et al., 2013). Further, E7 is able to 
interfere with interferon signaling by binding to transcription factors for interferon-induced genes (Um 
et al., 2002; Antonsson et al., 2006). 
Introduction 
 
 
20 
Components of the APM represent another class of targets. HPV
+
 cells show a repressed expression of 
immunoproteasome subunits and of TAP, which reduces the overall number of antigen-derived 
peptides available for HLA loading (Evans et al., 2001). In contrast, ERAP1 is overexpressed, which 
likely induces excessive trimming and progressive destruction of HPV epitopes (Steinbach et al., 
2017). Further, the E5 protein interferes with MHC class I surface expression. It interacts with the 
transmembrane domain of the MHC α-chain, traps MHC class I in alkalized vesicles in the Golgi 
apparatus and scavenges calnexin that usually stabilizes the α-chain before binding β2-microglobulin 
(Roman and Munger, 2013). 
Moreover, HPV
+
 tumors generate an immunosuppressive microenvironment comprised of 
immunosuppressive cytokines and cell types such as tumor associated macrophages (TAMs), myeloid-
derived suppressor cells (MDSCs), or Tregs (Lepique et al., 2009). 
Taken together, all of HPVs immune evasion mechanisms lead to a “low profile”, a state at which only 
few immunogenic epitopes are available. The restricted epitope repertoire limits the points of attack 
for the immune system during progressive disease. Thus, it is important to identify available HPV 
target epitopes in order to develop novel immunotherapies against HPV-related malignancies. 
1.3 Cancer Immunotherapy 
1.3.1 An overview of cancer immunotherapy approaches 
Cancer immunotherapy evolved over the past decades and today represents an emerging field of 
translational research and a promising strategy for cancer treatment or even cure. It aims at inducing or 
enhancing anti-tumor responses of the immune system and at overcoming immunosuppression. In the 
past decades, several unspecific and specific immunotherapeutic approaches showed efficacy and 
safety in clinical studies which led to approval by the FDA or the EMA (Riley et al., 2019). 
The earliest approved unspecific immunological medications were cytokines for promoting 
lymphocyte proliferation such as recombinant IFNα2 (1986) and IL-2 (1992) (Ahmed and Rai, 2003; 
Rosenberg, 2014). Another cytokine in clinical practice is granulocyte-macrophage colony-stimulating 
factor (GM-CSF). It promotes differentiation of myeloid cells and DCs, acts as adjuvant and 
contributes to the regulation of immunosuppression in the tumor microenvironment (Yan et al., 2017). 
Other cytokines, e.g. and TGFβ receptor type 1 inhibitors, are investigated for clinical use (Uhl et al., 
2004). 
Latest advances in unspecific immunotherapy were the development of immune checkpoint inhibitors. 
The most common checkpoint inhibitors in use are blocking PD-1/PD-L1 and CTLA4. As explained 
earlier, immune checkpoint interaction represent coinhibitory signaling that leads to T cell anergy and 
apoptosis in order to maintain self-tolerance and downregulate excessive immune responses. In turn, 
when blocking this signaling, T cells remain active and can mediate tumor cell killing (Riley et al., 
2019).  
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In contrast to generally activating the whole T cell pool, specific cancer immunotherapies target 
features that are predominantly expressed on tumor cells. Potential targets can be tumor-associated 
antigens (TAAs), cancer-testis antigens (CTs), onco-fetal antigens (OFs), tumor-specific antigens 
(TSA) or viral oncoproteins (Murphy and Weaver, 2017; Finn and Rammensee, 2018). TAAs are 
proteins that are also present on healthy tissue but are overexpressed by tumor cells, or proteins that 
are abnormal for the local tissue type but regularly expressed in other tissues. CTs represent tumor 
antigens, which are usually only expressed in male germ cells. OFs are proteins that are usually only 
expressed in fetal tissues, but re-expressed in tumors. In contrast, TSAs are solely expressed in tumor 
cells, such as mutation-derived neoepitopes. Viral oncoproteins represent a specific type of TSAs, as 
they are shared by all tumor cells but are derived from an infectious agent. These potential tumor 
rejection antigens have individual advantages and limitations considering different tumor entities. 
Therapeutic targets must be cautiously selected in order to induce an immune response directed 
against all tumor cells without harming healthy tissue. 
The first approved specific immunotherapy approaches were antibody based therapies, which utilize 
the potential of the effector mechanisms of the immune system by targeting tumor antigens (Stamova 
et al., 2012). Monoclonal antibodies (Mabs) can trigger innate immune responses such as complement-
mediated cytotoxicity and antibody-dependent cellular cytotoxicity or phagocytosis. Various tumor 
antigens are targeted by Mabs, e.g. CD20 (Rituximab), CD33 (Gemtuzumab) or human epidermal 
growth factor receptor 2 (Her2/neu) (Trastuzumab). Over the past decades, different bispecific 
antibody constructs have been developed. In order to specifically bind two targets, these constructs are 
engineered to provide two variable domains with different complementarity determining regions. For 
example, the bispecific antibody Blinatumomab is cross-linking CD3 on T cells and CD19 on B cells 
and was approved for treating B cell acute lymphocytic leukemia in 2014 (Krishnamurthy and Jimeno, 
2018). 
T cell-based therapies also aim at specific targets. Such therapies comprise adoptive cell transfer 
(ACT), e.g. of expanded tumor infiltrating lymphocytes (TILs) or of genetically engineered T cells 
with epitope-specific TCRs or chimeric antigen receptors (CARs) (Besser et al., 2013; Murphy and 
Weaver, 2017). CARs consist of antigen-recognition domains of antibodies coupled to intracellular 
signaling domains of the TCR. Thus, CAR T cells are not restricted to MHC-presented peptides. 
Currently, two CAR T cell therapies targeting CD19 are approved for treating B cell leukemia and 
lymphoma, but other antigens are investigated. Not yet approved but tested in clinical trials are TCR T 
cell therapies (NCT01352286, NCT01892293, NCT01343043, NCT01567891, NCT01350401 and 
NCT02588612) (Hughes et al., 2005). Here, T cells are genetically engineered to express TCRs with 
high target affinity. However, toxicities in clinical investigations demonstrated that TCR specificity is 
of utmost importance in order to prevent cross-reactivity against “self” (Morgan et al., 2013; Cameron 
et al., 2013). In contrast to CAR T cells, TCR T cells depend on matching peptide-MHC complexes. 
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A rather broad field of antigen-specific treatment strategies is referred to as cancer vaccines. These 
strategies aim at inducing a T cell-mediated immune response against tumor antigens. Cancer vaccines 
are dependent on delivery technologies in order to provide functionality at the tumor site. Delivery 
strategies comprise nanoparticle or liposome-based drug delivery, molecular conjugates, such as 
antibodies and albumin- or matrix-binding domains, depot-forming platforms, like Montanide ISA 51, 
implantable or injectable biomaterial scaffolds or transdermal microneedles, as reviewed (Riley et al., 
2019). Types of cancer vaccines include tumor cell lysates, DC-based vaccines, nucleic acid vaccines 
and protein- or peptide-based vaccines. Tumor cell lysates supply a broad range of tumor antigens, 
which can be presented by any HLA type (Chiang et al., 2015). Tumor lysates can also be used for 
generating DC vaccines (Garg et al., 2017). The first approved DC vaccine is Sipuleucel-T for 
treatment of prostate cancer. The principle of DC vaccines is based on autologous immature DCs, 
which are in vitro supplied with tumor antigen and maturation factors. The mature DCs, loaded with 
tumor antigen, are transfused back into the patient where they can induce anti-tumor T cell responses. 
Similarly, immune responses can be induced in vivo when tumor proteins or peptides are injected. For 
example, vaccination with the whole tumor protein NY-ESO1 efficiently primed CD8
+
 T cell 
responses (Karbach et al., 2011). 
Like the majority of whole antigens, peptides do not provide their own PAMPs or DAMPs and thus 
need adjuvants in order to stimulate strong and durable immune responses. However, in contrast to 
whole protein, peptide-based vaccinations do not pose the risk of introducing biological 
contaminations or DNA transforming functions. Moreover, peptide vaccines are attractive because 
fully characterized peptides can be synthetically produced in a fast, simple, cost-effective and 
reproducible manner. Freeze-drying of peptides facilitates storage and transport without the need of a 
cold chain (Skwarczynski and Toth, 2016). Another option to deliver peptide-based vaccines is 
encoding the peptide sequence in DNA or mRNA, which is internalized by APCs and translated into 
peptide, which is presented to epitope-specific T cells. Especially in the field of personalized 
medicine, mRNA-based vaccines encoding for individual maturation-derived neoepitopes represent 
promising treatment approaches (Sahin et al., 2017). Peptide vaccines consist of either long or short 
synthetic peptides (SLP or SSP, respectively). In contrast to protein-based approaches, a very narrow 
and targeted immune response against single epitopes can be induced, especially when SSPs are used 
(Chabeda et al., 2018). Synthetic long peptides are not HLA type-restricted and can contain sequences 
for both CD4
+
 and CD8
+
 T cell epitopes. They require uptake, antigen processing and presentation by 
DCs in order to activate CD4
+
 T cells and, via cross-presentation, CD8
+
 T cells. In contrast, short 
synthetic peptides can be externally loaded onto MHC class I as they contain only a single CD8
+
 T cell 
epitope. Thus, they lack the ability to induce CD4
+
 T cell responses if they are not accompanied by a 
Th epitope. Due to the specific binding preferences of MHC molecules, short peptide vaccines are 
HLA-restricted and can thus only induce immune responses in HLA-matching patients (Van Hall and 
Van der Burg, 2012). 
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1.3.2 In silico epitope prediction and its role in cancer immunotherapy 
Immunogenicity is dependent on several factors. Protein expression, antigen processing and transport, 
peptide-MHC binding affinity and competition, stability of the MHC complex and the available TCRs 
determine the repertoire of presented and recognized epitopes (Trolle and Nielsen, 2014). In vitro 
testing of all possible epitope candidates is not feasible, considering the variety of antigens that can be 
derived from a single pathogen or an established tumor cell, and the polymorphism of MHC alleles 
(Dendrou et al., 2018). Therefore, different computational methods have been developed to predict the 
T cell epitopes which are likely to result from the various steps involved in presentation. 
Proteasomal cleavage of MHC class I peptides can be predicted by the algorithms PAProC and 
NetChop 3.1 (Kuttler et al., 2000; Nielsen et al., 2005). Similarly, predictors for peptide-TAP binding 
likelihood, e.g. TAPPred, were developed and often integrated into combined prediction approaches 
for antigen processing such as NetCTL 1.2 and the Immune Epitope Database (IEDB) tools MHC-NP 
and MHC-I processing predictions (Bhasin and Raghava, 2004; Larsen et al., 2007; Giguère et al., 
2013; Tenzer et al., 2005). The combined approaches also include predictions for MHC class I 
binding. The stability of peptide-MHC class I complexes can be estimated by methods like 
NetMHCstab 1.0 (Jørgensen et al., 2014). Additional algorithms exist for the prediction of T cell 
immunogenicity, e.g. the IEDB tool Class I immunogenicity, and were integrated into prediction 
chains that consider processing and MHC class I binding such as NetTepi 1.0 (Calis et al., 2013; 
Trolle and Nielsen, 2014). 
MHC binding is the most crucial and selective step, as only peptides which harbor characteristic 
residues at specific anchor positions will bind to the MHC molecule (Yewdell and Bennink, 1999). 
The specific binding features characteristic for each MHC molecule can be deduced from 
experimentally determined MHC binders. Such experiments are for example in vitro competitive 
binding assays, which determine MHC affinity by the half-maximal inhibitory concentration (IC50) of 
a test peptide vs. a reference ligand, or immunoprecipitation of endogenous MHC complexes and 
subsequent high performance liquid chromatography (HPLC) and/or mass spectrometry (MS) 
identification of eluted ligands. Using this strategy, peptide motifs of MHC-bound peptides have been 
intensively studied by the group of Hans-Georg Rammensee (Falk et al., 1991; Rammensee et al., 
1993; Rammensee, 1995; Ghosh et al., 2019). Based on these motifs they developed SYFPEITHI, a 
database for MHC ligands and one of the first MHC binding predictors (Rammensee et al., 1999). The 
preferred binding chemistry was described for MHC class I and MHC class II molecules, and thus 
prediction methods are available for both. As explained before, MHC class II-associated peptides 
differ greatly in their length, which complicates precise prediction of ligands. In contrast, class I 
anchors are more conserved (Murphy and Weaver, 2017). Defined peptide motifs, uneconomical in 
vitro alternatives and the clinical value of CTL epitopes have been motivating the development of 
multiple different computational approaches mainly for MHC class I ligand prediction. 
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Existing MHC class I predictors use various strategies to predict binding. Approaches can be based on 
scoring matrices (SMs) and artificial neural network (ANN) machine learning methods. Additionally, 
there are consensus approaches that consider different methods to calculate new output. Machine 
learning of MHC predictors can be trained either allele-specific or pan-allelic. 
Matrix-based algorithms calculate a binding likelihood score, considering sequence similarity and 
amino acid frequency in comparison to known motifs. Position specific effects are weighted as well 
(see Figure 10 A). Existing methods differ in their statistical scoring functions. Well-known and 
widely used predictors based on scoring functions are RANKPEP, PSSMHCpan and the tools 
evaluated in this study: SYFPEITHI, IEDB SMM, IEDB SMMPMBEC, PickPocket 1.1, and, 
MixMHCPred 2.0.2 (Reche et al., 2002; Liu et al., 2017; Rammensee et al., 1999; Peters and Sette, 
2005; Kim et al., 2009; Zhang et al., 2009; Bassani-Sternberg et al., 2017). In detail, SYFPEITHI 
assigns each amino acid a position-dependent value of up to 10, based on frequency of occurrence in 
known MHC ligands, and adds the corresponding values to return a score for the evaluated peptide 
sequence. The stabilized matrix method (SMM) constructs a position-specific scoring matrix (PSSM) 
based on ligands in the training data (here IEDB), calculates the sum of residue contributions and 
transforms the result into a putative IC50 value. The SMM method is also used in the SMMPMBEC 
tool, which uses a peptide:MHC-binding covariance matrix prior to the SMM method, and in the pan-
allelic PickPocket 1.1 algorithm, that de-convolves the SMM data to pocket-specific binding events 
and generates a weighted average PSSM from all HLAs in the training data. MixMHCpred 2.0.2 was 
released in 2018 and represents the most recent scoring function-based predictor. In contrast to the 
other described methods, it is trained on a very large dataset of >115,000 MS-derived peptides 
associated to 123 HLA class I molecules. PSSMs are calculated based on peptide-associated MHC 
alleles and peptide lengths. Logarithms of the corresponding PSSMs at each position are summed to 
return a peptide score which is expressed as percentile rank, corresponding to the fraction of random 
8-14-mer peptides that score higher than the test peptide. 
In contrast to scoring function-based methods, predictors based on machine-learning are capable of 
identifying non-linear patterns in peptide binding data by using ANN algorithms. Generally, ANNs are 
composed of input, hidden and output layers, each containing different interconnected units (see 
Figure 10 B). The connections between units represent weights and biases. In a feed-forward structure, 
the signal of one unit can be used as input of a connected unit or a neighboring layer. Predictors based 
on ANNs are for example ConvMHC, HLA-CNN, MHCseqNet, DeepSeqPan and the methods 
described in this study: NetMHC 4.0, NetMHC 3.4, NetMHCpan 4.0, NetMHCpan 3.0, NetMHCpan 
2.8, MHCflurry 1.2, and MHCnuggets 2.0 (Han and Kim, 2017; Vang and Xie, 2017; Phloyphisut et 
al., 2019; Liu et al., 2019; Nielsen et al., 2003; Andreatta and Nielsen, 2016; Lundegaard et al., 2008a, 
2008b; Jurtz et al., 2017; Hoof et al., 2009; Nielsen and Andreatta, 2016; Nielsen et al., 2007; 
O’Donnell et al., 2018; Shao et al.). These machine-learning methods differ in their training data and 
allele-specificity. NetMHCpan 4.0 and MHCnuggets 2.0 are partially trained on MS-derived peptides. 
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MHCflurry 1.2 offers the optional inclusion of MS data which was dismissed in the analysis 
performed in this thesis. NetMHC 4.0 and NetMHC 3.4 return allele-specific prediction likelihoods, 
whereas NetMHCpan 4.0, NetMHCpan 3.0, NetMHCpan 2.8, MHCflurry 1.2, and MHCnuggets 2.0 
perform pan-allelic predictions. All selected ANN methods express predicted binding affinity as 
putative IC50 values. Detailed differences between predictors are not explained here due to the 
complex nature of ANNs. 
 
Figure 10. Key steps of MHC binding prediction methods. (A) Scoring functions are used to generate motifs 
of specific HLA-alleles and score query peptides accordingly. (B) Machine learning-based methods make use of 
models generated from training data interconnected in artificial neural networks. (C) Consensus methods  
integrate different prediction approaches to calculate a new binding likelihood score. Figure and legend adapted 
from (Mei et al., 2019). 
Consensus approaches aim to improve prediction performance by considering the output of individual 
methods combined in a weighted score (see Figure 10 C). Examples for such methods are 
NetMHCcons 1.1 and the IEDB tools consensus and recommended (Karosiene et al., 2012; Moutaftsi 
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et al., 2006; Sidney et al., 2008b). NetMHCcons 1.1 integrates NetMHC 3.4, NetMHCpan 2.8 and 
PickPocket 1.1 to return a putative IC50 value as binding affinity. IEDB consensus weighs the output 
of NetMHC 4.0, IEDB SMM and the CombLib predictor (Sidney et al., 2008b). IEDB recommended 
selectively decides for the best method available for a given MHC molecule, based on a previously 
observed performance ranking that favors IEDB consensus over NetMHC 4.0, SMM, NetMHCpan 3.0 
and CombLib. Both IEDB methods result in a percentile rank as output. 
Precise MHC binding prediction can be exploited to predict pathogen-derived peptides, which likely 
represent epitopes. Such epitopes demonstrate promising candidates for vaccination approaches. In a 
recent study, Croft et al. were using MS for the identification of vaccinia virus-derived epitopes in 
mice. They found that the majority of MHC-presented viral peptides were immunogenic (Croft et al., 
2019). This finding highlights the role of MS profiling and its potential impact on improving MHC-
epitope predictions as well as the relevance of MHC binding for the identification of T cell epitopes 
(Creech et al., 2018). Lately, MHC binding predictors have emerged as valuable tools in neoepitope 
identification strategies. Using next-generation sequencing methods, individual mutations are 
identified in tumor samples, RNA sequencing reveals expressed neo-antigens, and MHC binding 
predictions are performed to select promising neoepitopes. Infrequently predicted neoepitopes are 
validated for immunogenicity before they are used for the design of cancer vaccines (Ott et al., 2017; 
Sahin et al., 2017; Koşaloğlu et al., 2016). Thus, in the context of personalized medicine, MHC 
binding predictions greatly gained importance in order to identify patient-specific candidate targets for 
cancer immunotherapy. 
1.3.3 HPV-specific immunotherapies 
Compared to the conventional treatment options for HPV-induced malignancies, like surgery, 
radiation and chemotherapy, successful HPV-specific immunotherapy would provide a non-invasive 
alternative with low side effects and sustained immunity (Gulley, 2013). Although prophylactic 
vaccines against HPV exist, there is a continuous need for the development of immunotherapies 
against HPV-associated diseases as described above. HPV-specific immunotherapies are especially 
promising because of the expression of ideal target proteins, namely E6 and E7. They are 
constitutively expressed in all stages of progressing disease and carcinoma and are not subject of 
central tolerance because of their viral origin (zur Hausen, 2002). Therefore, E6 and E7 of the most 
prevalent high-risk HPV type HPV16 are the antigens of choice of most approaches (van der Burg et 
al., 2016). Generally, immunotherapy approaches can be divided into passive immunotherapies, which 
autonomously perform anti-tumor effects, and active immunotherapies, which stimulate the recipient’s 
immune system to generate cellular and/or humoral anti-tumor responses. 
In HPV-specific passive immunotherapies, HPV-targeting T cells are used in adoptive cell-based 
immunotherapy. For example, in a clinical phase II trial (NCT01585428), ACT of HPV-TILs was 
used to treat 18 patients with metastatic cervical cancer. In two cases, complete responses were 
observed and three patients showed partial responses (Stevanović et al., 2019). Another cellular 
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approach used against HPV-induced cancers are TCR-transgenic T cells. A first in human phase I/II 
clinical trial (NCT02280811) tested dose limiting toxicities of T cells expressing a TCR directed 
against E6/29-38 in twelve HLA-A*02:01
+
 patients with HPV16-related metastatic or recurrent 
cancers. They observed two partial responses in the group of 6 patients who received the highest dose 
of T cells (>10
11
 up to 2x10
11
 cells). A similar study using an E7/11-19 TCR is currently recruiting 
(NCT02858310). 
The majority of anti-HPV immunotherapy approaches are active, i.e. cancer vaccinations. However, as 
described above, immune evasion strategies of HPV can complicate effective immunization. The 
mucosal location of high-risk HPV-induced lesions and carcinomas represents another challenge for 
vaccination strategies. Specific T cells that express a molecular code associated with mucosal homing 
have to be addressed (Nardelli-Haefliger et al., 2013). This has been demonstrated to be linked to the 
route of vaccination, as T cells more efficiently migrate to mucosal tumor site if vaccination is applied 
orthotopically (Sandoval et al., 2013). Apart from orthotopic vaccination, T cells can be directed to the 
tumor site by specifically inducing mucosal T cells or by prime-pull approaches (Sun et al., 2015; Tan 
et al., 2018). As described above, various different approaches exist for cancer vaccination. Many of 
them are employed in the development of HPV vaccines. However, to date, no therapeutic HPV 
vaccines are approved by drug licensing authorities albeit numerous candidates are being tested in 
clinical trials (Khallouf et al., 2014; Liu et al., 2017; Chabeda et al., 2018). The most clinically 
advanced therapeutics are introduced in the following. 
Investigation of a bacterial vector, ADXS11-001 expressing a fusion protein of listeriolysin O (LLO) 
and E7 in Listeria monocytogenes, showed increased IFNγ+ T cells with E7-specificity and reduction 
in tumor size in patients with metastatic or advanced cervical cancer in a phase I/II study (Maciag et 
al., 2009). Based on these results, the study advanced into a phase III trial (NCT02853604). 
A viral vector in clinical trials is TA-HPV, a recombinant modified vaccinia virus Ankara (MVA) 
vector expressing E6 and E7 of HPV16 and HPV18. In phase II studies, 8 of 29 cervical cancer 
patients showed serological and 4 of 29 showed CTL-based HPV-specific responses after a single 
dose, whereas 10 of 12 high-grade VIN or VAIN patients showed an average decrease in lesion size of 
40% (Kaufmann et al., 2002; Baldwin et al., 2003). Another MVA vector is TG4001, expressing 
HPV16 E6/E7 and IL-2. In a phase II study, it was administered in 3 weekly subcutaneous injections 
and induced responses in ten HPV16-related CIN2/3 patients (48%), of which seven experienced 
regression (Brun et al., 2011). 
A HPV-specific DNA-based vaccine is VGX-3100, which encodes HPV16/18 E6/E7 proteins and is 
injected intramuscularly with subsequent electroporation. It passed a phase I trial in CIN2/3 patients 
with promising CD8
+
 T cell responses (14 of 18 patients) and increased HPV16 and HPV18 antibody 
titers (17 and 18 of 18, respectively) (Bagarazzi et al., 2012). In a subsequent randomized, double-
blind, placebo-controlled phase IIb trial, 49.5% of the vaccine recipients had histopathological 
regression of CIN lesions (Trimble et al., 2015). Several trials are currently recruiting to analyze the 
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VGX-3100 vaccine for use against anal neoplasia (NCT03603808 and NCT03499795), VIN 
(NCT03180684), and in phase III studies against CIN (NCT03185013 and NCT03721978). A 
combination of VGX-3100 and a recombinant IL-12 encoding molecular adjuvant (INO-9012) was 
recently demonstrated to induce HPV-specific CD8
+
 T cells in 18 of 21 head and neck cancer patients 
(Aggarwal et al., 2019). 
Protein-based vaccines contain all epitopes of an antigen and are not MHC-restricted. However, they 
are internalized as extracellular material and thus promote Th cell over CTL responses. Fusion proteins 
and adjuvants are used to increase T cell responses. A fusion protein of HPV16 L2, E6 and E7 used as 
subunit vaccine is called TA-CIN, which after 52 weeks showed complete regression of VIN in 12 of 
19 patients treated in combination with imiquimod (Daayana et al., 2010). 
One of the most intensively studied therapeutic HPV vaccination approaches is based on synthetic 
long peptides (SLPs), consisting of overlapping SLPs of HPV16 E6 and E7. This SLP mix was 
formulated with Montanide ISA-51 adjuvant and used to vaccinate 20 VIN patients subcutaneously in 
3-week intervals. All patients showed vaccine-induced T cell responses, and 9 of 19 patients had a 
complete clinical response. Interestingly, these patients showed stronger CD4
+
 than CD8
+
 T cell 
responses (Kenter et al., 2009). The same vaccine was used to treat advanced or recurrent 
gynecological carcinoma in 20 patients. Although inducing HPV16-specific T cell responses, in 9 of 
16 tested patients the tumors neither regressed nor were stopped from progressing (van Poelgeest et 
al., 2013). Currently, SLP mixes are tested in combination with chemotherapy and utomilumab (an 
antibody binding to 4-1BB, NCT03258008), or with the PD-1 checkpoint inhibitors cemiplimab 
(NCT03669718) and nivolumab (NCT02426892) in orophangeal cancer and various incurable 
HPV16
+
 tumors, respectively. 
A peptide vaccine based on a synthetic short peptide (SSP) will be analyzed in a currently recruiting 
phase I/IIb trial for the treatment of incurable HPV 16-related oropharyngeal, cervical and anal cancer 
in HLA-A*02
+
 patients (NCT02865135). Herein, the safety and efficacy of DPX-E7, a 
HPV16-E7/11-19 nanomer with metronomic cyclophosphamide, will be evaluated. Previous studies 
on single HPV16 epitopes were conducted with the E7/11-20 and E7/86-93 peptides together with a 
pan-DR T helper epitope (PADRE) for treatment of cervical carcinoma patients. In these studies, no 
antigen-specific CTL responses were observed (Ressing et al., 2000). In contrast, formulations with 
lipidated E7/86-93 or E7/86-93 together with E7/12-20 did induce antigen-specific T cell responses in 
cervical carcinoma and CIN/VIN patients, respectively (Steller et al., 1998). 
Results from the above mentioned conducted trials in HPV-mediated cancer patients indicate that 
whole protein and SLP vaccines can induce strong humoral and Th immunity but do not trigger 
effective CTL responses which are needed for tumor regression and clinical success. Ongoing studies 
will show if SLPs in combination with checkpoint inhibitors overcome the immunosuppressive tumor 
microenvironment. In contrast, SSP vaccines would provide only epitope-specific stimuli for CTLs 
and thus mediate a tumor-directed cytotoxic immune response. However, clinical trials using SSP 
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vaccines to treat HPV16 showed that this approach is challenging. Knowledge about the actual 
presentation of the targeted peptide is important, as immune escape mechanisms can lead to 
presentation of only some HPV epitopes on the surface of tumor cells (see section Immune evasion 
mechanisms of HPV above). Other requirements for ideal epitopes are disease-specificity – given in 
the case of HPV; conserved sequences – possible for some HPV epitopes; and knowledge about HLA 
type-specific peptide recognition and immunogenicity. 
The research group Immunotherapy and Immunoprevention of Angelika Riemer aims at overcoming 
the mentioned challenges and at developing a therapeutic vaccine against HPV16-induced 
malignancies based on the identification and validation of CTL epitopes. The identification of ideal 
HPV16 E6/E7-derived target epitopes is approached by first using computational prediction of 
potential HLA type-specific binders, followed by synthesis of predicted peptides and experimental 
validation. Subsequently, verified HPV E6 and E7 HLA ligands are investigated for HLA-restricted 
cell surface presentation on HPV16
+
 cancer cells using a targeted MS-strategy. In parallel, binding 
peptides are analyzed for immunogenicity in functional assays with HLA-matched peripheral blood 
mononuclear cells (PMBCs) of healthy donors. Bona fide presented immunogenic candidate epitopes 
are tested in different vaccine formulations in a preclinical tumor model in a HLA-humanized A2.DR1 
mouse strain. In order develop a HPV vaccine capable of immunizing >95% of the world 
population,the Riemer group is focusing on epitopes of the most prevalent HLA-types among 
supertypes. 
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2 Aims of this study 
As outlined above, HPV-related dysplasia and cancer remain a major worldwide health burden, 
although prophylactic HPV vaccination and screening programs were introduced. As standard of care 
treatments are invasive and come with side-effects, alternative treatment strategies such as cancer 
vaccination are needed. For the development of an effective therapeutic vaccine and other epitope-
targeting immunotherapeutic approaches against HPV16-associated malignancies, the selection of 
suitable target epitopes is crucial. T cell epitopes need to be presented in complex with HLA 
molecules. These have type-dependent binding preferences. Based on identified binding motifs, HLA 
ligands can be predicted in silico using online available computational methods. 
 
To identify ligands to the HLA class I supertype representatives, A*01:01, A*02:01, A*03:01, 
A*11:01, A*24:02, B*07:02 and B*15:01, prediction and experimental validation of potential HPV16 
E6/E7 derived HLA class I binders was the first aim of this study. In order to avoid missing possible 
true ligands, the individual strengths of various prediction algorithms were exploited, by using 15 
different prediction methods for peptides of 8aa to 11aa.in length. 
 
Experimental validation of predicted peptides resulted in a comprehensive dataset of peptides and their 
associated predicted and actual binding affinities. Such a dataset represents a valuable resource for 
assessing binding prediction performance. Therefore, the second aim of this study was to evaluate the 
used 15 predictors based on the HPV16 E6/E7 peptide dataset. 
 
As HPV16 evolved into genetically distinct variants, peptides derived from E6 and E7 variants with 
known amino acid substitutions were included in the HLA binding assessment. Regarding epitope-
based vaccine design, such protein regions affected by variants have implications, as they are not 
conserved and not shared by all HPV16 patients. For the purpose of investigating the influence of 
amino acid exchanges in the HPV16 E6 and E7 peptides, the third aim of this thesis was to compare 
HLA binding affinities of reference sequence- and variant-derived peptides. 
 
Only immunogenic HLA class I-presented HPV16 E6 and E7-derived peptides are suitable candidates 
for effective therapeutic vaccination. Accordingly, the fourth aim of this study was to discover 
functional T cell epitopes among the identified HPV16 E6/E7-derived HLA binders focusing on MS-
detected bona fide presented peptides. Functionality was assessed by the ability of peptides to induce 
IFNγ-secretion and to mediate cytotoxicity against HPV16+ cancer cells. 
 
Altogether, this thesis aimed at providing a widely usable performance evaluation of HLA class I 
ligand prediction methods, as well as at the definition of candidate epitopes for therapeutic HPV16 
vaccine design. 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Laboratory equipment 
Equipment Product name Company 
Agarose gel documentation 
Gel Jet Imager 2006 with Printer 
P39D 
Intas, Göttingen and Mitsubishi 
Electric, Tokio, Japan 
Analytical balance Entris Sartorius AG, Göttingen 
Automated cell counter Countess™ 
Thermo Fisher Scientific, Waltham, 
USA 
Automated cell counter Nucleo Counter® NC-200™ ChemoMetec, Allerod, Denmark 
Cell freezing container 
Nalgene® Mr. Frosty® Cryo 1°C 
Freezing Container 
Thermo Fisher Scientific, Waltham, 
USA 
Centrifuge Centrifuge 5417 R, 5418 Eppendorf, Hamburg 
Centrifuge Biofuge pico, fresco Heraeus, Hanau 
Centrifuge Megafuge 16 R Heraeus, Hanau 
Centrifuge Sunlab® Minizentrifuge SU1550 Labdiscount GmbH, Mannheim 
Centrifuge rotor for 
microcentrifuge 
F45-30-11 Eppendorf, Hamburg 
Centrifuge rotor for plates M-20, 75003624 
Thermo Fisher Scientific, Waltham, 
USA 
Centrifuge rotor for swinging 
buckets 
TX-400, 75003629 
Thermo Fisher Scientific, Waltham, 
USA 
Electrophoresis chamber for 
agarose gels 
Owl Easycast B2 
Thermo Fisher Scientific, Waltham, 
USA 
Electrophoresis chamber for 
agarose gels 
PerfectBlue™ gel system, Mini L 
Peqlab, VWR International GmbH, 
Darmstadt 
Enzyme-linked immunospot 
(ELISpot) plate reader 
CTL-Immunospot® S6 Ultra-UV CTL Europe, Bonn 
Flow cytometer 
fluorescence activated cell scanner 
(FACS) Canto II™ 
BD Biosciences, Franklin Lakes, 
NJ, USA 
Flow cytometer 
BD Accuri™ C6 with BD 
CSampler™ accessory kit 
BD Biosciences, Franklin Lakes, 
NJ, USA 
Freezer (-20°C) Mediline Liebherr, Biberach an der Riss 
Freezer (-20°C) 
 
Bosch, Stuttgart 
Freezer (-80°C) U725 Innova New Brunswick, Nürtingen 
Glassware Duran Schott, Mainz 
Glassware Fischerbrand 
Thermo Fisher Scientific, Waltham, 
MA, USA 
Ice machine FM 120 KE-50-HC Hoshizaki, Tokio, Japan 
Incubator (37°C, 5% CO2, cell 
culture) 
Heracell 150i 
Thermo Fisher Scientific, Waltham, 
USA 
Incubator (37°C, 5% CO2, cell 
culture) 
C200 Labotec, Göttingen 
Laminar flow hood 
SterilGard® Class II laminar flow 
hood 
The Baker Company, Sanford, USA 
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Equipment Product name Company 
Laminar flow hood Maxisafe 2020 
Thermo Fisher Scientific, Waltham, 
USA 
Light microscope Wilovert Standard 30 microscope Hund Wetzlar, Wetzlar 
Light microscope Axiovert 25 Carl Zeiss Microscopy GmbH, Jena 
Liquid nitrogen tank Locator 8 plus 
Barnstead/Thermolyne, Dubuque, 
IA, USA 
Liquid nitrogen tank ARPEGE110 NU 
Cryopal, Bussy-Saint-Georges, 
France 
Magnet for MACS Quadro MACS 
Miltenyi Biotech, Bergisch 
Gladbach 
Magnetic stirrer RSM-01S 
Phoenix Instrument GmbH, 
Garbsen 
Magnetic stirrer, heatable MR-Hel Standard Heidolph Instruments, Schwabach 
Microwave 
 
Sharp, Osaka, Japan 
Multichannel pipetting reservoir 
Multi-channel pipettor Trifill 
reservoir 
Roth, Karlsruhe 
Nano Drop ND-1000 
Thermo Fisher Scientific, Waltham, 
USA 
Nano Drop ND-8000 
Thermo Fisher Scientific, Waltham, 
USA 
polymerase chain reaction (PCR) 
cycler 
Gene Touch Thermal Cycler 
Biozym Scientific GmbH, 
Oldendorf 
pH Meter 
SevenCompact™ pH/Ionmeters 
S220 with pH Electrode InLab 
Ultra-Micro-ISM 
Mettler Toledo, Glostrup, Denmark 
Pipettes 
2µl, 20µl, 200µl, 1000µl, 50µl-
multichannel and 300µl-
multichannel Finnpipette F2 
Thermo Fisher Scientific, Waltham, 
USA 
Pipettes, glass 
 
Hirschmann Labortechnik, 
Eberstadt 
Pipetting controller Pipetboy acu 2 Integra Biosciences, Biebertal 
Pipetting device, 96-well format 
Bel-Art™ SP Scienceware™ 
Vaccu-Pette 
Bel-Art products, Wayne, USA 
Power supply EPS3500 Pharmacia, Uppsala, Sweden 
Power supply MP 250V 
MS Major Science, Saratoga, 
CA, USA 
Refrigerator (4°C) Mediline 
Liebherr, Biberach an der 
Riss 
Refrigerator (4°C) 
 
Bosch, Stuttgart 
Scale Kern EG 4200-2NM Kern & Sohn, Balingen 
Surgical tweezer and scissors 
 
Dimeda, Tuttlingen 
Thermomixer Thermomixer compact Eppendorf, Hamburg 
Vacuum pump N86KT.18 KNF Neuberger, Freiburg 
Vortexer Vortex-Genie 2 
Scientific Industries, Bohemia, 
USA 
Water bath 
 
GFL, Burgwedel 
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3.1.2 Consumables 
Product Company 
Aluminium foil CeDo GmbH, Mönchengladbach 
Blood collection set (Safty-lok™) BD, Franklin Lakes, NJ, USA 
Blood collection tubes (Sodium Heparin, 170 I.U.) BD, Plymouth, UK 
Cell culture dish (100mm x 20mm ) TPP, Trasadingen, Switzerland 
Cell culture flask (25cm
2
, 75cm
2
, 125cm
2
) TPP, Trasadingen, Switzerland 
Cell culture plate (12-, 24-, 48-well) Corning, Corning, NY, USA 
Cell culture plate (96-well), flat-bottom BD, Franklin Lakes, NJ, USA 
Cell culture plate (96-well), U-bottom TPP, Trasadingen, Switzerland 
Cell culture plate (96-well), V-bottom Greiner Bio-One, Frieckenhausen 
Cell culture plate “CytoOne” (6-well) Starlab, Hamburg 
Cell scraper Sarstedt, Newton, NC, USA 
Cling film CeDo GmbH, Mönchengladbach 
Countess® cell counting chamber slides Invitrogen, Carlsbad, CS, USA 
Cryogenic tubes Greiner Bio-One™ Cryo.s™  Thermo Fisher Scientific, Waltham, USA 
Cryogenic tubes Nalgene™ Thermo Fisher Scientific, Waltham, USA 
FACS tubes (5ml Polystrene round-bottom tube) BD, Franklin Lakes, NJ, USA 
Gloves Microflex, Reno, NV, USA 
Leucosep™ tubes Greiner Bio-One™ Thermo Fisher Scientific, Waltham, USA 
MACS Seperation Column LS Miltenyi Biotec, Bergisch Gladbach 
MultiScreen®-HA, 96-well plate, MAHAS4510 Merck Millipore, Cork, Ireland 
Nucleo Counter Via1-Cassettes™ ChemoMetec, Allerod, Denmark 
Parafilm Bemis, Neeah, WI, USA 
PCR reaction tube CapStrips Biozym Scientific GmbH, Oldendorf 
PCR reaction tube SoftStrips Biozym Scientific GmbH, Oldendorf 
PCR reaction tubes, single Biozym Scientific GmbH, Oldendorf 
Pipette tips, with and without filter Starlab, Hamburg 
Reaction tubes (0.2ml, 0.5ml, 1.5ml and 2ml) Starlab, Hamburg 
Reaction tubes, black, flip cap (1.5ml) NeoLab, Heidelberg 
Scalpel Feather, Osaka, Japan 
Syringe (20ml, 50ml BD Plastipak Luer-Lok™) BD, Drogheda, Ireland 
Syringe filter (pore size 0.22μm) TPP, Trasadingen, Switzerland 
Test tube (15ml and 50ml) nerbe plus GmbH, Winsen/Luhe 
Vacuum Filter (bottle top, pore size 0.22μm) TPP, Trasadingen, Switzerland 
3.1.3 Chemicals and biological reagents 
Product 
Catalog 
number 
Company 
6x DNA Loading Dye R0611 Thermo Fisher Scientific, Waltham, USA 
Agarose A8963 AppliChem GmbH, Darmstadt 
Albumin, from bovine serum albumin (BSA) A9418 Sigma-Aldrich, Taufkirchen 
Ammonium chloride (NH4Cl) P726.1 Roth, Karlsruhe 
Beta-2-(ß2) microglobulin 153903 MP Biomedicals, Illkirch, France 
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Product 
Catalog 
number 
Company 
Bovine serum albumin (BSA) A9418 Sigma-Aldrich, Taufkirchen 
Carboxyfluorescein succinimidyl ester (CFSE) C1157 Invitrogen, Carlsbad, CA, USA 
cytomegalovirus, Epstein-Barr virus, influenza 
virus (CEF) Peptide Pool HLA class I 
PA-CEF-001 
PANATecs - a brand of Protagen Protein 
Services GmbH, Heilbronn 
Citric acid X863.2 Roth, Karlsruhe 
Concanavalin A (ConA) from C. ensiformis C5275 Sigma-Aldrich, Taufkirchen 
Dimethyl sulfoxide (DMSO) D8418 Sigma-Aldrich, Taufkirchen 
Distilled water deoxyribonuclease  (DNase)/ 
ribonuclease (RNase) free 
821932 MP Biomedicals, Illkirch, France 
Ethanol (absolute) 
 
Sigma-Aldrich, Taufkirchen 
Ethylenediaminetetraacetic acid (EDTA) E6758 Sigma-Aldrich, Taufkirchen 
Far Red (FR) (dimethyldodecylamine oxide-
succinimidyl ester) 
C34564 Invitrogen, Carlsbad, CA, USA 
Ficoll-Paque™ PLUS GE17-1440-03 Sigma-Aldrich, Taufkirchen 
Formaldehyde, 37% in aqueous solution 0493-500ml 
VWR International, Fontenay-sous-Bois, 
France 
GelRed® Nucleic Acid Gel Stain in water 41003 Biotium, Fremont, USA 
Hydrogen chloride (HCl) 30024.29 
VWR International, Fontenay-sous-Bois, 
France 
Ionomycin 10634 Sigma-Aldrich, Taufkirchen 
Isopropanol 
 
Sigma-Aldrich, Taufkirchen 
NBT/BCIP-plus substrate for ELISpot MAB 3650-10 Mabtech, Nacka Strand, Sweden 
Paraformaldehyde (PFA) 335.3 Roth, Karlsruhe 
Phorbol myristate acetate (PMA) P8139 Sigma-Aldrich, Taufkirchen 
Potassium bicarbonate (KHCO3) X887.1 Roth, Karlsruhe 
Potassium chloride (KCl) 6781.1 Roth, Karlsruhe 
Potassium dihydrogen phosphate (KH2PO4) 3904.1 Roth, Karlsruhe 
Sodium acetate (C2H3NaO2) 6773.2 Roth, Karlsruhe 
Sodium azide (NaN3) A1430,0100  AppliChem GmbH, Darmstadt 
Sodium chloride (NaCl) 10428420 Thermo Fisher Scientific, Waltham, USA 
Sodium hydroxide (NaOH) P031.2 Roth, Karlsruhe 
Sodium phosphate dibasic dihydrate 
(Na2HPO4·2H2O) 
12694947 
Acros organics, Thermo Fisher Scientificm 
Geel, Belgium 
Streptavidin-Alkaline Phosphatase 3310-10 Mabtech, Nacka Strand, Sweden 
Tris(hydroxymethyl)amino-methane (TRIS) 167620010 
Acros organics, Thermo Fisher Scientificm 
Geel, Belgium 
Trypan blue stain (0.4%) T10282 Thermo Fisher Scientific, Waltham, USA 
Trypsin/EDTA  (0.04%/0.03%) C-41000 PromoCell GmbH, Heidelberg 
Tween20 (Polysorbat 20) Tween201 MP Biomedicals, Illkirch, France 
Zombie Aqua Fixable Viability Dye 423101 BioLegend, San Diego, CA, USA 
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3.1.4 Buffers and solutions 
Name Ingredients 
10x phosphate-buffered saline (PBS) 
1.37M NaCl 
27mM KCl 
100mM Na2HPO4 x 2H2O 
20mM KH2PO4 
pH 7.3 
50x Tris base, acetic acid and EDTA (TAE) buffer 
484g Tris 
41g C2H3NaO2 
37g EDTA 
pH 7.8 
ad. 2L ddH2O 
ACK lysis buffer 
0.829g NH4Cl (155mM) 
0.1g KHCO3 (10mM) 
0.38mg EDTA (0.1mM) 
pH 7.2-7.4 
ad. 100mL ddH2O 
Elution buffer 
50% 0.263M (v/v) citric acid 
50% 0.123M (v/v) Na2HPO4 x 2H2O 
pH 2.9 or 3.1 
FACS buffer 
1x PBS 
2% FCS 
0.1% (v/v) NaN3 
Fixation buffer 
1xPBS  
1% PFA 
Flow cytometry fix buffer 
1xPBS 
1% FCS 
2.5% formaldehyde 
MACS buffer 
1x PBS 
0.5% (v/v) FCS 
2mM EDTA 
Staining buffer 
1xPBS 
0.1% (w/v) BSA 
0.1% (v/v) NaN3 
Tween PBS (TPBS) 
1xPBS 
0.05% (v/v)Tween20 
3.1.5 Cell lines 
Name Description HPV-status 
Culture 
medium 
Reference Source 
1341-8346 
human, B-LCL, 
suspension 
negative 
B-LCL 
medium 
 
IHWG Cell Bank, 
Seattle, WA, USA 
BSM 
human, B-LCL, 
suspension 
negative 
B-LCL 
medium 
 
IHWG Cell Bank, 
Seattle, WA, USA 
E481324 
human, B-LCL, 
suspension 
negative 
B-LCL 
medium 
 
IHWG Cell Bank, 
Seattle, WA, USA 
EA 
human, B-LCL, 
suspension 
negative 
B-LCL 
medium 
 
IHWG Cell Bank, 
Seattle, WA, USA 
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Name Description HPV-status 
Culture 
medium 
Reference Source 
FH8 
human, B-LCL, 
suspension 
negative 
B-LCL 
medium 
 
IHWG Cell Bank, 
Seattle, WA, USA 
LKT3 
human, B-LCL, 
suspension 
negative 
B-LCL 
medium 
 
IHWG Cell Bank, 
Seattle, WA, USA 
WT100BIS 
human, B-LCL, 
suspension 
negative 
B-LCL 
medium 
 
IHWG Cell Bank, 
Seattle, WA, USA 
C33A 
human, cervical, 
adherent 
negative CXCA-D 
(Auersperg, 
1964) 
Kindly provided by 
Felix Hoppe-Seyler, 
F065 DKFZ, 
Heidelberg 
CaSki 
human, cervical, 
adherent 
HPV16 positive CXCA-R 
(Pattillo et al., 
1977) 
 
MRI-H-186 
human, cervical, 
adherent 
HPV16 positive CXCA-D 
(Schmitt and 
Pawlita, 2011) 
CLS, Eppelheim 
UM-SCC 104 
human, HNSCC, 
adherent 
HPV16 positive 
UM-
SCC104 
medium 
(Tang et al., 
2012) 
EMD Millipore 
Corporation, Cat. # 
SCC072 
3.1.6 Blood samples and buffy coats 
Blood samples were taken from healthy donors after their written informed consent. Sampling and use 
of blood samples were in accordance with the Institutional Review Board at the DKFZ and the 
University of Heidelberg, Heidelberg, Germany. Blood buffy coats of anonymous, healthy donors 
were obtained from the German Red Cross (DRK) blood transfusion service Mannheim through the 
blood bank Institut für Klinische Transfusionsmedizin und Zelltherapie (IKTZ) Heidelberg. 
3.1.7 Cell culture basal media and supplements 
Product 
Catalog 
number 
Company 
2-Mercaptoethanol 31350-010 
Life Technologies Europe BV, Bleiswijk, 
Netherlands 
Dulbecco’s Modified Eagle Medium 
(DMEM), high glucose (-hi) 
D5671 Sigma-Aldrich, Taufkirchen 
Dulbecco’s Modified Eagle Medium 
(DMEM), low glucose (-lo) 
D5546 Sigma-Aldrich, Taufkirchen 
Fetal Calf Serum (FCS) 10270 Thermo Fisher Scientific, Waltham, USA 
GM-CSF, recombinant human 215-GM 
Bio-techne, R&D Systems, Inc., 
Minneapolis, USA 
HEPES 11560496 
Gibco® by Life Technologies Europe BV, 
Bleiswijk, Netherlands 
Human serum, type AB H4522 Sigma-Aldrich, Taufkirchen 
IL-2, recombinant human 200-02 PeproTech, Rocky Hill, NJ, USA 
IL-4, recombinant human 204-IL-050 
Bio-techne, R&D Systems, Inc., 
Minneapolis, USA 
IL-6, recombinant human 206-IL-050 
Bio-techne, R&D Systems, Inc., 
Minneapolis, USA 
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Product 
Catalog 
number 
Company 
IL-7, recombinant human 207-IL PeproTech, Rocky Hill, NJ, USA 
IL-1β, recombinant human 201-LB-100 
Bio-techne, R&D Systems, Inc., 
Minneapolis, USA 
L-Glutamine 25030024 Thermo Fisher Scientific, Waltham, USA 
Lipopolysaccharide (LPS) tlrl-3pelps Invivogen, Toulouse, France 
MEM Non-essential amino acid solution 
(MEM-NEAA, 100X) 
11140-035 
Gibco® by Life Technologies Europe BV, 
Bleiswijk, Netherlands 
Penicillin/Streptomycin-Solution (P/S)                                        
10,000U penicillin and 10mg streptomycin 
per ml (100X) 
P0781 Sigma-Aldrich, Taufkirchen 
Prostaglandin E2 (PGE2) 14010 Cayman Chemical, Ann Arbor, USA 
Rosswell Park Memorial Institute medium 
1640 (RPMI)  
R0883 Sigma-Aldrich, Taufkirchen 
Sodium pyruvate 25-000-CIR Corning GmbH, Kaiserslautern 
TNFα, recombinant human 210-TA-100 
Bio-techne, R&D Systems, Inc., 
Minneapolis, USA 
3.1.8 Cell culture media 
Name Ingredients 
Standard 
10% (v/v) FCS 
2mM L-Glutamine 
Standard human 
10% (v/v) human serum, AB 
2mM L-Glutamine 
1X P/S 
10mM HEPES  
B-LCL medium 
RPMI 
15% (v/v) FCS 
2mM L-Glutamine 
1mM sodium pyruvate 
CXCA-D 
DMEM-hi 
Standard 
1X P/S 
CXCA-R 
RPMI 
Standard 
1X P/S 
DC medium 
DMEM-hi 
Standard human 
ELISpot medium 
RPMI 
5% (v/v) FCS 
2mM L-Glutamine 
1X P/S  
10mM HEPES 
0.1mM 2-mercaptoethanol 
T cell medium 
RPMI-1640 
Standard human 
0.1mM 2-mercaptoethanol 
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Name Ingredients 
UM-SCC104 medium 
DMEM-lo 
Standard 
1X MEM-NEAA 
3.1.9 Kits 
Name 
Catalog 
number 
Company 
BD Accuri C6 Plus Flow Cytometer Fluidic Kit 661393 BD Biosciences, Franklin Lakes, NJ, USA 
BD Cytofix/Cytoperm™ Kit 554715 BD Biosciences, Franklin Lakes, NJ, USA 
CD8
+
 T Cell Isolation Kit, human 130-096-495 Miltenyi Biotec, Bergisch Gladbach 
peqGOLD Gel Extraction Kit 732-2777 
Peqlab, VWR International GmbH, 
Darmstadt 
QIAamp DNA Mini Kit 51304 Qiagen, Hilden 
QIAquick PCR Purification Kit 28106 Qiagen, Hilden 
3.1.10 Molecular Markers 
Name Catalog number Company 
GeneRuler™ Ladder Mix, 100 bp -10000 bp SM0333 Thermo Fisher Scientific, Waltham, USA 
3.1.11 Oligonucleotides 
Nucleotides in italics indicate T7 (forward) and T3 (reverse) sequencing primer sequences, respectively. 
Nucleotides in bold stand for actual PCR primer sequences. 
Name Sequence 5' - 3' Tm [°C] 
E6_T7_for TAATACGACTCACTATAGGGCGAAACCGGTTAGTATAA 72.2 
E6_T3_rev ATTAACCCTCACTAAAGGGAGTATCTCCATGCATGATT 74.6 
E7_T7_for TAATACGACTCACTATAGGGATAATATAAGGGGTCGGTGG 73.8 
E7_T3_rev ATTAACCCTCACTAAAGGGACATTTTCGTTCTCGTCATCTG 77.8 
3.1.12 Antibodies 
3.1.12.1 Monoclonal antibodies for HLA typing 
Antigen Clone Host Label Isotype 
Catalog 
number 
Company 
human HLA-A2 BB7.2 mouse FITC IgG2b 551285 
BD Biosciences, San Diego, 
CA, USA 
human HLA-A24 22E1 mouse FITC IgG2b LS-C179736 
LifeSpan BioSciences, Inc., 
Seattle, USA 
human HLA-A3 GAP.A3 mouse APC IgG2a 17-5754-42 
eBioscience, Thermo Fisher 
Scientific, Waltham, USA 
human HLA-B7 BB7.1 mouse PE IgG1 372404 
BioLegend, San Diego, CA, 
USA 
Isotype Ctrl MOPC-173 mouse APC IgG2a 400220 
BioLegend, San Diego, CA, 
USA 
Isotype Ctrl MPC-11 mouse FITC IgG2b 400308 
BioLegend, San Diego, CA, 
USA 
Isotype Ctrl MOPC-21 mouse PE IgG1 400114 BioLegend, San Diego, CA, 
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Antigen Clone Host Label Isotype 
Catalog 
number 
Company 
USA 
3.1.12.2 Monoclonal antibodies for ELISpot assays 
Antigen Clone Host Label Isotype 
Catalog 
number 
Company 
Human IFN-γ 7-B6-1 mouse Biotin IgG1 3420-6-1000 Mabtech, Nacka Strand, Sweden 
Human IFN-γ 1-D1K mouse  - IgG1 3420-3-1000 Mabtech, Nacka Strand, Sweden 
3.1.12.3 Monoclonal antibodies for analysis of cytokine production in immune cells 
Antigen Clone Host Label Isotype 
Catalog 
number 
Company 
human CD3 REA613 
recombinant 
human 
PE-Vio770 IgG1 130-113-140 
Miltenyi Biotech 
GmbH, Bergisch 
Gladbach 
human CD4 RPA-T4 mouse FITC IgG1 555346 
BD Biosciences, San 
Diego, CA, USA 
human CD8 RPA-T8 mouse PerCP-Cy 5.5 IgG1 560662 
BD Biosciences, San 
Diego, CA, USA 
human IFNγ 4S.B3 mouse APC IgG1 502512 
BioLegend, San Diego, 
CA, USA 
human TNFα cA2 
recombinant 
human 
APC-Vio770 IgG1 130-120-491 
Miltenyi Biotech 
GmbH, Bergisch 
Gladbach 
granzyme B GB11 mouse PE IgG1 561142 
BD Biosciences, San 
Diego, CA, USA 
3.1.13 Peptides 
3.1.13.1 Control peptides.  
X: cysteine residue with coupled fluorescein; PMID: PubMed ID for reference 
Name Source Protein Region aa sequence HLA PMID 
HLA A1 FL consensus sequence   YLEPAXAKY A1 12559627 
HLA A2 FL HBV HBcg 18-27 FLPSDXFPSV A2 12559627 
HLA A3/11 FL  consensus sequence 
  
KVFPXALINK 
A3, 
A11 
12559627 
HLA A24 FL HIV-1 gp41 583-591 RYLKXQQLL A24 12559627 
HLA B7 FL Human p53 84-93 APAPAPXWPL B7 12559627 
HLA B15 FL Human 
40S ribosomal 
protein S15 
114-122 YLGEFSXTY B15 12559627 
HLA A1 binder consensus sequence   YLEPAIAKY A1 8047072 
HLA A2 epitope HIV-1 Nef 137-145 LTFGWCFKL A2 11152503 
HLA A2 epitope HTLV TAX 11-19 LLFGYPVYV A2 1373197 
HLA A3 binder consensus sequence 
  
KVFPYALINK A3 8047072 
HLA A11 binder HIV-1 Nef 73-82 QVPLRPMTYK A3, 8047072 
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Name Source Protein Region aa sequence HLA PMID 
A11 
HLA A24 binder HIV-1 gp41 583-591 RYLKDQQLL A24 1373204 
HLA B7 binder Human p53 84-93 APAPAPSWPL B7 12559627 
HLA B15 binder Human 
40S ribosomal 
protein S15 
114-122 YLGEFSITY B15 7806292 
CEF peptide pool Influenza A PB1 591-599 VSDGGPNLY A1 11792386 
CEF peptide pool Influenza A NP 44-52 CTELKLSDY A1 11792386 
CEF peptide pool EBV BMLF1 259-267 GLCTLVAML A2 11792386 
CEF peptide pool Influenza A Matrix 1 58-66 GILGFVFTL A2 11792386 
CEF peptide pool HCMV pp65 495-503 NLVPMVATV A2 11792386 
CEF peptide pool Influenza A NP 265-273 ILRGSVAHK A3 11792386 
CEF peptide pool EBV BRLF1 148-156 RVRAYTYSK A3 11792386 
CEF peptide pool EBV EBNA3A 603-611 RLRAEAQVK A3 11792386 
CEF peptide pool EBV EBNA3B 416-424 IVTDFSVIK A11 11792386 
CEF peptide pool EBV BRLF1 134-143 ATIGTAMYK A11 11792386 
CEF peptide pool EBV BRLF1 28-37 DYCNVLNKEF A24 11792386 
CEF peptide pool Influenza A NP 91-99 KTGGPIYKR A68 11792386 
CEF peptide pool HCMV pp65 417-426 TPRVTGGGAM B7 11792386 
CEF peptide pool EBV EBNA3A 379-387 RPPIFIRRL B7 11792386 
CEF peptide pool EBV EBNA3A 158-166 QAKWRLQTL B8 11792386 
CEF peptide pool EBV EBNA3A 325-333 FLRGRAYGL B8 11792386 
CEF peptide pool EBV BZLF1 190-197 RAKFKQLL B8 11792386 
CEF peptide pool Influenza A NP 380-388 ELRSRYWAI B8 11792386 
CEF peptide pool EBV EBNA3C 258-266 RRIYDLIEL B27 11792386 
CEF peptide pool Influenza A NP 383-391 SRYWAIRTR B27 11792386 
CEF peptide pool EBV EBNA3A 458-466 YPLHEQHGM B35 11792386 
CEF peptide pool EBV EBNA3C 281-290 EENLLDFVRF B44 11792386 
CEF peptide pool HCMV pp65 512-521 EFFWDANDIY B44 11792386 
3.1.13.2 HPV16 E6 and E7 peptides 
All HPV16 E6- and E7-peptides used in the course of this thesis are listed in Supplementary Table S1 in the 
Annex. 
3.1.14 Software 
Name Company/source 
BD Accuri™ C6 Software BD Biosciences, Franklin Lakes, NJ, USA 
BD CSampler™ Software BD Biosciences, Franklin Lakes, NJ, USA 
BD FACS Diva Software BD Biosciences, San José, CA, USA 
BIMAS http:// bimas.dcrt.nih.gov/molbio/hla_bind/ 
CTL ImmunoSpot 5.1.36 Professional DC CTL Europe, Bonn 
EndNote X9 Thomas Reuter, Philadelphia, PA, USA 
ExPASy compute pI/Mw tool https://web.expasy.org/compute_pi/ 
FlowJo V10 TreeStar, Ashland, OR, USA 
Fusion Vilber Lourmat, Eberhardzell 
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Name Company/source 
GIMP 2 https://gimp.org 
Immune epitope database (IEDB) MHC-I 
binding predictions 
http://tools.iedb.org/mhci/ 
Inkscape 0.91 https://www.inkscape.org/ 
Mendeley 1.17.10 Mendeley Ltd., Elsevier Inc., New York, NY, USA 
MHCcombine http://mhccombine.dkfz.de/mhccombine/ 
MHCflurry 1.2 https://github.com/openvax/mhcflurry 
MHCnuggets 2.0 https://github.com/KarchinLab/mhcnuggets-2.0 
MixMHCpred 2.0.2 https://github.com/GfellerLab/MixMHCpred 
MS Office 2010 (German version) Microsoft Corporation, Redmond, WA, USA 
NanoDrop 1000 Software V3.8 Thermo Fisher Scientific, Waltham, USA 
NetMHC 3.4 http://www.cbs.dtu.dk/services/NetMHC-3.4/ 
NetMHC 4.0 http://www.cbs.dtu.dk/services/NetMHC/  
NetMHCcons 1.1 http://www.cbs.dtu.dk/services/NetMHCcons/ 
NetMHCpan 2.8 http://www.cbs.dtu.dk/services/NetMHCpan-2.8/ 
NetMHCpan 3.2 http://www.cbs.dtu.dk/services/NetMHCpan-3.0/ 
NetMHCpan 4.0 http://www.cbs.dtu.dk/services/NetMHCpan/ 
Notepad++ v7.4.1 https://notepad-plus-plus.org 
NucleoView™ ChemoMetec, Allerod, Denmark 
Pickpocket 1.1 http://www.cbs.dtu.dk/services/PickPocket/ 
PRISM® 7 GraphPad, La Jolla, CA, USA 
R version 3.4.0 
The R Foundation for Statistical Computing, Vienna, Austria, 
https://www.R-project.org/ 
R studio version 1.1.423 RStudio, Inc., Boston, USA, https://www.rstudio.com/ 
Seq2Logo http://www.cbs.dtu.dk/biotools/Seq2Logo/ 
SigmaPlot 13 Systat Software, San José, CA, USA 
SnapGene GSL Biotech LLC, Chicago, USA 
SYFPEITHI http://www.syfpeithi.de/ 
3.2 Methods 
3.2.1 In silico methods 
Different MHC class I binding prediction methods were used to predict the binding affinity of all 
possible HPV16 E6 and E7 peptides, including variant peptides, to the major HLA types A1 (HLA-
A*01:01), A2 (HLA-A*02:01),A3 (HLA-A*03:01), A11 (HLA-A*11:01), A24 (HLA-A*24:02), B7 
(HLA-B*07:02) and B15 (HLA-B*15:01). The results of the majority of the binding predictors were 
obtained using a new web application developed in the context of this project. 
3.2.1.1 MHC class I binding and T cell epitope prediction 
Prediction of MHC class I binding peptides derived from HPV16 E6 and E7 proteins was performed 
using 15 prediction methods. The selected predictors were NetMHC 4.0 and NetMHC 3.4 (allele-
specific ANN), NetMHCpan 4.0, NetMHC 3.0, NetMHC 2.8, NetMHCflurry 1.2 and MHCnuggets 
2.0 (pan-specific ANN), NetMHCcons 1.1 (consensus), PickPocket 1.1 (pan-specific SM), IEDB 
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recommended (allele-specific selective), IEDB consensus (consensus), IEDB SMM, IEDB 
SMMPBEC, SYFPEITHI and MixMHCpred 2.0.2 (allele-specific SM). These algorithms return 
predicted MHC binding likelihood as putative half maximal inhibitory concentration (IC50) in nM, as 
percentile rank, corresponding to the fraction of random 8-14-mer peptides that score higher than the 
test peptide, or as affinity score (Table 1). Prediction results were obtained for HPV16 E6 and E7 
reference protein (Table 2) and amino acid change variants (Table 3). 
Table 1. Prediction methods used in this study. 
Predictor Approach Online access Score Reference Color  
NetMHC 4.0 ANN (as) DTU IC50 (Nielsen and Andreatta, 2016)  
NetMHC 3.4 ANN (as) DTU IC50 (Lundegaard et al., 2008a)  
NetMHCpan 4.0 ANN (ps) DTU IC50 (Jurtz et al., 2017)  
NetMHCpan 3.0 ANN (ps) DTU IC50 (Nielsen and Andreatta, 2016)  
NetMHCpan 2.8 ANN (ps) DTU IC50 (Hoof et al., 2009)  
NetMHCcons 1.1 consensus DTU IC50 (Karosiene et al., 2012)  
PickPocket 1.1 SM (ps) IEDB API IC50 (Zhang et al., 2009)  
IEDB SMMPMBEC SM (as) IEDB API IC50 (Kim et al., 2009)  
IEDB SMM SM (as) IEDB API IC50 (Peters and Sette, 2005)  
MHCflurry 1.2 ANN (ps) GitHub IC50 (O’Donnell et al., 2018)  
MHCnuggets 2.0 ANN (as) GitHub IC50 (Shao et al.)  
IEDB recommended selective IEDB API p-rank (Sidney et al., 2008b)  
IEDB consensus consensus IEDB API p-rank (Moutaftsi et al., 2006)  
MixMHCpred 2.0.2 SM (as) GitHub p-rank (Bassani-Sternberg et al., 2017)  
SYFPEITHI SM (as) SYFPEITHI API AU (Rammensee et al., 1999)  
Approach: ANN: artificial neural network, (as): allele-specific, (ps): pan-specific, consensus: combination of 
methods, SM: scoring matrices, selective: returns IEDB consensus, NetMHC 4.0, SMM, NetMHCpan 3.0 or 
CombLib. The choice is based on the expected predictive performance: consensus > ANN > SMM > 
NetMHCpan > CombLib, CNN: convolutional neural network. 
Online Access: DTU: Denmark Technical University, IEDB: Immune Epitope Database, API: application 
programming interface. 
Score: IC50: half maximal inhibitory concentration [nM], p-rank: percentile rank, AU: arbitrary units. 
 
Table 2. Reference amino acid sequences of the HPV16 E6 and E7 proteins. 
Protein UniProtKB Sequence 
HPV16 E6 P03126 
MHQKRTAMFQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRR
EVYDFAFRDLCIVYRDGNPYAVCDKCLKFYSKISEYRHYCYSLYGTT
LEQQYNKPLCDLLIRCINCQKPLCPEEKQRHLDKKQRFHNIRGRWTG
RCMSCCRSSRTRRETQL 
HPV16 E7 P03129 
MHGDTPTLHEYMLDLQPETTDLYCYEQLNDSSEEEDEIDGPAGQAEP
DRAHYNIVTFCCKCDSTLRLCVQSTHVDIRTLEDLLMGTLGIVCPICS
QKP 
UniProtKB: accession number in the UniProt knowledge base, bold and underlined: amino acids changed in 
protein variants. 
Based on the E6 ORF the translated E6 protein would comprise 158aa. However, two in-frame ATG 
start codons exist and translation can be initiated from the second ATG, leading to a 151aa protein 
starting from the second methionine (Smotkin and Wettstein, 1986; Androphy et al., 1987). 
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Table 3. Amino acid changes in HPV16 E6 and E7 protein variants. 
Variant Sublineage Amino acid changes in E6 Amino acid changes in E7 
E-v1 (reference) A1 - - 
E-v2 A2 L90V - 
E-v3  - H51N 
E-v4  L90V, E120D L28F 
E-2  R17T, L90V - 
E-Av1 A4 D32E N29S 
E-Av2  D32E, I34R N29S 
E-Av3  D32E N29S, S63F 
AA  Q21D, H85Y, L90V - 
Af-2v1 C R17I, Q21D, H85Y N29S 
Af-2v2  R17I, Q21D, E36Q, A68G, H85Y N29S 
Af-2 B2 R17G, Q21D, H85Y N29S 
E A3 N65S - 
Af-1 B1 R17T, Q21D, H85Y - 
NA, AA-2, AA-1 D1, D2, D3 Q21H, H85Y, L90V - 
Variant: nomenclature for amino acid changes as found in HPV16
+
 cell line samples, Sublineage: as defined by 
(Burk et al., 2013), bold: amino acid changes that were not present in HPV16
+
 cell line samples and therefore not 
included in the analysis. 
For the predictors NetMHC 4.0, NetMHC 3.4, NetMHCpan 4.0, NetMHC 3.0, NetMHC 2.8, 
NetMHCcons 1.1, PickPocket 1.1, IEDB recommended, IEDB consensus IEDB SMM, IEDB 
SMMPMBEC and SYFPEITHI the web application MHCcombine (see below) was used to 
automatically retrieve output and combine it into a single comma-separated value (.csv) file. This file 
was converted into a sortable excel sheet. Output of other predictors was merged manually via the 
peptide’s sequence. 
To select peptides for synthesis and subsequent analysis, general binding affinity thresholds were 
applied as indicated by the respective algorithm (IC50 ≤500nM, percentile rank ≤2 or affinity score >20 
in SYFPEITHI). In the course of experiments, thresholds were lowered systematically as binders were 
found beyond the initial thresholds. Testing of peptides with lower predicted binding likelihood was 
stopped when only nonbinders were detected experimentally. 
3.2.1.2 Web Application MHCcombine 
To profit from the individual strengths of diverse MHC class I prediction methods, their output needs 
to be combined. To facilitate querying of many algorithms, a web application has been developed that 
systematically combines the prediction results. The user needs to enter the amino acid sequence of a 
protein or peptide, select HLA-allele, predictors and peptide lengths and optionally enter a filename 
identifier. After submitting, the tool returns a file containing comma-separated values that can be 
converted into a sortable excel file. The initial concept of this tool was developed by Stephanie Hoppe 
and Jan Winter and development was continued by Maria Bonsack. The script was programmed by 
Jan Winter, Christine Zeller and Cyril Mongis. The user interface, the webpage that enables the user to 
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communicate with the web application, was created by Maria Bonsack and integrated by Cyril 
Mongis. Tobias Reber helped to provide the Web Application on DKFZ webpages. This tool is 
available via “http://mhccombine.dkfz.de/mhccombine/”. The webpage provides additional 
information how to use, interpret and cite the application and provided predictors, and 
recommendations on decision thresholds. 
3.2.1.3 Sequence motif analysis 
Sequence motif analysis of the investigated HPV16 E6 and E7 peptides was performed to investigate 
the similarity of predicted, tested and MHC binding peptides to known binding motifs. Peptides with 
predicted binding likelihood within the general thresholds of IC50 ≤500nM or percentile rank ≤2 were 
considered “predicted”, peptides tested in competitive binding assays were considered “tested” and all 
validated ligands were considered “binders”. The motifs of 8-, 9-, 10-, and 11-mer peptides of these 
three groups were investigated separately. To generate sequence motifs, the web tool Seq2Logo 2.0 
was used with default settings (Kullback-Leibler logo type, Hobohm1 clustering method with 
threshold 0.63). The motifs of the HPV16 peptides were compared to motifs of human linear epitopes 
from the immune epitope data base (IEDB). 
3.2.2 Molecular biological methods 
All centrifugations described for molecular biological methods were performed at room temperature 
(RT). 
3.2.2.1 Isolation of genomic DNA 
To extract genomic DNA from cells, the QIAamp DNA Mini Kit was used. Cells were harvested and 
counted as described in 3.2.3 Cell culture methods. Up to 5x10
6
 cells were used for isolation of DNA. 
The procedure was performed according to the protocol of the manufacturer. Briefly, the cells were 
lysed with proteinase K in special buffer. The lysate was loaded onto a spin column containing a 
silica-gel membrane that provides specific DNA binding. During centrifugation the DNA is adsorbed 
while contaminants, such as protein and cations, pass through the column. Residuals were removed by 
two following washing steps using different washing buffers. The pure and concentrated DNA was 
eluted from the spin column by centrifugation after a short incubation in elution buffer or DNase- and 
RNase-free water. Concentration of isolated DNA was measured (see below) and DNA was stored at -
20°C. 
3.2.2.2 Determination of DNA concentration 
To measure the concentration of isolated DNA the spectrophotometers NanoDrop 1000 or 8000 were 
used. To generate a baseline of light absorbance, the eluent was measured as blank. The instrument 
calculated the DNA purity and concentration in ng of 1µl sample based on the absorbance at 260 and 
280nm wavelength. The concentration of DNA was calculated based on the absorbances at 260nm and 
an extinction coefficient for DNA of 50(ng/µl)
-1
 cm
-1
 using the Beer-Lambert law (Equation 1. Beer-
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Lambert law). Purity of DNA can be identified by the ratio of absorbance as proteins would show 
maximum absorbance at 280nm. A ratio of absorbance A(260nm)/A(280nm) of ~1.8 is generally 
identifying “pure” DNA. 
Equation 1. Beer-Lambert law 
absorbance [A] = extinction coefficient [
1
M ∗ cm
] ∗ path length [cm] ∗ concentration [M] 
3.2.2.3 Polymerase chain reaction 
The principle of the polymerase chain reaction (PCR) was invented by Kary Mullis and Randall Saiki 
et al. to amplify DNA and specific DNA fragments for sequencing or proving their presence (Mullis et 
al., 1986). Short oligomers, called primers, are designed to complementary bind to the 3’ ends of the 
sense and anti-sense strands of the DNA template at flanking sites of the fragment of interest. In the 
first step of the PCR both strands are exposed by denaturation of dsDNA, breaking of the hydrogen 
bonds between complementary bases, at 92-95°C for 20-30s. In the second step, lowering the 
temperature to 50-65°C for 20-40s allows annealing of the primers specifically to the complementary 
sites of the template strands. During this step, the primer-template hybrid is bound by a thermo-stable 
DNA polymerase. During the third step, the temperature is increased to the optimum activity 
temperature of the used polymerase (72-80°C) which synthesizes new DNA complementary to the 
template strands using free dNTPs from the reaction mix. The elongation time is dependent of the 
fragment size and the efficiency of the polymerase. A buffer solution provides optimal reaction 
conditions and Mg
2+ 
ions stabilize the negatively charged phosphate backbone of DNA and dNTPs. 
The three steps of denaturation, annealing and extension are repeated for 20-45 cycles. In each cycle, 
the replicated DNA strands become new templates resulting in exponential amplification of the 
original sequence. Dependent on the polymerase, an initial hot start may be required to heat activate 
the enzyme at 92-95°C for 10min. Optionally, a final elongation can be performed at 72-80°C for 5-
15min to ensure full extension of remaining single-stranded DNA. After PCR cycles the reaction 
chamber containing the samples is cooled to 4°C for an indefinite time until samples are removed and 
stored. 
In this study, PCR reaction was used for sequencing of HPV16 E6 and E7 to identify variants with 
amino acid changes. Template DNA was used with specific primers in different reaction mixes. In 
negative control reactions template was substituted by DNase- and RNase-free water. PCR reaction 
mixes were prepared on ice and run on a pre-heated PCR cycler using different PCR programs. PCR 
products were assessed by gel electrophoresis (see below). 
3.2.2.4 PCR for sequencing of HPV16 E6 and E7 
Template DNA extracted from HPV16
+
 cell lines was used with HPV16 E6- and E7-specific primers 
(Table 4) to amplify the E6 and E7 genes for subsequent sequencing and determination of variants. 
The lists of components and the PCR program are given in Table 5 and Table 6, respectively.  
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Table 4. Primer pairs used for HPV16 E6- and E7-amplifying PCR. 
Pair Primers Amplicon [bp] 
E6 
E6_T7_for 
E6_T3_rev 
524 
E7 
E7_T7_for 
E7_T3_rev 
505 
Table 5. Components of the PCR reaction mix amplifying of HPV16 E6 and E7. 
Component Stock concentration Final concentration 50µl 
PCR buffer 10x 1x 5µl 
dNTPs 10mM 200µM 4µl 
MgCl2 solution 25mM 2.5mM 5µl 
Forward primer 10µM 1µM 5µl 
Reverse primer 10µM 1µM 5µl 
DNA template  400ng X µl 
DNA Polymerase AmpliTaq Gold 5U/µl 1.25U 0.25µl 
DNase- and RNase-free water   ad 50µl 
X: The volume of DNA template varies depending on the DNA concentration. 
Table 6. PCR program used for amplifying of HPV16 E6 and E7. 
Step Temperature [°C] Duration [min] 
Hot start 95 15 
Denaturation 94 1 
40 cycles Annealing 55 1 
Extension 72 2 
Final elongation 72 10 
Final hold 4 ∞ 
3.2.2.5 Agarose gel electrophoresis 
Agarose gel electrophoresis can be used to analyze DNA fragments. Due to the negatively charged 
phosphate backbone of the DNA strands, the DNA starts migrating through an agarose matrix towards 
the anode when an electric field is applied. Thereby, DNA fragments are separated by their length as 
shorter fragments migrate faster through the pores of the gel. A molecular marker that contains 
different DNA fragments of a defined size is co-loaded. The pore size, which can be determined by the 
concentration of agarose that polymerizes into the gel, influences the migration speed. To track the 
migration speed through the gel a loading dye can be added to the sample. To visualize the DNA 
fragments on the gel an intercalating dye, which is fluorescent under UV-light, is added before the gel 
polymerizes. The gel can be documented by taking a photograph during UV light exposure. 
Agarose gel electrophoresis was performed by dissolving 1% [m/v] agarose in 1xTAE buffer by 
heating using a microwave. The agarose solution was gently cooled before the intercalating dye 
GelRed (10.000x) was added to a 1x final concentration. The gel was poured into an electrophoresis 
chamber (Owl Easycast B2 for 100ml gels and PerfectBlue™ gel system Mini L for 50ml gels) using 
differently sized separators and combs to generate the desired number of pockets. After the gel 
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polymerized, the chamber was filled with 1xTAE buffer until the gel was completely covered. The 
separators and the comb were removed to allow the pockets to fill with buffer and the gel was 
arranged in direction of the electric field. The pockets were loaded with 1µg DNA or PCR product 
dissolved in 12µl DNase- and RNase-free water containing 1x DNA Loading dye (6x TriTrack DNA 
loading dye). Ready-to-use GeneRuler DNA ladder mix was loaded as molecular marker. A power 
supply was attached to the chamber and 100V were applied for ~90min until the tracking bands of the 
loading dye reached the last centimeter of the gel. The gels were imaged and analyzed (Annex, 
Supplementary Figure S1). 
3.2.2.6 Purification of DNA from agarose gels 
To isolate specific DNA fragments, the respective bands in an agarose gel were excised and the DNA 
purified using the peqGOLD Gel Extraction. The kit uses the principle of DNA-binding silica-gel 
membrane columns, as described for isolation of genomic DNA. All steps were performed as 
described in the manufacturer’s protocol. 
In brief, specific bands were cut with a scalpel from the agarose gel under UV light. The slice was 
transferred into a reaction tube and weighed. The equal volume [V/M] of binding buffer was added 
and the mix was incubated for 7min at 60°C on a shaking Thermomixer until the gel completely 
melted. To accelerate melting, the tube was vortexed after 3min. The pH value of the mix was 
monitored by controlling the color of the pH indicator in the buffer. If the color changed to orange or 
red, pH was adjusted by adding 5µl 3M sodium acetate (pH 5) until the indicator turned yellow. If 
necessary, 750µl aliquots of the DNA gel mix were loaded onto PerfectBind DNA Columns in 
collection tubes. The columns were centrifuged for 1min at 10,000x g and the flow-through was 
discarded. The membrane-bound DNA was washed with 750µl CG Wash buffer and centrifuged as 
before. Again, the flow-through was discarded and the column dried by centrifugation. The column 
was placed in a reaction tube and the DNA was eluted from the column by adding 30-50µl elution 
buffer and centrifugation for 1min at 5,000x g. The yield was determined by measuring the DNA 
concentration as described before. Purified DNA fragments were stored at -20°C. 
3.2.2.7 Purification of DNA from PCR products 
The components of the PCR reaction mix can interfere with downstream applications such as 
sequencing or subsequent PCR. To purify the PCR product from chemicals, enzyme and primers 
contained in the PCR reaction mix, the QIAquick PCR Purification Kit was used. The principle of this 
kit is comparable with the DNA extraction kit. The method was performed according to 
manufacturer’s protocol. Briefly, five volumes of PB buffer were added to the PCR sample and the pH 
checked by color indication. If the color changed to orange or violet the pH was adapted by adding 
10µl of 3M sodium acetate (pH 5) until it turned yellow again. The sample solution was loaded on a 
spin column and centrifuged at 17.900x g for 1min. As the DNA was bound to the membrane, the flow 
through containing the contaminants was discarded. To wash the bound DNA 750µl PE buffer were 
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applied and the column was centrifuged again for 1min. The flow-through was discarded and the 
column was dried by 1min centrifugation to remove residual ethanol. The column was placed in a 
reaction tube and the DNA was eluted from the column by incubating the sample for 1min in 30µl 
elution buffer or water and finally centrifuging for 1min. The DNA concentration was measured on 
NanoDrop instruments as described. Purified PCR products were stored at -20°C. 
3.2.2.8 Sequencing of HPV16 E6 and E7 genes 
The products of PCR with template DNA from HPV16
+
 cell lines and HPV16 E6- and E7-specific 
primers were sequenced by GATC Biotech (Konstanz). The concentration of PCR products was set to 
100ng/µl and 20µl of the samples were sent for sequencing with company-provided T7 primers.  
3.2.2.9 Analysis of HPV16 E6 and E7 sequences 
The nucleotide sequences for HPV16 E6 and E7 obtained from GATC Biotech (Konstanz) were in 
silico translated into protein sequences and compared to the HPV16 E6 and E7 reference sequences. If 
amino acid changes were detected, they were compared to the known changes in HPV16 sublineages 
to determine the HPV variant present in the respective HPV16
+
 cell line (Burk et al., 2013). 
3.2.3 Cell culture methods 
All cell culture methods were performed under sterile conditions in a laminar flow hood. Required 
equipment was sterilized by autoclaving or disinfected with ethanol. Cell culture solutions were 
sterilized by autoclaving or filtering through membrane filters with 0.22µm pore size. Consumables 
and basic cell culture medium and supplements were purchased sterilely packed. Cell lines were tested 
regularly to authenticate their identity and to rule out contamination with mycoplasma species, 
Squirrel monkey retrovirus (SMRV), EBV and cross-contamination with other cells (Multiplexion 
GmbH, Friedrichshafen). If not specifically mentioned otherwise, all centrifugations described for cell 
culture methods were performed for 5min at 350x g and RT. 
3.2.3.1 Thawing and freezing of cells 
Freezing and thawing procedures were carried out swiftly to prevent cell damage from toxic 
concentrations of cryo-protective additives such as DMSO. 
To dilute cells, suspended in freezing medium, immediately after thawing, a 15ml tube was filled with 
9ml pre-warmed cell culture medium. The cells, frozen in cryogenic tubes in a liquid nitrogen tank, 
were quickly thawed in a water bath heated to 37°C. Once the cell suspension had completely melted, 
the cells were transferred to the tube with pre-warmed medium. The cryogenic tube was washed with 
1ml culture medium to collect remaining cells. The cells were re-suspended and centrifuged. The 
supernatant was removed and the cell pellet was re-suspended in 10ml culture medium. The 
suspension was centrifuged again and the supernatant was decanted. The pelleted cells were re-
suspended in medium and seeded into a cell culture flask. Culture flasks were filled with 0.2ml 
medium per cm
2
 surface area (5ml for 25cm
2
, 15ml for 75cm
2
 and 25ml for 125cm
2
) and a maximal 
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cell density of 1x10
6
 cells/ml. After 12-24h or after adherent cells attached to the surface, the medium 
was exchanged (see below). 
For freezing, a cell suspension was centrifuged and supernatant was removed to suspend the cell pellet 
in 1ml freezing medium. For cell lines, freezing medium consisted of the cooled respective culture 
medium supplemented with 10% DMSO. Peripheral blood mononuclear cells (PBMCs) isolated from 
fresh blood or buffy coat preparations from healthy donors were frozen in human AB serum 
supplemented with 10% DMSO. Freezing medium was always freshly prepared. Cells were re-
suspended in a density ranging from 1x10
6
 to 1x10
8 
per ml and transferred into cryogenic tubes. The 
tubes were placed in a cell freezing container. Transferred into a -80°C freezer, the freezing container 
achieves consistent cooling of -1°C/min to prevent formation of intracellular ice crystals during 
cryopreservation. The frozen cryogenic tubes were transferred into a liquid nitrogen tank for long-term 
storage after a minimal period at -80°C of 4h. 
3.2.3.2 Culturing and passaging of cells 
Cell lines were cultured in a cell culture incubator providing a temperature of 37°C, a concentration of 
5% CO2 and 95% relative humidity. To contain cells, different sterile plastic consumables such as 
culture flasks (25cm
2
, 75cm
2
 and 125cm
2
) and well-plates (6-, 12-, 24-, 48- and 96-well plate formats) 
were used. Flasks were placed horizontally to culture adherent cells and vertically to culture 
suspension cells. Cells were monitored for cell layer growth and color of medium. The pH indicator in 
medium changes the color form pink to yellow as acidic metabolites change the pH. This reflects the 
consumption of nutrients in the medium. If adherent cells were not confluent when the color changed, 
the used medium was replaced with fresh. When adherent cells reached 80-100% confluency and 
when medium of suspension cells turned yellow, cultures were passaged. Passaging describes 
subculturing of cells to maintain or expand the cells in culture. Thus, cells are harvested and placed in 
fresh pre-warmed culture medium. Cell culture flasks were exchanged after three (adherent cells) to 
five (suspension cells) passages at the latest. 
For harvesting adherent cells the used medium was removed and cells were washed with 1xPBS to 
remove residual medium and calcium and magnesium ions. The cell layer was treated with 
trypsin/EDTA (0.04%/0.03%) solution and incubated at 37°C for several minutes until all cells 
rounded up and detached upon tapping the flask. The enzyme reaction was stopped by adding fresh 
culture medium. Cells were re-suspended and transferred into a 50ml test tube. After the suspension 
was centrifuged, the supernatant was discarded and the pellet re-suspended in fresh medium. A 
subculture of 1:2 to 1:10 or a defined number of cells was seeded into fresh cell culture flasks. 
Suspension cells were harvested by removing the used medium containing the cells. The suspension 
was transferred into a 50ml test tube and centrifuged as described for adherent cells. The cell pellet 
was re-suspended and a subculture of 1:2 to 1:20 or a defined number of was seeded into culture flasks 
containing fresh medium. To expand suspension cells, the same volume of fresh medium was added to 
the culture without passaging. As the suspension cells B-lymphoblastoid cell lines (B-LCLs) naturally 
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form aggregates, cultures were carefully shaken every other day to isolate cells and ensure supply with 
medium. 
3.2.3.3 Counting of cells 
Cells were counted using automated cell counters. The suspension of harvested cells was diluted in 
1xPBS or in culture medium. To measure cell concentration with the Countess, diluted cells were 
stained with the same volume trypan blue stain (0.4%) and 10µl were loaded onto counting chamber 
slides. The slides were pushed into the slit of the instrument. The display showed the cells of an area 
of 1mm
2 
in the middle of the slide. The view was focused and cells were automatically counted. The 
instrument returns the concentration of live and dead cells in the sample, calculated as cells/ml in the 
measured dilution. Viable cells were discriminated based on the exclusion of trypan blue stain by an 
intact cell membrane. The accuracy of the automated counting is dependent on the focal plane that was 
manually adjusted. To achieve more accurate counting results, the Nucleo Counter NC-200 was used. 
Diluted cells were loaded into a specialized cassette on which the fluorophores acridine orange and 
4′,6-diamidino-2-phenylindole (DAPI) were immobilized. In contact with cells, acridine orange as 
cell-permeable dye stains all cells giving a total cell count whereas DAPI, that passes membranes less 
efficiently, stains mainly dead cells. After loading the cassette with approximately 60µl cell dilution 
the cassette was immediately inserted and counted. The instrument returns the concentration of living 
and dead cells in cells/ml. After measurements with both instruments, the cell concentrations were 
multiplied with the respective dilution factor. 
3.2.4 Cellular assays 
If not specifically mentioned otherwise, all centrifugations described for cellular assays were 
performed for 5min at 350x g and RT. 
3.2.4.1 Flow cytometry 
Flow cytometry is used to measure the frequency of cells that have a specific property that is 
highlighted by a fluorescence signal. This feature is also called fluorescence activated cell scanning 
(FACS). The fluorescence can be acquired by genetic modification resulting in expression of a 
fluorescent protein or by labelling with a fluorescently conjugated ligand. A stained single cell 
solution is measured on a FACS instrument. Each cell passes one or more laser beams of different 
wavelengths. The light of the laser is scattered by the cells based on their properties and it excites the 
fluorescent dyes that emit light of a different wavelength. Forward scatter (FSC) is influenced by cell 
size and sideward scatter (SSC) is based on cell granularity. The emitted light is filtered and collected 
based on its wavelength and the amount of collected photons is used to calculate the fluorescence 
signal. After scanning the cells are usually discarded but the FACS principle can also be used to sort 
cells into tubes or plates. 
To measure cells on a flow cytometer, they were fluorescently labelled as described for the specific 
assays and washed with FACS buffer at least once. Cells were centrifuged and the supernatant was 
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discarded. Washed cells were fixed in a solution of 1% PFA/PBS for 15min at 4°C. After fixation, 
cells were washed again and finally re-suspended in FACS buffer. If not immediately analyzed, the 
cells were kept at 4°C for a maximum of 2 days. For each assay, autofluorescence of cells was 
determined by measuring unstained cells. If necessary the voltages of photomultipliers of different 
fluorescence channels were adjusted based on single color staining. Based on FSC and SSC 
characteristics, cell subpopulations were gated and analyzed for fluorescence signals. Flow cytometry 
was performed on a FACS Canto II instrument with FACS Diva software provided by the DKFZ flow 
cytometry core facility, or on an Accuri C6 equipped with the CSampler accessory kit and respective 
operating software provided by the division of Chronic Inflammation and Cancer (F180). The obtained 
flow cytometry data was analyzed using Flow Jo V10 software. 
3.2.4.2 Competition-based peptide-HLA binding assays 
Peptides were synthesized with >95% purity by the GMP unit of the DKFZ (D210) using the F-moc 
strategy in a fully automated multiple synthesizer and the product was characterized by analytical 
HPLC and MS (Merrifield, 1963; Carpino and Han, 1972). After delivery of the lyophilized peptides 
they were stored at -20°C until they were dissolved in DMSO in a concentration of 10mg/ml, 
aliquoted and frozen at -80°C for long-term storage. 
HPV16 E6- and E7-derived peptides were assessed for their binding affinity to selected HLA types in 
competitive cellular binding assays as previously described (Kessler et al., 2003, 2004). The principle 
of this assay is based on the competition for binding to specific HLA molecules between a test peptide 
and a fluorescently labeled reference peptide with known high binding affinity. The reference peptide 
is labelled with fluorescein isothiocyanate (FITC) coupled to a cysteine in the sequence. B-LCLs 
expressing the HLA type of interest were cultured and expanded and the test peptides were purchased 
and prepared as described. Peptides known to be ligands were chosen as positive controls and known 
nonbinders were negative controls. 
On a U-bottom 96-well plate, control and test peptides were titrated in 1xPBS in a 1:2 dilution series 
in 8 steps ranging from 600-4.69µM. On a second plate 25µl of 900nM fluorescently labeled reference 
peptide in 1xPBS were distributed. Using a multichannel pipette, 25µl of the titrated test and control 
peptides were transferred from the titration plate to the second plate. This incubation plate was stored 
at 4°C. In the meantime, B-LCLs were harvested and counted. A minimum of 6x10
4
 cells was needed 
per well. The required amount of cells was transferred into a 15ml test tube and washed twice with 
1xPBS centrifuging at 400x g. One tube was used for a maximum of 1.5x10
7
 cells. After washing, the 
cell pellet was loosened by tapping of the tube and the cells were rested on ice for 5-10min. To strip 
the cells from their bound endogenous peptides, they were treated with ice cold elution buffer with 
HLA specific pH (see Table 7) for exactly 90s. Instantly, the treated cells were washed twice with 
culture medium and centrifugation at 400x g. The cell pellet was re-suspended in culture medium 
supplemented with 2µg/ml β2-microglobulin to reconstitute the HLA class I complex. Finally, 100µl 
of the stripped cells were added to each wells with peptide mix and incubated over night at 4°C. The 
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next day, the fluorescence of cells was measured by flow cytometry using the Accuri C6 instrument. 
The B-LCLs were gated and mean fluorescence intensity (MFI) in the FITC channel was analyzed. 
Background and maximum fluorescence were measured from cells incubated without any added 
peptide and with only reference peptide, respectively. To determine the binding affinity of peptides, 
the MFI data was analyzed statistically (see Binding affinity calculation based on IC50). 
Table 7. HLA-alleles expressed by B-LCLs and required pH of elution buffer. 
B-LCL HLA class I alleles Elution buffer [pH] 
1341-8346 A*02:01; B*07:02; C*15:01 3.1 
BSM A*02:01; B*15:01; C*04:01 3.1 (HLA-A) and 2.9 (HLA-B) 
E481324 A*01:01; B*52:01; C*12:02 3.1 
EA A*03:01; B*07:02; C*07:02 2.9 (HLA-A) and 3.1 (HLA-B) 
FH8 A*11:01, A*34:02; B*82:01, B*27:05; C*03:02, C*01:02 3.1 
LKT3 A*24:02; B*54:01; C*01:02 3.1 
Bold: HLA-alleles of interest 
3.2.4.3 Peripheral blood mononuclear cell (PBMC) isolation 
Blood cells that have a round-shaped nucleus are referred to as PBMCs. They contain lymphocytic 
cells as well as monocytes and DCs and are therefore critical components of immunological assays. 
Human PBMCs are frequently isolated from different sources such as whole blood, buffy coats, buffy 
cones, leukapheresis products, cord blood or bone marrow. 
In this study, PBMCs were isolated either from fresh human blood samples or from buffy coats 
purchased from the DRK blood transfusion service Mannheim via the IKTZ Heidelberg. In both cases, 
blood was drawn from voluntary healthy blood donors after their written informed consent. The 
isolation of PBMCs using density gradient centrifugation was performed under sterile conditions. 
To create a density gradient, Ficoll-Paque™ PLUS was used. To prepare for PBMC isolation, Ficoll 
was equilibrated to RT and 15ml were distributed to leucosep tubes. The tubes were centrifuged for 
1min to have the Ficoll layer below the porous membrane in the tubes. The blood sample was diluted 
with 1xPBS 1:1 (fresh whole blood) or 1:5 (buffy coat) and up to 35ml diluted blood was distributed 
to each prepared leucosep tube. Next, the tubes were centrifuged using different conditions for whole 
blood or buffy coats (see Table 8). After initial separation, the blood fractions formed layers from top 
to bottom consisting of yellow serum and opaque white PBMCs above the membrane and clear Ficoll 
and a pellet of granulocytes and erythrocytes below the membrane. The serum was removed as far as 
possible without disturbing the PBMC layer. The remaining liquid above the layer from two leucosep 
tubes was collected in a 50ml tube, which was filled with 1xPBS up to 50ml to perform an initial wash 
step. After centrifugation, the supernatant was discarded and the cell pellet was inspected. If the pellet 
contained erythrocytes, e.g. stemming from aggregated cells that did not pass the porous membrane, 
red blood cell lysis was performed. To do so, cells were treated with 5ml ACK lysis buffer for 5min. 
This leads to ammonium diffusing through the cell membranes and establishing an equilibrium with 
ammonia, generating free OH
-
 ions. These OH
- 
ions are consumed by reacting with CO2 to HCO3
- 
that 
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is exchanged against Cl
-
 through a specific membrane transporter, a feature of red blood cells. The net 
influx of NH4Cl leads to swelling of these cells until they finally burst from osmotic pressure. After 
ACK treatment, the tube was filled up to 50ml with 1xPBS and washed twice. During these wash 
steps, two tubes were combined into one. Finally, one tube per donor remained. The pellet was re-
suspended in 50ml 1xPBS and cells were counted. The tube was centrifuged again and the pelleted 
cells were immediately used or prepared for cryopreservation. 
Table 8. Centrifugation conditions for fresh whole blood and buffy coat. 
Centrifugation step Whole blood Buffy coat 
1 – PBMC separation 260x g, 10min, RT, acc 9/9, dec 0/9 600x g, 25min, RT, acc 5/9, dec 0/9 
2 – initial wash 260x g, 10min, RT, acc 9/9, dec 9/9 300x g, 15min, RT, acc 9/9, dec 5/9 
3 – two repeated washes 260x g, 5min, RT, acc 9/9, dec 9/9 300x g, 10min, RT, acc 9/9, dec 9/9 
4 – final centrifugation 260x g, 5min, RT, acc 9/9, dec 9/9 300x g, 5min, RT, acc 9/9, dec 9/9 
acc: acceleration, dec: deceleration 
3.2.4.4 HLA-type screening of PBMCs using flow cytometry 
As buffy coats are typically not HLA-typed, flow cytometry was used to perform a quick screening of 
the HLA type of PBMC donors. Commercially available HLA type-specific antibodies with coupled 
fluorophores were purchased and stored at 4°C. Handling antibodies, all centrifugations and 
incubations were performed at 4°C and cold FACS buffer was used for washings. Specificity of 
antibodies and optimal dilutions were determined on B-LCLs of known HLA-type (Table 9). 
For HLA type screening, aliquots of 1x10
6
 PBMCs per donor were frozen as described (see  Thawing 
and freezing of cells) directly after isolation from buffy coats. After isolating PBMCs of up to 8 
donors, the aliquots were thawed and the cells were prepared In a V-bottom 96-well plate, 5x10
5
 
cells/well were seeded and washed. After discarding the supernatant, cells were re-suspended in 
staining dilutions consisting of antibody diluted in FACS buffer. Specificity of α-HLA antibody 
signals were controlled with unspecific isotype control antibodies coupled to the same fluorophore to 
exclude unspecific antibody binding via the Fc-receptor. Cells were incubated with staining dilutions 
for 25min in the dark. After incubation, cells were washed twice and fixed in 1% PFA in 1xPBS for 
10min at 4°C in the dark. Fixed cells were washed again and finally re-suspended in 100µl FACS 
buffer for flow cytometry using the Accuri C6 instrument. Background fluorescence was determined 
on unstained cells. 
Table 9. Antibody dilutions used in HLA type screenings of PBMCs isolated from buffy coats. 
Specificity Fluorophore Isotype Working dilution 
α-HLA A2 FITC IgG2b 1:400 
α-HLA A24 FITC IgG2b 1:400 
- (control) FITC IgG2b 1:200 
α-HLA A3 APC IgG2a 1:200 
- (control) APC IgG2a 1:200 
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α-HLAB7 PE IgG1 1:200 
- (control) PE IgG1 1:200 
3.2.4.5 Generation of epitope-specific T cell lines 
A substantial amount of T cells is needed to investigate immunogenicity of the many HPV16 E6 and 
E7 peptides. Therefore, T cells from PBMCs of healthy donors were expanded in peptide-specific T 
cell lines to allow memory T cells to develop effector function. T cells were expanded in short-term 
cell lines for the use in IFNγ-ELISpot assays and in long-term cell lines for the use in Vital-FR 
cytotoxicity assays. All cell culture steps were performed under sterile conditions as explained in the 
section Cell culture methods. 
3.2.4.6 Generation of short-term epitope-specific T cells lines for cultured IFNγ-ELISpot 
assays 
Short-term epitope-specific T cell lines were generated from isolated PBMCs of healthy blood donors 
(Figure 11). After thawing, the isolated cells were washed in T cell medium. Cells were centrifuged, 
the supernatant discarded and the cells re-suspended in T cell medium for counting. The suspension 
was set to a cell concentration of 1x10
6
cells/ml. Per test condition, one well of a 24-well plate was 
filled with 1ml T cell medium supplemented with 20ng recombinant human interleukin-7 (rhIL-7, 
final concentration in test 10ng/ml). Test epitopes were thawed and added to the wells. Next, the cell 
suspension was added to each well á 1ml per well per condition. The final concentrations of test 
epitopes was 10µg/ml peptides, 1:1000 diluted solvent (DMSO) served as unspecific negative control 
and 1:400 diluted CEF peptide pool as specific positive control. A T cell line to an immunologically 
foreign HLA-specific control peptide was added as epitope-specific negative control. 
The plates were covered with cling film and incubated. At the third day of culture, cells were fed with 
20U/ml rhIL-2. To this end, 4000U/ml rhIL-2 was supplemented to T cell medium and 10µl were 
added to each T cell line. Feeding was repeated at the seventh day of culture. If the medium turned 
yellow, a half-medium change was performed: T cell lines were re-suspended and centrifuged, 1ml 
(half) of the supernatant was discarded and replaced with 1ml fresh medium supplemented with 40U 
rhIL-2, and cells were re-suspended again. On the twelfth day of culture, cells were harvested and used 
for setting up IFNγ-ELISpot assays. 
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Figure 11. Schedule for generating short-term peptide-specific T cell lines. PBMCs were incubated with 
rhIL-7 and peptide to stimulate peptide-specific T cells. The T cells were fed twice with rhIL-2 to promote 
differentiation of memory T cells into effector T cells. After twelve days, T cell lines were harvested and used in 
INFγ-ELISpot assays. 
3.2.4.7 Generation of long-term epitope-specific T cell lines for Vital-FR cytotoxicity assays 
Long-term T cell lines were generated from isolated PBMCs of healthy blood donors with the aim to 
expand present memory T cells with specificity to a HPV16 E6-/E7-derived peptide (Figure 12). 
Cytotoxicity assessment was only performed with PBMCs from donors, which showed memory 
responses to specific epitopes in IFNγ-ELISpot assays. The generation of epitope-specific T cell lines 
requires repeated stimulation by autologous APCs. DCs are potent APCs that can activate naïve and 
memory T cells. The number of DCs in a blood sample can be increased by in vitro differentiation of 
the more plentiful monocytes resulting in so called mo-DCs or MDDCs (Feuerstein et al., 2000; 
Steinman, 1991). Therefore, prior to starting the T cell lines, an aliquot of donor PBMCs was thawed 
and used for isolation of monocytes. Monocytes were isolated by exploiting their ability to adhere to 
plastic. 
In brief, thawed PBMCs were washed in 1xPBS, centrifuged and supernatant was discarded. The 
pellet was re-suspended in DC medium, cells were counted and cell density was set to 5x10
6
 cells/ml. 
In a 6-well plate, 1x10
7 
cells/well were seeded and incubated for 3h. After incubation, the supernatant 
of the cells was removed and attached cells were gently washed twice with DC medium. All 
supernatant was collected as it contained all non-adherent lymphocytes. The adherent monocytes were 
supplied with 2ml DC medium supplemented with 1000U/ml GM-CSF and 500U/ml rhIL-4 and 
cultured for 6 days with a 500µl medium feeding on day 3. Thereby, monocytes differentiated into 
immature DCs. To mature DCs a stimulating cocktail consisting of 1000U/ml TNF-α, 10ng/ml rhIL-
1β, 10ng/ml rhIL-6, 1µg/ml PGE2 and 1U/ml LPS was added (Jonuleit et al., 1997; Feuerstein et al., 
2000). After 36-48h, the adherent matured DCs were harvested by gently scraping the bottom of the 
well with a cell scraper before transferring the suspension into a 50ml tube. Wells were washed twice 
with DC medium to collect any remaining cells. The cells were washed in serum-free DC medium, 
counted and set to a density of 1x10
6
 cells/ml serum-free DC medium. To pulse DCs with peptide, 1ml 
of the cell suspension was transferred into a 15ml tube and 10µg/ml peptide was added. One tube per 
test peptide was prepared and incubated for 3h with loose tube lid. During incubation, tubes were 
gently shaken every hour. The pulsed DCs were washed in DC medium, centrifuged and the 
supernatant discarded. The cell pellet was re-suspended in T cell medium supplemented with 10ng/ml 
rhIL-7 to be used for stimulation of T cells in a ratio of 200-50:1 (T cells/DCs). 
d12d7d3d0
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The generation of a T cell line starts at the harvest day of the first generation of autologous DCs which 
is also the starting day of a second autologous DC generation. The collected supernatant of the 
monocyte isolation containing the non-adherent lymphocytes was used to set up T cell lines. The cell 
suspension was centrifuged and supernatant was discarded. The cell pellet was re-suspended in T cell 
medium and cells were counted. Cells were centrifuged again and the pellet was re-suspended in T cell 
medium supplemented with 10ng/ml rhIL-7 to set a cell density of 1x10
7
 cells/ml. In a well of a 24-
well plate, 1ml T cell suspension was seeded and 1ml pulsed DCs of the first generation were added to 
set a T cell/DC ratio of 200:1 or better (usually up to 50:1). The T cells were incubated and fed with 
50U/ml rhIL-2 every second day. This feeding was performed as half-medium change as described for 
short-term T cell lines. By the eighth day of T cell culture, the second generation of autologous DC 
were matured, pulsed and used for a second stimulation of the T cells as described. The T cell line was 
harvested after 14 days of culture and used for Vital-FR cytotoxicity assays. 
 
Figure 12. Schedule for generating long-term epitope-specific T cell lines. PBMCs isolated from the blood of 
healthy donors were used to generate long-term epitope-specific T cell lines. Prior to starting the T cell culture, 
autologous monocytic cells were derived by adherence. The monocytic cells were cultured in the presence of 
GM-CSF and rhIL-4 to promote differentiation into DCs. Two days before starting the T cell lines, DCs were 
maturated by adding a cocktail containing TNFα, IL-1β, IL-6, PGE2 and LPS. The matured DCs were harvested 
and pulsed with the respective specific epitope. Pulsed DCs were used to stimulate PBMCs in the presence of 
rhIL-7 for the generation of long-term epitope-specific T cells lines. The used PBMCs were depleted for naïve 
DCs as the same aliquot was used to derive monocytic cells to start a second DC culture at the same time. The T 
cells were fed with rhIL-2 every other day to promote proliferation of effector T cells. At day eight, a second 
stimulation of T cells was performed with matured pulsed DCs. After 14 days of cultivation, the T cell line was 
harvested and used in Vital-FR cytotoxicity assays. 
3.2.4.8 IFNγ-ELISpot assay  
The ELISpot assay is a sensitive technique that allows qualitative and quantitative assessment of 
immune cells secreting a certain protein. Antibodies to that target protein are coated on a membrane 
and capture the secreted specific target. A different antibody coupled to an enzyme binds to the very 
same target. Added substrate is processed by the coupled enzyme and stains the membrane with a 
colored precipitated product. Thereby, every cell secreting the target protein can be traced by a spot on 
PBMC
isolation
d-8 d-5 d-2 d0
+rhIL-4
+GM-SCF
+rhIL-4
+GM-SCF DC
maturation
Test epitope
pulsing
Monocytes
d0 d3 d6 d8
+rhIL-4
+GM-SCF
+rhIL-4
+GM-SCF DC
maturation
Test epitope
pulsing
Monocytes
d0 d2 d4 d6 d8 d10 d12 d14
+rhIL-2 +rhIL-2 +rhIL-2 +rhIL-7 +rhIL-2 +rhIL-2+rhIL-7
PBMCs
(-monocytes)
Cytotoxicity
assays
+DCs +DCs
Materials and Methods 
 
 
59 
the membrane. An ELISpot assay assessing IFNγ secretion can detect CD4+ helper T cells, specifically 
Th1, and CD8
+
 cytotoxic T cells that recently recognized specific epitopes via the TCR (Schoenborn 
and Wilson, 2007). 
One day prior to setting up an ELISpot assay, the required amount of mixed cellulose ester plates were 
coated with 100µl of 2µg/ml IFNγ-capture antibody in sterile 1xPBS. The plate was sealed with 
Parafilm and incubated over night at 4°C. The next day, the antibody dilution was discarded and the 
membrane plates were washed three times with sterile 1xPBS. To reduce unspecific binding, the 
coated plates were blocked with ELISpot medium for 1h in a cell culture incubator. Epitopes were 
added to 1ml ELISpot medium and 100µl of the epitope dilution was distributed to the wells. 
Additionally to the HPV16 E6- and E7-derived peptides (10µg/ml final concentration) tested in 
sextuples, control conditions were added in triples. Solvent (DMSO, 1:1000 final dilution) was added 
as unspecific negative control and mitogen (Concanavalin A (ConA), 2µg/ml final concentration) was 
used as unspecific positive control for each short-term epitope-specific T cell line tested, to determine 
background activation and general IFNγ-secretion capacity. The T cell lines were re-suspended and 
1x10
5
 cells were added per well. The plates were incubated for 20-26h without moving them, to 
prevent formation of blurred spots. The next day, plates were washed twice with 1xPBS and twice 
with TPBS, which removes all cells. After each washing, plates were dragged over paper towels to 
remove liquid. Biotinylated α-human IFNγ antibody was diluted 1:1000 in sterile PBS and 100µl 
antibody solution was distributed to each well. Plates were covered with aluminum foil and incubated 
for 2h at room temperature. Next, plates were washed with TPBS four times and dried. Streptavidin-
ALP was diluted 1:2000 in sterile PBS and 100µl were dispensed per well. Again, plates were covered 
and incubated for 1.5h at room temperature. In the meantime, the NBT/BCIP substrate solution was 
equilibrated to room temperature. Directly before use, the substrate was filtered through a 0.22µm 
filter to remove precipitates. The plates were washed with TPBS four times and dragged over paper 
towels. The filtered substrate solution was distributed á 100µl/well and incubated at room temperature 
for 15-20min until spots developed on the membrane. The reaction was stopped by washing both sides 
of the membrane with tap water. The plates were air dried overnight and stored until analysis with the 
CTL-Immunospot S6 Ultra-UV analyzer. The operation software was used to scan and automatically 
count spots and to perform quality control. Automated counting allowed reducing subjectivity by 
setting spot morphology parameters applied to each well of the same donor. Quality control was used 
to exclude artefacts from counting, such as fiber, strong background staining or damaged membrane. 
Raw data resulting from scan, count and quality control were saved and analyzed as described below. 
3.2.4.9 Magnetic-activated cell sorting (MACS) 
To specifically analyze CTLs, T cell lines were sorted using MACS to isolate CD8
+
 T cells. The CD8
+
 
T cell isolation Kit was used with LS columns and the QuadroMACS according to manufacturer’s 
instructions. During the whole MACS procedure, cells were kept cold and pre-cooled (4°C) magnets 
and solutions were used. 
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The T cell lines were prepared and the cell number was determined. Cells were washed in 1xPBS and 
after centrifugation the supernatant was carefully removed without disturbing the pellet. Per 1x10
7
 
cells, the pellet was re-suspended in 40µl MACS buffer and 10µl Biotin-antibody cocktail was added. 
This cocktail contained biotin-conjugated monoclonal antibodies to CD4, CD15, CD16, CD19, CD34, 
CD36, CD56, CD123, TCR γ/δ and CD235a. The cell suspension was mixed and incubated at 4°C for 
5min. After incubation, 30µl MACS buffer and 20µl CD8
+
 T cell microbead cocktail were added per 
1x10
7
 cells. The microbead cocktail contained magnetic microbeads conjugated to monoclonal 
antibodies to CD14, CD61 and biotin. Cells were mixed and incubated for 10min at 4°C. Non-target 
cells (CD4
+
 T cells, monocytes, neutrophils, eosinophils, B cells, stem cells, DCs, NK cells, 
granulocytes, γ/δ T cells and erythroid cells) were magnetically labelled, whereas CD8+ T cells 
remained untouched. The volume was filled up to 500µl with MACS buffer. A LS column was placed 
into the magnetic field of the QuadroMACS and equilibrated by rinsing with 3ml MACS buffer. The 
buffer was collected and discarded. The collection tube was replaced and the cell suspension was 
applied onto the column. The flow-through containing the enriched CD8
+
 T cells was collected. The 
columns were washed three times with 3ml MACS buffer and flow through was combined with the 
effluent. As the non-target cells were not required for any experiment the LS column was discarded. 
The collected suspension was centrifuged and the supernatant discarded. The CD8
+
 T cells were re-
suspended in medium and counted for further use in Vital-FR cytotoxicity assays. 
3.2.4.10 Vital-FR cytotoxicity assay 
The Vital-FR assay is a flow cytometry based assay developed by Stanke et al. (Stanke et al., 2010). It 
was designed for limited sample size and increased sensitivity in analysis of antigen-specific CTL-
mediated cytotoxicity. In contrast to typical cytotoxicity assays, the effector cells are co-cultured in the 
presence of specific and unspecific target cells that are labeled with different fluorophores. Thereby, 
the number of effector cells can be decreased and killing of target cells can be measured by flow 
cytometry.  
For studying cytotoxicity to HPV16
+
 cervical carcinoma cells, the HLA-A2
+
 HPV16
+
 cell line CaSki 
was chosen as specific target, whereas HLA-A2
+
 HPV16
-
 C33A cells were selected as unspecific 
targets. One day prior to setting up the Vital-FR assay, the specific and unspecific target cells were 
harvested and counted. In a 50ml tube, 1x10
6
 cells in 1ml plain RPMI were stained with fluorescent 
dyes. The specific target cells, presenting the cognate peptide, were labeled with CFSE in a 
concentration of 5µM, and unspecific target cells, presenting irrelevant peptide, were labeled with 
0.25µM FarRed. The cells were incubated for 10min in a 37°C water bath and shaken every 3min. The 
tubes were filled up to 50ml with RPMI 10% FCS and centrifuged. The supernatant was discarded, 
cells were re-suspended in 15ml of their respective medium and cultured in T75 cell culture flasks 
until needed. The next day, target cells were harvested and re-suspended in T cell medium 
supplemented with 10U/ml rhIL-2 at a concentration of 6x10
4
 cells/ml. If the number of CD8
+
 T cells 
was low, target cells were diluted to a minimal concentration of 4x10
4
 cells/ml. The long-term epitope-
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specific T cell lines were harvested and CD8
+
 T cells were isolated using MACS as described above. 
Isolated CD8
+
 T cells were counted and re-suspended in T cell medium supplemented with 10U/ml 
rhIL-2. A 1:2 dilution series of CD8
+
 T cells was prepared in order to set effector:target ratios from 
minimally 40:1 - 1.25:1 to maximally 100:1 – 3.13:1. The T cells were dispensed in 100µl/well of a 
48-well plate. Per well, the same number of specific and unspecific target cells were added; 3000 
down to 2000 cells/well. Additionally, a sample of target cell co-culture without effector cells was 
prepared to determine the ratio between specific and unspecific target cells after incubation for 48h. 
One day after setting up the Vital-FR assay, cells were carefully re-suspended by pipetting a volume 
of 100µl once. After 48h incubation, cells were harvested and transferred into 1.5ml tubes. The wells 
of the 48-well plate were washed with T cell medium and remaining cells were collected in the 
respective reaction tubes. In case of adherent cells, the supernatant, the PBS wash and the trypsinized 
cells were collected. The cells were pelleted by centrifugation and supernatant was discarded. The 
cells were fixed with 1% PFS in PBS for 10min at 4°C in the dark. The fixed cells were washed with 
FACS buffer and re-suspended in 100µl FACS buffer for flow cytometry using a FACS Canto II with 
FACS Diva software. Single cultures of CFSE- and Far Red-labelled cells were used for 
compensation. Flow cytometry data of Vital-FR assays was analyzed using Flowjo V10. First, a time 
gate was set that excluded the last seconds of cell acquisition in order to avoid unspecific cell counts 
resulting from emptying samples. Next, the target cells were gated based on FSC and SSC properties. 
On this population, the cell counts for CFSE
+
 and FarRed
+
 cells were determined based on respective 
negative single stained control samples. 
3.2.4.11 Assessment of intracellular cytokine production of PBMCs 
The production of cytokines is a surrogate marker for T cell activation. CTLs intracellularly store the 
cytotoxin granzyme B in granules and further produce IFNγ and/or TNFα upon antigen stimulation. 
Inhibition of the Golgi apparatus-mediated cytokine secretions keeps the cytokines in the cell. 
Permeabilization of the cell membrane allows fluorescently-labeled antibodies to enter the cell and to 
stain intracellular cytokines. Thus, activated T cells can be quantified. Additionally, antibodies to 
surface markers allow investigation of distinct T cell subsets, such as CD8
+
 CTLs. 
To compare activation of freshly isolated and frozen PBMCs, 2x10
6
 cells per sample were stimulated. 
A mix of 10ng/ml PMA and 1mg/ml ionomycin is used to stimulate response in all T cells, as these 
compounds diffuse through the T cell membrane and directly induce intracellular signaling cascades 
involved in proliferation and cytokine production. Frozen PBMCs were additionally stimulated with 
CEF peptide pool and the E6/25-33 epitope (both at 10µg/ml final concentration) to test epitope-
specific activation. PBMCs were incubated in 200µl GolgiStop solution from the BD 
Cytofix/Cytoperm Kit under cell culture conditions. After 5h, cells were centrifuged at 4°C and 
supernatant was discarded. The cell pellet was stained in 50µl staining buffer containing 1:200 diluted 
Zombie Aqua dye for dead cell exclusion and the fluorescently-labeled antibodies for cell surface 
antigens listed in Table 10. Cells were incubated for 30min at 4°C in the dark. Subsequently, cells 
Materials and Methods 
 
 
62 
were washed three times in a total volume of 200µl staining buffer with all centrifugation steps carried 
out at 4°C. Cells were re-suspended in 100µl fixation/permeabilization solution of the BD 
Cytofix/Cytoperm Kit and incubated for 10min at 4°C. Next, cells were washed three times at 4°C in a 
total volume of 200µl Cytofix/Cytoperm Kit wash buffer. Supernatant was discarded and the cell 
pellet was re-suspended in 50µl staining buffer with a mix of the cytokine antibodies (Table 10). After 
30min incubation at 4°C in the dark, cells were again washed three times in 200µl wash buffer. After 
washing, the cell pellet was re-suspended in 200µl flow cytometry fix buffer and measured at the 
FACS Canto II flow cytometer. 
Table 10. Antibody panel for immunophenotyping of PBMCs. 
Antigen Specificity Fluorophore Working dilution 
Cell surface human CD3 PE-Vio770 1:50 
Cell surface human CD4 FITC 1:50 
Cell surface human CD8 PerCP-Cy 5.5 1:50 
Intracellular cytokine human IFNγ APC 1:50 
Intracellular cytokine human TNFα APC-Vio770 1:50 
Intracellular cytokine human granzyme B PE 1:50 
 
3.2.5 Statistical analysis 
3.2.5.1 Binding affinity calculation based on IC50 
The MFI values obtained from flow cytometry of the competitive binding assays were analyzed 
statistically to determine the binding affinity of HPV16 E6- and E7-derived peptides. The cells’ 
background fluorescence was subtracted from all MFI values. The resulting value obtained for every 
test peptide condition was expressed relative to the maximal fluorescence to calculate the percentage 
of reference peptide inhibition (see Equation 2). The relative inhibition (y) was plotted against the test 
peptide concentration (x) (SigmaPlot V13.0, Systat Software). Non-linear regression analysis was used 
to determine the test peptide concentration at which 50% of the reference peptide is inhibited 
(Equation 3). This value is defined as half maximal inhibitory concentration (IC50) and describes the 
binding affinity. Test peptides showing an IC50 ≤100µM were considered HLA ligands, with high 
(≤5µM), intermediate (5< X ≤15µM) and low binding affinity (15< X ≤100µM). Peptides showing a 
binding affinity >100µM were classified as nonbinders. The assay was performed twice for 
nonbinders and at least three times for binders. 
Equation 2. Relative inhibition 
Inhibition [%] = (1 −
MFI(test) − MFI(background)
MFI(max ) − MFI(background)
) × 100 
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Equation 3. Non-linear regression 
𝑦 = 𝑎 +
𝑏
1 + (
𝑥
𝑐)
𝑑
 
a-d: constants in this equation 
3.2.5.2 Performance evaluation of prediction algorithms 
The experimentally determined binding affinities were used to evaluate the prediction performance of 
algorithms. First, tested peptides were sorted from high to low predicted binding likelihoods. Next, 
predictions were assessed to be true (T) or false (F) based on the experimentally validated binding 
affinity. Receiver operating characteristics (ROC) curves were plotted for every prediction method, 
HLA type and peptide length using Prism 7 software. In ROC curves, the rate of true positives (TPR, 
the frequency of true predicted binders among all binders) is shown on the y-axis dependent on the 
rate of false positives (FPR, the frequency of nonbinders falsely predicted to be binders among all 
nonbinders) on the x-axis. Each point on the ROC curve corresponds to a peptide with a discrete 
predicted binding likelihood value. The potential sensitivity and specificity of this value are 
represented by the associated TPR and 1-FPR, respectively. Thereby, the predictors’ capacity to 
discriminate between binders and nonbinders was illustrated and the suitability of thresholds was 
estimated. A perfect prediction method would have a ROC curve with a coordinate of (0;1). 
Consequently, the area under the ROC curve (AROC) would be 1. The AROC is commonly used to 
evaluate and compare prediction methods (Bradley, 1997). For MHC binding prediction algorithms, 
AROC values of ≥0.9 were described to indicate excellent, values of 0.8-0.9 intermediate and <0.8 poor 
performance (Lin et al., 2008). 
By applying thresholds to the predicted binding likelihood, peptides were categorized into predicted 
positives (P, binders) and predicted negatives (N, nonbinders). Based on the experimental assessment 
the predictions were further categorized into true positives (TP), false positives (FP), true negatives 
(TN) and false negatives (FN). The frequencies of these fractions were used to calculate threshold-
specific sensitivity, specificity, accuracy (Equation 4) and positive predictive value (PPV, Equation 5). 
Different thresholds were compared based on these statistics. 
Equation 4. Prediction accuracy 
accuracy =
TP + TN
P + N
 
Equation 5. Positive predictive value (PPV) 
PPV =
TP
TP + FP
 
3.2.5.3 Calculation and validation of criteria-based decision thresholds 
Threshold-specific sensitivity, specificity and accuracy were used to characterize and identify optimal 
decision thresholds for each set of predictor, HLA type and peptide length. Criteria for optimal 
Materials and Methods 
 
 
64 
thresholds were defined by 1) specificity ≥0.66 (FPR ≤0.33, respectively), 2) TPR ≥ 2xFPR and 3) 
highest possible sensitivity within the limits of 1) and 2). Such “criteria-based” thresholds were 
calculated for each set. To statistically validate sensitivity, specificity and accuracy obtained by the 
thresholds, bootstrapping was performed. To do so, the peptide dataset was randomly split into 2/3 
training data and 1/3 test data. From training data, the optimal threshold was determined using the 
described criteria. This optimal threshold was applied to the test data and threshold-specific 
sensitivity, specificity and accuracy were derived. The procedure was repeated 100 times and the 
median optimal threshold as well as the confidence interval for sensitivity, specificity and accuracy 
was calculated based on this bootstrapping. To compare the median optimal threshold to the generally 
used high (IC50 ≤50nM, percentile rank ≤0.5) intermediate (IC50 ≤500nM, percentile rank ≤2) and low 
(IC50 ≤5000nM) binding affinity thresholds, a second bootstrapping was performed. Again, the peptide 
dataset was randomly sampled into 1/3 of test data. The different thresholds were applied to the test 
data, and for each threshold sensitivity, specificity and accuracy were calculated. The differences of 
mean values of 100 resampling runs were compared by one-way ANOVA for repeated measures 
followed by Dunnett’s multiple comparisons test using Prism 7 software. The basic bootstrapping 
algorithm for R software was established by Diana Tichy from the Department of Biostatistics (C060). 
In order to analyze multiple predictors and decision thresholds at the same time, the original 
bootstrapping script was altered by Maria Bonsack. 
3.2.5.4 Comparison of criteria-based and bootstrapping-validated thresholds 
The calculation of bootstrapping-validated thresholds was only meaningful for the analysis of pooled 
peptide lengths as sample size of individual peptide lengths was limited. For pooled peptide length 
bootstrapping-validated thresholds were compared to criteria-based thresholds to investigate if 
prediction accuracy obtained by using criteria-based thresholds is representative for the whole 
statistical population, e.g. peptide sets different from the HPV16 E6-/E7-derived peptides. The 
significance of the difference of means was analyzed performing two-tailed Student’s t tests 
(significance, P<0.05). 
3.2.5.5 ELISpot analysis 
IFNγ-ELISpot assays were analyzed using Microsoft Excel Software. The numbers of spot forming 
units (SFU) after quality control were obtained from the raw data of the CTL Immunospot Analyzer. 
In order to have dividable numbers, one count was added to all SFU values. All short-term T cell line 
samples were controlled for responding to the unspecific stimulation with the mitogen ConA. Only if a 
donor responded to the positive control stimulation with CEF peptide pool, the assay was regarded as 
successful. The mean SFU count was calculated for the sextuples stimulated with cognate peptide and 
the triplicates stimulated with solvent (background). Outliers were identified by Grubbs’ test 
(significance level α=0.05) and excluded from calculation of the mean SFU. First, the stimulation 
index (SI) was determined as the ratio between the mean SFU of cognate peptide and background. 
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Second, the mean SFU per 1x10
6
 cells was calculated. Only if stimulation resulted in SI ≥2 and ≥200 
SFU per 1x10
6
 cells, the used epitope was considered immunogenic. If peptides were found to be 
immunogenic in multiple donors, mean and standard deviation (SD) of SI was determined. ELISpot 
assay results were illustrated using Prism 7 software. 
3.2.5.6 Vital-FR analysis 
The FACS cell counts of specific and unspecific target cells were analyzed using Flowjo V10 
software. Calculations were performed using Microsoft Excel Software. Per replicate, the frequency of 
specific and unspecific target cells was calculated relative to the sample without effector cells. The 
percentage of specific target cell killing was calculated based on the ratio between specific and 
unspecific target cells normalized to the co-culture without effector cells. Prism 7 software was used 
for graphical illustration. 
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4 Results 
4.1 In silico predicted and in vitro validated HLA binding affinity of HPV16 E6 
and E7 peptides  
4.1.1 MHC class I binding prediction methods predict numerous potential HLA-
binding HPV16 E6- and E7-derived peptides.  
As outlined, for the development of a therapeutic vaccine it is crucial to know distinct T cell target 
epitopes on the target cell that can be used to trigger immune responses. In case of HPV16-associated 
disease, the oncoproteins E6 and E7 represent ideal target antigens. They are pivotal for inducing and 
maintaining the carcinogenic phenotype and are constitutively expressed in all stages of HPV16-
mediated malignancy. MHC displaying of these viral antigens renders an infected cell distinct from 
healthy tissue. As both proteins play essential roles in driving cell transformation, their sequence is 
highly conserved, which reduces the possibility of immune escape once a specific T cell target is 
recognized (Mirabello et al., 2017). Thus, the first part of this study aimed to identify T cell target 
epitopes derived from HPV16 E6 and E7 proteins. 
Translation of the full E6 and E7 ORFs of the HPV16 reference genome would result in 158 and 98 
amino acid (aa) long proteins, respectively. However, translation of E6 can start at the second 
methionine and result in a 151aa protein (Smotkin and Wettstein, 1986; Androphy et al., 1987). 
Together, both proteins comprise 956 theoretically possible 8-, 9-, 10- and 11-mer peptides. When 
including amino acid change variants of E6 and E7, 1506 different peptide sequences can be derived, 
which would have to be tested for binding for all HLA types of interest. The experimental assessment 
of MHC binding affinity of many peptides is time consuming and expensive as it requires every 
peptide to be synthesized and repeatedly tested. In order to reduce the number of peptides assessed 
experimentally, in silico MHC class I binding prediction methods were employed. As only HLA 
class I-presented peptides have the potential to be CTL epitopes, the binding affinities of HPV16 E6-
/E7-derived peptides to seven frequent HLA types were predicted: A1 (A*01:01), A2 (A*02:01), A3 
(A*03:01), A11 (A*11:01), A24 (A*24:02), B7 (B*07:02) and B15 (B*15:01). A total of 15 different 
online available prediction algorithms were used in order to exploit the individual strengths of each 
method: NetMHC4.0, NetMHC 3.4, NetMHCpan 4.0, NetMHCpan 3.0, NetMHCpan 2.8, 
NetMHCcons 1.1, PickPocket 1.1, IEDB SMMPMBEC, IEDB SMM, MHCflurry 1.2, MHCnuggets 
2.0, IEDB recommended, IEDB consensus, MixMHCpred 2.0.2 and SYFPEITHI. The algorithms 
differ in their prediction approach, training data and unit of binding likelihood (Table 1, in section 
MHC class I binding and T cell epitope prediction). Not all methods allow to predict 8-, 9-, 10- and 
11-mer peptides to each HLA type. IEDB SMMPMBEC and IEDB SMM do not predict 8- and 11-
mers for B15. SYFPEITHI does not allow making predictions for B15 nor any 8-mer, and prediction 
of peptides of 11aa length is only available for A1. 
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All prediction results were collected and analyzed. A summary of the predicted binding likelihood of 
analyzed peptides is shown in Supplementary Table S1 in the Annex. To facilitate handling the 
prediction output, the web application MHCcombine was developed in the lab. It allows automatic 
querying of selected prediction methods and returns the joined prediction results in .csv-format, which 
can be opened and sorted in Excel. During the course of this project, MHCcombine was modified in 
order to allow querying of up to 12 of the selected predictors, and it was provided online via DKFZ 
webpages. Data obtained by MHCcombine was used for prediction analysis. 
First, the generally used decision threshold of a predicted high binding affinity (IC50-value ≤50nM or a 
percentile rank ≤0.5) was applied to discriminate positively and negatively predicted peptides. This 
resulted in very low numbers of positives (Table 11, columns “High binding affinity threshold 
(BAT)”). However, MixMHCpred 2.0.2, a predictor that was recently developed and trained on mass 
spectrometry data, was observed to predict more peptides. For example, A2 ligand prediction using 
MixMHCpred 2.0.2 resulted in 12 positives, whereas other predictors returned only 2-5 predicted 
binders (Table 11). For A1, A3 and A24, applying the high binding affinity decision threshold led to 
no predicted positives for the majority of predictors. Therefore, the general intermediate binding 
affinity threshold (IC50-value ≤500nM or a percentile rank ≤2) was used next. This uniformly resulted 
in more predicted peptides (Table 11, columns “Intermediate BAT”). Counting the amount of different 
positively predicted peptides, it was obvious that not all methods predict the same potential HLA 
ligands. For example, only 38 of 77 (49.4%) different predicted A1 ligands were predicted by a single 
predictor. By comparing the predicted binding likelihoods of individual peptides, it was clear that even 
highly ranked candidates of one predictor sometimes scored beyond the decision threshold for another 
method. For example, the peptide E7/78-86 (TLEDLLMGT) was predicted to bind A2 with a binding 
affinity ≤500nM only by PickPocket 1.1, whereas other methods scored it ≤5000nM (Annex, 
Supplementary Table S1). This resulted in a considerable fraction of peptides predicted to be binders 
by one or more predictors, but lying beyond the intermediate binding affinity threshold of other 
predictors. To investigate whether a less stringent threshold would show more homogenous prediction 
results, the general decision threshold for low binding affinity (IC50-value ≤5000nM) was applied. 
Naturally, the amount of positively predicted peptides increased further. However, the discrepancies 
between prediction methods remained (Table 11, columns “Low BAT”). 
The number of positively predicted peptides ranged between 15 (B7) to 87 (B15) for the high, 51 (B7) 
to 155 (B15) for the intermediate and 207 (B7) to 444 (A2) for the low binding affinity threshold. 
Thus, peptide prediction did reduce the number of peptides to be tested. However, applying the low 
binding affinity threshold led to numbers of potential binders that can hardly be handled in validation 
experiments. Therefore, the intermediate binding affinity threshold was used, with a focus on peptides 
predicted by more than one method, to select peptides for initial HLA binding validation and epitope 
identification. In subsequent iterations of experimental assessment of binding affinity, the decision 
thresholds were lowered stepwise until only additional nonbinders were found by less stringent 
thresholds.
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Table 11. Predicted peptides as per indicated decision thresholds. 
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 A1 A2 
NetMHC 4.0 1 2 15 4 19 85 
NetMHC 3.4 0 4 15 5 15 83 
NetMHCpan 4.0 0 1 16 3 18 70 
NetMHCpan 3.0 0 2 14 3 17 65 
NetMHCpan 2.8 0 3 24 5 22 84 
NetMHCcons 1.1 0 3 20 5 19 81 
PickPocket 1.1 0 0 65 4 38 242 
IEDB SMMPMBEC 0 3 53 3 27 226 
IEDB SMM 0 5 57 3 38 258 
MHCflurry 1.2 1 4 20 2 11 86 
MHCnuggets 2.0 1 5 24 2 25 152 
IEDB recommended 2 19 - 2 9 - 
IEDB consensus 5 21 - 2 14 - 
MixMHCpred 2.0.2 11 38 - 12 44 - 
Different peptides 22 77 214 15 99 444 
 A3 A11 
NetMHC 4.0 0 11 54 3 14 66 
NetMHC 3.4 0 15 58 6 26 76 
NetMHCpan 4.0 0 12 48 1 13 67 
NetMHCpan 3.0 0 12 58 3 14 70 
NetMHCpan 2.8 0 15 66 3 30 86 
NetMHCcons 1.1 0 15 66 6 27 80 
PickPocket 1.1 0 6 124 0 5 131 
IEDB SMMPMBEC 0 20 173 1 37 211 
IEDB SMM 0 16 180 3 39 218 
MHCflurry 1.2 1 14 80 6 29 132 
MHCnuggets 2.0 2 32 89 5 34 79 
IEDB recommended 0 16 - 2 20 - 
IEDB consensus 2 21 - 8 26 - 
MixMHCpred 2.0.2 14 30 - 9 25 - 
Different peptides 17 63 338 17 80 346 
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 A24 B7 
NetMHC 4.0 0 6 58 1 7 36 
NetMHC 3.4 0 11 51 1 11 33 
NetMHCpan 4.0 0 7 39 2 9 35 
NetMHCpan 3.0 0 9 43 1 7 39 
NetMHCpan 2.8 0 13 59 5 13 47 
NetMHCcons 1.1 0 8 56 3 11 39 
PickPocket 1.1 0 6 123 0 14 101 
IEDB SMMPMBEC 0 3 134 0 7 98 
IEDB SMM 0 11 145 1 25 135 
MHCflurry 1.2 0 21 152 3 13 47 
MHCnuggets 2.0 1 23 182 2 18 51 
IEDB recommended 0 25 - 0 17 - 
IEDB consensus 3 35 - 2 19 - 
MixMHCpred 2.0.2 21 67 - 13 29 - 
Different peptides 24 100 321 15 51 207 
 B15 
NetMHC 4.0 3 17 106 
NetMHC 3.4 5 47 119 
NetMHCpan 4.0 3 18 110 
NetMHCpan 3.0 4 18 111 
NetMHCpan 2.8 4 33 121 
NetMHCcons 1.1 4 39 118 
PickPocket 1.1 0 2 115 
IEDB SMMPMBEC 13 47 202 
IEDB SMM 17 61 230 
MHCflurry 1.2 6 40 181 
MHCnuggets 2.0 21 64 176 
IEDB recommended 9 69 - 
IEDB consensus 59 85 - 
MixMHCpred 2.0.2 21 46 - 
Different peptides 87 155 410 
BAT: binding affinity threshold 
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4.1.2 Competition-based cellular binding assays identify HPV16 E6- and E7-derived 
ligands to investigated HLA types.  
In order to validate HLA binding affinity, selected peptides were synthesized and binding affinity was 
determined experimentally in cellular competition-based binding assays as described (Kessler et al., 
2003, 2004). B-LCL cells expressing the investigated HLA molecules were stripped of endogenous 
peptide by acid treatment. To reconstitute the HLA complex, β2-microglobulin and a mix of two 
peptides was supplied. The mix consisted of a fixed concentration of a fluorescently-labeled reference 
peptide with a known high HLA affinity and a test peptide at a range of concentrations. If the test 
peptide bound to the HLA in question, it competitively replaced the reference peptide in the cleft of 
the HLA molecule. Measuring the fluorescence of bound reference peptide resulted in decreased 
fluorescence intensity with increasing concentrations of test peptide. Analyzing a dilution series of test 
peptide allowed defining the test peptide concentration at which 50% binding of the reference peptide 
was replaced, referred to as experimental IC50-value (Figure 13 A). Binders were grouped into 
peptides with strong (IC50 ≤5µM), intermediate (5µM <IC50 ≤15µM) and weak (15µM <IC50 ≤100µM) 
experimental binding affinity. A nonbinder was characterized by an IC50 >100µM (Figure 13 B). Thus, 
a low IC50 value is representative of high binding affinity. However, determined IC50-values greatly 
depend on the chosen reference peptide. High-affinity reference peptides, as used in this study, result 
in higher IC50 values than assays performed with reference peptides of lower affinity. 
Using the outlined binding assay protocol, 508 HPV16 E6-/E7-derived peptides were assessed in the 
lab before the start of this thesis project, resulting in 224 binders and 284 nonbinders. However, 
progress in the development of prediction methods and inclusion of E6/E7 variants revealed new 
candidates for HLA binding validation and epitope identification. Hence, HLA binding of 271 
peptides was additionally tested in the scope of this thesis. This resulted in the identification of 69 new 
binders. Figure 13 C shows the individual experimental IC50 results of these 69 validated HLA ligands 
(25.5% of tested peptides), the 202 nonbinders are listed in Table 12. Nonbinders were tested at least 
twice, whereas IC50 of binders was minimally determined three times (refer to column “n” in Figure 13 
C and Table 12).  
The majority of the tested peptides (58) were analyzed for binding to A1, and 20 HLA ligands were 
identified. Five peptides showed strong, three intermediate and twelve weak experimental binding 
affinities. Of 39 peptides tested for A2-binding, only 5 weak binders could be identified. Three out of 
35 predicted ligands to A3 were actual binders with strong affinity. For A11, 52 peptides were 
analyzed for binding, and of 10 identified ligands five each showed intermediate and weak affinities. 
Because A24 had already been studied extensively in previous work, only 16 new candidate peptides 
were assessed. Surprisingly, the majority of these were true binders. Of these ten binders, five bound 
strongly, one intermediately and four weakly to the HLA molecule. Only six out of 22 peptides 
examined for B7 affinity were binders, three of them with strong, one with intermediate and two with 
weak binding. Of 49 tested peptides for B15, 15 were actual ligands. For three ligands a strong binding 
affinity was determined, two showed intermediate and the remaining ten weak binding.  
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Figure 13. Competition-based binding assays identify HLA-ligands. The fluorescence of cells incubated with 
a labeled reference ligand and different concentrations of test peptide was measured by flow cytometry. The test 
peptide concentration at which 50% of the reference peptide binding was inhibited, referred to as IC50 value, was 
calculated. Representative examples of a binder (A) and a nonbinder (B) are shown. Detailed IC50 results of all 
binders are grouped by HLA type (C). Amino acid changes in the sequence of HPV16 E6/E7 variant-derived 
peptides are highlighted in red. Bar graphs represent the mean IC50-values and SD. Dashed grey lines indicate 
different binding strength levels (≤5µM=high, 5µM<IC50≤15µM=intermediate, 15µM<IC50≤100µM=low 
binding affinity). 
 
Results 
 
 
73 
Table 12. List of experimentally validated HPV16 E6-/E7-derived nonbinders. 
Sequence n  Sequence n  Sequence n 
A1 
IHDIILQCVY 4  SKISEYRHY 4  AFRDLCIVY 4 
IVYRDGNPY 4  SLYGTTLEQQY 4  AGQAEPDRAHY 4 
KFYSKISEY 4  TTDLYCYE 3  CIVYRDGNPYA 5 
LCIVYRDGNPY 4  VYRDGNPYGV 4  CLKFYSKISEY 4 
LDLQPETTDLY 4  YRHYCYSLY 5  CTELQTTIHDI 3 
LQPETTDLY 4  YSKISEYRY 4  DFAFRDLCIVY 4 
LQPETTDLYCY 4  YSLYGTTL 3  FAFRDLCIVY 4 
LSDSSEEEDEI 3  YSKISEYRHY 4  FYSKISEYRHY 2 
NIRGRWTGRCM 5  QAEPDRAHY 5  FYSKISEYRY 4 
QLLRREVYDFA 4  TIHDIILECVY 4  FYSKISEYRYY 4 
QPETTDLYCY 5  TTDLYCYEQLN 3  HDIILECVY 4 
QQLLRREVY 4  YSKISEYRYY 2  IHDIILECVY 6 
SEYRYYCY 4  YAVCDKCLKFY 2    
A2 
AVCDKCLKFYS 3  KISEYRYYC 5  TELQTTIHDII 2 
CKCDSTLRLCV 2  LKFYSKIS 2  TIHEIILEC 5 
DIRTLEDLL 2  LMGTLGIVCP 3  TKLPQLCTEL 2 
DKCLKFYS 2  PQLCTELQTTI 2  TLEDLLMGT 4 
DLQPETTDL 2  PTLHEYMLDL 2  TLEQQYNKPL 4 
EYMLDLQPET 5  QERPIKLPDL 2  TLHEYMLDLQ 2 
FQDPQERPTKL 4  QERPTKLPQL 2  TLRLCVQS 2 
GIVCPICS 2  RLCVQSTHVDI 2  TLRLCVQST 2 
HVDIRTLEDL 2  RYYCYSVYGT 2  VDIRTLEDL 2 
IHDIILECV 2  SEEEDEIDGPA 2  YSVYGTTL 2 
IILECVYCKQQ 2  STHVDIRTL 2    
IKLPDLCTEL 5  STLRLCVQST 2    
A3 
AFRDLCIVY 3  IVCPICSQKP 2  QLLRREVYD 3 
CTELQTTIHDI 2  IVYRDGNPYA 3  QQLLRREVY 3 
CVYCKQQLL 2  KCLKFYSK 2  RGRWTGRCMSC 2 
DLLMGTLGI 2  KQRFHNIRGRW 3  RHYCYSLYGT 2 
DLQPETTDLY 2  KQRHLDKKQRF 2  RLCVQSTHVD 2 
EVYDFAFRD 2  LLIRCINCQ 3  SVYGTTLEQQY 3 
EVYDFAFRDL 2  LLRREVYDFA 2  TLEDLLMGTL 2 
GTLGIVCPI 3  MLDLQPETT 2  TLRLCVQSTH 2 
HNIRGRWTGR 2  QAEPDRAHY 2  TTLEQQYNKPL 2 
HVDIRTLED 2  QLCTELQTT 2  YGTTLEQQYNK 3 
ISEYRHYCY 3  QLCTELQTTI 2    
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Sequence n  Sequence n  Sequence n 
A11 
AFRDLCIVYRD 3  HYCYSLYGTTL 3  SEYRHYCYSLY 5 
AGQAEPDRA 2  IILECVYCKQ 2  SKISEYRHYCY 2 
CDKCLKFY 3  IRCINCQK 2  SLYGTTLEQQY 3 
CPEEKQRHLDK 3  IVCPICSQKP 2  SVYGTTLEQ 3 
CTELQTTIHDI 2  KISEYRHYC 3  SVYGTTLEQQY 2 
CTELQTTIHEI 3  KISEYRHYCYS 2  TFCCKCDSTLR 2 
CVYCKQQL 2  KPLCPEEK 3  TLHEYMLDL 3 
DEIDGPAG 2  LKFYSKISEYR 2  TTDLYCYEQLN 2 
DIILECVYCKQ 2  MSCCRSSRTRR 3  TTIHEIILE 3 
FRDLCIVY 3  PAGQAEPDRA 2  TTLEQQYNKP 2 
FYSKISEYR 2  RDGNPYAVCDK 2  TTLEQQYNKPL 2 
GIVCPICS 2  REVYDFAFR 4  VCDKCLKFY 2 
GIVCPICSQKP 2  RLCVQSTHVD 2  VQSTHVDIR 3 
GTTLEQQYNKP 2  RTLEDLLMGT 2  YSKISEYRH 2 
A24 
CYEQLSDSSE 2  LMGTLGIV 3  RDGNPYAV 3 
DFAFRDLCIVY 3  LYGTTLEQ 3  TTLEQQYNK 3 
B7 
CKQQLLRREV 8  NPYAVCDKCLK 6  SSRTRRETQL 6 
CPEEKQRHLD 8  QERPRKLPQL 7  TLEDLLMG 9 
DPQERPTKL 11  QPETTDLYCY 6  YCYSLYGTTL 7 
EPDRAHYNIVT 8  QYNKPLCDLL 11  YCYSVYGTTL 6 
FAFRDLCIV 6  RGRWTGRCMS 6    
LLRREVYDFAF 9  RKLPQLCTEL 6    
B15 
AEPDRAHY 2  KQRFHNIRG 2  RLCVQSTHVD 2 
AGQAEPDRAH 2  LECVYCKQQL 2  RSSRTRRETQL 4 
CLKFYSKISE 2  LGIVCPICSQ 2  RTLEDLLM 2 
CQKPLCPEEK 3  LQTTIHDIIL 2  STLRLCVQST 2 
DFAFRDLCIV 3  LYGTTLEQQY 3  TLEDLLMGTL 3 
DIILECVY 2  MLDLQPETTD 2  TLGIVCPICS 2 
DLLMGTLGIV 2  PQLCTELQTT 2  TLRLCVQSTH 2 
DRAHYNIVTF 3  QLCTELQTTI 2  YMLDLQPETT 2 
ELQTTIHDII 2  QQLLRREVYD 2  YSLYGTTL 3 
HGDTPTLHEY 2  QQYNKPLCDLL 2  YSVYGTTL 2 
IILECVYCKQ 4  QYNKPLCDLL 5    
IVCPICSQKP 2  RAHYNIVTFC 2    
bold and underlined: amino acid changes in E6-/E7-variant-derived peptides   
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4.1.3 MHC class I binding predictions do not match experimental binding results.  
To assess how well predicted binding affinity matched reality, all binding data of HPV16 E6/E7-
drived peptides was analyzed, including prior work in the light of present prediction methods. The 
commonly used intermediate binding affinity thresholds (IC50-value ≤500nM or a percentile rank ≤2) 
were applied and predicted binding was compared to experimental binding. 
The complete dataset comprised 779 peptides analyzed for binding to one of the selected HLA types: 
70 for A1, 156 for A2, 105 for A3, 137 for A11, 129 for A24, 55 for B7 and 127 for B15 (Figure 14 
and Annex, Supplementary Table S1). For 78 peptides, binding affinities to the analyzed HLA types 
were reported before (Annex, Supplementary Table S2). Overall, 374 peptides were predicted to be 
binders by any algorithm, but only 293 peptides were actual binders. Moreover, there was only a 
partial overlap between predicted and experimentally validated HLA ligands. For example, the 
predictions indicated 55 peptides positive for A24 binding (TP+FP), but only 42 of these were truly 
binding (TP) and 13 were false positives (FP). Further, 24 peptides with experimentally validated 
binding affinity were falsely predicted to be nonbinders (FN). Fifty actual nonbinders were correctly 
identified to be negatives (TN). For all analyzed HPV16 E6/E7-derived peptides, 78 of 293 (26.6%) 
actual binders were predicted negatives and only 215 of 374 (57.5%) predicted positives were true 
HLA ligands.  
Overall, the disparity between predicted and real HLA binding warranted a thorough prediction 
performance evaluation. 
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Figure 14. Evaluation of HLA class I binding predictions based on experimental binding results. Bar 
graphs represent the numbers of tested HPV16 E6 and E7 peptides (including aa variants) per HLA type. Tested 
peptides are grouped according to true and predicted binding affinity. Binders are represented by black and dark 
grey, nonbinders by light grey and white bars. Peptides were considered to be predicted positively (P, dark and 
light grey) if the predicted binding affinity of any predictor was below IC50 ≤500nM or percentile rank ≤2, 
respectively. Beyond this threshold, peptides were considered to be negatively predicted (N, white and black). 
Prediction results were classified to be true (T) or false (F) based on experimental validation of binding. The 
table below the bar graph summarizes the numbers of peptides by group. To the right of the table the numbers of 
all binders (293), all predicted positives (374) and all tested peptides (779) are indicated. 
4.2 Performance evaluation of MHC class I binding prediction methods based 
on experimentally validated HPV16 E6- and E7-derived ligands  
4.2.1 Prediction algorithm results discriminating binders from nonbinders vary 
depending on HLA type and peptide length. 
In order to find the most suitable prediction method, the prediction performance of the algorithms was 
analyzed in detail. Peptides were sorted by their predicted binding affinity and predictions were 
classified into true and false based on experimental binding of peptides. Each binder was considered a 
true positive event and each nonbinder a false positive event. The rates of true positives (TPR, also 
sensitivity) and false positives (FPR, also 1-specificity) were plotted as receiver operating 
characteristics (ROC) curves (Figure 15), allowing evaluation of the predictive strength of an 
algorithm independent of decision thresholds. ROC curves were analyzed for each HLA type and 
pooled as well as individual 8-, 9-, 10- and 11-mer peptide lengths. To compare ROC curves, the area 
under the curve (AROC) was calculated (Figure 16). A perfect ROC curve would show a maximal TPR 
(1) and a minimal FPR (0). Thus, AROC corresponding to perfect discrimination between binders and 
nonbinders equals 1. According to Lin et al. AROC >0.9 indicate excellent performance and AROC <0.8 
demonstrate poor predictive capability (Lin et al., 2008). 
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The prediction performance analysis of ROC curves and AROC based on the dataset of HPV16 E6-/E7-
derived peptides revealed that none of the analyzed predictors perfectly discriminated binders from 
nonbinders. Only slight differences in prediction performance between algorithms were observed 
when peptides of pooled lengths were considered. However, when analyzing peptide lengths 
individually for each HLA type, differences became more pronounced. 
Overall, the prediction of 9-mers was observed to be most precise, which is reflected by reaching 
excellent AROC values of >0.9 (Figure 16). For 9-mers and 10-mers, the predictors performed quite 
uniformly. However, for the HLA types with smaller datasets, A1 and B7, the performance of 10-mer 
prediction was poor, with mean AROC of ~0.5 for A1 and ~0.7 for B7. Performances for 8-mer and 11-
mer predictions were generally less precise but here precision depended on the analyzed HLA 
molecule. Best performance of 11-mer prediction was observed for A24 with quite consistent AROC 
values between algorithms, but an only intermediate mean AROC of ~0.8. A3 showed the poorest AROC 
values for 11-mer predictions with a range of 0.32 (IEDB consensus) to 0.54 (IEDB SMMPMBEC 
and MixMHCpred 2.0.2). For 8-mer predictions, the most pronounced differences between prediction 
methods were seen. Multiple algorithms reached perfect discrimination (AROC 1) for A11 binding 
predictions. On the other hand, the AROC values for A24 ranged between 0.18 (IEDB SMMPMBEC 
and IEDB SMM) and 0.86 (NetMHCpan 4.0 and NetMHCpan 3.0). For other HLA types, similar but 
less extreme discrepancies between predictors were observed. 
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Figure 15. Receiver operating characteristics (ROC) curves of predictors for different HLA types and 
pooled and individual peptide lengths. The rate of true (TPR) and false (FPR) positive predictions of each 
predictor were analyzed for each HLA type and peptide length. The gray diagonal line represents a 50:50 chance 
of correct prediction. Exact numbers are given in Supplementary Table S3 in the Annex. (n) Number of peptides 
per group. (*) Numbers of pooled peptides differ for some predictors because prediction for some peptide 
lengths was not available.  
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Figure 16. Area under the ROC curves (AROC) of predictors for different HLA types and pooled and 
individual peptide lengths. Prediction performance was measured by AROC. Perfect discrimination between 
binders and nonbinders results in AROC=1. Exact numbers are given in Supplementary Table S3 in the Annex. (n) 
Number of peptides per group. (*) Numbers of pooled peptides differ for some predictors because prediction for 
some peptide lengths was not available. 
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Overall, prediction methods based on artificial neural networks (ANN) using a pan-specific approach 
showed the best performances. Algorithms of the NetMHC family were always found among the well 
performing predictors. In particular for A1 and B15, predictors NetMHCpan 4.0 or NetMHCpan 3.0 
were found to be the best choice. The MHCflurry 1.2 method showed the best results for binding 
predictions to A2, but for other HLA types it was average. MHCnuggets 2.0 can be recommended for 
all HLA types except A1 and B15. In contrast, it is generally not advisable to use PickPocket 1.1 for 
any other prediction than A1. MixMHCpred 2.0.2 only showed very convincing performance for A3. 
The algorithms IEDB SMMPMBEC, IEDB SMM and SYFPEITHI were mostly found among the 
poor performing prediction methods. However, due to partly confined datasets, comparability in the 
pooled peptide length analysis is limited for affected predictors (marked with asterisks in Figure 15 
and Figure 16). 
It became clear that none of the HLA binding predictors distinctively outperformed other methods, as 
no single method showed outstandingly well AROC values. However, for specific HLA types and 
peptide lengths, some prediction methods indeed showed superior performances. Thus, evaluation of 
ROC curves and AROC demonstrated that it is advisable to always select the most suitable algorithm, 
depending on the analyzed HLA type and peptide length. 
4.2.2 Commonly used decision thresholds result in low prediction sensitivity.  
The decision threshold is decisive for the statistical power of a prediction algorithm. To analyze the 
influence of different thresholds, accuracy (ratio of true predictions over all data points), sensitivity 
(TPR) and specificity (1-FPR) of the high (IC50-value ≤50nM or a percentile rank ≤0.5), intermediate 
(IC50-value ≤500nM or a percentile rank ≤2) and low (IC50-value ≤5000nM) binding affinity 
thresholds were compared. Predictors expressing binding likelihood as percentile rank only 
recommend two decision thresholds, which were here analyzed with the high and intermediate 
thresholds, respectively. The predictor SYFPEITHI does not recommend any decision thresholds and 
the scoring system differs from all other predictors. Thus, it was excluded from this analysis. 
Analysis of accuracy revealed comparable results for predictors when high and intermediate binding 
affinity thresholds were used (Annex, Supplementary Figure S2). In contrast, the low binding affinity 
thresholds led to greater accuracy differences among prediction methods. The general dependence on 
HLA type and peptide length that had been detected by ROC curve analysis was also reflected by 
accuracy values. The high binding affinity threshold only yielded high accuracy for A2 8-mers and A3 
11-mers. The least stringent low binding affinity thresholds were able to increase accuracy for the 
HLA types A1, A24, B7 and B15. Otherwise, the intermediate binding affinity threshold resulted in 
best accuracy values. 
As accuracy is defined as the rate of all true predictions, a low capability to predict true positives may 
be masked by a high number of correct predictions of true negatives. Therefore, threshold-dependent 
sensitivity and specificity were calculated to evaluate prediction performance. Figure 17 shows the 
sensitivity and specificity of predictors using the high, intermediate and low binding affinity 
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thresholds for HLA specific binding prediction. The most favorable results would be 1 (represented by 
a fully colored pie) for both specificity and sensitivity, meaning that all and only binders would be 
predicted. 
 
Figure 17. Threshold-dependent sensitivity and specificity of predictors for different HLA types. Grouped 
by HLA type and predictor, pie charts represent the sensitivity and specificity of a predictor by applying 
different decision thresholds (different tones of grey): high (IC50 ≤50nM or percentile rank ≤0.5), intermediate 
(inter, IC50 ≤500nM or percentile rank ≤2) or low (IC50 ≤5000nM) binding likelihood. Pies completely filled 
with grey would indicate perfect values. 
As expected, the lowest sensitivities and highest specificities were observed when applying the high 
binding affinity thresholds (columns “high” in Figure 17). Naturally, the use of less stringent 
thresholds led to an increase in sensitivity accompanied by a loss of specificity (columns “inter” and 
“low” in Figure 17). For the well-studied A2 allele applying the commonly used intermediate binding 
affinity thresholds yielded a maximum sensitivity of only 0.39 (PickPocket 1.1 and IEDB 
SMMPMBEC), whereas using the low binding affinity thresholds resulted in increased sensitivity of 
0.54 (NetMHCpan 3.0) up to 0.93 (PickPocket 1.1). Likewise, the less stringent thresholds appeared to 
decrease specificity, ranging from 0.36 (PickPocket 1.1) to 0.81 (NetMHCpan 4.0) compared to 0.84 
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(MixMHCpred 2.0.2) to 0.99 (IEDB recommended) obtained with intermediate binding affinity 
thresholds. Similar results were observed for other HLA types.  
Overall, sensitivity resulting from intermediate binding affinity thresholds was surprisingly low. As 
the low binding affinity thresholds were able to increase sensitivity without resulting in generally poor 
specificity, the use of less stringent decision thresholds should be considered to increase finding true 
HLA ligands. 
4.2.3 Novel individual decision thresholds increase prediction sensitivity.  
In order to find suitable thresholds, which balance the gain in sensitivity against a loss in specificity, 
new optimal thresholds were calculated individually for each analyzed predictor, HLA type and 
peptide length. To describe characteristics of an optimal decision threshold, three criteria were defined 
in the scope of this thesis: (1) the minimum specificity obtained should be ≥0.66 (equal to a maximum 
FPR ≤0.33), (2) there should always be minimally twice as many true positives than false positives 
(TPR≥2xFPR), and (3) within these first two criteria the TPR should be as high and FPR as low as 
possible (Annex, Supplementary Figure S3). Optimal “criteria-based” thresholds were calculated by 
applying these criteria. 
For single length analysis of 8-, 9-, 10- and 11-mers, these thresholds and associated measures of 
performance (AROC, PPV, specificity and sensitivity) are listed in Supplementary Table S3 in the 
Annex. In general, criteria-based thresholds often resulted in values even less stringent than low 
binding affinity thresholds in case of predictors with a good performance as indicated by a high AROC. 
For poor performing prediction methods, calculation of criteria-based thresholds resulted rather in 
values between intermediate and low binding affinity thresholds. 
As the criteria-based thresholds were calculated only based on the HPV16 E6-/E7-derived peptide 
dataset, it was necessary to statistically validate if the obtained performance measures are 
representative for any other dataset. In order to test applicability of thresholds, a bootstrapping method 
was performed. Bootstrapping allowed to resample the HPV dataset 100-times and to calculate the 
criteria-based threshold based on random 2/3 of data (“training data”). On the other third (“test data”), 
the calculated threshold was applied, and associated sensitivity, specificity and accuracy were derived 
to determine confidence intervals. The mean threshold determined of 100 bootstrappings was termed 
“validated threshold”. To compare the sensitivity, specificity and accuracy achieved by the individual 
validated thresholds to the generally used high (IC50-value ≤50nM or a percentile rank ≤0.5), 
intermediate (IC50-value ≤500nM or a percentile rank ≤2) and low (IC50-value ≤5000nM) binding 
affinity thresholds, a second bootstrapping was performed. Again, the HPV dataset was resampled 
100-times, each threshold was applied to a random third of the HPV dataset and performance 
measures were calculated as confidence intervals (Figure 18). 
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Figure 18. Bootstrapping-based comparison of sensitivity, specificity and accuracy of predictors by 
applying individually recommended “validated” or generally used thresholds. 
(Figure continues, see Figure legend on the following page) 
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Figure 18. Bootstrapping-based comparison of sensitivity, specificity and accuracy of predictors by 
applying individually recommended “validated” or generally used thresholds. Results are shown for (A) 
HLA A2 and (B) HLA A24. Recommended thresholds were calculated and validated by bootstrapping as 
described. In a second bootstrapping, sensitivity, specificity and accuracy of predictors applying the 
recommended thresholds were compared to general thresholds for predicting high (IC50 ≤50nM or percentile 
rank (%) ≤0.5), intermediate (inter, IC50 ≤500nM or percentile rank (%) ≤2) or low (IC50 ≤5000nM) binding 
likelihood. Box plots and whiskers show bootstrapping quartiles and the 95% confidence interval of data, 
respectively. Numbers indicate significant differences of means, which were determined by one-way ANOVA 
followed by Dunnett multiple comparisons test (significance, p<0.05). Asterisks indicate p-values. 
(***) p<0.001, (**) p<0.01, (*) p<0.05, (ns) not significant 
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Figure 18 shows the confidence intervals and means for threshold-dependent sensitivity, specificity 
and accuracy for A2 and A24. Analysis for A1, A3, A11, B7 and B15 is shown in Supplementary 
Figure S4 in the Annex. Overall, the use of the validated threshold led to a significant increase in 
sensitivity, and to a relevant increase (change by ≥0.1) compared to the high and intermediate binding 
affinity thresholds. In comparison to the low binding affinity thresholds, the validated threshold also 
significantly increased sensitivity for most predictors, especially in case of the NetMHC family. 
However, for the prediction algorithms IEDB SMMPMBEC and IEDB SMM sensitivity was 
decreased, because validated thresholds were more stringent than the low binding affinity thresholds. 
If sensitivity was lost, specificity was gained and vice versa. However, the improved sensitivity 
surpassed the specificity deficit. This is documented by the concomitant increases in accuracy. For 
example, when comparing validated vs. low binding affinity thresholds for A2, the accuracy was 
relevantly increased (for NetMHCcons 1.1, PickPocket 1.1, IEDB SMMPMBEC, IEDB SMM and 
MHCnuggets 2.0), insignificantly changed (NetMHC 4.0, NetMHC 2.4, NetMHCpan 2.8 and 
MHCflurry 1.2) or only slightly lowered (NetMHCpan 4.0 and NetMHCpan 3.0). Overall, accuracy 
was either not affected or even increased for other HLA types (A1, A11, A24, B7, B15). For A3, 
differences between accuracy resulting from validated and low binding affinity thresholds varied. 
The calculation of individual thresholds based on defined criteria allowed more sensitive prediction of 
HLA-binding peptides without a strong negative influence on prediction accuracy. In contrast, 
accuracy was even increased to a minor extent for many prediction settings. Thus, systematically using 
less stringent validated thresholds increased the number of correctly predicted HLA ligands and 
limited false positives to a tolerable fraction. 
4.2.4 Criteria-based thresholds and bootstrapping-validated thresholds result in 
similar prediction performance. 
Due to the limited sample size of datasets for individual peptide lengths, the calculation of validated 
thresholds could only be performed for pooled peptide lengths. In order to provide an estimate of how 
representative criteria-based thresholds are for the whole statistical population, their associated 
performance measures were directly compared with the respective validated thresholds (Figure 19 and 
Annex, Supplementary Figure S5). 
In the majority of cases validation resulted in the same binding likelihood as for criteria-based 
thresholds. Thus, sensitivity, specificity and accuracy were rarely affected. A greater divergence 
between validated and criterion-based threshold led to significant changes in the performance 
measures. In the few cases where significant changes were detected, the difference was <0.1. Relevant 
accuracy differences >0.1 were only observed for A3 binding prediction by NetMHCcons 1.1 and 
IEDB recommended. However, variation between the validated and criteria-based threshold did not 
necessarily follow a change in accuracy, as can be seen for A2 prediction by NetMHCpan 3.0 and 
IEDB consensus. Therefore, individual criteria-based thresholds were fair to use for analysis of 
individual peptide lengths where validated thresholds were not available. 
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Figure 19. Comparison of predictor performance measures between applying criteria-based thresholds 
and validated thresholds. Validated thresholds (left) were calculated by bootstrapping as described. Criteria-
based thresholds (right) were calculated by applying criteria (FPR ≤0.33 (specificity ≥0.66), TPR (sensitivity) 
≥2x FPR and the highest possible sensitivity within the first two criteria) to the respective complete HPV16 
E6/E7 peptide set. In a second bootstrapping, the two thresholds were applied and confidence intervals of and 
sensitivity, specificity and accuracy were calculated for 100 samplings. Box plots and whiskers show 
bootstrapping quartiles and the 95% confidence interval of data, respectively. Significant differences of means 
were determined using Student’s t test (significance, p<0.05). (***) p<0.001, (**) p<0.01, (*) p<0.05, (ns) not 
significant 
4.2.5 Applying the recommended thresholds increases the number of predicted true 
binders. 
Comparison of decision threshold-dependent prediction performance showed that using the 
individualized and more tolerant validated and criteria-based thresholds increased prediction 
sensitivity. The effect of applying these thresholds to the predictions for the HPV dataset is shown for 
A2 and A24 in Figure 20 and for A1, A3, A11, B7 and B15 in Supplementary Figure S6 in the Annex. 
Peptides were sorted according to their experimental binding affinity (first column) and separated into 
binders (blue) and nonbinders (red). Predicted binding likelihoods of predictors (following columns) 
are shown for individual (left) and pooled peptide lengths (right) using the intermediate binding 
affinity thresholds (dark colors; IC50 ≤500nM or percentile rank ≤2) or the criteria-based or validated 
thresholds (light colors), respectively. 
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Figure 20. Classification of HLA binding prediction of HPV16 E6/E7 peptides to HLA A2 and A24 
according to application of different thresholds. HLA-ligands derived from HPV16 E6/E7 were validated by 
experimental assessment (first column) and categorized into binders (blue) and nonbinders (red). Following 
columns indicate the peptides’ predicted binding likelihood classified by different thresholds. Criteria-based 
(single lengths) or recommended thresholds (pooled lengths) separate peptides into predicted (blue), not 
predicted (red) or threshold calculation not possible (grey). Further, predictions were classified into predicted 
within (dark shade) or beyond (light shade) the general threshold of IC50 ≤500nM or percentile rank ≤2. 
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For A2, applying the commonly used intermediate binding affinity thresholds the predictions yielded 
only about a third of all true binders and did not prevent prediction of some false positives (dark blue). 
However, for A24, the generally used thresholds positively predicted only a minority of actual binders. 
Only MixMHCpred 2.0.2 correctly predicted more than half of the actual binders. Detailed 
performance measures for applying individual criteria-based thresholds and validated thresholds are 
listed in Supplementary Table S3 in the Annex. 
Overall, the generally used thresholds are more suitable for 9- and 10-mer prediction, whereas only 
few binders were detected among 8- and 11-mer peptides. Criteria-based (for single peptide lengths) 
and validated thresholds (for pooled lengths) increased the numbers of predicted true binders (light 
blue) or reduced prediction of false positives where intermediate binding affinity thresholds were too 
tolerant (dark red). However, whenever less stringent thresholds were used, this increased the amount 
of false positive predictions. Essentially, this applies for all analyzed HLA types. However, for HLA 
types where AROC analysis revealed less precise prediction performance, e.g. A24, using intermediate 
binding affinity thresholds led to very poor results. Here, recommended thresholds were superior in 
predicting actual HLA ligands.  
4.3 HPV16 variants and their HLA-binding E6 and E7 peptides 
4.3.1 HPV16 positive cell lines are infected with different genomic HPV variants. 
Based on differences within the L1 ORF HPV16 is differentiated into several lineages and 
sublineages. Sequences of E6 and E7 are more conserved than L1, albeit not free of mutational 
changes. Mutations can lead to aa substitutions that affect the possible E6 and E7 epitope repertoire. 
Therefore, all HPV16-positive cell lines available in the lab were characterized for mutations in E6 
and E7 sequences (listed in Annex, Supplementary Table S4). For the majority of cell lines in our 
collection, this was already performed by Stephanie Hoppe, a previous group member. However, the 
two cell lines UM-SCC104 and MRI-H-186 were newly acquired and their E6 and E7 variants needed 
to be determined. 
E6 and E7 sequences were obtained as described in the section “Sequencing of HPV16 E6 and E7 
genes” and compared to the HPV16 reference sequence (sublineage A1 European, variant E-v1). 
Sequence alignment revealed nucleotide changes and associated aa substitutions (Annex, 
Supplementary Table S5). UM-SCC104 showed a single mutation in the E6 gene. The T371G 
mutation resulted in the aa change L90V. The E7 sequence was completely identical to the reference 
sequence. For MRI-H-186, both genes were identical to the reference sequence. Thus, the two cell 
lines were identified to be of the A2 and A1 European sublineages (variant E-v2 and E-v1), 
respectively. 
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4.3.2 Genomic variants of HPV16 result in different HLA ligands. 
Experimental binding affinities of analyzed variant peptides were compared to reference sequence 
counterparts to evaluate the effect of aa changes on the repertoire of HLA ligands. Considering known 
binding sequence motifs for the different HLA types, not all aa changes occurring in HPV16 E6 and 
E7 are equally likely to interfere with HLA binding. For HLA class I, the second and last positions 
have been shown to serve as anchor residues. Thus, it was expected that especially aa changes in 
anchor positions alter binding capacity. With regards to the binding motifs of the analyzed HLA types, 
prevalent HPV16 E6 and E7 variants were assessed for potentially relevant aa changes at anchor 
positions (Table 13). Substitutions were considered relevant if a beneficial amino acid was exchanged 
for a disadvantageous one and vice versa. Based on this assessment, four mutations, E6 E120D, E6 
D32E E6 A68G and E7 N29S, were not expected to influence binding to any investigated HLA type. 
The substitution H51N in E7 should only affect A3-ligands. Half of the prevalent aa changes were 
estimated to influence binding to three or more HLA types. Some HLA types were expected to be 
more affected than others if aa substitutions would occur in anchor residues. For example, five or more 
variants could hypothetically alter binding to A1, A3, A24 and B15, whereas only a single change 
might have implications for B7 binding affinity. 
Table 13. List of amino acid changes prevalent HPV16 E6- and E7-variants and their potential relevance 
for HLA binding. 
Amino acid change A1 A2 A3 A11 A24 B7 B15 Count 
E6 
R17I  X X X X   4 
R17T X  X X    3 
Q21D X      X 2 
D32E        - 
I34R  X X  X   3 
E36Q X X     X 3 
A68G        - 
H85Y X    X  X 3 
L90V     X  X 2 
E120D        - 
E7 
L28F  X X X X   4 
N29S        - 
H51N   X     1 
S63F X    X X X 4 
 Total 5 4 5 3 6 1 5  
X: potentially changing binding capacity if occurring at anchor position 
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Figure 21 shows binding affinities of variant peptides side-to-side with their reference sequence-
derived counterparts, if available, and peptide sequence motifs for each HLA type. The exact reference 
counterpart was not analyzed for all variant peptides, e.g. if HLA binding predictions were negative. 
Among the 86 analyzed variant peptides, of which eight showed double aa changes, 18 changes were 
detected in anchor residues (marked with asterisks in Figure 21), 10 changes occurred at the N-
terminus, 12 in the second last position (C-terminus -1) and 54 times any middle residue was affected. 
Among the 18 peptides with residue changes at anchor positions, five were expected to alter binding 
capacity to HLA types; three were supposed to have a positive effect and two a negative effect. 
Indeed, the A24 peptide E6 L90V/81–90 (SEYRHYCYSV) was found to be a nonbinder in contrast to 
the reference peptide SEYRHYCYSL (11.98µM) and the peptide E6 L90V/82-90 EYRHYCYSV 
showed only intermediate (8.70µM) compared to high binding capacity (0.32µM) seen for 
EYRHYCYSL. For the variant peptides with expected positive effects (FYSKISEYRY and 
YSKISEYRY (A1), FQDPQERPI (A2)) exact were predicted to be nonbinders. Although exact 
counterparts were not among tested peptides, it can be expected that aa substitutions were indeed 
beneficial for HLA-binding. Additionally, three more variant-derived peptides showed affected 
binding affinity when compared to the exact reference-derived counterpart, albeit their substitutions at 
anchor positions were considered irrelevant. The aa changes E6 A68G and E7 N29S increased the 
binding affinity of the peptides E6/67-77 and E7/19-29 to HLA A1. Binding affinity to A3 was 
unexpectedly reduced for the E6 L90V/89-99 peptide. 
In summary, the comparison of HPV16 E6 and E7 reference sequence- and variant-derived peptides 
revealed that certain variant peptides do exhibit different binding affinities than their counterparts. 
Overall, 15 aa changes were found to have a positive effect (affinity gained) and 18 a negative effect 
(affinity reduced). However, most substitutions were located in the middle part of the peptides and not 
at anchor positions. 
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Figure 21. Influences of amino acid changes in HPV16 E6/E7 variants on HLA binding affinity. IC50-values 
of HPV16 E6-/E7-derived peptides binding to specific HLA types have been determined in cellular competitive 
binding assays. HPV16 E6/E7 variant peptides, harboring amino acid changes (red), were compared to the 
reference sequence-derived counterparts. Affected anchor residues were marked with asterisks. Bar graphs 
illustrate mean ± SD of the IC50 concentration on a black background to visually highlight binders. Dotted grey 
lines indicate levels of high (≤5µM) intermediate (5µM<IC50≤15µM) and low (15µM< IC50≤100µM) binding 
affinity. Nonbinder sequences are written in gray color. For each HLA type, sequence motifs of HLA ligands  
are given to the right of the bar graph (derived from the Immune Epitope Database). Amino acid (aa) 
characteristics are highlighted in different colors. Motifs display abundance of aa in letter size. Underrepresented 
aa are below the horizontal black line. Motifs were adapted from the Seq2Logo web tool. 
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4.4 Evaluation of peptide immunogenicity using T cell lines  
4.4.1 Flow cytometry characterizes HLA-type of PBMCs isolated from buffy coats. 
In the context of this study, buffy coat preparations were used to isolate PBMCs from the blood of 49 
healthy donors. The yield of PBMCs ranged from 80 million to 1350 million cells with a mean PBMC 
yield of 425±227 million cells. Typically, healthy blood donors are not characterized for HLA 
expression. Thus, HLA typing was required. As large numbers of PBMCs were needed for functional 
assessment of HLA ligands, a HLA typing methods with minimal cell input was desired. 
HLA typing is typically performed by PCR with HLA type-specific primers. However, simultaneous 
characterization of many alleles requires substantial amounts of template DNA. Compared to PCR, 
fewer input cells (~200.000 per sample) are required for FACS analysis with fluorescently labeled 
HLA-specific antibodies, and several HLA-molecules can be investigated simultaneously by staining 
with differently marked antibodies. Four HLA-specific and directly labeled antibodies against A2, A3, 
A24 and B7 were purchased and tested in cells of known HLA type. Figure 22 shows the results of 
antibody characterization by flow cytometry. For each antibody, testing of different dilutions, isotype 
binding and binding to unspecific HLA types is shown. All concentrations show separate positive 
peaks. For anti-HLA-A3-APC, anti-HLA-B7-PE and anti-HLA-A24-FITC the 1:200 dilution was 
found to be the highest dilution able to stain a distinct positive population, whereas for anti-HLA-A2-
FITC the 1:400 dilution was chosen. None of the antibody-matching isotype controls induced any 
background signal. The anti-HLA-A24-FITC antibody showed unspecific binding to the HLA types 
expressed by both mismatched control cell lines E481324 (A*01:01; B*52:01) and FH8 (A*11:01; 
A*34:02; B*82:01; B*27:05) and was therefore excluded from the antibody panel for HLA 
assessment. 
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Figure 22. Analysis of HLA-specific antibodies for flow cytometry. Antibody-stained cells of known HLA 
type were analyzed using flow cytometry. Histograms show numbers and fluorescence intensities of cells. Upper 
panels: cell lines positive for the respective HLA type were stained with fluorescently-coupled HLA-specific 
antibody at different dilutions (indicated below the figure) and compared to unstained cells. Middle panels: 
HLA-independent unspecific binding of antibody was analyzed by staining with a respective antibody isotype 
control coupled to the same fluorophore. Lower panels: HLA-dependent unspecific binding was assessed by 
staining of the cell lines E481324 (green) and FH8 (grey), expressing HLA types different from the respective 
antibody specificity. 
The three antibodies to A2, A3 and B7 were used for HLA typing of 49 healthy blood donors, 16 of 
whom were typed only for A2. Representative results of two donors are shown in Figure 23. Donor 
D25 showed a positive peak distinct from the isotype control antibody only for anti-HLA-A2-FITC 
and was thus determined to be A2
+
 A3
-
 B7
-
. In contrast, donor D30 showed no FITC signal for the A2-
specific antibody, but specific peaks for anti-HLA-A3-APC and anti-HLA-B7, and was thus defined to 
be A2
-
 A3
+
 B7
+
. The results for all donors are listed in Table 14. Overall, 18 (36.7%) of tested donors 
expressed A2, 10 (30.3%) A3 and 6 (18.2%) B7.  
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Figure 23. HLA-typing of healthy donors by flow cytometry. Isolated PBMCs of healthy donors were stained 
with specific fluorescently-coupled anti-HLA antibodies and analyzed by flow cytometry. Representative results 
of two donors are shown. Lymphocytes were gated based on forward (FSC) and sideward scatter (SSC) 
properties. Lymphocytes were further analyzed for fluorescence intensity of the respective fluorophore coupled 
to the used antibody. Markers for positivity were set based on the fluorescence intensities measured for staining 
with isotype controls (left). The HLA typing result is summarized below the figure. 
Table 14. Results for flow cytometry based HLA typing of healthy blood donors. 
Donor HLA-A2 HLA-A3 HLA-B7 
D1 +   
D2 -   
D3 -   
D4 - + + 
D5 +   
D6 +   
D7 +   
D8 - - - 
D9 +   
D10 -   
D11 -   
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Donor HLA-A2 HLA-A3 HLA-B7 
D12 +   
D13 -   
D14 +   
D15 - - - 
D16 -   
D17 -   
D18 - + + 
D19 - - - 
D20 -   
D21 +   
D22 - - - 
D23 + - - 
D24 - + - 
D25 + - - 
D26 + + + 
D27 + - - 
D28 - - - 
D29 - - - 
D30 - + + 
D31 - - - 
D32 + - - 
D33 + - - 
D34 - - - 
D35 - + - 
D36 - - - 
D37 - + - 
D38 - - - 
D39 - - - 
D40 - - - 
D41 - - + 
D42 - - - 
D43 - + - 
D44 - + - 
D45 + + - 
D46 + - - 
D47 - - - 
D48 + - - 
D49 + - + 
Total 18/49 (36.7%) 10/33 (30.3%) 6/33 (18.2%) 
+: positive, -: negative, blank: not analyzed 
4.4.2 IFNγ-ELISpot assays identify immunogenic HPV16 E6 and E7 peptides.  
In order to identify true T cell epitopes as candidates for vaccine development, it is necessary to 
confirm that HLA ligands induce T cell reactivity. To this end, healthy donors were screened for 
HPV16 E6- and E7-specific memory responses by IFNγ-ELISpot assays. As frequencies of HPV16-
specific T cells are known to be low in the peripheral blood, isolated PBMCs were cultured for twelve 
days in the presence of a HLA-specific ligand to stimulate and expand T cells recognizing this peptide 
prior to setting up the assay. A response was considered positive if the stimulation index (fold-change 
over unspecific background with solvent DMSO) was ≥2 and if the mean number of SFUs was ≥200 
per million cells. General ability of the cells to produce IFNγ was tested by unspecific stimulation with 
the mitogen Concanavalin A (ConA). The mean SFU of three wells for background and six wells for 
specific stimulation was calculated. Positive and negative epitope control stimulations were included. 
Results 
 
 
96 
Overall, 24 donors were screened for reactions to identified HLA-A2 and HLA-A3 ligands. Fifteen 
donors were A2
+
, eight were A3
+
 and one donor was A2
+
 A3
+
. Figure 24 shows representative 
examples for an A2
+
 Donor (D6) and an A3
+
 donor (D24). In donor D6, six A2-binding HPV16 E6-
/E7-derived peptides elicited responses that fulfilled one of the two criteria, but only four fulfilled both 
and were thus considered positive (E7/11-19, E7/12-19, E7/80-90 and E7/81-90). For D24, nine 
peptides were found that reached SI or SFU values above either respective threshold, and five which 
excited responses exceeding both (E6/68-77, E6/75-83, E6/106-115, E6/107-115 and E6/129-138). 
The immunogenicity results for all analyzed donors are summarized in Figure 24 C. In total, 18 A2- 
and 13 A3-associated epitopes were identified. For both HLA types one peptide was found to induce 
responses in the maximal number of four donors, which were E7/11-19 (A2) and E6/68-77 (A3). 
E7/11-19 was also the peptide inducing the strongest immune reactions. The two peptides E7/11-20 
and E7/77-87 were reactive in three A2
+
 donors. Six more A2 peptides were reactive in two donors 
and nine induced positive responses only in single donors. Also for HLA-A3, two peptides were found 
to be reactive in three donors and two by two donors. Responses against eight A3 epitopes were only 
detected in single donors. Comparing the intensity of the responses against A2-restricted peptides with 
A3-ligands, A3-mediated responses clearly involved fewer INFγ-positive cells. 
In order to identify epitope-responses shared by multiple donors, previous experiments on 
immunogenicity of HPV16 E6- and E7-derived peptides were re-assessed using the same ELISpot 
analyzer and results were added to the current dataset (Figure 25). A list of all IFNγ-responses can be 
found in Supplementary Table S6 in the Annex. The previous analysis included investigation of other 
HLA types. Peptides which were found to be ligands to several HLA types were treated as potential 
epitopes to the binding HLA molecules in reactive donors with incomplete HLA typing. Thus, the 
promiscuous epitope E6/68-77, which is binding to A1, A3, A11 and B15, was found to be 
immunogenic in donors positive for each of these HLA molecules, although being detected primarily 
in context of HLA-A3 assays. Moreover, Figure 25 highlights immunogenic sequence hotspots. 
Especially in the extensively investigated HLA types A2 and A3, regions with multiple immunogenic 
peptides can be found. The regions from aa 7 to 21 and 78 to 90 in the E7 protein are hotspots for A2-
restricted epitopes, whereas for A3 the regions from 68 to 83 and 106 to 115 in the E6 protein harbor 
many immunogenic peptides. 
In IEDB, 34 HPV16 E6- and E7-derived peptides were reported to induce IFNγ-responses (Annex, 
Supplementary Table S2). Of thirteen reported A2 epitopes, eight were validated in the course of 
IFNγ-ELISpot assays and one peptide was not investigated, as it did not show HLA-A2 binding in 
competition-based binding assays. Eleven identified A2 epitopes were not reported before. Only one 
of two reported A3 epitopes experimentally showed binding and IFNγ-responses. Half of the twelve 
IFNγ-inducing A3 epitopes were known to be HLA A3 ligands. 
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Figure 24. HLA-specific immunogenic HPV16 E6-/E7-derived peptides identified by IFNγ-ELISpot 
assays. ELISpot assays allow for investigation of IFNγ-producing cells upon re-stimulation with specific 
peptide. Results of representative donors are shown for HLA-A2
+
 (D6) and A3
+
 (D24) (A). The mean spot 
forming units (SFU) of wells were scanned and counted (B). Responses were considered positive if the 
stimulation index (fold-change over background) was ≥2 and mean SFU was ≥200 per million cells. 
Immunogenic peptides were assessed for all donors resulting in mean SI (C) (n, numbers of responding donors). 
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Figure 25. HLA-ligands and immunogenicity detected in donors. Determined HLA ligands are displayed at 
their respective position within the E6 or E7 protein. Shades of red illustrate immunogenicity in donors. Ligands 
that did not exhibit immunogenicity are shown in grey. As HLA typing of donors was incomplete, 
immunogenicity of ligands binding to multiple HLA types is shown for each associated molecule. 
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4.4.3 Epitope-specific T cell lines can induce specific lysis of HPV16+ target cells.  
To investigate the potential of immunogenic epitopes to mediate target cell lysis, the killing capacity 
of MACS-purified CD8
+
 T cell lines was assessed in a cytotoxicity assay. As cell numbers were 
limited, the flow cytometry-based Vital-FR assay was chosen. It allows simultaneous assessment of 
differently labeled specific and unspecific target cells, which reduced the required number of effector 
cells in contrast to typically used radioactive chromium-release assays (Stanke et al., 2010). 
Experiments were performed for HLA-A2
+
 healthy blood donors who showed a memory response in 
the IFNγ-ELISpot assays. PBMCs were expanded in long-term epitope-specific T cell lines for 15 
days by two stimulations with peptide-pulsed autologous DCs in an interval of seven days. From these 
cell lines, CD8
+
 T cells were isolated by untouched magnetic cell sorting. The effector cells (E) were 
co-cultured with same numbers of CFSE-labeled A2
+
 HPV16
+
 CaSki (specific) and FarRed-labeled 
A2
+
 HPV16
-
 C33A (unspecific) target cells (T) at different ratios (E:T). 
Effector cells from five donors were examined for specific killing induced by in total nine different 
immunogenic HPV16 E6-/E7-derived peptides as shown in Figure 26. Numbers of replicates and E:T 
ratios varied, as experiments had to be adapted to low CD8
+
 T cell numbers yielded after isolation 
from long-term epitope-specific T cell lines. Surprisingly, all epitopes assessed for one donor showed 
similar results. Either all or none were capable of mediating specific target cell killing. A lack of 
specific killing of epitope-specific T cells was observed in donors D6, D21 and D25, albeit all 
analyzed epitopes had been shown to induce IFNγ-responses in these donors in earlier ELISpot assays. 
In order to investigate if liquid nitrogen storage time between IFNγ-ELISpot and Vital-FR cytotoxicity 
assays influenced functionality of cells, and may thus explain the discrepancy between ELISpot and 
cytotoxicity assay results, cytokine production capacity of freshly isolated PBMCs and frozen PBMCs 
from donor D25 was compared. Production of the intracellular cytokines INFγ, TNFα and granzyme B 
was measured by flow cytometry (Annex, Supplementary Figure S7. Upon stimulation with 
PMI/Ionomycin, cytokine production by freshly isolated PBMCs was readily observed, whereas 
frozen PBMCs exhibited only a very weak production of IFNγ. 
The well-known epitope E7/11-19 (Riemer et al., 2010) was analyzed in four out of five donors, of 
which half had specific T cells with the capability to kill CaSki cells. Among the remaining eight 
epitopes, the four that shared a core sequence with E7/11-19 (E7/11-20, E7/11-21, E7/12-19 and 
E7/12-20) were able to induce cytolysis, whereas the other half (E7/80-90, E7/81-90, E6/25-33 and E6 
H85Y, L90V 83-90) was not. The three epitopes E7/11-19, E7/11-20 and E7/12-20 were previously 
demonstrated to induce cytolysis (Annex, Supplementary Table S2). These results indicate that HLA-
A2 epitopes from the E7 hotspot region 7-21 may represent good candidates for vaccine development. 
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Figure 26. Cytotoxicity mediated by CD8
+
 T cells specific for HPV16 E6-/E7-derived A2-restricted 
epitopes. Frequencies of specific and unspecific target cells and specific killing after co-culture with epitope-
specific CD8
+
 T cells, as assessed by flow cytometry-based Vital-FR assays. CD8
+
 T cells were isolated from 
long-term T cell lines stimulated weekly with epitope-pulsed autologous DCs. Isolated effector cells (E) were 
co-cultured at different ratios with 3000 specific A2
+
 HPV16
+
 CFSE
+
 CaSki cells (red) and 3000 unspecific A2
+
 
HPV16- FarRed
+
 C33A cells (blue) as targets (T). Upper panels show frequencies of both cell lines relative to 
culture without effector cells (E:T=0). Lower panels show specific killing (black) calculated by the frequency of 
specific to unspecific target cells. 
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5 Discussion 
This thesis aimed at identifying candidate epitopes for therapeutic HPV16 vaccine design, as well as 
providing a detailed performance evaluation of widely used HLA class I binding prediction methods. 
The first outlined research aim was attained by assessing the HLA class I binding affinity of 271 
predicted HPV16 E6- and E7-derived peptides Thereby, 69 out of 271 peptides were identified to be 
HLA ligands in the scope of this study. Combined with earlier results, 293 HPV16 E6- and E7-derived 
peptides were validated to be binders. The total dataset of 779 analyzed peptide-HLA combinations 
was used to evaluate the prediction performance of the 15 employed HLA class I binding prediction 
methods, which was the second aim of this thesis. Importantly, the evaluation revealed that prediction 
methods are not 100% precise, which confirms the continuous need for experimental validation of 
prediction results. The evaluation included detailed performance measures and novel individual 
threshold calculations for all combinations of analyzed predictors, HLA types and peptide lengths in 
order to provide recommendations for the best performance of available methods. The third aim of this 
thesis was accomplished when comparison of reference- and variant-derived peptides showed that 
many amino acid changes influenced the HLA binding affinities. To achieve the fourth aim, HLA A2- 
and A3-binding HPV16 E6- and E7-peptides were functionally characterized. Assessing the capacity 
to elicit IFNγ-secretion, 31 HLA ligands were identified to be immunogenic epitopes. Moreover, by 
investigating the potential to mediate specific killing of HPV16
+
 target cells, five A2-associated CTL 
epitopes were found. 
 
The HPV16 E6/E7 dataset comprised 779 peptide binding affinity measurements for seven frequent 
HLA class alleles, which are representatives for HLA supertypes. In contrast, earlier datasets used for 
performance evaluation of prediction methods included several thousand peptide measurements. For 
example, Yu et al. investigated 1,230 HLA-A*02:01-restricted and 234 HLA-B*35:01-restricted 9-
mer peptides with experimentally validated binding/non-binding (Yu et al., 2002). An even larger 
dataset of 48,828 peptide-binding affinity measurements for 48 MHC class I alleles of different 
species was used for benchmarking by Peters et al. (Peters et al., 2006). This dataset included 9- and 
10-mer peptides related to 36 HLA alleles, ranging from 92 (HLA-A*30:02) up to 4,405 (HLA-
A*02:01) analyzed peptides per HLA allele. However, these large datasets have been utilized to 
develop and train predictors. Therefore, Lin et al. used an independent dataset comprised of 
experimental binding affinities of 176 peptides for seven HLA alleles, six of which were analyzed in 
the scope of this thesis (Lin et al., 2008). All of the peptides were 9-mers derived from two antigens. A 
comprehensive dataset of 960 experimentally validated binders and nonbinders of seven HLA class I 
alleles, covering different antigens of HIV, influenza and cancer, was employed for prediction 
performance assessment by Gowthaman et al. (Gowthaman et al., 2010). However, as authors did not 
describe the detailed composition of this dataset, the peptide lengths and exact number of investigated 
peptides per HLA allele are unknown. Up-to-date performance evaluations can be accessed via the 
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IEDB as weekly benchmarks are performed on data that are newly entered into the database (Trolle et 
al., 2015). Nonetheless, such datasets are small in size and varying in HLA allele and peptide length 
coverage. In contrast to existing benchmark datasets, the HPV16 E6/E7 dataset is not focused on 9-
mer peptides, but also included HLA class I binding experimental assessment of 8-, 10- and 11-mers. 
Thus, it represents a comprehensive independent dataset suitable for performance evaluation of HLA 
class I binding prediction methods. Its value for the field has been demonstrated by recent studies, 
which used our HPV16 E6/E7 data as validation datasets for the development of the predictors 
MHCflurry and MHCnuggets (O’Donnell et al., 2018; Shao et al.). 
The binding affinity of HPV16 E6- and E7-drived HLA ligands was experimentally validated in 
cellular-based competitive binding assays as described by Kessler et al. (Kessler et al., 2004). Other 
experimental binding datasets were generated using cell free assays, e.g. competitive binding assays 
with purified MHC and radiolabeled peptide probes or reporter assays based on a conformation-
dependent anti-HLA class I antibody (Sidney et al., 2001; Harndahl et al., 2009). The cellular assays 
represent a more natural setting. However, cells express several HLA types at the same time. Thus, 
test peptides with high affinity to the investigated and another free HLA molecule might not compete 
with the reference peptide and therefore may not be detected as binders. In this study, known high 
affinity binder or consensus peptides (i.e., peptides with the most beneficial amino acid at each 
position) were chosen as reference peptides. This resulted in IC50-values in the µM-range, which is in 
strong contrast to predicted IC50-values in nM-range. Because of this difference between predicted and 
experimentally determined binding strength, predicted and experimental binding were only compared 
in a binary way, as binding or nonbinding. 
Specific features of the HPV16 E6/E7 peptide binding data might have influenced the prediction 
performance assessment. First of all, sample sizes differ for sub-datasets. Especially peptides binding 
to the HLA types A1 and B7 and of 8- and 11-aa peptide length are underrepresented in this study and 
the respective results should be interpreted with caution. However, as described, previous datasets 
rarely included any 8- or 11-mer peptides, which makes our evaluation of these peptide lengths 
valuable, albeit being limited. Performance measures might have been overestimated as the dataset 
only contains a selection of all possible E6-/E7-derived peptides, concentrated at the top-range of 
predicted binding likelihoods. Moreover, the HPV16 E6/E7 dataset contains a few previously reported 
HLA binders, which likely are part of the training data of predictors. On the other hand, the 
performance assessment of prediction methods that are extensively trained on heterogeneous data 
might be impaired, as this study addressed only HLA binding. Especially predictors trained on MS 
data, which is naturally selected for processing, HLA binding affinity, peptide binding competition for 
HLA molecules and bona fide peptide presentation, would be affected (Creech et al., 2018). 
Additionally, cysteine-containing peptides are underrepresented in MS data due to technical reasons 
(Bassani-Sternberg et al., 2017; Abelin et al., 2017). As HPV16 E6 and E7 proteins are cysteine-rich, 
prediction method performance of MS-data trained algorithms might suffer from evaluation based on 
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this dataset. Furthermore, it has to be considered that only a single viral protein dataset was 
investigated. However, predictions are mostly based on HLA binding motifs that do not differentiate 
peptide sources. Although lacking a validation dataset of comparable size and composition, we were 
able to validate threshold-dependent performance measures by a bootstrapping method. 
To date, many different algorithms for HLA class I binding prediction exist, and - with the advent of 
deep learning - new ones are constantly being developed (Han and Kim, 2017; Liu et al., 2019; 
Phloyphisut et al., 2019). This is driven by the advance of immunotherapies in personalized cancer 
treatment, where the prediction of suitable target epitopes remains a major challenge (Sahin and 
Türeci, 2018; Nogueira et al., 2018). The development of medical interventions based on HLA class I 
binding predictions requires reliable prediction methods. When comparing the different algorithms, we 
found the training-data dependent ANN methods superior to position-specific-scoring-matrix-based 
approaches, which is in line with previous studies (Gowthaman et al., 2010; Trolle et al., 2015; Lin et 
al., 2008; Yu et al., 2002; Peters et al., 2006). However, these studies did not include predictors trained 
on MS data, which were not outperforming other methods. Moreover, none of the prior evaluations 
examined prediction performance for individual peptide lengths due to the focus on 9-mer peptides. 
The generally used decision thresholds of IC50 ≤50nM and IC50 ≤500nM were suggested based on a 
study published in 1994, focusing on validated 9- and 10-mer HLA-A2 ligands predicted by the SMM 
algorithm (Sette et al., 1994). Later, based on corresponding measurements for 9- and 10-mer peptides 
with IC50 values >400nM in two experimental binding assay systems, the group recommended 
evaluating prediction performance by the ability to classify peptides into binders and nonbinders at a 
cutoff of 500 nM (Peters et al., 2006). These thresholds are now commonly applied across different 
predictors, HLA types and peptide lengths. However, practical examples imply that these thresholds 
might be too stringent for epitope prediction. Peptides eluted from HLA and identified by MS were 
found to have IC50-values >500nM, as shown by Bassani-Sternberg and colleagues (Bassani-Sternberg 
et al., 2016). Duan et al. described that 8/10 investigated immunogenic neoepitopes were predicted 
with an affinity of IC50 >500nM (Duan et al., 2014). Similar results were observed by Engels et al., 
who however additionally reported that only targeted high affinity binders led to tumor eradication, 
whereas targeting intermediate and low affinity binders resulted in relapse (Engels et al., 2013). 
Recently, MS data from our lab showed that also HPV16 E6- and E7-derived A2-restricted ligands of 
low affinity are presented on HPV16
+
 CaSki cells (Blatnik et al., 2018). Thus, applying the commonly 
used stringent decision thresholds is not generally suitable, which was demonstrated by a low 
sensitivity measured in our performance evaluation. 
Low sensitivity is a drawback, especially when prediction methods are employed with the objective of 
identifying a high number of potential candidates. Thus, suitability of the commonly used thresholds is 
questionable. However, more tolerant low binding affinity thresholds (IC50 ≤5000nM) were not 
generally improving prediction performance. For this reason, we defined optimal individual decision 
thresholds for each predictor, HLA type and peptide length. Earlier work by Paul et al. already 
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recommended HLA type dependent thresholds for 38 HLA-A and -B types (Paul et al., 2013). In line 
with our results, thresholds of IC50 values >500nM were suggested for the majority (27 of 38) of 
alleles. For the remaining 11 types, including A2 and A11, thresholds below IC50 500nM were 
proposed. However, in contrast to the comprehensive recommendations given in this thesis, Paul and 
colleagues focused only on the SMM predictor and 9-mer peptides. 
Our performance evaluation revealed that individual strengths of many approaches should be exploited 
and that the best methods for the HLA/peptide length to be investigated should be used. This is 
feasible using the web application MHCcombine, development of which was completed in the course 
of this thesis. MHCcombine facilitates using up to 12 different prediction algorithms. If offered by the 
algorithm, it allows querying individual prediction results for 8-11-mers for different HLA types 
combined in a spreadsheet. This is a decisive advantage over a previous method that provides the 
consensus output of several predictors and only allows 9-mer prediction (Trost et al., 2007). 
The HPV16 E6/E7 dataset also included binding affinity measurements of HPV16 protein variants 
containing amino acid substitutions. Previous findings of a large whole-genome study of HPV16 
identified more SNPs in E6 than in in E7, which is generally conserved (Mirabello et al., 2017). 
Indeed, sequencing of E6 and E7 genes of HPV16
+
 cell lines in the cell bank of the research group 
revealed several SNPs resulting in amino acid substitutions, which mainly occurred in E6. In peptides, 
substitutions at anchor positions but also in the middle sequence drastically changed HLA binding 
properties. Based on known HLA binding motifs, effects are expected to be position-dependent (Falk 
et al., 1991; Kubo et al., 1994; Rammensee et al., 1999). Conventionally, certain amino acids at 
specific anchor positions are extremely important for HLA binding, whereas middle positions are 
more variable in their degree of influence. However, our results indicated that the role of the central 
peptide sequence in HLA binding might be more important than anticipated. Moreover, middle 
sequence amino acids are mainly involved in TCR interaction (Garboczi et al., 1996; Garcia et al., 
1998; Calis et al., 2013). Hence, changed HLA binding affinity and chemical properties in middle 
residues of HPV16 E6/E7 variants might cause abolition of existing or creation of new target epitopes 
(Chowell et al., 2015). In this regard, HPV16 E6/E7 variant-derived epitopes are likely to be 
associated with a different T cell repertoire, which could be related to the reported differences in 
outcomes observed for infections with HPV16 variants (Zehbe et al., 1998; Tu et al., 2006; Xi et al., 
2007; Zuna et al., 2011). 
 
As outlined above, HLA binding and thus HLA presentation of a peptide is absolutely crucial for it to 
be a T cell epitope, however it is not sufficient for T cell recognition (Sidney et al., 2008a). The 
expression and processing of proteins is as important as effects of competition for HLA binding 
between peptides and the stability of the formed HLA complex. On the other side, the host T cell 
repertoire determines if a presented peptide can be recognized and if immune responses are induced. 
Further, the presented peptide needs to be different from endogenous peptides, as well as to be 
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presented in a stimulatory environment in order to elicit the immune responses desired for target cell 
killing. All these aspects are currently not heuristically considered by prediction methods. Thus, the 
functional characterization of identified HPV16 E6-/E7-derived HLA ligands was required in order to 
identify T cell epitopes. 
To assess HPV16 E6- and E7-derived T cell epitopes, large numbers of PBMCs were required. As 
using buffy coats did not allow multiple blood drawings from the same donors, experiments were 
limited by the number of PBMCs isolated from a buffy coat. In order to perform consecutive 
experiments, it was necessary to work with varying numbers of frozen cell aliquots. However, 
handling of cells during freezing and thawing may influence cell viability or function (Owen et al., 
2007) Also in our hands, analysis of one donor, who did not mediate target cell killing in cytotoxicity 
assays albeit demonstrating IFNγ-secretion in ELISpot assays, suggested that cytokine responses of 
frozen cells were impaired.  
To determine the HLA type of donors, staining with HLA-specific conjugated antibodies and flow 
cytometry analysis were performed, as this method is suitable for work with low PBMC numbers. The 
limited availability of labeled HLA-type-specific antibodies without cross-reactivity narrowed the 
reliable characterization to three types: A2, A3 and B7. HLA type frequencies did not perfectly match 
with the reported distribution in the German population of 49.9%, 28.6% and 24.5%, respectively 
(González-Galarza et al., 2015), which is most likely due to the relatively small number of tested 
samples. Incomplete HLA-typing did not allow excluding cross-reactions associated with peptide 
presentation by uncharacterized HLA molecules. With complete HLA typing, e.g. by PCR of 
amplified HLA class I gene loci using HLA type-specific primers, cross-reactivity can be ruled out 
and more HLA types can be investigated in the future. 
Earlier experiments with several voluntary HLA-typed blood donors showed no T cell reactivity 
against HPV16 E6-/E7-derived peptides (data not shown). As these donors were mostly young 
adults (age <30), this cohort had the chance of being prophylactically vaccinated against HPV16 and 
likelihood for exposure was low. Thus, we decided to work with buffy coat preparations of healthy 
blood donors. As blood donations were anonymous, HPV16 infection history was not known. To 
increase the chances for previous undetected or transient HPV16 infection, buffy coats from donors 
above the age of 40 were requested. Moreover, donors should preferably be female, because immune 
responses are expected to be stronger and more frequent in women (Bosch et al., 2013). However, the 
latter request was not always fulfilled. Although frequencies of HPV16 E6- and E7-specific T cells in 
the peripheral blood are known to be low, immunogenicity of target epitopes was detected in 18 of 24 
analyzed donors (Youde et al., 2000; de Jong et al., 2005). This shows that our donor selection criteria 
are beneficial for detecting immune responses. Naturally, immune responses are varying by individual 
and thus, epitope immunogenicity is not likely to be the same for all donors. However, we identified 
immunogenic hotspot sequences in the E6 and E7 proteins, harboring epitopes detected in more than 
one donor. Based on shared epitope-specificity of measured memory T cell responses, peptide-
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presentation on respective HLA class I molecules can be inferred. Such a conclusion is supported by 
the finding that the majority of HLA class I-presented viral peptides are immunogenic (Croft et al., 
2019). Along the same lines, a targeted LC-MS strategy applied in our research group will additionally 
characterize the identified 293 HLA binders for natural translation, processing and bona fide HLA-
presentation on HPV16
+
 target cells. 
Despite donor-to-donor variations, five A2-restricted CTL epitopes derived from the HPV16 E7/7-21 
hotspot region were found to mediate specific lysis of HPV16
+
 target cells. However, because of the 
observed differences in the capability of epitope-specific target cell killing, results need to be 
reproduced with cells from more donors. The used flow cytometry-based cytotoxicity assay was 
perfectly suited for this study, as it was designed to assess minute frequencies of CD8
+
 T cells’ 
cytolytic function with 30 times higher sensitivity than the standard 
51
chromium-release assay (Stanke 
et al., 2010). This assay reduces the number of required input cells by co-incubation of effector cells 
together with only 1x10
3
 specific and 1x10
3 
unspecific target cells. For the purpose of this thesis, A2
+
 
HPV16
+
 CaSki cells represented ideal specific target cells. The presentation of 11 HPV16 E6-/E7-
derived epitopes on HLA-A*02:01 molecules on the surface of CaSki cells has already been proven by 
mass spectrometry (Blatnik et al., 2018). Out of the peptides tested for cytotoxicity induction in this 
thesis, the three peptides E7/11-19, E7/80-90 and E7/81-90 were reliably detected by MS on CaSki, 
and three other peptides (E7/11-20, E7/11-21 and E7/12-19) were found at the limit of detection. 
However, the peptides E7/12-20, E6/25-33 and the H85Q, L90V-variant-derived E6/83-90 peptide 
were not yet reliably detected to be displayed by HLA-A2 on CaSki cells. Thus, not all of the tested 
peptides were known to be presented on the specific target cells prior to cytotoxicity assays. In 
contrast, unspecific target cells should not present the specific epitopes, but should ideally be 
otherwise identical to the specific target cells. Currently, C33A is the only available HPV16
-
 cervical 
cancer cell line, and luckily it is HLA-A2
+ 
(Yee et al., 1985). However, C33A cells grow faster than 
CaSki cells (doubling time 1.26 days vs. 3.2 days according to Cellosaurus) (Bairoch, 2018). In order 
to compensate different proliferation kinetics, specific killing was calculated based on the ratios 
between specific and unspecific target cells relative to co-cultures without effector cells. However, an 
unspecific decrease in C33A cell numbers was observed at high E:T ratios. It remains unclear if this is 
either an effect of unspecific killing or of undernutrition. Alternatively, HLA-matched peptide-pulsed 
B cells could be used as target cells in future assays. Autologous B cell lines can be generated from 
isolated PBMCs, but the approach would consume the anyway limited number of PBMCs and the 
process requires at least 14 days prior to starting the T cell line culture (von Bergwelt-Baildon et al., 
2002; Liebig et al., 2009). Allogenic B-LCLs are easier to culture and would represent uniform 
controls over multiple donors, but as they are immortalized by EBV-transformation, unspecific killing 
by EBV-specific donor T cells might occur (Tosato and Cohen, 2007). However, the use of either 
B cells would allow investigating additional HLA types. 
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Previously, 89 different HPV16 E6-/E7-derived epitopes were reported in IEDB in context of the 
investigated HLA types. Overall, 102 peptide-HLA combinations were investigated, as some epitopes 
were associated with multiple HLA types. Of these, twelve combinations were not assessed in this 
study, due to negative binding predictions. Moreover, 25 reported HLA epitopes, of which 21 were 
described to be HLA ligands, did not demonstrate HLA binding in competition-based binding assays 
and were thus not functionally characterized. A special case is the peptide E7/78-86, which was 
characterized to be a binder in earlier experiments, but did not exhibit binding in later experiments. 
Hence, it was considered to be a nonbinder in the course of this thesis. Nonetheless it was detected to 
be presented on CaSki cells by targeted LC-MS (Blatnik et al., 2018) and showed immunogenicity in 
previous IFNγ-ELISpot assays. Thus, this peptide likely is a true epitope. Taken together, the majority 
of IEDB-registered HLA epitopes (64 of 102) was validated. More importantly, binding assays 
identified 229 HLA ligands that were not previously reported. Additionally, IFNγ-ELISpot assays 
revealed 13 A3 epitopes, of which only one was known to induce IFNγ-responses before. For A2, 18 
IFNγ-inducing epitopes were identified, of which 8 were reported before, but 10 were novel. Also the 
cytotoxicity-mediating capacity of two out of five A2 epitopes has been demonstrated for the first 
time. Consequently, new promising target epitopes for HPV16 immunotherapy were identified in the 
course of this thesis. 
 
The overall aim of the research group is to develop a therapeutic vaccine against HPV16 based on 
targeting the oncogenic proteins E6 and E7. The described HPV16 target identification approach 
pursued by the research group represents an approach often described as “reverse immunology” (Celis 
et al., 1994; Boon and van der Bruggen, 1996). First, potential HLA class I ligand peptides from a 
protein sequence are predicted in silico based on known binding motifs. Subsequently, candidate 
peptides are synthesized and actual HLA binding and induction of T cell immune responses is tested in 
vitro in order to identify targets for vaccine development. Our recently published achievements proved 
this strategy to be suitable for the detection of immunogenic HLA-A2-presented HPV16 E6 and E7 
peptides (Blatnik et al., 2018). As an essential part of this approach, numerous E6- and E7-derived 
HLA ligands, A2- and A3-associated T-cell epitopes and five A2-restricted CTL epitopes were 
identified in the scope of this thesis. Thus, among all possible antigen-derived peptides, promising 
candidates for development of a therapeutic HPV16 vaccine were successfully characterized. 
Especially immunogenic peptides shared by multiple donors represent promising candidates for 
vaccine development. Moreover, the results obtained in this thesis imply that studying HPV16 E6-/E7-
variants is clinically relevant. In HPV lesions, typically the HPV types but not the exact genomic 
variants are determined. Consequently, immunotherapy should ideally be focused on epitopes which 
are conserved between HPV16 variants. As outlined above, functional epitope-specific vaccination is 
dependent on the HLA types of patients. To avoid HLA-typing of patients, vaccine formulations can 
contain “promiscuous” epitopes, which are epitopes binding to multiple HLA types, or combine 
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epitopes for HLA supertypes. As described above, the selected alleles in this study have a high 
population frequency and are the representatives of supertypes. A vaccine combining epitopes for each 
of the five supertypes covered herein is expected to provide a population coverage of ≥95% (Reche 
and Reinherz, 2007). Some of the candidate epitopes validated in the scope of this thesis were already 
analyzed in various vaccine formulations tested in a HLA-humanized A2.DR1 mouse model (Kruse et 
al., 2019). In this preclinical study, prophylactic and therapeutic epitope-specific vaccination provided 
survival benefits as well as anti-tumor effects in A2.DR1-mice challenged with PAP-A2 tumor cells. 
To further assess clinical relevance and therapeutic potential at a precancerous stage, the described 
epitope identification strategy will be extended to the investigation of clinical samples of CIN patients. 
In summary, this study describes the identification of a part of an epitome map for HPV16 E6- and 
E7-derived targets with clear translational potential. Knowledge on validated HLA-specific targets 
allows developing of various immunotherapies. The characterized HPV16 E6-/E7-derived epitopes 
can be employed for immunomonitoring, finding of epitope-specific TCRs for engineered T cell 
therapy, stimulation of isolated TILs for adoptive cell transfer and, obviously, for peptide-based 
vaccination approaches. 
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Supplementary Table S1. HLA binding prediction scores and experimental binding affinity of HPV16 E6- and E7-derived peptides. 
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A1 
E7/2-11 HGDTPTLHEY 1.03±0.59 1142 250 679 414 267 257 2146 384 315 313 309 0.45 0.35 0.08 28 
E6/80-88 ISEYRHYCY 1.20±0.96 33 55 56 108 81 67 1146 293 300 40 25 0.25 0.25 0.01 27 
E6 D32E/30-39 IHEIILECVY 1.25±0.65 19613 21523 14364 12453 8016 13142 11604 2299 3082 13013 20469 4.90 4.70 11.00 24 
E6 H85Y/80-88 ISEYRYYCY 1.25±1.06 32 84 51 94 88 86 1062 319 323 31 29 0.25 0.25 0.02 27 
E6 D32E/29-39 TIHEIILECVY 1.46±0.82 18897 8800 10976 10956 4236 6096 3308 2139 773 7199 6141 2.80 2.75 8.00 16 
E7/14-23 DLQPETTDLY 1.62±0.91 3676 1275 1324 2246 2343 1728 4288 1041 941 194 1893 0.95 0.70 0.20 19 
E6 A68G/67-77 YGVCDKCLKFY 1.81±1.35 11404 17179 6597 7392 14186 15625 12382 11097 6012 16400 17746 5.60 5.65 2.00 18 
E6/68-77 AVCDKCLKFY 2.52±1.22 3210 3631 1547 1140 5683 4551 2123 1305 1753 6850 11927 1.30 1.05 1.00 18 
E6/74-83 LKFYSKISEY 7.72±0.00 17014 9154 15773 14949 30939 16855 27876 1650 1270 12423 30978 3.00 2.75 4.00 16 
E7 N29S/19-29 TTDLYCYEQLS 10.45±10.39 14480 2391 7867 8697 1631 1978 2365 6717 75861 1449 2154 32.10 31.95 2.00 18 
E6 E36Q/29-39 TIHDIILQCVY 11.26±20.22 11046 8673 8854 8612 2834 4963 3100 1771 641 4615 7203 1.10 1.15 6.00 16 
E7/18-25 ETTDLYCY 11.52±7.17 1749 322 4421 3575 211 262 2417 21858 40545 254 187 23.05 23.05 7.00 N/A 
E6/92-99 GTTLEQQY 12.52±6.85 11702 2008 14781 15251 1216 1568 3933 3764 16632 1059 2537 11.25 11.20 6.00 N/A 
E6/23-31 CTELQTTIH 13.09±15.44 6706 3087 2137 1037 2040 2510 1766 2486 3331 1528 4233 1.95 1.65 0.30 15 
E6/79-88 KISEYRHYCY 15.66±10.16 331 2027 1230 1377 2366 2193 1968 765 867 1453 367 0.55 0.45 2.00 15 
E6 H85Y/79-88 KISEYRYYCY 16.68±15.01 203 1425 1069 1252 2455 1864 1747 607 799 1099 432 0.55 0.45 0.90 16 
E6/82-91 EYRHYCYSLY 16.92±3.78 13541 4120 16338 19356 25392 10191 12249 1478 1193 13900 23159 2.00 1.70 3.00 17 
E7/4-11 DTPTLHEY 24.92±13.05 6601 2006 8641 7096 2190 2100 5211 26461 41299 1204 7031 23.60 23.55 6.00 N/A 
E6/81-91 SEYRHYCYSLY 32.04±12.55 18653 18138 8914 21042 15291 16583 7054 525 2838 10236 13368 4.50 4.50 2.00 18 
E6 A68G/68-77 GVCDKCLKFY 32.41±51.84 5164 4547 2474 1835 6808 5560 2752 1275 1981 8632 13079 1.40 1.15 2.00 17 
E6 H85Y/82-91 EYRYYCYSLY 35.16±11.67 9287 3982 12804 16601 25133 9973 12791 1544 1233 14285 18354 1.10 0.80 4.00 17 
E6 H85Y/78-88 SKISEYRYYCY 38.09±34.22 403 19758 958 2391 27963 23445 22696 13621 3556 13995 5216 2.95 2.90 4.00 17 
E6/80-89 ISEYRHYCYS 39.31±27.97 2049 18380 4700 5104 15306 16855 13502 7457 8410 7803 994 4.45 4.20 0.80 13 
Annex 
 
(Continued) 
125 
P
e
p
ti
d
e 
ID
a
 
S
e
q
u
e
n
c
e
b
 
E
x
p
. 
IC
5
0
 ±
 S
D
c  
N
e
tM
H
C
 4
.0
d
 
N
e
tM
H
C
 3
.4
 d
 
N
e
tM
H
C
p
a
n
 4
.0
 d
 
N
e
tM
H
C
p
a
n
 3
.0
 d
 
N
e
tM
H
C
p
a
n
 2
.8
 d
 
N
e
tM
H
C
c
o
n
s 
1
.1
 d
 
P
ic
k
P
o
c
k
e
t 
1
.1
 d
 
IE
D
B
 S
M
M
P
M
B
E
C
 d
 
IE
D
B
 S
M
M
 d
 
M
H
C
fl
u
r
ry
 1
.2
 d
 
M
H
C
n
u
g
g
e
ts
 2
.0
 d
 
IE
D
B
 r
ec
o
m
m
e
n
d
e
d
e  
IE
D
B
 c
o
n
se
n
su
se
 
M
ix
M
H
C
p
r
e
d
2
.0
.2
e  
S
Y
F
P
E
IT
H
If
 
E7/19-28 TTDLYCYEQL 41.65±38.75 3004 3204 3137 2318 1701 2340 2443 2226 2629 1250 3287 1.65 1.40 0.40 18 
E6 H85Y/80-89 ISEYRYYCYS 43.40±9.46 1240 16575 4530 4699 14985 15795 11604 6927 7060 7415 1095 3.60 3.50 0.90 13 
E6/78-88 SKISEYRHYCY 45.72±27.05 709 19881 1125 2744 28588 23828 25564 15639 3516 15008 5972 2.95 2.90 5.00 16 
E6/81-88 SEYRHYCY 46.44±20.50 1014 19115 7833 12175 18241 18679 10191 11314 9439 15813 12167 6.55 6.55 71.00 N/A 
E7/19-27 TTDLYCYEQ 83.36±15.02 4336 5319 3126 1899 2317 3511 1453 3601 4504 1049 17540 2.40 2.15 0.50 17 
E6/23-33 CTELQTTIHDI nb 16586 3663 11743 11643 4426 4019 9246 54853 40459 2204 17921 24.10 24.05 2.00 15 
E6/29-39 TIHDIILECVY nb 17802 9128 8155 8316 3345 5530 3237 1982 671 6112 7234 2.40 2.30 6.00 16 
E6/30-39 IHDIILECVY nb 13152 15699 8007 5279 1752 5239 5267 1591 1931 6432 20030 2.15 1.75 5.00 26 
E6/31-39 HDIILECVY nb 17445 17026 14334 16437 24096 20258 6331 3850 3842 16523 13338 5.70 5.55 13.00 17 
E6/42-50 QQLLRREVY nb 21851 19260 24239 26617 26226 22452 7776 20064 20585 19336 31692 20.00 18.50 3.00 17 
E6/43-53 QLLRREVYDFA nb 26757 21133 34347 35934 32145 25983 31399 1123 514 21021 23626 9.35 8.85 48.00 2 
E6/51-61 DFAFRDLCIVY nb 11506 15873 12061 8603 10669 13000 9146 991 2042 14222 15999 2.40 2.40 12.00 16 
E6/52-61 FAFRDLCIVY nb 4526 5066 3342 1998 1736 2953 4197 2689 3032 1481 6285 1.80 1.55 4.00 16 
E6/53-61 AFRDLCIVY nb 19580 18827 25814 24198 21830 20258 3530 6675 6959 14491 16380 11.60 10.10 14.00 18 
E6/54-61 FRDLCIVY nb 13549 2913 21049 21874 2145 2497 6400 33544 27538 967 1397 16.90 16.85 2.00 N/A 
E6/57-67 LCIVYRDGNPY nb 15340 15200 13075 14874 21200 17985 9654 3624 465 7410 6043 1.55 1.40 5.00 16 
E6/58-68 CIVYRDGNPYA nb 27746 20711 26037 23974 27990 24087 46353 1876 1159 22102 15057 11.50 11.00 37.00 0 
E6/59-67 IVYRDGNPY nb 7734 11980 6340 5740 3695 6647 1438 5063 4792 6607 13311 2.60 2.30 2.00 15 
E6/67-77 YAVCDKCLKFY nb 6323 11458 1060 1403 5157 7692 7776 11754 9269 8405 1649 8.35 8.65 1.00 18 
E6/69-77 VCDKCLKFY nb 6457 5882 5057 4559 2287 3666 2443 1206 1001 2477 6886 0.95 0.65 0.03 26 
E6/73-83 CLKFYSKISEY nb 12283 11678 7773 9822 8283 9866 6683 1645 149 5032 12989 0.85 0.75 2.00 17 
E6/75-83 KFYSKISEY nb 18273 19888 20154 16829 21792 20814 4527 8738 6959 15877 30918 7.80 7.65 4.00 16 
E6/76-86 FYSKISEYRHY nb 7546 14923 11024 11374 15750 15291 14564 20759 5094 9714 8796 4.65 4.90 0.90 17 
E6/77-86 YSKISEYRHY nb 2088 434 2005 2071 5411 1526 9448 548 685 737 322 0.75 0.50 0.20 21 
E6/78-86 SKISEYRHY nb 27567 20630 35294 36816 40418 28795 23445 92559 83859 17555 22814 46.00 44.50 7.00 16 
E6/83-91 YRHYCYSLY nb 8111 17209 12767 14964 9459 12722 6331 2555 1839 8487 17722 1.25 0.95 0.70 17 
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E6/88-95 YSLYGTTL nb 22765 18459 21967 21545 13158 15625 15710 866 3250 19706 34277 2.95 2.95 18.00 N/A 
E6/89-99 SLYGTTLEQQY nb 7370 8510 4838 7260 4101 5901 2193 4626 646 8079 7447 0.85 1.15 0.70 17 
E6/90-99 LYGTTLEQQY nb 18888 7355 18184 18512 22188 12791 11113 1237 1999 14080 15189 4.10 3.90 4.00 15 
E6/134-144 NIRGRWTGRCM nb 34058 21649 38169 38473 33146 26840 43439 2601 9528 23134 33104 32.50 32.00 56.00 0 
E6 A68G/60-69 VYRDGNPYGV nb 24101 24096 31686 27659 33878 28640 50000 29960 23110 24136 33172 21.50 20.00 71.00 0 
E6 E36Q/30-39 IHDIILQCVY nb 7212 14102 6692 4127 1109 3954 5155 1740 1918 5023 18897 1.40 1.10 3.00 26 
E6 H85Y/76-85 FYSKISEYRY nb 2954 1534 2244 1951 5926 3017 7609 707 591 4802 7497 0.70 0.45 2.00 17 
E6 H85Y/76-86 FYSKISEYRYY nb 2231 12330 7691 6120 9562 10875 9654 11408 5496 9244 6775 4.95 5.25 0.50 17 
E6 H85Y/77-85 YSKISEYRY nb 471 282 670 545 761 464 2241 626 545 301 188 0.45 0.40 0.08 21 
E6 H85Y/77-86 YSKISEYRYY nb 462 231 780 635 2109 696 6263 380 464 575 169 0.35 0.20 0.08 21 
E6 H85Y/81-88 SEYRYYCY nb 647 18977 7419 11869 17519 18181 8120 44834 30335 14843 5752 17.55 17.55 74.00 N/A 
E7/13-23 LDLQPETTDLY nb 10702 17537 7768 9004 21942 19611 16228 3042 100 7967 2949 0.65 0.75 2.00 17 
E7/15-23 LQPETTDLY nb 7998 10499 5255 7312 7205 8711 2169 2645 3166 5389 16183 1.85 1.55 0.60 17 
E7/15-25 LQPETTDLYCY nb 16310 14564 12041 15648 9073 11479 7209 13589 2924 12110 5727 3.95 3.95 3.00 17 
E7/16-25 QPETTDLYCY nb 8074 5773 9370 7907 6441 6096 10642 498 546 10190 23714 0.70 0.40 0.60 25 
E7/19-26 TTDLYCYE nb 12345 3668 7559 8170 3349 3511 3100 11107 20415 2604 3600 13.30 13.25 1.00 N/A 
E7/19-29 TTDLYCYEQLN nb 16817 5300 11705 13612 4002 4626 2216 6702 38996 5595 3279 23.65 23.55 2.00 18 
E7/42-52 AGQAEPDRAHY nb 21457 17310 11592 24816 24890 20814 19088 8774 2819 15554 31073 5.75 5.70 6.00 16 
E7/43-52 GQAEPDRAHY nb 15534 12466 9864 15671 23790 17224 14099 4117 3348 13404 22907 3.40 3.35 2.00 16 
E7/44-52 QAEPDRAHY nb 4645 6096 3125 6669 5871 5998 4936 3728 2544 1302 3869 1.55 1.30 0.02 25 
E7 N29S/28-38 LSDSSEEEDEI nb 11966 4024 14067 13692 6246 5017 5933 16912 7329 1196 1551 7.20 7.15 2.00 15 
A2 
E7/83-93 LMGTLGIVCPI 0.38±0.38 248 558 215 262 79 211 121 206 1452 167 79 8.30 8.05 21.00 N/A 
E7/82-91 LLMGTLGIVC 1.03±0.40 325 916 462 355 1028 969 646 351 475 2426 478 2.75 2.45 6.00 15 
E7/86-93 TLGIVCPI 1.27±1.54 980 183 2177 2198 393 269 212 174 167 578 34 1.00 0.80 5.00 N/A 
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E7/11-19 YMLDLQPET 1.40±0.94 21 5 22 30 7 6 41 21 21 46 23 0.40 0.40 0.30 21 
E7/85-93 GTLGIVCPI 1.96±1.93 203 155 75 107 121 137 176 387 427 309 139 4.40 4.40 7.00 21 
E7/84-93 MGTLGIVCPI 1.98±1.89 393 7314 296 322 10428 8711 3033 1294 1642 7561 1418 6.60 6.20 81.00 11 
E7/11-20 YMLDLQPETT 2.19±2.71 176 44 187 237 25 33 184 170 165 280 102 1.45 1.20 0.50 19 
E7/11-21 YMLDLQPETTD 2.37±1.67 4352 9395 9156 11401 2402 4727 503 940 889 6288 902 5.90 5.95 3.00 N/A 
E6 D32E/28-38 TTIHEIILECV 2.47±1.71 3025 1499 4527 8614 994 1222 586 863 705 2555 520 4.95 5.05 6.00 N/A 
E7/7-15 TLHEYMLDL 2.68±1.86 49 48 61 65 95 68 93 133 136 285 142 2.10 2.10 0.20 24 
E7/77-87 RTLEDLLMGTL 2.69±2.94 3257 577 2582 3837 768 667 802 241 324 2830 1712 2.65 2.75 3.00 N/A 
E6 R17I/9-17 FQDPQERPI 2.72±1.59 1166 1943 2258 2044 2713 2302 414 816 742 736 570 1.50 2.10 5.00 11 
E7/82-90 LLMGTLGIV 3.30±2.58 25 19 17 16 20 20 12 25 26 65 122 0.50 0.50 2.00 29 
E7/12-20 MLDLQPETT 3.60±0.73 1812 2403 2362 2157 2440 2417 561 1298 1162 3880 1038 7.90 7.90 5.00 16 
E6 Q21D/18-28 KLPDLCTELQT 3.68±2.63 6743 1079 6485 11935 1007 1039 674 778 1489 1494 7691 9.45 9.25 0.90 N/A 
E6/29-38 TIHDIILECV 3.69±2.17 276 303 316 320 145 210 269 445 450 971 179 2.65 2.35 2.00 23 
E6/52-60 FAFRDLCIV 4.34±2.11 155 115 156 115 150 132 105 152 149 284 83 2.30 2.30 5.00 20 
E6 D32E/29-38 TIHEIILECV 5.88±1.81 259 331 409 452 153 225 249 495 512 1428 150 2.85 2.55 2.00 24 
E6 D32E, I34R/29-38 TIHEIRLECV 7.26±2.50 1219 12901 1587 1686 18908 15625 3686 3898 3745 2624 252 10.35 4.65 1.00 24 
E6 Q21D/18-26 KLPDLCTEL 7.45±1.77 23 12 49 47 18 15 52 35 34 246 261 0.60 0.60 0.02 25 
E7/11-18 YMLDLQPE 8.07±3.69 5042 2323 8103 7304 768 1333 234 822 2479 782 2057 7.85 8.00 29.00 N/A 
E6/18-26 KLPQLCTEL 10.07±3.22 108 87 281 227 130 107 70 127 114 739 933 1.80 1.80 0.06 24 
E7/80-90 EDLLMGTLGIV 14.20±2.47 971 18371 1511 1600 34740 25153 22696 2019 1161 14678 1134 7.35 7.05 67.00 N/A 
E6 D32E/25-33 ELQTTIHEI 15.51±9.74 20154 29997 2930 26076 33645 31740 43439 401264 369922 2296 2381 64.00 6.60 0.20 22 
E7/7-17 TLHEYMLDLQP 19.35±12.57 11451 9301 14462 20258 12314 10700 1926 283 90 13891 5243 2.95 1.60 10.00 N/A 
E6 R17I/9-19 FQDPQERPIKL 20.75±15.64 8579 3176 6087 11214 740 1534 653 3501 12215 2232 3482 29.05 28.75 1.00 N/A 
E6 H85Y/83-90 YRYYCYSL 21.01±8.92 14920 6045 20213 23243 2298 3726 1926 19762 15639 2964 15411 23.10 22.65 39.00 N/A 
E6 D32E, I34R/28-38 TTIHEIRLECV 29.14±16.90 10174 3865 12699 17971 3479 3666 953 11355 6136 5310 952 21.30 20.75 5.00 N/A 
E7/76-86 IRTLEDLLMGT 31.85±22.45 8340 24652 5149 9448 39274 31229 50000 2946 3531 15750 15290 16.05 15.75 44.00 N/A 
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E7/82-92 LLMGTLGIVCP 31.96±20.21 3240 5188 2994 3969 2069 3290 281 877 671 4453 340 4.75 4.85 5.00 N/A 
E6 H85Y, L90V/83-90 YRYYCYSV 32.29±15.14 9128 2368 19446 22112 2302 2327 735 17492 7083 907 8357 13.50 13.50 33.00 N/A 
E6/18-28 KLPQLCTELQT 34.50±19.55 10551 3392 8531 16616 4714 3997 855 1715 3311 4006 15762 16.05 15.25 3.00 N/A 
E6 H85Y/84-93 RYYCYSLYGT 35.20±17.55 15989 4749 13986 11860 12796 7776 3849 972 1152 7614 18301 19.25 10.25 14.00 11 
E6/28-38 TTIHDIILECV 35.72±4.66 3484 1444 3945 7569 909 1146 549 883 781 1683 636 5.40 5.45 6.00 N/A 
E6/25-33 ELQTTIHDI 36.90±8.41 6830 7890 9733 9680 9381 8571 205 3072 3077 4896 12715 14.00 14.00 2.00 20 
E7/66-74 RLCVQSTHV 37.18±10.65 558 781 719 571 765 776 36 213 208 730 661 2.80 2.80 0.20 20 
E7/81-91 DLLMGTLGIVC 41.25±39.26 2747 9628 10688 5639 23175 14964 4107 2149 1066 8055 1175 7.65 7.75 22.00 N/A 
E6/34-44 ILECVYCKQQL 45.15±8.59 8508 4362 4136 5306 813 1884 514 3429 9139 4866 3433 25.55 25.25 3.00 N/A 
E6/79-87 KISEYRHYC 47.56±29.56 6936 6671 3524 2063 4164 5267 1534 1612 1390 3712 575 8.70 8.70 0.50 13 
E7/81-90 DLLMGTLGIV 52.58±19.28 120 755 251 171 3220 1559 172 132 103 2104 225 0.90 0.85 7.00 25 
E6 H85Y, L90V/81-90 SEYRYYCYSV 52.62±28.64 6255 1041 7486 6926 3334 1864 704 206 175 1084 8890 2.75 1.40 13.00 16 
E7/12-19 MLDLQPET 53.66±12.03 4073 1760 11632 9488 444 884 561 926 3992 4315 120 9.85 10.00 12.00 N/A 
E6 H85Y/79-89 KISEYRYYCYS 59.11±35.98 25067 9962 18205 21152 2895 5382 2290 646 486 7743 1041 21.55 16.05 11.00 N/A 
E7/86-94 TLGIVCPIC 62.31±18.61 4822 11770 5803 4733 8538 10027 1844 6433 5130 3341 777 18.00 18.00 23.00 11 
E7/77-86 RTLEDLLMGT 72.72±17.36 2565 1045 2254 2033 3454 1905 1422 531 535 1887 1414 3.75 2.80 4.00 17 
E6 H85Y/81-90 SEYRYYCYSL 74.36±19.14 11629 3457 14031 12377 4922 4129 1844 656 575 3410 15416 5.70 4.15 16.00 16 
E6/9-19 FQDPQERPRKL nb 20790 9208 17751 23015 4827 6683 1347 7314 18319 6435 6353 47.00 41.50 2.00 N/A 
E6/20-30 PQLCTELQTTI nb 8717 4517 13293 14067 11283 7131 3380 237 271 13500 13251 2.80 2.45 15.00 N/A 
E6/21-29 QLCTELQTT nb 6636 13552 7781 6313 10642 11987 632 5278 5372 6238 3158 18.00 18.00 1.00 20 
E6/21-30 QLCTELQTTI nb 1394 1316 1091 1593 1060 1183 419 355 293 2846 1913 2.55 1.85 3.00 20 
E6/24-34 TELQTTIHDII nb 22327 10259 27527 29225 30114 17600 11858 640 997 18465 27720 22.00 16.50 66.00 N/A 
E6/29-37 TIHDIILEC nb 3935 6557 2853 2984 6472 6505 2470 3487 3192 5756 718 15.00 15.00 0.50 16 
E6/29-39 TIHDIILECVY nb 8437 23412 13566 16111 24586 23957 39837 1933 1264 18480 18935 8.55 8.25 28.00 N/A 
E6/30-38 IHDIILECV nb 11618 15173 21610 21292 9987 12316 1710 7752 8056 11801 1766 17.00 17.00 12.00 16 
E6/33-40 IILECVYC nb 5793 1668 16281 13576 1958 1814 735 4941 1251 2605 707 5.20 5.30 17.00 N/A 
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E6/33-41 IILECVYCK nb 4246 4793 14731 17699 15200 8525 784 954 1245 3547 10477 5.50 5.50 2.00 19 
E6/33-43 IILECVYCKQQ nb 18479 10179 30770 33495 19263 14023 3380 354 298 12839 13234 14.90 8.90 6.00 N/A 
E6/34-41 ILECVYCK nb 13211 15745 23842 28087 23501 19192 5869 641 11072 12046 9997 18.45 17.85 19.00 N/A 
E6/35-45 LECVYCKQQLL nb 19399 21000 11673 18246 31770 25842 19296 28066 61647 15989 22006 57.00 51.50 33.00 N/A 
E6/37-44 CVYCKQQL nb 28998 12404 21594 22673 4644 7568 1051 15165 33901 13189 9010 44.00 42.50 24.00 N/A 
E6/37-45 CVYCKQQLL nb 3574 4148 2647 3027 2847 3435 442 1979 2033 5418 4447 12.00 12.00 0.50 16 
E6/41-49 KQQLLRREV nb 10474 9569 12030 12405 9835 9707 1568 4050 3237 11152 11329 15.00 15.00 3.00 14 
E6/42-51 QQLLRREVYD nb 30968 28321 37816 38189 38363 32966 33505 23649 14206 22971 22316 48.50 41.00 45.00 4 
E6/42-52 QQLLRREVYDF nb 22055 18764 27432 30679 18406 18579 20149 3517 3698 19049 27983 31.00 25.50 51.00 N/A 
E6/43-52 QLLRREVYDF nb 11087 10566 12025 13898 8393 9397 1377 1300 1048 11557 10734 6.80 5.25 9.00 17 
E6/43-53 QLLRREVYDFA nb 3519 2023 2327 5855 891 1347 255 1228 2523 799 1692 12.70 12.75 9.00 N/A 
E6/44-53 LLRREVYDFA nb 2797 3637 1707 2360 1474 2315 784 1548 1260 2160 3118 5.85 4.90 38.00 16 
E6/44-54 LLRREVYDFAF nb 13944 11801 13612 15236 8001 9759 3168 19150 8052 10422 10541 26.65 25.55 20.00 N/A 
E6/50-59 YDFAFRDLCI nb 7051 6139 8597 9357 14096 9296 7446 3663 20724 5783 11153 22.25 20.85 16.00 12 
E6/50-60 YDFAFRDLCIV nb 6606 8297 5664 9827 6861 7527 1637 830 713 8538 2371 5.25 5.10 13.00 N/A 
E6/52-61 FAFRDLCIVY nb 3192 6631 8256 6485 18170 10934 27279 1922 1856 6897 3568 7.85 6.85 25.00 6 
E6/53-61 AFRDLCIVY nb 24893 28282 34843 32066 33334 30727 50000 244023 258887 15569 24685 36.00 35.00 56.00 4 
E6/59-68 IVYRDGNPYA nb 1071 1159 587 858 758 938 503 543 568 2605 1751 3.25 2.85 2.00 12 
E6/59-69 IVYRDGNPYAV nb 3288 1197 518 2531 132 397 142 14628 15449 291 147 30.65 30.75 2.00 N/A 
E6/60-69 VYRDGNPYAV nb 15455 15777 19493 18526 21913 18579 7209 3190 2615 4585 4613 22.50 13.50 4.00 14 
E6/61-69 YRDGNPYAV nb 4312 3941 4991 7287 5938 4831 660 907 896 697 4654 5.90 5.90 0.80 16 
E6/67-76 YAVCDKCLKF nb 15272 20390 18813 18867 23085 21734 36534 8726 11181 14274 15813 30.00 20.95 9.00 9 
E6/68-78 AVCDKCLKFYS nb 24098 12361 24857 29926 22102 16583 5267 791 794 7890 10062 22.25 16.75 8.00 N/A 
E6/71-78 DKCLKFYS nb 39199 28441 45915 48134 45858 36141 50000 9243 132 23125 10243 31.60 30.10 95.00 N/A 
E6/72-80 KCLKFYSKI nb 12145 9867 16905 17601 16790 12860 3807 15397 14227 5453 1239 26.00 26.00 4.00 14 
E6/74-81 LKFYSKIS nb 40511 26199 45297 46367 41928 33144 50000 4751 183 22200 21960 35.80 34.30 94.00 N/A 
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E6/77-87 YSKISEYRHYC nb 24619 26570 16012 19293 30891 28640 50000 20473 3845 20768 18289 33.50 28.00 60.00 N/A 
E6/79-89 KISEYRHYCYS nb 25556 14150 20250 22368 5450 8759 2874 809 376 9022 2516 21.85 16.35 8.00 N/A 
E6/81-90 SEYRHYCYSL nb 14260 6383 15061 13026 6617 6505 2265 1140 945 5811 22900 10.25 7.85 12.00 16 
E6/86-95 YCYSLYGTTL nb 3602 1628 8328 9415 5072 2874 2693 1101 1440 4780 4277 6.25 5.25 3.00 15 
E6/88-95 YSLYGTTL nb 17993 5198 19224 20909 1016 2302 1017 23112 12001 2281 15868 20.80 20.50 48.00 N/A 
E6/88-97 YSLYGTTLEQ nb 2507 15537 6125 4849 26117 20149 15045 4091 3610 4946 3926 10.80 9.85 34.00 6 
E6/89-97 SLYGTTLEQ nb 4296 2395 7750 6626 5633 3666 482 2744 3267 4063 2451 2.40 2.10 2.00 20 
E6/89-98 SLYGTTLEQQ nb 8398 4206 14694 13854 8949 6129 1017 1640 1744 4484 3220 8.35 6.85 2.00 19 
E6/89-99 SLYGTTLEQQY nb 14538 4751 13567 18915 11581 7406 3686 1105 879 9041 15338 9.15 8.10 2.00 N/A 
E6/93-103 TTLEQQYNKPL nb 17677 1268 9390 16075 3431 2077 1691 560 405 10436 15385 15.00 9.50 8.00 N/A 
E6/94-103 TLEQQYNKPL nb 7527 6380 9945 8846 5238 5775 1146 2488 3439 8247 11421 10.75 9.35 16.00 18 
E6/97-106 QQYNKPLCDL nb 9780 6150 8598 8779 4791 5412 1109 2182 1776 7262 5721 8.35 6.85 3.00 15 
E6/97-107 QQYNKPLCDLL nb 14734 7209 7396 13660 2442 4197 1236 2473 2517 7882 7924 16.10 15.10 8.00 N/A 
E6/98-108 QYNKPLCDLLI nb 23709 7711 31894 35466 27522 14564 19932 2433 1918 12473 16903 27.00 21.50 49.00 N/A 
E6/99-108 YNKPLCDLLI nb 14169 11218 20471 22341 27418 17505 18280 5634 6346 10629 13515 18.00 16.35 28.00 12 
E6/101-111 KPLCDLLIRCI nb 9569 4519 24361 21676 19674 9448 8759 344 416 11670 17447 3.70 3.30 13.00 N/A 
E6/102-111 PLCDLLIRCI nb 2554 6081 6553 4404 5002 5500 531 2798 2585 6228 5845 8.80 7.85 6.00 20 
E6/105-115 DLLIRCINCQK nb 20836 23689 32321 33081 36110 29267 16583 2755 1374 15381 16105 22.50 17.00 26.00 N/A 
E6/106-113 LLIRCINC nb 9263 2451 18082 14592 2460 2456 802 533 235 5841 963 1.95 1.95 19.00 N/A 
E6/106-114 LLIRCINCQ nb 7168 8472 18562 17772 12566 10302 605 4607 5716 6195 1226 5.80 5.80 10.00 19 
E6/106-115 LLIRCINCQK nb 11949 13794 17020 16705 15713 14723 3134 2060 3087 8211 8589 11.95 10.40 8.00 14 
E6/125-135 HLDKKQRFHNI nb 13960 3145 13409 17238 1447 2134 266 6028 4168 2299 2414 20.15 19.05 7.00 N/A 
E6/143-151 CMSCCRSSR nb 28503 23210 18476 18386 25890 24482 19506 19881 16000 14190 8515 45.00 34.00 24.00 10 
E6/143-152 CMSCCRSSRT nb 16992 14740 13952 12198 7741 10700 2146 11424 10034 10536 16824 31.50 22.50 23.00 12 
E6 D32E/25-35 ELQTTIHEIIL nb 14053 4108 13078 17333 3974 4041 674 2826 1076 10684 7722 10.75 9.65 11.00 N/A 
E6 D32E/29-37 TIHEIILEC nb 3629 6115 3470 3635 6195 6162 2241 3912 3541 7047 575 15.00 15.00 0.50 17 
Annex 
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E6 H85Y/79-87 KISEYRYYC nb 2350 2754 1586 675 1329 1915 1062 734 669 1617 328 5.80 5.80 0.90 13 
E6 H85Y, L90V/84-93 RYYCYSVYGT nb 18722 6392 15049 13147 13233 9196 3933 1548 2130 9614 18721 24.50 16.00 21.00 11 
E6 I34R/34-44 RLECVYCKQQL nb 11255 4311 6180 7445 1266 2340 599 3275 9139 6057 5553 26.50 25.25 2.00 N/A 
E6 L90V/80-90 ISEYRHYCYSV nb 16198 9576 17417 22763 7510 8479 1926 2892 1374 2895 1854 17.00 12.20 42.00 N/A 
E6 L90V/81-90 SEYRHYCYSV nb 36945 32011 7819 38204 39377 35559 50000 211748 295447 2209 17162 80.50 1.85 9.00 16 
E6 L90V/86-93 YCYSVYGT nb 35996 24663 30514 41704 43190 32611 50000 3792 9467 6803 11141 38.00 38.40 26.00 N/A 
E6 L90V/86-95 YCYSVYGTTL nb 34593 34945 8457 39893 38687 36732 50000 180643 198372 4415 5541 74.50 6.35 3.00 15 
E6 L90V/88-95 YSVYGTTL nb 14823 8504 25590 25934 10648 9499 2969 38356 15930 6135 18257 23.10 29.00 64.00 N/A 
E6 Q21D/21-30 DLCTELQTTI nb 8440 7163 11452 13562 14092 10027 974 638 587 10315 4259 4.45 2.95 6.00 19 
E6 R17I, Q21D/13-22 QERPIKLPDL nb 32740 32349 37283 37703 36784 34610 50000 54679 38061 17464 25739 58.50 51.50 38.00 17 
E6 R17I, Q21D/17-26 IKLPDLCTEL nb 282 9456 354 225 17803 13000 2391 2327 3503 12549 5733 9.50 9.20 5.00 18 
E6 R17T/9-19 FQDPQERPTKL nb 32258 27800 9862 41501 43665 34798 50000 53973 14925 3131 6014 59.00 34.80 2.00 N/A 
E6 R17T/13-22 QERPTKLPQL nb 40296 33748 36315 43633 43533 38357 50000 481748 1731729 19319 28266 93.00 52.00 14.00 17 
E6 R17T/17-26 TKLPQLCTEL nb 1719 1170 4225 2086 1041 1103 696 1358 1160 15669 10494 5.55 16.20 6.00 16 
E7/6-15 PTLHEYMLDL nb 718 10537 3461 1675 24965 16228 5155 6149 4597 10994 4078 11.10 10.70 51.00 14 
E7/7-16 TLHEYMLDLQ nb 1879 8104 5804 3735 13194 10358 2874 4496 5052 8318 2363 12.25 11.35 12.00 16 
E7/10-19 EYMLDLQPET nb 293 22329 1594 1171 37220 28795 50000 15879 16768 19111 5311 19.50 19.20 72.00 5 
E7/10-20 EYMLDLQPETT nb 1548 21352 5367 6152 39252 28952 50000 6240 4752 19607 15102 18.40 18.75 62.00 N/A 
E7/12-22 MLDLQPETTDL nb 3950 2378 2557 4519 278 815 216 3974 4111 2691 2870 17.20 17.25 4.00 N/A 
E7/14-22 DLQPETTDL nb 17945 17374 17660 19296 19864 18579 514 6583 6182 12823 13825 19.00 13.00 2.00 23 
E7/15-23 LQPETTDLY nb 25371 21287 24832 24655 29823 25153 16764 40591 41602 15306 24304 38.00 38.00 26.00 6 
E7/15-25 LQPETTDLYCY nb 28443 14305 30165 34365 27128 19611 17505 13937 6052 17471 23640 43.00 37.50 11.00 N/A 
E7/21-28 DLYCYEQL nb 17632 7060 16955 17410 1650 3417 287 3980 3726 8137 15383 12.15 11.85 10.00 N/A 
E7/27-35 QLNDSSEEE nb 28773 25047 29820 27846 32684 28640 1691 24913 34923 14869 7730 36.00 35.00 2.00 14 
E7/32-42 SEEEDEIDGPA nb 39189 25923 42407 44656 40383 32260 45854 842 2202 21110 30162 53.00 48.00 43.00 N/A 
E7/59-69 CKCDSTLRLCV nb 18788 7516 34804 35739 32220 15541 7692 233 98 16497 10737 13.85 7.85 6.00 N/A 
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E7/63-72 STLRLCVQST nb 8271 8321 9472 10846 15416 11294 5382 4975 4107 8078 19931 11.85 10.35 26.00 18 
E7/64-71 TLRLCVQS nb 22847 14993 29625 31783 19456 17131 10993 11990 414 14923 5419 9.65 8.15 44.00 N/A 
E7/64-72 TLRLCVQST nb 7303 13963 5811 6676 9195 11294 2290 6721 6578 8243 10780 2.70 2.50 11.00 20 
E7/64-74 TLRLCVQSTHV nb 6275 3185 5424 9657 1511 2205 442 6858 4965 4643 4912 18.90 18.75 7.00 N/A 
E7/65-74 LRLCVQSTHV nb 1815 12227 2131 1971 21181 16141 3417 4548 5991 6258 9347 13.25 12.35 13.00 14 
E7/66-76 RLCVQSTHVDI nb 14791 1688 10274 14378 3207 2327 316 828 3971 5067 14924 20.15 19.15 5.00 N/A 
E7/67-77 LCVQSTHVDIR nb 34584 29802 36134 37864 43876 36141 50000 40474 10738 21318 23858 59.00 54.00 79.00 N/A 
E7/69-76 VQSTHVDI nb 31123 16006 31479 34281 7294 10816 1947 39340 99589 14870 11340 59.00 57.50 47.00 N/A 
E7/71-79 STHVDIRTL nb 13065 13272 21278 21370 21158 16764 3202 11205 9641 13081 13014 23.00 23.00 2.00 22 
E7/73-82 HVDIRTLEDL nb 12562 11704 14168 13627 8122 9759 2123 10042 9279 12415 12644 18.45 17.35 11.00 18 
E7/73-83 HVDIRTLEDLL nb 21136 8487 20053 26313 5721 6978 2216 1825 1004 11757 14871 21.00 15.50 41.00 N/A 
E7/74-82 VDIRTLEDL nb 25952 26391 33994 35515 32812 29425 5998 56811 43763 14061 17424 39.00 38.00 19.00 17 
E7/75-83 DIRTLEDLL nb 28506 26616 27806 31428 34841 30561 9654 71520 68251 16933 25804 45.00 43.00 49.00 18 
E7/77-84 RTLEDLLM nb 15876 8515 18336 19712 4251 5998 1844 20598 19152 2484 11543 26.00 25.50 34.00 N/A 
E7/78-87 TLEDLLMGTL nb 356 462 277 204 481 472 428 623 752 3978 3283 3.75 3.35 3.00 22 
E7/81-89 DLLMGTLGI nb 2529 3947 1728 1328 3076 3473 151 567 551 1247 1000 3.80 3.80 13.00 25 
E7/82-89 LLMGTLGI nb 212 123 329 184 14 42 48 706 740 40 201 3.20 3.00 6.00 N/A 
E7/83-90 LMGTLGIV nb 1106 911 3868 1875 269 495 114 574 468 1731 275 2.25 2.00 9.00 N/A 
E7/83-91 LMGTLGIVC nb 7548 13788 7937 6752 7538 10191 1290 5425 4625 5957 1409 17.00 17.00 38.00 11 
E7/83-92 LMGTLGIVCP nb 12140 13613 13463 13136 15166 14407 1249 6619 8760 10010 2069 18.10 16.60 32.00 16 
E7/88-95 GIVCPICS nb 31844 23041 34495 34852 23275 23067 5155 8353 464 16979 8633 17.85 16.35 72.00 N/A 
E7/88-96 GIVCPICSQ nb 24415 22439 29028 24846 30796 26265 2315 63450 88127 16340 10984 47.00 47.00 31.00 16 
E7/78-86 TLEDLLMGT nb*±3.01 842 1421 994 609 1898 1646 345 840 989 2140 2061 7.30 7.30 4.00 20 
A3 
E6/109-119 RCINCQKPLCP 1.71±0.22 35545 19965 40526 38523 42313 29109 50000 297 9243 20093 13227 56.00 53.00 17.00 N/A 
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E6 L90V/84-94 RHYCYSVYGTT 2.03±0.71 32699 10627 31415 37526 30380 17985 11479 691 2929 23034 22676 32.50 29.50 29.00 N/A 
E6/106-115 LLIRCINCQK 2.06±0.97 172 90 80 79 128 107 2123 70 79 37 39 0.90 0.50 2.00 29 
E6/72-80 KCLKFYSKI 3.80±0.80 28008 20793 30831 26463 26765 23572 19506 59753 69470 21373 23384 37.00 33.50 36.00 8 
E7/89-97 IVCPICSQK 4.06±1.38 275 155 239 182 204 178 419 159 153 194 170 0.55 0.95 0.05 31 
E6/89-99 SLYGTTLEQQY 6.68±2.49 234 955 132 163 131 354 1422 4685 2778 1272 199 6.65 6.60 0.50 N/A 
E6/107-115 LIRCINCQK 7.03±3.61 375 593 146 162 227 366 586 489 465 204 406 1.10 1.50 0.80 24 
E7/88-97 GIVCPICSQK 7.06±2.83 343 169 158 157 200 185 1864 108 100 215 95 1.00 0.55 0.40 24 
E6/68-77 AVCDKCLKFY 9.68±2.59 932 1276 1365 991 1939 1576 4990 548 455 2047 458 2.15 1.50 0.70 20 
E6/33-41 IILECVYCK 11.02±3.27 226 126 226 266 153 139 368 243 225 100 352 0.70 1.15 0.40 23 
E6/75-84 KFYSKISEYR 11.40±0.71 319 329 1046 924 1119 608 1028 279 317 535 397 1.60 1.20 2.00 11 
E6/59-67 IVYRDGNPY 11.58±1.76 975 1081 695 661 696 869 784 797 756 610 219 1.60 1.90 2.00 28 
E6/93-101 TTLEQQYNK 15.55±5.05 493 248 658 1048 521 360 330 439 360 494 233 1.00 1.35 0.20 13 
E6/92-101 GTTLEQQYNK 17.96±1.67 1292 2536 805 1092 1578 2000 2290 971 906 1026 185 3.50 2.80 3.00 11 
E6/129-138 KQRFHNIRGR 23.03±4.59 1603 1119 1270 1769 2365 1628 2443 650 676 933 59 3.45 11.35 2.00 10 
E6/125-133 HLDKKQRFH 29.58±13.63 3475 3086 8302 8408 7001 4651 9048 1881 1909 3505 191 2.70 2.90 2.00 15 
E6/37-46 CVYCKQQLLR 36.33±19.78 113 232 320 378 248 240 428 248 211 56 285 1.15 0.95 0.40 21 
E6/68-75 AVCDKCLK 38.20±10.85 6961 752 7695 5533 637 693 1551 21975 13611 220 3622 3.45 3.15 6.00 N/A 
E6/75-83 KFYSKISEY 52.27±21.55 519 479 955 884 671 567 1655 572 665 1313 2433 1.45 1.80 0.30 17 
E6/84-91 RHYCYSLY 64.46±20.70 10604 2148 12511 10536 1563 1834 2874 33879 42158 5011 5542 21.00 20.70 18.00 N/A 
E6/8-18 MFQDPQERPRK 64.67±1.05 17041 12848 10200 9191 5057 8032 7287 11659 3705 2965 2296 13.10 12.70 6.00 N/A 
E6/21-29 QLCTELQTT nb 33763 24928 37823 37793 40224 31740 30727 164953 186982 20733 27714 54.50 51.50 17.00 16 
E6/21-30 QLCTELQTTI nb 21471 25775 26475 28167 33188 29267 48930 56114 44895 20494 22316 41.00 34.50 16.00 17 
E6/23-33 CTELQTTIHDI nb 35474 18831 35971 37597 36069 26124 47367 9742 291 24218 31137 32.10 29.10 70.00 N/A 
E6/29-39 TIHDIILECVY nb 8104 7833 7412 7794 3159 4990 5044 15089 9179 10239 702 24.90 24.20 23.00 N/A 
E6/32-41 DIILECVYCK nb 1829 6948 2341 1882 9298 8076 4990 1449 1564 6024 2167 5.15 13.05 20.00 22 
E6/34-41 ILECVYCK nb 6671 706 4308 3160 353 498 2290 20842 13517 890 1268 3.05 2.80 7.00 N/A 
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E6/37-45 CVYCKQQLL nb 11113 14359 11524 11532 11896 13071 2722 3291 2943 9444 9319 4.10 3.60 3.00 15 
E6/37-47 CVYCKQQLLRR nb 2849 1030 2459 2238 348 599 503 526 1636 95 222 3.05 2.65 0.50 N/A 
E6/38-46 VYCKQQLLR nb 11111 14467 15505 16175 17115 15710 3033 5667 5556 5567 14952 5.50 5.00 0.80 7 
E6/42-50 QQLLRREVY nb 17322 16461 19322 18987 20352 18280 13213 19114 18698 10250 9654 15.50 14.15 42.00 18 
E6/43-50 QLLRREVY nb 21022 4694 23910 20930 4800 4727 11479 32729 43339 7983 10287 26.85 26.75 69.00 N/A 
E6/43-51 QLLRREVYD nb 29240 21987 36077 34485 31004 26124 11356 17273 14250 16006 9252 29.50 26.00 33.00 23 
E6/43-52 QLLRREVYDF nb 17677 24725 20195 19300 22371 23572 22452 12476 15639 14022 25863 29.00 24.50 17.00 21 
E6/44-52 LLRREVYDF nb 24721 21110 22277 21305 23841 22452 10993 48235 50327 15832 31322 31.50 27.50 73.00 20 
E6/44-53 LLRREVYDFA nb 21628 21822 20707 17155 23537 22573 25564 8167 7002 11632 9194 27.00 20.50 67.00 16 
E6/48-55 EVYDFAFR nb 19611 1119 15071 13702 1792 1415 561 31618 47850 1768 4497 33.40 33.30 17.00 N/A 
E6/48-56 EVYDFAFRD nb 31121 24018 34382 36902 37790 30069 2722 28272 22584 21154 15093 35.00 31.50 11.00 18 
E6/48-57 EVYDFAFRDL nb 22911 24229 23922 24652 26645 25426 8208 18368 22605 18611 21963 37.00 30.50 5.00 15 
E6/52-61 FAFRDLCIVY nb 6639 10871 7683 6734 6605 8479 5382 13276 12308 5604 5377 15.30 23.00 41.00 13 
E6/52-62 FAFRDLCIVYR nb 10465 3456 6145 5944 1780 2483 1249 970 855 2491 4055 1.90 1.10 29.00 N/A 
E6/53-61 AFRDLCIVY nb 7947 13978 9238 8918 9152 11294 5869 11333 10686 9428 10574 7.75 7.80 7.00 17 
E6/53-62 AFRDLCIVYR nb 5086 5136 3393 4587 6229 5651 3237 1556 1649 4400 7403 5.45 13.15 5.00 15 
E6/58-67 CIVYRDGNPY nb 3007 6794 2175 1467 9008 7860 9973 2698 2071 4835 5943 5.75 13.65 29.00 17 
E6/59-68 IVYRDGNPYA nb 7479 17009 8808 7085 7300 11113 4576 4593 3298 5575 519 7.80 15.50 13.00 19 
E6/67-75 YAVCDKCLK nb 8225 11823 6884 7155 9130 10414 2146 6100 5405 3822 2534 4.85 4.90 16.00 10 
E6/68-76 AVCDKCLKF nb 13832 19620 16946 18441 16787 18181 4242 18722 19943 7890 14977 12.25 11.70 0.30 22 
E6/70-79 CDKCLKFYSK nb 10655 10806 14495 15320 20437 14803 9866 1675 3035 4405 6634 8.15 15.50 14.00 13 
E6/72-79 KCLKFYSK nb 12372 528 17170 14702 998 727 2905 22435 13393 1162 3831 3.35 3.10 3.00 N/A 
E6/73-83 CLKFYSKISEY nb 1541 7090 1363 895 1720 3492 9866 1134 1659 2095 355 3.05 2.75 5.00 N/A 
E6/74-83 LKFYSKISEY nb 3754 11717 4158 3146 16994 14099 28485 4386 6842 9632 15399 11.15 19.00 18.00 9 
E6/75-85 KFYSKISEYRH nb 8574 5102 13864 12156 2831 3807 5267 2942 8929 8079 12451 24.40 23.70 7.00 N/A 
E6/79-86 KISEYRHY nb 12913 611 13744 12212 1275 884 3380 32880 35882 1746 7149 15.40 15.30 23.00 N/A 
Annex 
 
(Continued) 
135 
P
e
p
ti
d
e 
ID
a
 
S
e
q
u
e
n
c
e
b
 
E
x
p
. 
IC
5
0
 ±
 S
D
c  
N
e
tM
H
C
 4
.0
d
 
N
e
tM
H
C
 3
.4
 d
 
N
e
tM
H
C
p
a
n
 4
.0
 d
 
N
e
tM
H
C
p
a
n
 3
.0
 d
 
N
e
tM
H
C
p
a
n
 2
.8
 d
 
N
e
tM
H
C
c
o
n
s 
1
.1
 d
 
P
ic
k
P
o
c
k
e
t 
1
.1
 d
 
IE
D
B
 S
M
M
P
M
B
E
C
 d
 
IE
D
B
 S
M
M
 d
 
M
H
C
fl
u
r
ry
 1
.2
 d
 
M
H
C
n
u
g
g
e
ts
 2
.0
 d
 
IE
D
B
 r
ec
o
m
m
e
n
d
e
d
e  
IE
D
B
 c
o
n
se
n
su
se
 
M
ix
M
H
C
p
r
e
d
2
.0
.2
e  
S
Y
F
P
E
IT
H
If
 
E6/79-88 KISEYRHYCY nb 573 430 626 421 573 495 2216 461 672 509 203 2.55 1.95 3.00 18 
E6/80-88 ISEYRHYCY nb 14211 16316 14320 15431 14386 15291 4288 10504 11690 12714 13604 10.45 9.90 38.00 10 
E6/81-91 SEYRHYCYSLY nb 8860 4532 13641 16141 3851 4174 5044 5066 5114 3824 8599 14.40 13.70 18.00 N/A 
E6/84-93 RHYCYSLYGT nb 20569 20078 27449 27461 24874 22330 8388 3027 958 18230 15439 18.95 12.45 18.00 8 
E6/89-97 SLYGTTLEQ nb 4285 5751 1228 1059 4304 4963 933 6300 6963 2302 10187 5.40 5.55 0.40 20 
E6/89-98 SLYGTTLEQQ nb 5756 14450 2199 1801 10113 12052 5743 8651 11122 2883 8347 14.30 22.00 2.00 20 
E6/91-101 YGTTLEQQYNK nb 11681 18702 6768 8477 13689 15967 8950 10732 6820 9250 7260 19.55 18.90 25.00 N/A 
E6/93-103 TTLEQQYNKPL nb 27206 23949 28951 31980 28659 26265 8854 3554 1288 22232 28607 18.70 15.20 7.00 N/A 
E6/94-101 TLEQQYNK nb 10744 1343 10289 8604 1231 1290 3933 20746 13579 2690 1352 3.50 3.20 7.00 N/A 
E6/105-115 DLLIRCINCQK nb 2443 4239 2405 1146 3336 3766 3492 3018 218 1672 164 0.70 0.30 7.00 N/A 
E6/106-114 LLIRCINCQ nb 18801 22264 11564 8157 24479 23318 15710 87571 99038 12144 24530 31.00 27.00 56.00 16 
E6/113-122 CQKPLCPEEK nb 9042 6642 6630 6276 4342 5353 8032 3452 2001 7556 9345 6.00 13.60 3.00 15 
E6/116-124 PLCPEEKQR nb 34913 23558 36869 36295 35864 28952 9866 54873 43934 15986 25450 46.00 43.00 12.00 20 
E6/122-129 KQRHLDKK nb 12994 767 13836 14324 1853 1190 4626 21475 13768 978 771 4.20 4.10 9.00 N/A 
E6/122-132 KQRHLDKKQRF nb 33979 22040 34184 32190 30127 25703 42052 350 6321 18526 23787 45.50 42.50 10.00 N/A 
E6/129-136 KQRFHNIR nb 14665 2543 13352 14638 2352 2443 2635 31400 50105 7403 2866 35.20 35.00 49.00 N/A 
E6/129-139 KQRFHNIRGRW nb 15846 17671 20876 16748 19344 18478 15208 1908 4873 17770 11061 15.85 15.45 33.00 N/A 
E6/133-142 HNIRGRWTGR nb 919 17425 6983 5548 19060 18280 5743 8186 17147 5285 10897 16.25 15.60 20.00 11 
E6/134-142 NIRGRWTGR nb 3240 7258 8766 8302 7651 7487 1006 2974 3426 2543 1758 3.75 3.95 6.00 20 
E6/136-146 RGRWTGRCMSC nb 32156 19609 31960 29346 30468 24349 22696 280 3410 20397 16936 32.50 29.50 35.00 N/A 
E6/139-148 WTGRCMSCCR nb 12286 9643 10630 8888 11571 10584 1968 4065 3751 8770 13838 9.65 16.00 46.00 7 
E6/142-151 RCMSCCRSSR nb 274 2109 229 339 6679 3746 3308 1397 1687 2146 2106 4.20 3.80 3.00 14 
E6/143-151 CMSCCRSSR nb 712 373 666 891 608 477 667 660 435 698 665 1.20 1.50 3.00 10 
E6/143-153 CMSCCRSSRTR nb 10382 5750 5407 4846 1196 2621 2216 4312 1373 1256 274 2.95 2.15 3.00 N/A 
E6/144-151 MSCCRSSR nb 19626 2700 17132 13413 2101 2378 1438 34192 53812 4265 2270 40.40 40.30 32.00 N/A 
E6/144-152 MSCCRSSRT nb 28749 21058 27339 24517 27263 23957 8032 21152 24592 15119 15448 31.50 28.00 62.00 5 
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E6/144-153 MSCCRSSRTR nb 4818 2154 5367 4521 3957 2921 2077 989 721 1521 603 3.75 11.45 6.00 8 
E6/144-154 MSCCRSSRTRR nb 15035 7562 11875 11276 2469 4312 1805 4137 5079 2449 205 16.55 16.30 5.00 N/A 
E6 L90V/89-99 SVYGTTLEQQY nb 721 1352 29778 347 244 573 1028 5763 4729 1982 738 12.15 12.10 0.50 N/A 
E7/7-15 TLHEYMLDL nb 15136 15410 18168 19458 18613 16946 3530 14137 12583 13479 18477 11.10 10.60 5.00 14 
E7/12-20 MLDLQPETT nb 32543 23566 34478 35580 37857 29745 32788 133463 126415 21275 30442 49.00 46.00 73.00 16 
E7/14-23 DLQPETTDLY nb 22015 15400 21016 21953 25320 19718 30396 12855 8039 15293 23937 28.50 22.00 28.00 19 
E7/44-52 QAEPDRAHY nb 27771 22103 31369 32322 33002 27132 15208 79499 75823 21057 26847 38.00 34.50 45.00 15 
E7/49-57 RAHYNIVTF nb 13237 16839 12923 11467 19464 18083 4152 33991 44238 9594 24294 16.85 16.25 20.00 16 
E7/50-60 AHYNIVTFCCK nb 2918 2252 7882 10306 1675 1936 1947 332 586 943 220 1.05 0.65 3.00 N/A 
E7/51-60 HYNIVTFCCK nb 3308 2689 4138 4050 4067 3308 2969 127 108 2199 1681 2.20 10.05 6.00 11 
E7/52-60 YNIVTFCCK nb 7848 15180 6165 7522 7282 10527 2315 9558 10252 3253 2464 7.20 7.30 20.00 13 
E7/53-60 NIVTFCCK nb 12936 3323 13003 10965 1813 2443 2607 21131 13517 1844 3885 3.65 3.55 13.00 N/A 
E7/63-73 STLRLCVQSTH nb 20788 2931 16029 18133 4771 3746 2722 1150 2896 6091 11072 17.00 13.50 7.00 N/A 
E7/64-73 TLRLCVQSTH nb 5914 4257 4625 5806 2514 3272 9146 3508 3624 4631 4644 8.30 16.00 15.00 25 
E7/65-74 LRLCVQSTHV nb 19670 26030 25703 21694 40063 32435 50000 64131 67639 23725 31114 43.00 36.50 46.00 3 
E7/66-73 RLCVQSTH nb 15734 1369 10452 9517 1104 1229 4430 30898 50220 5586 739 35.45 35.25 7.00 N/A 
E7/66-74 RLCVQSTHV nb 9250 13538 15291 10478 13990 13723 5382 8637 8069 9182 10371 6.80 6.80 10.00 15 
E7/66-75 RLCVQSTHVD nb 18733 20298 30799 26869 29709 24614 16946 5809 3675 12125 10380 21.50 16.00 12.00 18 
E7/73-81 HVDIRTLED nb 29041 21958 34614 35870 30385 25842 7609 61145 46752 19553 17602 36.00 32.50 26.00 16 
E7/78-87 TLEDLLMGTL nb 23060 25539 30577 31871 31332 28332 25564 41983 39555 20850 29865 41.50 35.00 29.00 16 
E7/81-89 DLLMGTLGI nb 21838 21578 30568 31164 32692 26551 6063 63586 57916 20583 23491 29.50 25.50 58.00 17 
E7/81-90 DLLMGTLGIV nb 19532 22196 25829 23382 34987 27876 32788 17461 15893 19686 25085 30.50 24.50 70.00 13 
E7/82-91 LLMGTLGIVC nb 12569 17786 25636 25372 26190 21501 11356 1884 1973 6641 20295 7.35 13.55 34.00 19 
E7/85-93 GTLGIVCPI nb 16710 22145 14216 16237 16243 18985 2033 60864 61489 12525 15363 21.55 21.10 24.00 4 
E7/87-97 LGIVCPICSQK nb 4666 11010 3029 1894 3492 6195 6331 11986 2696 4029 1338 6.75 6.20 16.00 N/A 
E7/89-98 IVCPICSQKP nb 3036 26229 5633 3345 35410 30396 26408 55217 27114 14125 10856 21.10 29.00 16.00 15 
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A11 
E6/106-115 LLIRCINCQK 1.36±0.30 351 147 200 197 119 132 1637 179 166 74 34 1.50 1.15 4.00 17 
E7/88-97 GIVCPICSQK 2.22±0.84 185 79 113 109 87 83 2579 123 138 57 102 1.35 1.05 0.30 19 
E6/52-62 FAFRDLCIVYR 2.67±1.28 6087 1546 1171 1597 158 495 704 1392 229 199 356 2.65 2.20 10.00 N/A 
E7/89-97 IVCPICSQK 3.16±0.78 49 22 79 67 63 38 392 54 50 33 88 0.45 0.35 0.09 21 
E6/93-101 TTLEQQYNK 4.71±1.74 24 18 18 28 20 19 167 30 25 17 17 0.30 0.25 0.01 21 
E6/68-77 AVCDKCLKFY 4.80±0.55 220 312 420 534 400 354 3033 767 589 488 216 2.50 2.20 2.00 15 
E6/33-41 IILECVYCK 4.98±1.33 43 22 53 36 32 27 241 83 80 30 25 0.55 0.45 0.30 18 
E6/9-18 FQDPQERPRK 5.01±2.17 5528 3496 5224 5868 3275 3380 20590 1306 830 1263 3336 4.20 2.90 14.00 11 
E6/107-115 LIRCINCQK 5.21±2.43 1089 2360 338 287 324 874 1158 697 836 399 1185 2.25 2.00 8.00 16 
E6/92-101 GTTLEQQYNK 5.26±2.57 127 76 58 93 92 84 1333 119 65 29 20 0.80 0.75 0.40 23 
E6/94-101 TLEQQYNK 6.03±2.84 3132 1354 7465 5308 349 685 3237 3425 15058 377 1230 11.05 10.65 22.00 N/A 
E6/32-41 DIILECVYCK 6.80±2.41 448 483 924 496 1165 751 2216 452 315 612 189 2.00 1.65 13.00 18 
E6/31-41 HDIILECVYCK 7.45±0.64 2169 6604 1213 971 6536 6575 4063 79 131 4300 89 1.90 1.65 10.00 N/A 
E7/87-97 LGIVCPICSQK 7.64±2.77 1807 4075 1627 1398 889 1905 5933 1801 596 1572 820 3.80 3.75 26.00 N/A 
E6/34-41 ILECVYCK 8.34±3.03 4751 642 4510 2359 241 395 2123 201 284 163 139 0.70 0.30 8.00 N/A 
E6 D32E/31-41 HEIILECVYCK 8.70±4.08 2171 6972 1220 971 7181 7093 3726 159 1503 2828 418 7.70 7.45 12.00 N/A 
E6 D32E/32-41 EIILECVYCK 8.79±1.87 459 261 616 398 437 339 1805 441 349 261 82 2.05 1.70 11.00 18 
E6/68-75 AVCDKCLK 9.72±3.73 1413 25 3434 2359 56 38 819 422 3249 28 1027 2.95 2.90 7.00 N/A 
E6/67-75 YAVCDKCLK 11.35±2.66 1462 2153 834 980 1371 1719 1485 935 850 305 5722 2.45 2.00 9.00 12 
E6 D32E, I34R/31-41 HEIRLECVYCK 11.67±3.82 13242 5695 11653 11660 5677 5682 3380 305 1539 3796 1269 8.85 7.65 9.00 N/A 
E6/142-151 RCMSCCRSSR 12.19±1.50 1928 11341 1956 1721 5277 7734 4626 5765 17492 10367 21148 12.65 11.65 4.00 9 
E6/68-78 AVCDKCLKFYS 13.16±3.30 9183 1847 12748 11471 6654 3511 3033 69 1033 761 61 5.85 5.30 0.80 N/A 
E7/52-60 YNIVTFCCK 13.23±7.77 2722 2772 780 961 821 1510 1109 1253 1423 1366 1154 3.30 2.60 18.00 13 
E6/105-115 DLLIRCINCQK 14.75±5.33 4278 2803 5361 3140 2240 2510 4478 1966 1148 3142 372 6.05 5.65 30.00 N/A 
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E7/53-60 NIVTFCCK 15.96±4.18 8169 166 7719 5011 157 162 2391 2888 3039 177 629 3.15 2.75 6.00 N/A 
E6/66-75 PYAVCDKCLK 15.99±2.11 8296 18387 7230 7038 23080 20702 31399 9546 5766 6694 10152 8.60 7.15 48.00 14 
E6 I34R/34-41 RLECVYCK 17.52±4.56 4437 277 2509 1319 199 235 1453 322 307 117 265 0.75 0.35 4.00 N/A 
E6/59-67 IVYRDGNPY 19.84±4.91 576 407 541 480 369 386 704 483 449 218 156 1.45 1.35 11.00 10 
E6/65-75 NPYAVCDKCLK 22.27±17.81 19279 3338 12853 18020 11107 6096 3726 510 131 5561 5143 4.85 4.30 6.00 N/A 
E7 S63F/56-66 TFCCKCDFTLR 24.31±10.02 19753 2790 17962 21979 7353 4527 6683 423 661 1348 6041 7.45 6.90 16.00 N/A 
E6/48-55 EVYDFAFR 27.75±5.14 9342 94 6461 4961 107 100 419 1464 556 146 266 0.85 0.45 10.00 N/A 
E7/50-60 AHYNIVTFCCK 28.96±12.39 4515 1025 3048 5909 874 948 1844 266 113 1799 3427 1.95 1.55 2.00 N/A 
E6/37-46 CVYCKQQLLR 36.49±6.55 506 291 357 349 113 181 561 648 297 55 50 1.90 1.55 0.50 24 
E6/67-77 YAVCDKCLKFY 40.88±5.62 2635 21532 10968 7709 8055 13142 11479 1834 1159 7953 13620 6.00 5.70 62.00 N/A 
E6/91-101 YGTTLEQQYNK 47.05±8.49 963 9590 540 957 3197 5530 6331 1873 1374 4319 6339 6.25 6.05 10.00 N/A 
E6/68-76 AVCDKCLKF 48.82±11.21 9085 13066 10508 12744 11306 12183 3134 4000 3633 3531 6299 5.55 4.65 2.00 19 
E6/53-62 AFRDLCIVYR 53.65±13.73 6053 5149 2782 3801 3766 4406 8208 2715 2923 2623 5953 6.15 4.85 8.00 18 
E6/79-88 KISEYRHYCY 55.30±14.40 264 222 716 554 463 320 2011 698 642 97 106 2.60 2.30 21.00 6 
E6/69-79 VCDKCLKFYSK 58.43±5.66 16577 4488 16473 20499 2959 3646 11113 2901 11275 2927 4468 28.35 27.75 3.00 N/A 
E6/80-88 ISEYRHYCY 62.36±12.84 4912 6762 7399 7568 6917 6829 2417 3945 4210 1090 1075 5.70 5.00 52.00 10 
E6/139-148 WTGRCMSCCR 82.74±12.11 15228 5497 5392 4431 1326 2693 1263 3372 2398 3412 2002 8.00 6.75 27.00 18 
E6/8-18 MFQDPQERPRK nb 11309 3363 9296 10202 1758 2443 7287 1847 17 1280 5135 2.05 1.05 3.00 N/A 
E6/18-25 KLPQLCTE nb 41574 23226 38757 38182 36610 29109 50000 143764 296319 16633 23568 80.50 80.00 66.00 N/A 
E6/23-33 CTELQTTIHDI nb 35051 20321 35188 35926 29034 24349 33505 1847 1164 22799 24855 27.75 25.25 44.00 N/A 
E6/27-36 QTTIHDIILE nb 25662 23215 17923 15821 28102 25564 26695 27659 21971 5541 15293 29.00 24.50 19.00 17 
E6/28-36 TTIHDIILE nb 9741 6489 6683 5708 12956 9146 3726 2845 1553 2152 9126 3.70 2.80 3.00 18 
E6/28-37 TTIHDIILEC nb 15893 23057 21278 20096 17149 19825 4936 3731 5406 13870 14442 10.95 10.05 6.00 17 
E6/29-37 TIHDIILEC nb 17265 18314 24875 27745 22615 20368 4626 5483 6044 14935 15950 11.30 10.85 8.00 14 
E6/29-39 TIHDIILECVY nb 4812 5405 2673 3895 1041 2365 6400 4926 35490 2175 560 39.85 39.45 48.00 N/A 
E6/32-42 DIILECVYCKQ nb 12219 7740 25455 17383 40060 17696 50000 1642 3237 15002 19725 13.60 12.45 46.00 N/A 
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E6/33-42 IILECVYCKQ nb 2187 24375 3232 1575 19168 21617 12517 27532 52101 3679 7104 19.65 18.65 32.00 7 
E6/37-44 CVYCKQQL nb 39605 20488 31864 31728 18718 19611 8297 4108 696 14035 17919 23.90 23.40 55.00 N/A 
E6/37-47 CVYCKQQLLRR nb 4832 1260 2457 2404 182 479 612 78 232 94 114 2.65 2.25 0.40 N/A 
E6/38-46 VYCKQQLLR nb 6611 8382 9908 8471 8972 8664 2265 2643 2015 4227 15378 4.10 3.35 10.00 14 
E6/47-55 REVYDFAFR nb 13510 17314 10984 12365 10367 13429 3344 5943 8323 2239 15158 10.55 10.15 27.00 9 
E6/48-56 EVYDFAFRD nb 22421 15320 29166 33872 30898 21852 1290 3048 3567 10001 14611 17.45 13.95 3.00 14 
E6/52-61 FAFRDLCIVY nb 6696 4063 5787 4891 2976 3473 2782 3061 2365 2112 1561 5.80 4.45 59.00 6 
E6/53-63 AFRDLCIVYRD nb 27978 12086 26498 26640 38835 21734 50000 416 397 23325 24906 14.50 11.50 69.00 N/A 
E6/54-61 FRDLCIVY nb 36720 22894 37300 37093 28083 25426 50000 234234 69304 22575 27541 48.50 48.00 31.00 N/A 
E6/58-67 CIVYRDGNPY nb 4176 5581 1954 1550 5378 5471 14099 2863 2280 1202 1713 5.60 4.40 61.00 6 
E6/62-72 RDGNPYAVCDK nb 21484 7901 22986 23426 15751 11113 7287 405 216 2351 7852 6.15 5.75 8.00 N/A 
E6/63-73 DGNPYAVCDKC nb 36277 26843 40097 40539 46011 35177 50000 6569 24496 22645 33805 60.50 58.00 94.00 N/A 
E6/64-72 GNPYAVCDK nb 12578 18284 9064 5427 9189 12930 6400 7397 7300 3811 8955 9.60 8.90 32.00 14 
E6/69-77 VCDKCLKFY nb 30699 22591 27152 27718 21307 21971 32788 130326 176319 19430 25705 54.00 51.00 42.00 0 
E6/70-77 CDKCLKFY nb 38208 21756 36761 37951 30934 25983 50000 10535 636 19012 29119 19.35 18.85 52.00 N/A 
E6/70-79 CDKCLKFYSK nb 5288 12019 6894 8274 10721 11356 6978 1086 4829 1058 9526 7.90 6.65 22.00 11 
E6/71-79 DKCLKFYSK nb 18144 19383 27730 25329 28657 23572 6400 16789 18980 5625 12559 22.00 19.00 14.00 11 
E6/72-79 KCLKFYSK nb 6484 1728 15934 15542 1122 1392 3272 12096 11214 1689 9415 9.05 8.65 5.00 N/A 
E6/73-83 CLKFYSKISEY nb 19570 9932 8921 7377 7205 8479 27279 3323 10817 7637 5332 28.70 28.15 61.00 N/A 
E6/74-84 LKFYSKISEYR nb 15476 12298 12678 11848 10622 11417 6063 1642 496 13037 11586 5.35 4.40 60.00 N/A 
E6/75-83 KFYSKISEY nb 4210 4948 4132 4278 4103 4502 4107 2594 2373 4973 18754 4.35 3.65 8.00 3 
E6/75-84 KFYSKISEYR nb 2367 584 1633 1605 1462 928 1551 625 622 1137 6674 3.60 2.55 5.00 9 
E6/75-85 KFYSKISEYRH nb 25752 8713 19655 18416 9791 9246 7692 161 1671 14699 27147 18.00 15.00 10.00 N/A 
E6/76-84 FYSKISEYR nb 11508 12364 7323 7460 10358 11294 1453 7781 7367 7599 11446 9.10 8.35 56.00 8 
E6/77-84 YSKISEYR nb 19079 3096 13960 10650 1468 2134 2100 15405 5981 5074 14433 6.95 6.75 63.00 N/A 
E6/77-85 YSKISEYRH nb 19254 16361 21121 23417 12001 14023 4335 17260 15146 13898 20138 21.00 17.50 87.00 10 
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E6/78-88 SKISEYRHYCY nb 3460 19566 12020 7956 23662 21501 37740 1554 4899 8211 17267 16.80 16.45 17.00 N/A 
E6/79-86 KISEYRHY nb 15027 2286 19199 17932 1679 1957 5621 67398 72738 1523 11312 35.75 35.40 22.00 N/A 
E6/79-87 KISEYRHYC nb 11648 14766 19173 20197 14166 14407 2782 2911 2827 10281 2609 5.55 4.80 17.00 6 
E6/79-89 KISEYRHYCYS nb 11597 11997 14596 13338 5419 8076 4936 699 7501 4377 247 22.00 20.95 19.00 N/A 
E6/81-89 SEYRHYCYS nb 25883 19890 20097 23398 27662 23445 4478 10940 18548 7243 27180 29.50 26.00 40.00 3 
E6/81-91 SEYRHYCYSLY nb 20957 6186 11631 17142 4371 5211 6829 7736 11752 4964 24634 30.25 30.05 35.00 N/A 
E6/84-91 RHYCYSLY nb 26264 10994 18175 20679 3180 5901 7054 39233 18355 11030 28424 16.50 16.40 17.00 N/A 
E6/85-95 HYCYSLYGTTL nb 37470 25551 32541 36003 32211 28640 41599 45761 62244 22095 30317 73.00 70.50 86.00 N/A 
E6/88-97 YSLYGTTLEQ nb 16898 21458 5992 4900 15327 18181 9973 15305 19048 5990 17462 16.35 15.85 36.00 16 
E6/89-97 SLYGTTLEQ nb 5669 13070 2519 1994 9063 10875 1805 5001 5168 910 20130 6.90 6.15 2.00 15 
E6/89-99 SLYGTTLEQQY nb 1707 1606 508 751 579 963 2843 2246 8572 1394 2182 22.35 22.45 4.00 N/A 
E6/92-102 GTTLEQQYNKP nb 4733 21741 9681 6918 37343 28485 43912 783 3674 14847 16813 13.85 13.45 17.00 N/A 
E6/92-99 GTTLEQQY nb 29129 9316 28051 28460 6620 7860 10875 45777 9263 4644 9252 14.00 13.50 61.00 N/A 
E6/93-102 TTLEQQYNKP nb 710 25384 1893 1706 30885 27876 12653 34028 37831 14394 16619 16.20 15.85 6.00 11 
E6/93-103 TTLEQQYNKPL nb 7924 21009 14605 16816 16392 18579 6611 1598 2085 16752 22578 9.45 8.95 9.00 N/A 
E6/101-109 KPLCDLLIR nb 16969 19683 15103 15434 15356 17411 2524 2302 2240 8793 21212 8.05 7.60 33.00 13 
E6/108-115 IRCINCQK nb 18779 18875 21088 16016 17465 18181 20814 15763 1559 8481 16023 3.15 3.00 19.00 N/A 
E6/113-122 CQKPLCPEEK nb 4576 2973 4838 5449 1259 1936 11356 2387 1202 3343 1925 4.55 3.35 6.00 13 
E6/115-122 KPLCPEEK nb 28490 12327 32109 29853 12098 12249 5743 1034 459 8723 16931 5.25 5.20 53.00 N/A 
E6/116-124 PLCPEEKQR nb 32709 23219 37177 36830 32555 27427 13649 97281 81339 16598 29756 51.50 48.50 41.00 15 
E6/118-128 CPEEKQRHLDK nb 36268 18581 35259 36150 27538 22696 26408 1206 306 13099 17701 27.55 25.05 23.00 N/A 
E6/122-129 KQRHLDKK nb 11498 4979 18901 23658 3343 4085 13357 3861 4072 2586 2227 4.15 3.75 25.00 N/A 
E6/129-136 KQRFHNIR nb 25255 10718 19893 21443 4510 6978 9346 7721 31100 5788 8921 22.55 22.45 32.00 N/A 
E6/129-138 KQRFHNIRGR nb 12019 14503 4445 4250 6159 9448 12930 15200 12046 5409 10893 12.25 10.55 41.00 9 
E6/134-142 NIRGRWTGR nb 20180 20213 17811 14494 13249 16316 3646 18622 21004 5891 18208 24.00 20.50 47.00 15 
E6/140-148 TGRCMSCCR nb 18365 18486 14196 11665 12020 14883 4576 26244 32307 7303 13808 26.00 22.50 61.00 8 
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E6/143-151 CMSCCRSSR nb 1843 2401 1773 1592 512 1109 1290 2183 1366 488 1272 3.20 2.55 10.00 14 
E6/143-153 CMSCCRSSRTR nb 12933 13841 9396 8620 978 3666 4676 9874 11671 2050 6312 27.80 26.60 12.00 N/A 
E6/144-151 MSCCRSSR nb 13501 327 11910 8485 461 388 1196 19528 7191 745 637 7.55 7.30 13.00 N/A 
E6/144-152 MSCCRSSRT nb 23954 18779 27596 22982 25499 21852 7692 21283 20198 11061 9725 27.50 24.00 59.00 10 
E6/144-153 MSCCRSSRTR nb 1644 1031 2309 1534 1231 1127 2123 853 738 904 1212 3.45 2.75 18.00 18 
E6/144-154 MSCCRSSRTRR nb 9728 1378 5072 5471 653 948 1534 79 499 1091 1068 3.85 3.30 4.00 N/A 
E6/145-153 SCCRSSRTR nb 26662 19672 24146 18884 24619 22090 8388 29925 37265 15486 27913 35.50 32.00 0.80 11 
E6 D32E/23-33 CTELQTTIHEI nb 32014 16635 32406 32670 25839 20702 24218 1895 711 22160 24837 20.80 17.80 26.00 N/A 
E6 D32E/28-36 TTIHEIILE nb 6961 5687 6279 5394 13543 8759 4152 2825 1568 1936 8587 3.60 2.80 3.00 18 
E6 L90V/89-97 SVYGTTLEQ nb 2254 5675 734 643 3693 4576 776 1538 1582 222 12523 3.55 2.85 0.20 19 
E6 L90V/89-99 SVYGTTLEQQY nb 369 354 100 181 143 226 1222 691 2291 373 222 9.20 9.05 0.70 N/A 
E7/7-15 TLHEYMLDL nb 22420 18281 22887 23312 21434 19825 7366 22858 26080 14281 25502 27.50 24.00 54.00 10 
E7/18-25 ETTDLYCY nb 27010 7943 27712 28057 9094 8479 3380 23749 45789 3114 12560 30.30 30.20 18.00 N/A 
E7/18-26 ETTDLYCYE nb 23907 19260 16298 16808 30867 24349 4727 23444 18806 7639 19569 27.00 23.50 19.00 12 
E7/19-27 TTDLYCYEQ nb 10164 15002 11982 10078 16057 15541 4335 12707 12031 2173 19452 10.60 9.80 7.00 11 
E7/19-29 TTDLYCYEQLN nb 29490 9840 32337 35659 29561 17038 21971 1098 1104 10812 9480 19.10 16.10 39.00 N/A 
E7/31-40 SSEEEDEIDG nb 42990 29440 45399 46389 45071 36337 50000 109353 85872 21626 33015 69.00 66.00 33.00 17 
E7/36-43 DEIDGPAG nb 46217 23914 47383 48003 47892 33869 50000 158362 41282 27793 34959 74.00 73.50 48.00 N/A 
E7/41-50 PAGQAEPDRA nb 41497 30039 44969 46355 46427 37333 50000 820030 482892 23063 32517 79.50 76.50 91.00 1 
E7/42-50 AGQAEPDRA nb 32898 21926 40701 41723 43042 30727 50000 310477 299433 19488 31857 62.00 59.00 49.00 5 
E7/51-60 HYNIVTFCCK nb 1042 1761 1214 1213 1013 1340 1728 961 1007 986 2066 3.30 2.85 14.00 11 
E7/55-63 VTFCCKCDS nb 20535 18556 18465 15433 17410 17888 2315 13123 13593 6336 1326 21.50 18.00 41.00 11 
E7/56-66 TFCCKCDSTLR nb 22831 8579 20910 22934 9971 9246 8854 671 675 2175 10407 13.15 9.15 13.00 N/A 
E7/63-71 STLRLCVQS nb 11216 8885 8399 7312 8634 8759 3066 3750 3866 2592 8124 6.05 5.25 1.00 18 
E7/63-73 STLRLCVQSTH nb 21889 449 8508 11210 979 663 3237 2757 1812 3677 12740 13.50 12.20 5.00 N/A 
E7/66-75 RLCVQSTHVD nb 31503 27490 38874 36666 38339 32435 26124 89708 165520 16440 26199 51.00 47.50 46.00 8 
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E7/68-77 CVQSTHVDIR nb 3271 3233 2116 2449 1566 2253 2011 8163 5700 1292 1393 8.30 7.15 10.00 20 
E7/69-77 VQSTHVDIR nb 3616 4855 5840 6053 4921 4883 2905 2183 2199 1799 2502 4.15 3.45 9.00 10 
E7/71-80 STHVDIRTLE nb 17397 19635 10690 8181 20654 20149 24218 24936 18529 2351 11709 15.90 15.35 6.00 16 
E7/77-84 RTLEDLLM nb 28534 8942 25150 25073 4760 6540 3308 28884 63644 8568 11670 37.50 37.00 15.00 N/A 
E7/77-86 RTLEDLLMGT nb 17957 20735 11548 10615 11108 15208 3454 7275 4919 5428 12450 13.00 10.60 5.00 11 
E7/85-93 GTLGIVCPI nb 11139 13790 4369 5656 7782 10358 1236 4831 5988 6941 15101 7.90 7.10 2.00 16 
E7/88-95 GIVCPICS nb 37711 18661 36952 36530 22815 20590 19296 1861 2192 12178 21861 19.35 18.85 38.00 N/A 
E7/88-98 GIVCPICSQKP nb 7427 24720 9779 5978 36023 29907 50000 1519 19683 19797 18277 33.45 32.95 24.00 N/A 
E7/89-98 IVCPICSQKP nb 2205 27040 4961 2826 33583 30069 22943 198989 216197 16509 16847 31.15 30.15 39.00 11 
A24 
E6/87-94 CYSLYGTT 0.08±0.00 18030 11113 27793 26920 8751 9866 4676 12171 8495 2537 5050 10.55 11.60 33.00 N/A 
E6 L90V/86-95 YCYSVYGTTL 0.08±0.11 188 5938 298 305 12415 8571 4936 1488 1913 4369 5506 2.30 2.00 3.00 10 
E6/87-95 CYSLYGTTL 0.10±0.02 107 113 205 189 286 180 477 655 578 79 58 0.75 0.60 0.06 20 
E6/85-95 HYCYSLYGTTL 0.10±0.03 1871 496 783 649 503 501 903 2075 6502 358 1107 11.30 13.45 0.80 N/A 
E6/49-57 VYDFAFRDL 0.10±0.04 1877 769 726 967 596 678 1146 1306 1030 884 105 1.65 1.55 0.20 23 
E7 S63F/56-65 TFCCKCDFTL 0.11±0.17 1907 1649 2338 1735 1390 1518 1947 1398 2102 691 1316 2.80 2.15 2.00 18 
E7/49-57 RAHYNIVTF 0.15±0.07 763 1699 1104 910 334 751 1518 2014 1647 770 589 1.80 1.45 0.80 10 
E6 L90V/87-95 CYSVYGTTL 0.24±0.04 142 120 184 206 304 191 482 643 586 85 79 0.85 0.60 0.07 20 
E6/82-90 EYRHYCYSL 0.32±0.10 856 807 532 573 352 534 419 853 999 205 327 1.30 0.95 0.04 19 
E6/49-59 VYDFAFRDLCI 0.40±0.29 2481 189 2074 2621 365 263 1392 7909 3927 648 75 5.40 7.45 3.00 N/A 
E6/66-76 PYAVCDKCLKF 0.48±0.21 1977 236 1844 3418 386 301 893 670 2729 83 34 3.05 5.20 0.50 N/A 
E6/98-107 QYNKPLCDLL 0.54±0.24 2235 1042 536 614 517 731 1469 820 1096 329 324 1.85 1.20 0.30 23 
E6/98-108 QYNKPLCDLLI 0.56±0.08 2769 449 1162 1660 151 260 913 7693 10967 135 94 19.90 21.95 1.00 N/A 
E7/56-65 TFCCKCDSTL 0.58±0.55 9077 5078 8383 5243 4108 4576 3726 3473 4940 3332 1741 4.40 3.55 3.00 17 
E6 L90V/90-99 VYGTTLEQQY 0.68±0.05 6615 7372 8381 8526 3113 4779 3033 1492 1895 1630 785 2.70 1.95 0.50 12 
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E6/18-26 KLPQLCTEL 0.83±0.07 11101 13344 6747 6113 8995 10934 2315 8279 8844 1551 9767 8.40 7.65 0.40 13 
E6/60-69 VYRDGNPYAV 0.95±0.39 3260 2003 2111 1934 1597 1795 1347 825 920 402 790 1.70 1.05 0.80 13 
E7 S63F/56-63 TFCCKCDF 1.03±0.41 18965 7402 16431 11201 2218 4041 1277 5772 7519 2719 6732 10.20 11.10 14.00 N/A 
E6/67-76 YAVCDKCLKF 1.09±0.30 12915 9223 7693 7763 7291 8208 4727 4706 3004 4306 1737 4.60 4.20 4.00 12 
E7/48-57 DRAHYNIVTF 1.32±0.35 6106 11562 12097 11145 18181 14564 12382 3645 3355 2429 983 3.55 2.85 4.00 11 
E6/26-34 LQTTIHDII 1.42±0.23 11192 10542 12843 14956 14228 12249 5621 5807 6586 7615 5027 6.40 5.65 2.00 12 
E6/82-91 EYRHYCYSLY 1.59±0.41 6231 3583 7218 7320 5263 4335 4527 1081 1330 703 6922 2.15 1.45 2.00 11 
E6 D32E/26-34 LQTTIHEII 1.65±0.37 7820 5961 11329 12345 10228 7776 5382 4073 4504 5914 4255 4.60 4.30 1.00 13 
E6/66-74 PYAVCDKCL 1.97±0.77 9731 3772 7066 5470 5884 4702 3272 3373 2470 1091 235 3.15 2.80 0.80 20 
E7/50-57 AHYNIVTF 2.41±0.76 12214 4182 10388 7996 1684 2664 2874 53495 140650 535 331 42.65 44.60 14.00 N/A 
E6/98-106 QYNKPLCDL 2.97±0.67 5603 4509 3321 2279 1869 2905 1017 2183 2475 774 1138 3.05 2.80 0.09 21 
E6/51-59 DFAFRDLCI 3.27±0.99 5300 2280 8359 6895 7359 4107 3202 1941 1363 2322 858 2.05 1.80 6.00 17 
E6/88-95 YSLYGTTL 3.36±1.09 5320 17026 10801 9147 7313 11113 4936 86559 120542 7199 1116 40.85 43.10 22.00 N/A 
E6/76-83 FYSKISEY 3.36±2.28 17138 7035 12705 12310 1131 2827 3607 10973 18161 2205 1033 16.85 18.10 2.00 N/A 
E6/38-45 VYCKQQLL 3.51±1.64 1910 2178 3319 2262 267 759 1158 14700 3992 52 135 6.20 8.45 4.00 N/A 
E6/44-54 LLRREVYDFAF 3.84±0.77 23190 7208 14267 18252 3850 5267 3646 1556 1387 2028 491 5.85 5.65 19.00 N/A 
E6/49-58 VYDFAFRDLC 4.30±0.37 7810 14614 5873 6027 7541 10471 4626 582 721 3262 9637 1.65 0.85 6.00 14 
E6/48-57 EVYDFAFRDL 4.75±0.58 10889 26900 7301 7779 26976 26985 20814 25981 33863 10585 11189 14.70 13.90 24.00 12 
E6/76-85 FYSKISEYRH 4.76±0.60 4654 9583 19540 17447 6083 7609 5211 818 360 2558 1544 1.10 0.45 4.00 11 
E6/90-99 LYGTTLEQQY 5.63±3.15 10663 9201 11003 9536 3570 5743 3530 1674 2316 1942 1818 3.30 2.50 1.00 10 
E7/47-57 PDRAHYNIVTF 5.75±4.30 20603 17668 20625 25910 18064 17888 18083 1500 6111 7038 3584 14.35 14.10 9.00 N/A 
E7/51-59 HYNIVTFCC 6.06±2.70 3701 6548 7451 5298 6494 6505 579 586 1098 883 2588 1.85 1.60 0.60 12 
E6/87-96 CYSLYGTTLE 6.87±1.89 1125 7385 5861 3660 15918 10816 5044 415 319 1460 771 0.80 0.40 4.00 12 
E6/72-80 KCLKFYSKI 7.50±2.33 2342 2669 17531 14133 3487 3050 1655 1371 1998 699 767 2.50 2.30 0.40 16 
E6/35-44 LECVYCKQQL 8.13±0.64 37771 33156 37066 38822 36027 34610 49462 32185 35214 10865 22228 38.00 36.00 30.00 10 
E6 L90V/82-90 EYRHYCYSV 8.64±0.72 3061 2457 1399 1604 1622 2000 963 1853 2386 518 1884 2.90 2.70 0.40 9 
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E6/76-86 FYSKISEYRHY 10.60±1.96 14076 2765 8763 11705 1544 2066 3891 9018 6517 2915 1074 12.55 13.45 0.70 N/A 
E6/66-75 PYAVCDKCLK 10.93±1.40 26543 17628 27683 25169 25705 21385 20368 4494 2442 6886 2263 13.75 11.75 11.00 12 
E6/50-59 YDFAFRDLCI 11.01±0.86 2957 17550 4658 2878 6759 10875 14252 3620 3025 12352 1705 3.35 2.70 30.00 10 
E6/81-90 SEYRHYCYSL 11.98±1.32 825 14977 744 480 8304 11173 11858 5354 8684 4777 7562 5.35 5.00 24.00 10 
E7/51-58 HYNIVTFC 16.51±1.47 23030 7863 21161 22350 7787 7818 2290 1325 5677 4943 6470 9.65 9.60 11.00 N/A 
E6/38-47 VYCKQQLLRR 22.28±2.19 13917 10568 28045 25203 16490 13142 11356 3553 1311 3204 1079 3.65 3.15 1.00 13 
E6/47-54 REVYDFAF 23.27±1.19 23692 7169 23030 18654 9647 8297 3766 5074 3035 1850 9089 7.45 7.40 45.00 N/A 
E6/131-139 RFHNIRGRW 23.93±3.24 2159 2788 1704 1124 621 1311 1121 2104 1716 354 812 2.25 2.05 0.50 6 
E6 A68G/60-69 VYRDGNPYGV 24.65±2.54 4789 2905 3668 3729 2450 2664 1602 1376 1544 679 810 2.30 1.65 1.00 13 
E6/128-136 KKQRFHNIR 28.64±3.18 35997 29829 38575 36419 37407 33324 50000 28181 31378 18840 6674 35.50 34.00 45.00 2 
E7 L28F/21-28 DLYCYEQF 29.23±2.92 24390 14260 20680 23229 7056 10027 5099 23513 30001 2811 202 25.10 25.05 26.00 N/A 
E6/127-134 DKKQRFHN 31.27±15.48 46950 40157 48607 48874 48881 44390 50000 33675 34288 25047 6880 67.00 66.50 75.00 N/A 
E6 L90V/90-97 VYGTTLEQ 31.98±16.05 25903 7583 32850 34571 10002 8711 5044 1123 59 3436 6321 3.90 3.85 7.00 N/A 
E6/75-85 KFYSKISEYRH 32.00±4.31 19160 22292 34292 32363 19059 20590 9866 4075 8671 8006 7593 18.65 18.40 3.00 N/A 
E6 L90V/87-96 CYSVYGTTLE 32.71±2.44 1650 8585 6458 4246 16616 11922 5099 394 323 1570 974 0.90 0.40 5.00 12 
E7/67-76 LCVQSTHVDI 34.74±11.56 21249 25625 32845 34208 26981 26265 10302 36783 42729 9468 11136 25.00 25.50 33.00 11 
E6/86-96 YCYSLYGTTLE 36.66±4.08 2314 30606 9766 7611 39763 34987 24218 5599 7535 16140 14997 13.85 15.95 55.00 N/A 
E6 L90V/88-95 YSVYGTTL 37.88±0.91 7092 20039 11347 11242 14992 17317 9654 95567 32972 8065 1382 23.85 26.10 14.00 N/A 
E6/75-83 KFYSKISEY 41.70±23.44 14961 14099 5644 4220 4664 8120 3344 11040 11006 4294 28390 10.70 10.05 0.60 9 
E6/38-46 VYCKQQLLR 46.40±5.14 6745 4118 20124 17707 15602 7989 4626 1524 1724 1776 1457 2.30 2.05 0.70 15 
E6/128-135 KKQRFHNI 46.84±2.41 24112 13730 29623 30642 9434 11417 14723 12368 26190 3941 1140 23.50 23.45 63.00 N/A 
E6/127-135 DKKQRFHNI 55.95±3.54 25336 24382 38730 39079 38876 30893 41152 13645 11057 8260 3169 18.00 16.00 3.00 11 
E6/125-135 HLDKKQRFHNI 60.80±1.43 35115 16930 30329 35515 17357 17131 24218 19639 15598 10190 6917 42.00 40.50 15.00 N/A 
E6 L90V/81-91 SEYRHYCYSVY 63.32±8.71 18432 28728 22981 18169 30610 29745 50000 9957 13617 12712 32388 26.40 26.15 39.00 N/A 
E7/69-76 VQSTHVDI 84.61±2.96 29711 15729 33856 33737 15104 15374 8032 46592 10427 7668 14279 16.50 16.00 64.00 N/A 
E6/11-19 DPQERPRKL nb 40129 34851 44372 45928 45152 39837 50000 105187 62897 18732 21547 51.50 50.00 3.00 16 
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E6/36-46 ECVYCKQQLLR nb 31380 39352 37342 38120 43553 41375 50000 9730 12025 25524 16348 33.00 31.50 45.00 N/A 
E6/42-52 QQLLRREVYDF nb 18490 3737 13841 13219 3235 3473 4242 3035 10425 2629 25332 21.90 21.65 9.00 N/A 
E6/43-52 QLLRREVYDF nb 6035 7442 9138 8434 3289 4936 3237 1856 2629 1310 1172 3.15 2.45 11.00 13 
E6/44-52 LLRREVYDF nb 4528 7209 5067 3268 4035 5382 2123 3281 3464 1643 5880 3.80 3.55 3.00 10 
E6/45-54 LRREVYDFAF nb 9033 12546 13888 15282 15576 13947 5267 1873 1895 3396 6883 2.80 1.95 8.00 12 
E6/47-57 REVYDFAFRDL nb 14574 25290 6586 8447 25531 25426 30069 12221 11352 11116 16109 21.75 22.45 18.00 N/A 
E6/48-58 EVYDFAFRDLC nb 22725 39872 25416 24586 39680 39837 37740 15385 41028 20922 22169 47.75 47.55 49.00 N/A 
E6/50-60 YDFAFRDLCIV nb 16421 31557 26268 21789 19151 24482 40271 18928 13185 18867 20628 24.75 24.95 33.00 N/A 
E6/51-60 DFAFRDLCIV nb 20731 19913 20286 19690 18672 19296 19932 40239 38170 7286 12721 23.50 24.50 44.00 6 
E6/51-61 DFAFRDLCIVY nb 33255 18144 32031 33778 24872 21154 25842 949 10048 13383 31992 32.00 30.50 14.00 N/A 
E6/59-68 IVYRDGNPYA nb 27618 36911 29113 30399 37469 37132 44390 10015 7811 14404 27624 17.10 15.10 14.00 0 
E6/62-69 RDGNPYAV nb 38038 18403 38619 39114 19560 18985 25564 587 109 10139 9244 12.70 12.20 33.00 N/A 
E6/64-74 GNPYAVCDKCL nb 34978 35991 27741 26546 34797 35367 33144 15564 14292 16939 30659 39.50 38.00 52.00 N/A 
E6/65-74 NPYAVCDKCL nb 18381 36136 15643 10468 36642 36337 50000 166207 127562 19232 31871 35.90 35.65 37.00 10 
E6/73-83 CLKFYSKISEY nb 37525 35096 23225 24856 26618 30561 50000 11223 15779 26915 35882 45.00 43.50 31.00 N/A 
E6/76-84 FYSKISEYR nb 7664 3686 9578 9771 4156 3912 4626 2094 1980 2517 3041 2.60 2.30 0.50 13 
E6/80-90 ISEYRHYCYSL nb 3113 13390 2355 2834 12137 12722 11987 11861 22703 8899 2261 33.90 35.95 21.00 N/A 
E6/81-91 SEYRHYCYSLY nb 9612 24433 16610 10564 22661 23572 50000 10306 10141 10111 29162 18.55 20.45 34.00 N/A 
E6/85-94 HYCYSLYGTT nb 9118 13239 13727 13921 13999 13575 3849 7172 16662 4160 8822 8.90 8.05 6.00 10 
E6/86-95 YCYSLYGTTL nb 135 5738 342 269 13312 8759 5099 1218 1458 4045 6021 1.80 1.60 3.00 10 
E6/90-97 LYGTTLEQ nb 29647 10217 35137 35254 11432 10816 5869 1251 154 3972 4449 6.50 6.00 9.00 N/A 
E6/90-98 LYGTTLEQQ nb 14067 10130 26818 28990 13417 11604 3237 3373 2126 3472 4616 4.20 3.60 0.90 11 
E6/93-101 TTLEQQYNK nb 40786 28244 33754 39059 39153 33144 12249 72604 61324 22380 24601 53.00 51.50 27.00 5 
E6/96-106 EQQYNKPLCDL nb 30404 28837 23578 24508 29712 29267 31740 10522 30625 18047 28302 50.00 48.50 39.00 N/A 
E6/97-106 QQYNKPLCDL nb 14362 25657 11155 8432 22418 23957 24218 38340 51135 14481 12744 20.95 20.45 14.00 10 
E6/109-117 RCINCQKPL nb 23544 22414 37656 37135 26694 24482 8571 22027 24470 10266 5407 23.00 21.00 9.00 12 
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E6/124-132 RHLDKKQRF nb 2766 1862 9996 5098 10835 4502 1222 1510 1389 624 1086 2.05 1.85 0.08 14 
E6/126-135 LDKKQRFHNI nb 24255 26354 33721 39332 22184 24218 31740 25683 15802 10760 2755 18.50 17.50 19.00 11 
E6/128-137 KKQRFHNIRG nb 39485 40557 40205 40321 44254 42509 50000 101076 98564 18274 21785 55.00 53.00 61.00 1 
E6/128-138 KKQRFHNIRGR nb 44708 37019 42683 42717 41857 39409 50000 51063 35406 25756 15922 78.00 76.50 59.00 N/A 
E6/138-146 RWTGRCMSC nb 4276 14865 11769 8183 12458 13649 1710 2004 4061 1252 3796 4.25 4.00 4.00 1 
E6/138-147 RWTGRCMSCC nb 9956 15827 17843 12646 16822 16316 6683 1131 1674 2328 5274 2.65 1.80 8.00 0 
E6 L90V/81-90 SEYRHYCYSV nb 3325 25053 2608 1674 13278 18181 27279 21660 36284 8284 13788 15.20 14.55 62.00 0 
E6 L90V/82-91 EYRHYCYSVY nb 10241 4655 11271 11142 9522 6683 4936 961 1224 1111 6591 2.30 1.45 2.00 9 
E6 L90V/85-93 HYCYSVYGT nb 18142 18075 14351 13021 19694 18883 1319 5861 8084 5787 12623 10.50 10.00 4.00 11 
E6 L90V/85-94 HYCYSVYGTT nb 8440 11811 13983 14147 14401 13071 3646 5870 13053 3960 10863 7.85 7.05 7.00 10 
E6 L90V/85-95 HYCYSVYGTTL nb 2450 459 796 668 601 526 865 1672 4376 428 1546 6.90 8.95 2.00 N/A 
E6 L90V/87-94 CYSVYGTT nb 18438 12605 27337 26634 8493 10358 4676 13222 10645 2701 4869 12.60 13.60 26.00 N/A 
E6 L90V/90-98 VYGTTLEQQ nb 10684 9604 24869 28209 11957 10758 2782 2786 1869 3000 5310 2.75 2.20 0.50 13 
E7/10-18 EYMLDLQPE nb 13459 10614 25762 24906 23465 15795 2607 3334 3852 2628 2045 5.45 4.65 6.00 10 
E7/10-19 EYMLDLQPET nb 21243 15043 25810 27656 19675 17224 5682 9720 6248 4745 2955 12.95 13.45 6.00 10 
E7/10-20 EYMLDLQPETT nb 26570 4960 29579 33132 12872 7989 5621 18540 9206 2314 1013 25.00 23.50 3.00 N/A 
E7/22-31 LYCYEQLNDS nb 26308 21157 30784 33079 26731 23828 10527 12754 4883 7872 12899 15.00 13.00 13.00 10 
E7/24-32 CYEQLNDSS nb 25011 28364 31257 31068 25891 27132 6469 23821 17932 7807 12342 21.50 19.50 5.00 10 
E7/24-33 CYEQLNDSSE nb 27772 28748 33039 33222 30776 29745 12117 1930 2476 10511 4374 14.80 12.80 13.00 10 
E7/51-60 HYNIVTFCCK nb 16645 11946 12502 11612 13070 12517 5099 4137 3773 8950 6282 6.70 6.20 5.00 11 
E7/56-66 TFCCKCDSTLR nb 29079 19569 32333 26034 27384 23067 26408 4700 6384 16551 8039 21.50 20.00 14.00 N/A 
E7/61-69 CDSTLRLCV nb 35315 34576 34181 37420 29048 31740 50000 90565 58834 17019 24742 41.50 40.00 63.00 0 
E7/67-77 LCVQSTHVDIR nb 37951 38141 42730 44115 42413 40271 50000 10644 5944 23082 14498 29.50 28.00 71.00 N/A 
E7/74-82 VDIRTLEDL nb 26183 25706 32842 31431 23061 24349 19296 25642 22575 14396 16245 23.50 21.50 3.00 15 
E7/74-83 VDIRTLEDLL nb 23644 28546 31902 30708 17687 22452 34238 19171 23000 16245 21666 21.00 20.00 12.00 16 
E7/77-87 RTLEDLLMGTL nb 26563 7563 19336 23834 6693 7093 4288 20707 17461 7132 16783 36.50 35.00 4.00 N/A 
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E7/78-87 TLEDLLMGTL nb 28965 29750 28756 30400 22660 25983 15710 41846 49172 11968 11965 31.50 29.50 8.00 12 
E7/82-91 LLMGTLGIVC nb 31101 35423 38468 41830 37725 36534 16054 3645 8886 8536 16133 20.50 18.50 20.00 0 
E7/83-90 LMGTLGIV nb 36257 26354 37668 38662 26576 26551 17131 3276 572 9288 20393 13.10 12.60 44.00 N/A 
E7 L28F/19-28 TTDLYCYEQF nb 4301 9903 5931 5744 3968 6263 5044 3211 4322 2204 2344 4.00 3.35 5.00 12 
E7 L28F/20-28 TDLYCYEQF nb 3242 4913 11619 10716 3811 4335 1710 1585 1533 2109 1817 2.15 1.95 0.80 14 
E7 L28F/22-30 LYCYEQFND nb 8080 16105 23406 25552 25674 20258 1319 1694 1106 1737 1691 1.90 1.60 5.00 11 
E7 L28F/22-31 LYCYEQFNDS nb 18526 17546 25488 29358 22678 19932 6903 7900 3418 6067 10241 7.25 7.00 9.00 11 
E7 L28F/24-32 CYEQFNDSS nb 23616 27069 28994 27366 22685 24748 5933 18662 14984 6992 10442 19.00 17.00 5.00 10 
E7 N29S/24-33 CYEQLSDSSE nb 26823 27718 32607 33222 32326 29907 11858 1639 1999 8763 3987 14.00 12.00 14.00 10 
E7 N29S/24-34 CYEQLSDSSEE nb 34616 23322 38610 39947 32372 27576 10993 4888 6139 12394 3008 26.00 24.50 14.00 N/A 
B7 
E6/107-117 LIRCINCQKPL 0.15±0.06 10602 750 4560 3065 236 421 1568 26888 49182 1945 299 31.40 31.25 16.00 N/A 
E6/15-22 RPRKLPQL 0.20±0.06 35 45 15 44 5 15 117 401 286 8 18 0.65 0.60 0.02 N/A 
E6/148-158 RSSRTRRETQL 0.32±0.16 13278 3233 9899 8042 1635 2302 4779 15016 49069 3295 344 31.90 31.25 0.50 N/A 
E6/136-144 RGRWTGRCM 0.35±0.10 167 682 737 544 723 700 462 236 294 88 106 0.60 0.60 0.70 10 
E6/15-23 RPRKLPQLC 0.41±0.28 286 131 71 100 310 202 309 425 583 57 85 1.00 1.00 0.20 14 
E6/15-24 RPRKLPQLCT 0.50±0.18 170 80 414 496 79 79 586 199 638 62 65 1.50 1.35 0.50 22 
E6/19-28 LPQLCTELQT 0.64±0.52 3061 5373 5644 4632 3231 4174 1585 14277 24936 2064 2558 24.25 24.75 8.00 18 
E6/15-25 RPRKLPQLCTE 0.68±0.25 3632 1025 4260 5682 447 678 573 3528 88 305 1170 1.10 1.30 0.80 N/A 
E6 R17T/15-25 RPTKLPQLCTE 0.69±0.37 16556 14182 17526 14473 4408 7946 1766 4442 88 2877 5994 2.75 2.10 5.00 N/A 
E7/5-12 TPTLHEYM 0.71±0.48 6867 509 5515 6604 859 660 605 162 42 1465 1945 0.55 0.45 5.00 N/A 
E6/151-158 RTRRETQL 1.14±0.48 4307 2161 2410 3896 358 884 2340 27902 16596 302 435 17.90 17.85 7.00 N/A 
E6/19-26 LPQLCTEL 1.30±0.43 591 192 405 427 46 94 234 721 333 285 127 0.75 0.70 0.60 N/A 
E6/11-19 DPQERPRKL 3.94±1.82 6673 5180 8586 6431 3666 4335 236 1084 922 4448 9055 1.50 1.50 0.40 20 
E7/5-13 TPTLHEYML 4.50±3.30 522 921 482 505 487 671 372 566 394 118 214 1.70 1.70 0.90 20 
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E7/49-57 RAHYNIVTF 4.65±2.28 2595 2136 1074 1801 1100 1534 1453 1133 1256 1032 2408 3.80 3.80 2.00 9 
E6/142-151 RCMSCCRSSR 4.72±5.40 26769 19179 23568 25546 27683 22943 23445 666 650 8606 11803 15.25 12.25 5.00 3 
E6/118-126 CPEEKQRHL 5.90±3.90 2464 3283 1529 893 723 1543 275 811 692 1394 496 2.50 2.50 0.30 20 
E6/136-146 RGRWTGRCMSC 13.95±14.34 20222 7396 20480 19735 7505 7446 8479 12461 10985 2587 201 13.50 13.05 5.00 N/A 
E6/95-103 LEQQYNKPL 14.86±2.04 16354 17963 14910 13789 22381 20040 2874 8244 11612 6260 14323 16.00 16.00 16.00 11 
E6/101-111 KPLCDLLIRCI 16.12±10.66 12510 2000 7330 6870 1253 1585 667 4483 3818 801 8533 4.65 4.20 7.00 N/A 
E7/46-55 EPDRAHYNIV 18.36±13.23 1084 4462 2782 2352 3279 3828 1362 1308 687 6278 2912 1.75 1.45 6.00 18 
E6/59-69 IVYRDGNPYAV 20.28±10.18 29570 5251 26764 26980 4553 4910 9048 4566 16704 7480 1782 24.50 23.00 12.00 N/A 
E7/83-93 LMGTLGIVCPI 21.78±29.30 34058 18547 29391 30687 15999 17224 18478 11791 1516 14798 19969 18.05 16.55 70.00 N/A 
E7/82-89 LLMGTLGI 22.70±11.69 21900 16001 24323 29523 11224 13429 5044 3196 279 9659 23137 3.65 3.50 80.00 N/A 
E6/101-108 KPLCDLLI 35.23±12.60 8853 642 5418 6518 1846 1091 743 240 167 1815 4125 0.85 0.70 14.00 N/A 
E6/134-144 NIRGRWTGRCM 54.83±5.62 12158 1451 10711 12005 533 879 1422 41645 213211 1904 486 49.20 48.75 15.00 N/A 
E6/13-22 QERPRKLPQL nb 11032 17593 13332 13747 16500 17038 6469 5870 19401 10893 20635 21.85 21.75 3.00 14 
E6/17-26 RKLPQLCTEL nb 17333 12454 20344 18396 8347 10246 10642 1415 475 9299 14022 4.95 4.55 4.00 13 
E6/19-27 LPQLCTELQ nb 8417 17659 16362 11909 15276 16405 1017 2939 1836 5938 2141 4.70 4.70 6.00 11 
E6/19-29 LPQLCTELQTT nb 11800 4094 12515 11771 3142 3587 1568 14144 10347 4420 9518 10.65 10.25 5.00 N/A 
E6/37-44 CVYCKQQL nb 29637 16733 17574 24776 8492 11922 6063 19572 29041 9462 11733 31.50 30.50 25.00 N/A 
E6/40-49 CKQQLLRREV nb 33314 23223 29492 29879 26691 24882 10758 2580 360 10096 6283 24.30 21.30 22.00 7 
E6/44-54 LLRREVYDFAF nb 26385 10221 25001 22487 4236 6575 4242 3904 18828 2863 5648 23.50 22.00 26.00 N/A 
E6/52-60 FAFRDLCIV nb 19885 21410 17280 19560 21764 21617 4883 75711 70289 15649 20914 36.00 36.00 57.00 6 
E6/65-74 NPYAVCDKCL nb 3555 3032 2858 2834 548 1290 646 1681 1773 1510 4046 4.10 4.60 2.00 21 
E6/65-75 NPYAVCDKCLK nb 19960 23132 23422 20023 18483 20702 6978 1814 286 9321 23033 4.05 3.55 14.00 N/A 
E6/78-86 SKISEYRHY nb 32669 24243 42055 40921 40546 31399 50000 1432716 1293868 25507 39741 73.00 67.00 66.00 0 
E6/81-90 SEYRHYCYSL nb 23378 13200 13972 16945 16285 14643 12791 2054 1922 11602 20969 14.55 11.55 8.00 10 
E6/86-95 YCYSLYGTTL nb 20702 11320 15841 18704 9160 10191 3380 888 619 4907 17037 10.70 7.20 3.00 11 
E6/88-95 YSLYGTTL nb 23550 11859 12209 15487 3030 5998 2635 58836 13032 8042 14825 19.15 19.00 13.00 N/A 
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E6/98-107 QYNKPLCDLL nb 35724 27858 33348 36165 33600 30561 30396 34884 31320 23056 31855 55.00 52.00 20.00 11 
E6/109-117 RCINCQKPL nb 10882 13630 10021 5830 4578 7903 3380 4844 6308 3949 3583 12.00 12.00 9.00 12 
E6/118-127 CPEEKQRHLD nb 16926 11329 24314 16454 31074 18781 4527 1232 313 11978 11639 4.40 4.00 6.00 11 
E6/136-145 RGRWTGRCMS nb 4482 13789 14621 14415 15608 14643 14407 623 430 836 915 1.70 2.15 21.00 4 
E6/149-158 SSRTRRETQL nb 2017 4523 2816 2090 1226 2352 3202 1492 1667 2539 9124 3.95 4.45 0.70 13 
E6 L90V/86-95 YCYSVYGTTL nb 20272 9222 15299 18450 9897 9551 3134 767 616 4962 18781 10.70 7.20 2.00 11 
E6 R17T/11-19 DPQERPTKL nb 7596 6571 6523 5653 3913 5072 281 1578 1346 4980 9871 4.00 4.00 0.20 21 
E7/6-13 PTLHEYML nb 15643 25868 22197 17191 40592 32435 50000 104145 128236 22647 25118 38.85 38.60 94.00 N/A 
E7/16-25 QPETTDLYCY nb 28507 19458 26394 26188 23556 21385 12791 18777 18443 18331 34949 35.50 32.50 19.00 10 
E7/16-26 QPETTDLYCYE nb 36819 25550 38389 37789 34278 29585 6683 4738 1122 19944 32526 24.20 23.20 26.00 N/A 
E7/39-49 DGPAGQAEPDR nb 37208 25009 44391 38803 47632 34610 50000 31229 13798 28303 35912 35.50 34.50 80.00 N/A 
E7/40-48 GPAGQAEPD nb 10408 19898 22759 18549 23090 21501 1109 7164 16822 5409 2912 19.00 19.00 5.00 14 
E7/46-53 EPDRAHYN nb 38616 25321 37677 40246 32286 28640 4936 1785 4246 19453 29277 33.50 32.50 83.00 N/A 
E7/46-56 EPDRAHYNIVT nb 15185 14656 22448 19907 9877 12052 2443 639 474 6608 12837 2.60 1.85 6.00 N/A 
E7/78-85 TLEDLLMG nb 39378 30118 43834 45979 42804 35946 50000 10131 1084 26009 36709 31.20 30.20 98.00 N/A 
B15 
E6/73-83 CLKFYSKISEY 0.50±0.28 3334 339 1149 978 113 195 1905 N/A N/A 100 47 0.70 0.10 0.40 N/A 
E6 L90V/81-91 SEYRHYCYSVY 2.87±0.84 4699 91 1130 1137 113 102 1209 N/A N/A 508 96 0.80 0.10 2.00 N/A 
E6 L90V/83-91 YRHYCYSVY 3.56±1.20 1307 1005 1237 1221 938 974 1407 877 859 900 2968 5.00 5.00 3.00 N/A 
E6/81-91 SEYRHYCYSLY 3.73±2.09 11011 372 2054 1945 272 318 1710 N/A N/A 1402 390 1.90 1.00 3.00 N/A 
E6/74-83 LKFYSKISEY 3.83±2.91 670 289 360 329 926 517 3417 354 105 464 261 3.85 3.15 2.00 N/A 
E6 L90V/84-91 RHYCYSVY 3.91±1.26 3245 761 2200 3892 731 747 1673 N/A N/A 2824 4821 0.80 0.10 16.00 N/A 
E7/43-52 GQAEPDRAHY 4.07±1.50 19 14 27 39 32 21 1551 20 3 17 19 0.30 0.20 0.02 N/A 
E6/68-77 AVCDKCLKFY 4.10±2.35 1317 495 2645 3065 1447 851 9866 69 28 179 67 2.30 1.10 1.00 N/A 
E6/79-88 KISEYRHYCY 4.67±0.95 533 165 674 722 683 336 5382 164 89 188 35 3.50 2.80 3.00 N/A 
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E7/15-23 LQPETTDLY 4.68±1.28 115 73 308 233 476 188 1097 132 114 86 52 0.80 0.80 0.09 N/A 
E6/84-91 RHYCYSLY 4.85±1.96 9120 2654 4021 6469 1359 1905 2315 N/A N/A 6001 7308 1.00 0.10 29.00 N/A 
E6/52-61 FAFRDLCIVY 5.07±2.18 72 145 54 30 70 100 1196 35 29 85 37 1.25 1.10 0.80 N/A 
E6/41-50 KQQLLRREVY 5.80±2.97 76 24 75 178 160 62 2123 5 4 30 20 0.40 0.25 0.20 N/A 
E6/83-91 YRHYCYSLY 6.00±1.26 4254 5652 2396 2227 2650 3870 2123 3380 3436 2232 5112 15.00 15.00 4.00 N/A 
E6/53-61 AFRDLCIVY 6.13±2.15 460 278 1057 1031 744 454 2722 477 426 424 481 2.80 2.80 0.20 N/A 
E6/59-67 IVYRDGNPY 6.22±1.77 61 64 32 46 46 54 776 104 96 53 30 0.70 0.70 0.20 N/A 
E7/15-25 LQPETTDLYCY 7.30±2.00 1905 81 2382 2535 473 196 3001 N/A N/A 107 20 0.60 0.10 0.80 N/A 
E6 L90V/89-99 SVYGTTLEQQY 7.51±2.18 3382 133 319 640 140 137 2391 N/A N/A 256 11 0.70 0.10 0.06 N/A 
E7/82-90 LLMGTLGIV 7.54±1.87 2323 1172 937 861 2089 1568 2905 1449 1556 535 181 8.00 8.00 22.00 N/A 
E6/58-67 CIVYRDGNPY 7.98±2.78 110 362 114 126 212 278 2169 76 54 41 76 2.05 1.85 5.00 N/A 
E6/42-50 QQLLRREVY 8.12±3.38 194 144 207 300 343 221 1209 207 166 231 494 1.10 1.10 0.07 N/A 
E6/89-99 SLYGTTLEQQY 8.18±4.40 1741 68 230 338 79 73 1620 N/A N/A 117 10 0.50 0.10 0.04 N/A 
E6/57-67 LCIVYRDGNPY 10.49±0.99 983 1474 301 495 1370 1422 2365 N/A N/A 340 849 0.20 0.10 7.00 N/A 
E6/82-91 EYRHYCYSLY 10.57±7.23 9585 1259 7669 7003 10190 3587 10875 1651 1518 5190 16655 18.50 16.10 14.00 N/A 
E6/18-26 KLPQLCTEL 11.13±2.74 5950 8263 4086 3979 6874 7568 4831 5533 5260 3836 4431 15.00 15.00 0.40 N/A 
E6/44-54 LLRREVYDFAF 11.22±6.36 1705 46 399 382 36 41 1362 N/A N/A 68 5 0.50 0.10 5.00 N/A 
E6/75-83 KFYSKISEY 11.36±9.44 1026 900 986 1178 944 923 1362 881 813 600 218 4.80 4.80 0.07 N/A 
E6/45-54 LRREVYDFAF 12.52±5.40 6140 3350 4932 5790 5318 4219 4430 86 49 1691 10904 3.65 1.70 24.00 N/A 
E6/44-52 LLRREVYDF 12.88±2.32 282 170 94 88 159 164 1158 218 180 73 82 1.20 1.20 0.70 N/A 
E6/97-106 QQYNKPLCDL 14.38±8.21 1346 478 1621 1829 2584 1109 3807 316 139 600 1783 5.00 3.75 2.00 N/A 
E7/49-57 RAHYNIVTF 15.72±15.79 82 87 62 65 67 77 423 166 184 60 36 0.50 0.50 0.20 N/A 
E6/67-77 YAVCDKCLKFY 19.64±11.44 11119 438 3384 2994 709 558 4335 N/A N/A 1314 69 2.00 1.10 7.00 N/A 
E7/7-15 TLHEYMLDL 19.98±4.76 5412 7918 4781 3961 6941 7406 2722 4121 4634 3188 11909 14.00 14.00 2.00 N/A 
E6/42-52 QQLLRREVYDF 20.84±1.26 6524 1211 3005 4778 1250 1229 2443 N/A N/A 1396 899 0.90 0.10 6.00 N/A 
E6/60-67 VYRDGNPY 21.93±13.93 2754 1126 3245 3951 2808 1776 5933 N/A N/A 813 9058 0.60 0.10 6.00 N/A 
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E7/42-52 AGQAEPDRAHY 23.28±4.09 1407 712 1362 1405 3431 1559 11987 N/A N/A 523 49 0.30 0.10 2.00 N/A 
E6/26-34 LQTTIHDII 24.11±6.46 6475 11974 3183 3202 7508 9499 3344 4841 3837 3508 5950 16.00 16.00 52.00 N/A 
E6/129-139 KQRFHNIRGRW 28.75±12.42 12284 1308 6520 10845 2365 1756 9346 N/A N/A 3209 274 3.00 2.20 3.00 N/A 
E7/43-51 GQAEPDRAH 28.79±16.56 1527 1933 887 1672 1814 1864 3001 2910 2296 628 120 12.00 12.00 0.30 N/A 
E6/77-86 YSKISEYRHY 29.36±13.83 48 55 236 175 217 109 3686 130 182 50 42 4.65 4.55 2.00 N/A 
E6/76-86 FYSKISEYRHY 32.33±8.76 5410 3255 6033 5921 3230 3254 7131 N/A N/A 6512 4016 0.80 0.10 11.00 N/A 
E6/40-50 CKQQLLRREVY 33.39±18.26 2925 10652 2678 3766 3731 6297 11113 N/A N/A 11115 1934 0.60 0.10 20.00 N/A 
E6/43-50 QLLRREVY 36.81±17.10 4022 583 4959 7374 515 549 5933 N/A N/A 334 5919 0.80 0.10 10.00 N/A 
E6/31-39 HDIILECVY 37.48±12.61 1976 3786 4656 2733 2787 3254 1277 1294 1125 1365 4676 5.10 5.10 6.00 N/A 
E6/29-39 TIHDIILECVY 37.75±17.06 2106 151 1127 1073 208 177 3308 N/A N/A 596 12 0.60 0.10 0.70 N/A 
E6/59-68 IVYRDGNPYA 38.45±10.14 935 14388 545 872 8218 10875 29425 1526 987 5431 6597 13.80 13.10 19.00 N/A 
E7/15-24 LQPETTDLYC 38.45±10.85 2365 3924 6028 4566 17186 8208 22696 74 22 2586 6154 2.55 0.95 10.00 N/A 
E6/122-132 KQRHLDKKQRF 38.74±15.84 3955 92 1482 4350 368 184 1766 N/A N/A 264 55 0.70 0.10 0.20 N/A 
E7/82-89 LLMGTLGI 42.43±21.41 14125 410 6789 6293 954 625 3933 N/A N/A 465 686 3.60 2.80 82.00 N/A 
E6/136-144 RGRWTGRCM 43.73±9.05 2545 5050 3340 4008 6047 5530 1926 1841 1614 1820 284 8.20 8.20 3.00 N/A 
E6/67-76 YAVCDKCLKF 46.75±21.63 1324 2551 721 342 950 1559 2169 1174 960 590 822 14.30 13.10 6.00 N/A 
E7/43-53 GQAEPDRAHYN 46.88±22.26 2848 15787 2698 2978 18728 17131 16946 N/A N/A 8454 4269 0.60 0.10 5.00 N/A 
E6/68-76 AVCDKCLKF 47.83±8.39 2323 3332 1426 1434 2357 2812 2193 1452 1040 763 2484 5.80 5.80 0.50 N/A 
E6/81-88 SEYRHYCY 48.91±15.52 8495 497 7695 6850 664 576 2241 N/A N/A 1628 633 1.00 0.10 5.00 N/A 
E6/30-39 IHDIILECVY 54.36±24.59 4433 4551 6136 4466 17359 8854 26985 25 3 9240 13570 2.00 0.25 42.00 N/A 
E6/134-144 NIRGRWTGRCM 56.25±15.87 25100 6712 17382 16677 5392 5998 6756 N/A N/A 4269 1716 25.00 20.00 45.00 N/A 
E6/59-69 IVYRDGNPYAV 58.67±16.94 13626 5894 5189 7816 4571 5182 14252 N/A N/A 6853 126 4.30 3.50 14.00 N/A 
E6/78-86 SKISEYRHY 58.91±4.96 2652 2875 1679 1436 1778 2265 3001 1758 1256 3237 5011 2.70 2.50 3.00 N/A 
E6/79-86 KISEYRHY 68.31±17.99 3431 116 3403 4276 248 171 5682 N/A N/A 213 80 0.80 0.10 17.00 N/A 
E6/113-121 CQKPLCPEE 70.23±6.13 11536 15412 13486 16285 13831 14564 8297 3917 3999 7714 7521 16.00 16.00 10.00 N/A 
E6/78-88 SKISEYRHYCY 75.26±44.92 11407 6192 8779 9065 2957 4288 5682 N/A N/A 6824 2359 2.20 1.30 9.00 N/A 
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E6/43-52 QLLRREVYDF 75.66±18.15 2564 2179 1583 1215 2771 2456 6129 147 87 331 3135 4.40 2.80 12.00 N/A 
E6/76-83 FYSKISEY 77.10±23.81 7638 4276 2380 2370 2405 3219 3646 N/A N/A 2415 8619 0.90 0.10 0.70 N/A 
E7/67-76 LCVQSTHVDI 79.92±23.62 12925 15141 16211 13894 21041 17888 15208 1822 580 9607 28889 14.75 13.35 59.00 N/A 
E7/82-91 LLMGTLGIVC 84.41±38.55 1730 3877 6468 7102 2838 3326 7946 37 45 247 408 3.05 1.55 10.00 N/A 
E6/20-29 PQLCTELQTT nb 34905 12222 34093 33438 34643 20590 50000 641 165 12046 14487 43.15 54.15 23.00 N/A 
E6/21-30 QLCTELQTTI nb 11462 15403 9069 9800 5611 9296 10414 729 994 2414 872 17.15 15.05 5.00 N/A 
E6/25-34 ELQTTIHDII nb 17096 13342 15214 14309 21356 16855 21040 426 2781 7744 25711 39.50 30.00 77.00 N/A 
E6/26-35 LQTTIHDIIL nb 3065 1470 1433 1308 3942 2404 3933 43 31 1052 105 2.80 1.15 33.00 N/A 
E6/32-39 DIILECVY nb 18539 5131 15902 16568 2804 3807 4527 N/A N/A 6207 19659 7.20 6.70 35.00 N/A 
E6/33-42 IILECVYCKQ nb 28329 21095 31088 31827 30029 25153 50000 7738 1350 10988 6441 45.00 36.50 61.00 N/A 
E6/35-44 LECVYCKQQL nb 18025 16905 16756 16640 17026 16946 6331 2956 1420 3833 20951 35.00 25.00 47.00 N/A 
E6/37-44 CVYCKQQL nb 30864 14668 21054 26148 9278 11667 6829 N/A N/A 3813 8169 33.00 31.00 45.00 N/A 
E6/42-51 QQLLRREVYD nb 2592 22405 4021 5027 34471 27876 50000 323 110 13999 26753 4.80 3.20 44.00 N/A 
E6/47-54 REVYDFAF nb 4471 177 8117 7894 360 253 759 N/A N/A 320 2285 0.80 0.10 71.00 N/A 
E6/51-60 DFAFRDLCIV nb 28432 22902 20253 19142 34491 28179 50000 5710 569 18609 27215 40.00 31.50 96.00 N/A 
E6/52-60 FAFRDLCIV nb 11153 10769 4422 4062 8949 9812 4288 16864 14521 4740 8652 31.00 31.00 49.00 N/A 
E6/73-82 CLKFYSKISE nb 20676 14658 20294 23745 18325 16405 33505 113 66 10128 857 24.10 14.10 27.00 N/A 
E6/81-90 SEYRHYCYSL nb 4629 7856 5064 4283 3731 5412 2874 1126 231 3966 938 7.90 6.10 24.00 N/A 
E6/88-95 YSLYGTTL nb 15086 1579 9888 13124 834 1152 2265 N/A N/A 739 3989 4.40 4.30 16.00 N/A 
E6/89-97 SLYGTTLEQ nb 4880 5667 8402 7925 9831 7487 10081 2606 1816 3680 502 8.80 8.80 7.00 N/A 
E6/90-99 LYGTTLEQQY nb 10883 5292 8193 8952 8539 6719 11987 926 517 2786 16393 12.70 10.50 9.00 N/A 
E6/95-103 LEQQYNKPL nb 3725 4599 11395 10517 8319 6162 1926 2958 2780 2764 5060 13.00 13.00 21.00 N/A 
E6/97-107 QQYNKPLCDLL nb 16933 3872 6080 8662 2481 3100 3726 N/A N/A 3028 492 7.70 7.10 4.00 N/A 
E6/98-107 QYNKPLCDLL nb 28147 25392 24378 24646 27133 26265 34610 60345 197811 17064 30368 77.50 69.00 38.00 N/A 
E6/106-114 LLIRCINCQ nb 7809 9423 17114 15786 13060 11113 13947 3451 2168 4894 1091 3.30 3.00 41.00 N/A 
E6/107-115 LIRCINCQK nb 15500 16852 18955 20384 17580 17131 18280 29850 29242 6841 15362 29.00 29.00 19.00 N/A 
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E6/107-117 LIRCINCQKPL nb 8294 1034 6136 4241 1126 1079 5044 N/A N/A 1327 112 1.00 0.10 53.00 N/A 
E6/113-122 CQKPLCPEEK nb 21798 11881 18226 22047 15451 13502 25842 701 1085 6583 16051 37.00 27.00 6.00 N/A 
E6/122-129 KQRHLDKK nb 29632 18220 28410 29028 17987 18181 29425 N/A N/A 9377 28606 29.00 31.00 26.00 N/A 
E6/129-137 KQRFHNIRG nb 2107 3728 4659 5308 6175 4804 9551 2443 2188 3899 936 10.00 10.00 8.00 N/A 
E6/143-151 CMSCCRSSR nb 15117 16483 16100 17865 16801 16583 7287 10964 10162 6857 19560 25.00 18.00 29.00 N/A 
E6/144-151 MSCCRSSR nb 33102 14502 31263 27740 20793 17411 16405 N/A N/A 9089 9978 39.00 37.00 65.00 N/A 
E6/144-152 MSCCRSSRT nb 20597 13773 24486 21090 19495 16405 9448 12301 11967 9844 12417 28.00 22.00 62.00 N/A 
E6/148-158 RSSRTRRETQL nb 28366 6721 24116 25513 10521 8433 7527 N/A N/A 5674 170 32.00 27.00 16.00 N/A 
E6/149-158 SSRTRRETQL nb 11299 15989 17521 16278 10058 12722 6683 9029 6184 2627 10123 31.50 29.55 12.00 N/A 
E6/150-158 SRTRRETQL nb 35474 19929 34055 38393 35085 26408 19718 339586 344350 22124 35163 79.00 78.00 16.00 N/A 
E6/151-158 RTRRETQL nb 24588 7125 19529 20971 4177 5471 6469 N/A N/A 3000 8987 19.00 31.00 36.00 N/A 
E6 L90V/82-91 EYRHYCYSVY nb 5809 445 5150 4957 5567 1576 7692 246 236 2409 10811 8.05 6.10 12.00 N/A 
E6 L90V/88-95 YSVYGTTL nb 10415 351 7446 9535 386 368 1602 N/A N/A 383 2123 1.20 0.30 13.00 N/A 
E7/2-11 HGDTPTLHEY nb 9071 2358 4080 3324 14783 5901 13502 508 189 4794 14936 7.00 4.65 9.00 N/A 
E7/11-20 YMLDLQPETT nb 16163 5248 13971 15539 7457 6263 17696 214 232 2715 5685 23.50 13.00 8.00 N/A 
E7/12-21 MLDLQPETTD nb 37581 25456 34771 36368 36930 30727 50000 922 1898 21095 35014 61.50 68.00 50.00 N/A 
E7/14-23 DLQPETTDLY nb 1131 618 2981 1986 4723 1710 8388 45 46 3901 11524 2.45 1.60 2.00 N/A 
E7/27-35 QLNDSSEEE nb 17376 13421 31284 32349 28656 19611 11858 7161 7889 13514 16923 31.00 23.00 4.00 N/A 
E7/42-51 AGQAEPDRAH nb 1583 17824 2036 3483 30012 23192 50000 4588 4190 3360 4007 26.10 24.60 24.00 N/A 
E7/44-52 QAEPDRAHY nb 3474 4410 6088 5004 6219 5239 10191 3605 3319 2522 1219 14.00 14.00 2.00 N/A 
E7/45-52 AEPDRAHY nb 8989 1571 17889 16044 7200 3362 7860 N/A N/A 1797 3135 1.00 0.10 16.00 N/A 
E7/48-57 DRAHYNIVTF nb 831 3130 1024 846 15827 7054 6829 706 252 5063 19192 7.30 6.60 31.00 N/A 
E7/49-58 RAHYNIVTFC nb 1857 20441 2398 2053 16485 18280 18083 4223 2853 8021 9063 22.65 21.10 33.00 N/A 
E7/63-72 STLRLCVQST nb 21261 22774 13381 14105 21151 21852 50000 7025 1090 10169 16313 36.50 26.50 54.00 N/A 
E7/64-73 TLRLCVQSTH nb 6302 6671 3603 3357 2810 4335 13649 884 3114 1126 202 24.10 22.10 3.00 N/A 
E7/66-73 RLCVQSTH nb 17595 3111 13985 15172 3972 3511 10302 N/A N/A 1230 263 6.40 5.90 53.00 N/A 
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E7/66-74 RLCVQSTHV nb 1399 622 3977 3307 2498 1249 5325 1066 944 992 632 2.30 1.50 4.00 N/A 
E7/66-75 RLCVQSTHVD nb 12566 16735 18570 19160 18972 17792 25017 148 134 5693 1677 7.95 6.90 21.00 N/A 
E7/69-79 VQSTHVDIRTL nb 11578 627 4918 7355 1586 995 2241 N/A N/A 871 17 2.40 1.50 8.00 N/A 
E7/77-84 RTLEDLLM nb 26819 5700 15109 15406 2892 4063 5621 N/A N/A 1999 6238 23.00 31.00 85.00 N/A 
E7/78-87 TLEDLLMGTL nb 21717 9843 14779 13333 16478 12722 14407 606 2953 4318 18454 44.50 34.50 11.00 N/A 
E7/81-90 DLLMGTLGIV nb 14331 7013 9292 7669 27380 13797 37740 239 223 13806 21420 18.00 10.40 86.00 N/A 
E7/83-91 LMGTLGIVC nb 2284 4750 9196 10941 3830 4265 4676 849 1549 1163 4264 8.00 8.00 23.00 N/A 
E7/83-93 LMGTLGIVCPI nb 5377 139 5684 3805 432 245 2905 N/A N/A 300 17 0.80 0.10 75.00 N/A 
E7/85-93 GTLGIVCPI nb 6259 10035 3917 3304 6199 7903 4382 4886 5284 4512 1968 19.00 19.00 75.00 N/A 
E7/86-93 TLGIVCPI nb 18481 7105 18271 20397 9723 8342 10642 N/A N/A 3543 8859 7.10 6.60 84.00 N/A 
E7/86-95 TLGIVCPICS nb 30590 20044 28227 29407 33263 25842 50000 2720 967 14463 17789 46.00 38.50 82.00 N/A 
E7/87-96 LGIVCPICSQ nb 4074 19216 20330 17865 23359 21269 40709 995 178 2725 2511 6.25 4.50 78.00 N/A 
E7/88-96 GIVCPICSQ nb 6329 10914 18113 15377 15978 13213 19932 8491 5321 6001 669 18.00 18.00 34.00 N/A 
E7/89-98 IVCPICSQKP nb 29504 25580 31503 36517 31417 28332 50000 8583 408 10301 2896 40.00 31.50 43.00 N/A 
a: Peptide ID contains the protein (E6/E7), amino acid changes compared to the reference sequence (e.g. L90V), and region within the amino acid sequence 
b: Peptide sequence, amino acid changes are highlighted in red 
c: Experimental binding capacity expressed IC50 ± SD 
d: Prediction score as putative IC50 value (the lower, the better) 
e: Prediction score as percentile rank (the lower, the better) 
f: SYFPEITHI-specific prediction score in arbitrary units (the higher, the better) 
N/A: Prediction was not available 
nb: nonbinder 
*: Recent A2 binding assays for E7/78-86 showed no binding affinity. However, prior binding assays resulted in binding affinity for A2. 
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Supplementary Table S2. HPV16 E6/E7-derived peptides and their reported binding affinities 
Peptide ID Sequence A1
 a
 A2
 a
 A3
 a
 A11
 a
 A24
 a
 B7
 a
 B15
 a
 IEDB ID
 b
 Exp. binding affinity
 c
 Functionality
 d
 
E6/1-9 MHQKRTAMF     ligand   41674 A24: -  
E6/7-15 AMFQDPQER  ligand ligand ligand    3089 
A2: -; 
A3: - ; 
A11: - 
 
E6/9-18 FQDPQERPRK    ligand    111289 A11: 5.01±2.17  
E6/15-22 QERPRKLPQL      ligand  (Bourgault Villada et al., 2010) B7: nb  
E6/15-22 RPRKLPQL      ligand  (Bourgault Villada et al., 2010) B7: 0.20±0.06  
E6/15-24 RPRKLPQLCT      IFNγ  911841 B7: 0.50±0.18  
E6/18-26 KLPQLCTEL  
ligand, 
IFNγ 
     32085 A2: 10.07±3.22  
E6/19-26 LPQLCTEL      ligand  (Bourgault Villada et al., 2010) B7:  1.30±0.43  
E6/21-29 QLCTELQTT  ligand      111674 A2: nb  
E6/21-30 QLCTELQTTI  ligand       A2: nb  
E6/25-33 ELQTTIHDI  ligand      111250 A2: 36.90±8.41 A2: IFNγ 
E6/26-34 LQTTIHDII  
ligand, 
cytolysis 
  ligand   39002 
A2: -; 
A24: 1.42±0.23 
 
E6/29-37 TIHDIILEC  ligand      110720 A2: nb  
E6/29-38 TIHDIILECV  
ligand, 
IFNγ, 
cytolysis 
     64320 A2: 3.69±2.17 A2: IFNγ 
E6/30-38 IHDIILECV  ligand      111421 A2: nb  
E6/32-41 DIILECVYCK    ligand    111199 A11: 6.80±2.41 A11: IFNγ 
E6/33-41 IILECVYCK   
ligand, 
IFNγ 
ligand    26568 
A3: 11.02±3.27; 
A11: 4.98±1.33 
 
E6/37-46 CVYCKQQLLR    IFNγ    911713 A11: 36.49±6.55 A11: IFNγ 
E6/42-50 QQLLRREVY   ligand ligand    52063 A3: nb; A11: -  
E6/44-52 LLRREVYDF     ligand   37754 A24: nb  
E6/49-57 VYDFAFRDL     
ligand, 
IFNγ, 
cytolysis 
  71988 A24: 0.10±0.04  
E6/52-60 FAFRDLCIV  
ligand, 
IFNγ, 
cytolysis 
   ligand  15173 
A2: 4.34±2.11; 
B7: nb 
A2: IFNγ 
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Peptide ID Sequence A1
 a
 A2
 a
 A3
 a
 A11
 a
 A24
 a
 B7
 a
 B15
 a
 IEDB ID
 b
 Exp. binding affinity
 c
 Functionality
 d
 
E6/54-61 FRDLCIVY ligand  ligand ligand    (Bourgault Villada et al., 2010) 
A1: nb; 
A3: - ; 
A11: nb 
 
E6/59-67 IVYRDGNPY   ligand ligand    29519 
A3: 11.58±1.76; 
A11: 19.84±4.91 
A3: IFNγ; 
A11: IFNγ 
E6/65-74 NPYAVCDKCL      IFNγ  911816 B7: nb  
E6/66-74 PYAVCDKCL     
ligand, 
IFNγ 
  50064 A24: 1.97±0.77  
E6/68-75 AVCDKCLK    ligand    111129 A11: 9.72±3.73 A11: IFNγ 
E6/68-77 AVCDKCLKFY    IFNγ    911710 A11: 4.80±0.55 A11: IFNγ 
E6/69-77 VCDKCLKFY cytolysis       67833 A1: nb  
E6/75-83 KFYSKISEY   ligand     30892 A3: 52.27±21.55 A3: IFNγ 
E6/77-86 YSKISEYRHY ligand       111973 A1: nb  
E6/79-87 KISEYRHYC  
ligand, 
IFNγ, 
cytolysis 
     111456 A2: 47.56±29.56  
E6 L90V/80-
88 
CYSVYGTTL    ligand    111184 A11: 62.36±12.84  
E6/80-88 ISEYRHYCY 
ligand, 
IFNγ 
  ligand    28484 
A1: 1.20±0.96; 
A11: 62.36±12.84 
 
E6/82-90 EYRHYCYSL     
ligand, 
IFNγ 
  110846 A24: 0.32±0.10  
E6/87-95 CYSLYGTTL     
ligand, 
IFNγ 
  7439 A24: 0.10±0.04 A24: IFNγ 
E6/89-97 SLYGTTLEQ   ligand     59598 A3: nb  
E6/97-106 QQYNKPLCDL  
ligand, 
IFNγ, 
cytolysis 
     604613 A2: nb  
E6/92-101 GTTLEQQYNK    ligand    111384 A11: 5.26±2.57 A11: IFNγ 
E6/93-101 TTLEQQYNK   ligand ligand    66689 
A3: 15.55±5.05; 
A11: 4.71±1.74 
A3: IFNγ; 
A11: IFNγ 
E6/98-106 QYNKPLCDL     
ligand, 
IFNγ 
  111698 A24: 2.97±0.67  
E6/98-107 QYNKPLCDLL     IFNγ   (Hara et al., 2005) A24: 0.54±0.24 A24: IFNγ 
E6/102-110 PLCDLLIRC  ligand      111630 A2: nb  
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Peptide ID Sequence A1
 a
 A2
 a
 A3
 a
 A11
 a
 A24
 a
 B7
 a
 B15
 a
 IEDB ID
 b
 Exp. binding affinity
 c
 Functionality
 d
 
E6/106-115 LLIRCINCQK   ligand 
ligand, 
IFNγ, 
cytolysis 
   37421 
A3: 2.06±0.97; 
A11: 1.36±0.30 
A3: IFNγ; 
A11: IFNγ 
E6/118-126 CPEEKQRHL      IFNγ  110197 B7: 5.90±3.90  
E6/125-133 HLDKKQRFH   ligand     24182 A3: 29.58±13.63  
E6/131-139 RFHNIRGRW     ligand   53711 A24: 23.93±3.24  
E7/2-11 HGDTPTLHEY ligand       111395 A1: 1.03±0.59  
E7/5-13 TPTLHEYML      IFNγ  911868 B7: 4.50±3.30  
E7/7-15 TLHEYMLDL  
ligand, 
IFNγ, 
cytolysis 
 ligand    64830 
A2: 2.68±1.86; 
A11: nb 
 
E7/7-17 TLHEYMLDLQP  ligand      768668 A2: 19.35±12.57 A2: IFNγ 
E7/10-19 EYMLDLQPET  ligand      768427 A2: nb  
E7/11-18 YMLDLQPE  ligand      768725 A2: 8.07±3.69 A2: IFNγ 
E7/11-19 YMLDLQPET  
ligand, 
IFNγ, 
cytolysis 
     75074 A2: 1.40±0.94 A2: IFNγ; cytolysis 
E7/11-20 YMLDLQPETT  
ligand, 
IFNγ, 
cytolysis 
     75075 A2: 2.19±2.71 A2: IFNγ; cytolysis 
E7/11-21 YMLDLQPETTD  ligand      768729 A2: 2.37±1.67 A2: IFNγ; cytolysis 
E7/12-19 MLDLQPET  ligand      768546 A2: 53.66±12.03 A2: IFNγ; cytolysis 
E7/12-20 MLDLQPETT  
ligand, 
IFNγ, 
cytolysis 
     41919 A2: 3.60±0.73 A2: IFNγ; cytolysis 
E7/14-22 DLQPETTDL  ligand      (Bauer et al., 2000) A2: nb  
E7/15-23 LQPETTDLY       IFNγ 911800 B15: 4.68±1.28  
E7/18-25 ETTDLYCY ligand       110220 A1: 11.52±7.17  
E7/19-27 TTDLYCYEQ ligand       66569 A1: 83.36±15.02  
E7/37-45 EIDGPAGQA ligand       12414 A1: -  
E7/44-52 QAEPDRAHY ligand       50240 A1: nb  
E7/49-57 RAHYNIVTF     ligand   53112 A24: 0.15±0.07  
E7/51-60 HYNIVTFCCK   IFNγ     164805 A3: nb  
Annex 
 
(Continued) 
158 
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 a
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 a
 B15
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 IEDB ID
 b
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 c
 Functionality
 d
 
E7/61-69 CDSTLRLCV     
IFNγ, 
cytolysis 
  168256 A24: nb  
E7/66-74 RLCVQSTHV  ligand      54496 A2: 37.18±10.65 A2: IFNγ 
E7/67-76 LCVQSTHVDI     
IFNγ, 
cytolysis 
  169070 A24: 34.74±11.56 A24: IFNγ 
E7/73-81 HVDIRTLED ligand       25028 A1: -  
E7/73-82 HVDIRTLEDL  ligand      (Bauer et al., 2000) A2: nb  
E7/75-83 DIRTLEDLL  ligand      (Bauer et al., 2000) A2: nb  
E7/76-86 IRTLEDLLMGT  ligand      113033 A2: 31.85±22.45  
E7/77-86 RTLEDLLMGT  
ligand, 
IFNγ, 
cytolysis 
     139234 A2: 72.72±17.36 A2: IFNγ 
E7/77-87 RTLEDLLMGTL  ligand      768628 A2: 2.69±2.94 A2: IFNγ 
E7/78-86 TLEDLLMGT  ligand      111833 A2: nb* A2: IFNγ 
E7/78-87 TLEDLLMGTL  ligand       A2: nb  
E7/80-90 EDLLMGTLGIV  ligand      768404 A2: 14.20±2.47 A2: IFNγ 
E7/81-90 DLLMGTLGIV  ligand      139028 A2: 52.58±19.28 A2: IFNγ 
E7/81-91 DLLMGTLGIVC  cytolysis      688709 A2: 41.25±39.26 A2: IFNγ 
E7/82-90 LLMGTLGIV  
ligand, 
IFNγ, 
cytolysis 
     37573 A2: 3.30±2.58  
E7/83-93 LMGTLGIVCPI     
ligand, 
IFNγ 
  165037 A24: -  
E7/85-93 GTLGIVCPI  
ligand, 
IFNγ, 
cytolysis 
     22738 A2: 1.96±1.93 A2: IFNγ 
E7/86-93 TLGIVCPI  
ligand, 
IFNγ, 
cytolysis 
     64818 A2: 1.27±1.54 A2: IFNγ 
E7/86-94 TLGIVCPIC  
ligand, 
cytolysis 
     64819 A2: 62.31±18.61  
E7/87-93 LGIVCPI  ligand      36171 A2: -  
E7/87-95 LGIVCPICS  ligand      111480 A2: -  
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 a
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 a
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 a
 A11
 a
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 a
 B7
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 B15
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 IEDB ID
 b
 Exp. binding affinity
 c
 Functionality
 d
 
E7/88-97 GIVCPICSQK    
ligand, 
IFNγ, 
cytolysis 
   20471 A11: 2.22±0.84 A11: IFNγ 
E7/89-97 IVCPICSQK   ligand 
ligand, 
IFNγ 
   29222 
A3: 4.06±1.38; 
A11: 3.16±0.78 
A3: IFNγ; 
A11: IFNγ 
a: HLA-restricted epitopes reported to exhibit HLA binding, induce IFNγ-responses (IFNγ) or mediate cytotoxiyity (cytolysis) 
b: Epitope identifier in IEDB; if epitope is not entered in IEDB specific reference is given 
c: Experimental binding affinity is expressed as IC50-value ± Standard deviation in µM;   nb: nonbinder;   -: not tested 
d: Functionality assessed as IFNγ-responses in ELISpoot assays (IFNγ) or cytotoxicity assays (cytolysis)  
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Supplementary Table S3. HLA-type and peptide length-dependent threshold recommendations and performance indicators for prediction methods 
Predictora AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Val. 
Thresholdc 
(PPV [%]) 
Specificity 
Sensitivity 
HLA A1 8-mers (n=8) 9-mers (n=15) 10-mers (n=23) 11-mers (n=24) Pooled lengths (n=70) 
NetMHC 4.0 0.75 11702 0.75 0.91 6706 0.73 0.65 3676 0.70 0.63 709 1.00 0.73 6706 0.76±0.11 
(80.00) 1.00 (57.14) 1.00 (72.73) 0.62 (100.00) 0.29 (64.29) 0.64±0.14 
NetMHC 3.4 0.75 2008 1.00 0.95 5319 0.91 0.57 4547 0.70 0.48 2391 1.00 0.67 5319 0.77±0.09 
(100.00) 0.75 (80.00) 1.00 (75.00) 0.69 (100.00) 0.14 (62.96) 0.60±0.12 
NetMHCpan 4.0 0.63 4421 1.00 0.93 3126 0.82 0.62 1547 0.90 0.78 6597 0.88 0.72 6597 0.73±0.10 
(100.00) 0.25 (66.67) 1.00 (83.33) 0.38 (60.00) 0.43 (60.71) 0.63±0.11 
NetMHCpan 3.0 0.75 7096 1.00 0.95 1899 0.91 0.59 1835 0.90 0.71 8697 0.71 0.72 5105 0.81±0.09 
(100.00) 0.50 (80.00) 1.00 (83.33) 0.38 (50.00) 0.71 (66.67) 0.56±0.14 
NetMHcpan 2.8 0.69 2190 0.75 0.93 2317 0.82 0.44 267 1.00 0.56 4236 0.82 0.63 2835 0.83±0.09 
(75.00) 0.75 (66.67) 1.00 (100.00) 0.08 (50.00) 0.43 (66.67) 0.50±0.15 
NetMHCcons 1.1 0.75 2100 1.00 0.95 3511 0.91 0.50 257 1.00 0.52 4963 0.88 0.66 4552 0.75±0.09 
(100.00) 0.75 (80.00) 1.00 (100.00) 0.08 (50.00) 0.29 (58.33) 0.51±0.16 
PickPocket 1.1 0.69 5211 0.75 0.95 1766 0.91 0.62 4288 0.90 0.57 3308 0.82 0.64 4289 0.77±0.08 
(75.00) 0.75 (80.00) 1.00 (87.50) 0.54 (50.00) 0.43 (61.54) 0.58±0.14 
IEDB 
SMMPMBEC 
0.56 3764 0.75 0.86 2486 0.82 0.46 384 0.90 0.52 525 1.00 0.60 608 0.93±0.06 
(50.00) 0.25 (60.00) 0.75 (50.00) 0.08 (100.00) 0.14 (62.50) 0.18±0.10 
IEDB SMM 0.38 16632 0.75 0.75 323 1.00 0.48 315 1.00 0.43 641 0.76 0.52 315 0.95±0.04 
(66.67) 0.50 (100.00) 0.50 (100.00) 0.08 (20.00) 0.14 (50.00) 0.06±0.07 
MHCflurry 1.2 0.69 1204 0.75 0.93 1528 0.82 0.53 313 1.00 0.51 4615 0.88 0.65 1529 0.83±0.09 
(75.00) 0.75 (66.67) 1.00 (100.00) 0.15 (50.00) 0.29 (65.00) 0.45±0.14 
MHCnuggets 2.0 0.56 2537 0.75 0.80 4233 0.82 0.62 3287 0.80 0.60 2154 0.88 0.67 5217 0.77±0.09 
(66.67) 0.50 (60.00) 0.75 (77.78) 0.54 (33.33) 0.14 (58.33) 0.50±0.13 
IEDB 
recommended 
0.38 11.25 0.75 0.77 0.25 1.00 0.52 0.55 0.90 0.55 1.10 0.82 0.59 0.55 0.96±0.05 
(66.67) 0.50 (100.00) 0.50 (75.00) 0.23 (25.00) 0.14 (71.43) 0.17±0.10 
IEDB consensus 0.38 11.20 0.75 0.77 0.25 1.00 0.49 0.35 0.90 0.55 1.15 0.82 0.59 0.35 0.98±0.03 
(66.67) 0.50 (100.00) 0.50 (50.00) 0.08 (25.00) 0.14 (75.00) 0.13±0.09 
MixMHCpred 
2.0.2 
0.44 6.00 0.50 0.86 0.50 0.73 0.60 0.08 0.90 0.45 2.00 0.47 0.56 0.05 0.95±0.05 
(50.00) 0.50 (57.14) 1.00 (50.00) 0.08 (25.00) 0.43 (50.00) 0.06±0.06 
HLA A2 8-mers (n=21) 9-mers (n=39) 10-mers (n=46) 11-mers (n=50) Pooled lengths (n=156) 
NetMHC 4.0 
0.83 
9128 0.81 
0.86 
1812 0.96 
0.78 
2565 0.69 
0.83 
11451 0.71 
0.79 
6937 0.70±0.06 
(57.14) 0.80 (90.91) 0.71 (42.11) 0.73 (60.00) 0.94 (50.75) 0.73±0.08 
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Predictora AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Val. 
Thresholdc 
(PPV [%]) 
Specificity 
Sensitivity 
NetMHC 3.4 
0.81 
6045 0.69 
0.83 
2403 0.92 
0.86 
4749 0.80 
0.68 
4362 0.74 
0.79 
6045 0.72±0.06 
(50.00) 1.00 (83.33) 0.71 (56.25) 0.82 (50.00) 0.56 (52.31) 0.74±0.09 
NetMHCpan 4.0 
0.76 
11632 0.88 
0.90 
5803 0.72 
0.80 
2254 0.80 
0.80 
10688 0.68 
0.80 
8103 0.70±0.07 
(60.00) 0.60 (65.00) 0.93 (53.33) 0.73 (54.17) 0.81 (50.00) 0.74±0.08 
NetMHCpan 3.0 
0.74 
9488 0.88 
0.87 
4733 0.76 
0.81 
2033 0.80 
0.81 
11935 0.79 
0.78 
9488 0.67±0.07 
(60.00) 0.60 (66.67) 0.86 (53.33) 0.73 (63.16) 0.75 (48.53) 0.71±0.10 
NetMHcpan 2.8 
0.80 
2302 0.69 
0.85 
4164 0.84 
0.81 
4922 0.83 
0.72 
4714 0.71 
0.79 
4923 0.74±0.06 
(50.00) 1.00 (73.33) 0.79 (57.14) 0.73 (54.55) 0.75 (55.38) 0.78±0.09 
NetMHCcons 1.1 
0.81 
2327 0.75 
0.85 
5267 0.76 
0.83 
8711 0.69 
0.72 
5382 0.71 
0.80 
5383 0.74±0.06 
(50.00) 0.80 (64.71) 0.79 (47.62) 0.91 (54.55) 0.75 (56.25) 0.79±0.09 
PickPocket 1.1 
0.76 
735 0.75 
0.83 
561 0.80 
0.76 
704 0.86 
0.68 
953 0.76 
0.76 
954 0.74±0.05 
(50.00) 0.80 (68.75) 0.79 (54.55) 0.55 (57.89) 0.69 (53.33) 0.71±0.10 
IEDB 
SMMPMBEC 
0.60 
926 0.75 
0.84 
3072 0.72 
0.91 
1294 0.83 
0.65 
283 0.94 
0.78 
1715 0.70±0.06 
(42.86) 0.60 (63.16) 0.86 (62.50) 0.91 (60.00) 0.19 (50.75) 0.74±0.09 
IEDB SMM 
0.51 
167 0.94 
0.85 
3077 0.76 
0.90 
1642 0.74 
0.61 
90 1.00 
0.73 
1277 0.68±0.07 
(50.00) 0.20 (66.67) 0.86 (52.63) 0.91 (100.00) 0.06 (46.03) 0.64±0.10 
MHCflurry 1.2 
0.84 
4315 0.69 
0.92 
4896 0.76 
0.89 
3410 0.89 
0.74 
7743 0.71 
0.83 
5310 0.74±0.06 
(50.00) 1.00 (70.00) 1.00 (69.23) 0.82 (54.55) 0.75 (56.72) 0.82±0.08 
MHCnuggets 2.0 
0.73 
8357 0.69 
0.88 
1038 0.84 
0.81 
1418 1.00 
0.84 
7691 0.68 
0.82 
3482 0.73±0.06 
(44.44) 0.80 (75.00) 0.86 (100.00) 0.73 (56.00) 0.88 (55.38) 0.77±0.10 
IEDB 
recommended 
0.70 
1.00 1.00 
0.80 
8.70 0.68 
0.85 
6.60 0.80 
0.76 
16.05 0.71 
0.77 
10.35 0.71±0.06 
(100.00) 0.20 (57.89) 0.79 (56.25) 0.82 (54.55) 0.75 (51.52) 0.73±0.09 
IEDB consensus 
0.70 
0.80 1.00 
0.85 
6.60 0.72 
0.89 
6.20 0.77 
0.75 
9.25 0.79 
0.77 
8.98 0.70±0.06 
(100.00) 0.20 (58.82) 0.71 (55.56) 0.91 (58.82) 0.63 (49.25) 0.70±0.10 
MixMHCpred 
2.0.2 0.65 
12.00 0.81 
0.74 
0.50 0.88 
0.68 
2.00 0.94 
0.66 
6.00 0.74 
0.68 
5.00 0.72±0.06 
(40.00) 0.40 (70.00) 0.50 (66.67) 0.36 (52.63) 0.63 (46.43) 0.56±0.10 
HLA A3 8-mers (n=13) 9-mers (n=34) 10-mers (n=35) 11-mers (n=23) Pooled lengths (n=105) 
NetMHC 4.0 
0.91 
10604 0.91 
0.89 
3475 0.92 
0.94 
1603 0.89 
0.34 
234 1.00 
0.78 
6962 0.73±0.07 
(66.67) 1.00 (77.78) 0.88 (70.00) 1.00 (100.00) 0.25 (41.03) 0.78±0.14 
NetMHC 3.4 
0.55 
752 0.73 
0.91 
3086 0.96 
0.97 
2536 0.89 
0.45 
955 1.00 
0.84 
3086 0.78±0.06 
(25.00) 0.50 (87.50) 0.88 (70.00) 1.00 (100.00) 0.25 (48.57) 0.79±0.14 
NetMHCpan 4.0 
0.82 
12511 0.73 
0.88 
8302 0.85 
0.95 
1365 0.93 
0.42 
132 1.00 
0.78 
7696 0.68±0.07 
(40.00) 1.00 (63.64) 0.88 (77.78) 1.00 (100.00) 0.25 (35.71) 0.71±0.15 
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Predictora AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Val. 
Thresholdc 
(PPV [%]) 
Specificity 
Sensitivity 
NetMHCpan 3.0 
0.82 
10536 0.73 
0.88 
8408 0.77 
0.95 
1769 0.89 
0.39 
163 1.00 
0.78 
5534 0.77±0.06 
(40.00) 1.00 (53.85) 0.88 (70.00) 1.00 (100.00) 0.25 (44.12) 0.72±0.14 
NetMHcpan 2.8 
0.73 
637 0.91 
0.90 
7001 0.92 
0.98 
2365 0.96 
0.36 
131 1.00 
0.79 
2366 0.79±0.07 
(50.00) 0.50 (77.78) 0.88 (87.50) 1.00 (100.00) 0.25 (47.06) 0.75±0.15 
NetMHCcons 1.1 
0.64 
693 0.91 
0.90 
4651 0.96 
0.98 
2000 0.96 
0.39 
354 1.00 
0.82 
2000 0.85±0.06 
(50.00) 0.50 (87.50) 0.88 (87.50) 1.00 (100.00) 0.25 (57.14) 0.77±0.14 
PickPocket 1.1 
0.68 
1551 0.82 
0.78 
1655 0.88 
0.92 
4990 0.71 
0.36 
1422 0.84 
0.73 
2874 0.72±0.06 
(33.33) 0.50 (66.67) 0.75 (46.67) 1.00 (25.00) 0.25 (39.47) 0.70±0.15 
IEDB 
SMMPMBEC 0.36 
21975 0.64 
0.90 
1881 0.96 
0.96 
971 0.93 
0.54 
691 0.79 
0.80 
1881 0.82±0.06 
(20.00) 0.50 (87.50) 0.88 (77.78) 1.00 (33.33) 0.50 (51.61) 0.77±0.15 
IEDB SMM 
0.55 
13611 0.64 
0.88 
1909 0.96 
0.96 
906 0.89 
0.36 
2778 0.53 
0.79 
2930 0.76±0.06 
(20.00) 0.50 (87.50) 0.88 (70.00) 1.00 (10.00) 0.25 (43.24) 0.78±0.13 
MHCflurry 1.2 
0.64 
220 1.00 
0.85 
3505 0.85 
0.97 
2047 0.93 
0.41 
1272 0.84 
0.79 
3506 0.72±0.06 
(100.00) 0.50 (63.64) 0.88 (77.78) 1.00 (25.00) 0.25 (41.46) 0.82±0.13 
MHCnuggets 2.0 
0.32 
3622 0.45 
0.90 
2433 0.92 
0.98 
458 0.96 
0.46 
199 0.95 
0.81 
3623 0.73±0.07 
(14.29) 0.50 (77.78) 0.88 (87.50) 1.00 (50.00) 0.25 (40.48) 0.82±0.14 
IEDB 
recommended 0.64 
3.45 0.82 
0.88 
2.70 0.96 
0.98 
3.50 0.93 
0.33 
6.65 0.68 
0.77 
3.50 0.86±0.06 
(33.33) 0.50 (87.50) 0.88 (77.78) 1.00 (14.29) 0.25 (55.56) 0.71±0.14 
IEDB consensus 
0.64 
3.15 0.82 
0.88 
2.90 0.96 
0.98 
11.35 0.89 
0.32 
6.60 0.63 
0.77 
11.35 0.68±0.07 
(33.33) 0.50 (87.50) 0.88 (70.00) 1.00 (12.50) 0.25 (38.10) 0.79±0.13 
MixMHCpred 
2.0.2 0.64 
6.00 0.91 
0.87 
2.00 0.88 
0.99 
3.00 0.86 
0.54 
0.50 0.89 
0.82 
6.00 0.74±0.07 
(50.00) 0.50 (70.00) 0.88 (63.64) 0.57 (33.33) 0.25 (43.59) 0.80±0.13 
HLA A11 8-mers (n=24) 9-mers (n=40) 10-mers (n=33) 11-mers (n=40) Pooled lengths (n=137) 
NetMHC 4.0 0.98 9342 0.94 0.95 9085 0.77 0.82 1928 0.85 0.76 9183 0.70 0.85 9342 0.72±0.07 
(85.71) 1.00 (56.25) 1.00 (75.00) 0.85 (52.94) 0.69 (57.14) 0.89±0.08 
NetMHC 3.4 0.98 1354 0.94 0.94 13066 0.71 0.87 5497 0.70 0.73 6972 0.70 0.86 6972 0.72±0.06 
(85.71) 1.00 (50.00) 1.00 (64.71) 0.77 (57.89) 0.85 (58.06) 0.87±0.08 
NetMHCpan 4.0 1.00 7719 1.00 0.92 7399 0.71 0.83 2782 0.70 0.71 5361 0.81 0.85 7720 0.72±0.07 
(100.00) 1.00 (47.06) 0.89 (62.50) 0.69 (58.33) 0.54 (55.74) 0.83±0.09 
NetMHCpan 3.0 1.00 5308 1.00 0.90 980 0.97 0.82 1721 0.70 0.71 7709 0.70 0.84 7568 0.68±0.06 
(100.00) 1.00 (87.50) 0.78 (60.00) 0.92 (50.00) 0.62 (52.31) 0.84±0.08 
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Predictora AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Val. 
Thresholdc 
(PPV [%]) 
Specificity 
Sensitivity 
NetMHcpan 2.8 1.00 349 1.00 0.94 6917 0.87 0.86 5277 0.70 0.69 158 0.96 0.85 7182 0.69±0.07 
(100.00) 1.00 (66.67) 0.89 (66.67) 0.85 (50.00) 0.08 (53.73) 0.87±0.07 
NetMHCcons 1.1 0.98 685 0.94 0.94 6829 0.87 0.86 4406 0.70 0.72 7093 0.67 0.86 7734 0.71±0.07 
(85.71) 1.00 (66.67) 0.89 (64.71) 0.77 (57.14) 0.92 (57.58) 0.93±0.07 
PickPocket 1.1 0.94 3237 0.89 0.90 2417 0.74 0.75 4626 0.70 0.75 6331 0.70 0.77 3726 0.67±0.07 
(75.00) 1.00 (50.00) 0.89 (62.50) 0.77 (55.56) 0.77 (49.18) 0.72±0.10 
IEDB 
SMMPMBEC 
0.95 3425 0.89 0.92 1253 1.00 0.86 2715 0.75 0.66 510 0.81 0.84 1966 0.74±0.06 
(75.00) 1.00 (100.00) 0.78 (66.67) 0.85 (58.33) 0.54 (55.17) 0.77±0.09 
IEDB SMM 0.81 3249 0.72 0.92 3633 0.68 0.86 2923 0.70 0.71 229 0.93 0.82 1539 0.80±0.06 
(50.00) 0.83 (44.44) 0.89 (64.71) 0.69 (66.67) 0.31 (62.00) 0.76±0.11 
MHCflurry 1.2 1.00 377 1.00 0.94 3531 0.71 0.81 1263 0.75 0.72 1799 0.81 0.84 3412 0.67±0.06 
(100.00) 1.00 (50.00) 1.00 (64.29) 0.85 (50.00) 0.38 (50.77) 0.80±0.09 
MHCnuggets 2.0 0.98 1230 0.94 0.97 6299 0.87 0.83 5953 0.70 0.81 6339 0.67 0.90 6339 0.78±0.06 
(85.71) 1.00 (69.23) 1.00 (64.71) 0.77 (57.14) 0.92 (64.41) 0.94±0.06 
IEDB 
recommended 
0.94 11.05 0.67 0.94 5.70 0.74 0.87 6.15 0.70 0.83 8.85 0.81 0.87 8.60 0.67±0.06 
(50.00) 1.00 (52.94) 1.00 (62.50) 0.77 (70.59) 0.92 (55.88) 0.91±0.06 
IEDB consensus 0.94 10.65 0.67 0.94 5.00 0.74 0.87 4.85 0.70 0.82 7.65 0.81 0.87 7.65 0.68±0.06 
(50.00) 1.00 (52.94) 1.00 (62.50) 0.46 (70.59) 0.92 (55.88) 0.94±0.06 
MixMHCpred 
2.0.2 
0.91 10.00 0.94 0.71 2.00 0.84 0.75 4.00 1.00 0.66 3.00 0.89 0.72 10.50 0.67±0.06 
(83.33) 0.83 (44.44) 0.44 (100.00) 0.62 (50.00) 0.23 (45.61) 0.64±0.11 
HLA A24 8-mers (n=18) 9-mers (n=36) 10-mers (n=46) 11-mers (n=29) Pooled lengths (n=129) 
NetMHC 4.0 
0.79 
25903 0.75 
0.76 
7820 0.71 
0.76 
9077 0.75 
0.78 
20603 0.67 
0.73 
12915 0.70±0.09 
(92.31) 0.86 (72.22) 0.68 (71.43) 0.77 (60.00) 0.82 (69.35) 0.65±0.07 
NetMHC 3.4 
0.71 
11113 0.75 
0.81 
6548 0.82 
0.78 
14977 0.67 
0.78 
17668 0.72 
0.76 
11562 0.75±0.08 
(88.89) 0.57 (82.35) 0.74 (68.00) 0.77 (61.54) 0.73 (73.33) 0.67±0.08 
NetMHCpan 4.0 
0.86 
33856 0.75 
0.82 
12843 0.71 
0.77 
12097 0.75 
0.74 
22981 0.67 
0.74 
14268 0.71±0.09 
(92.86) 0.93 (75.00) 0.79 (73.91) 0.77 (60.00) 0.82 (69.84) 0.65±0.08 
NetMHCpan 3.0 
0.86 
34571 0.75 
0.81 
12345 0.71 
0.76 
11145 0.71 
0.72 
18252 0.72 
0.74 
12346 0.73±0.07 
(92.86) 0.93 (73.68) 0.74 (70.83) 0.64 (61.54) 0.73 (71.67) 0.66±0.08 
NetMHcpan 2.8 
0.79 
10002 0.75 
0.81 
10228 0.82 
0.76 
12415 0.88 
0.77 
19059 0.72 
0.78 
12415 0.78±0.08 
(91.67) 0.79 (83.33) 0.79 (82.35) 0.82 (64.29) 0.82 (76.67) 0.70±0.07 
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Predictora AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Val. 
Thresholdc 
(PPV [%]) 
Specificity 
Sensitivity 
NetMHCcons 1.1 
0.79 
10027 1.00 
0.81 
10934 0.71 
0.79 
14564 0.67 
0.78 
20590 0.72 
0.78 
13142 0.68±0.08 
(100.00) 0.64 (76.19) 0.84 (69.23) 0.64 (64.29) 0.82 (72.86) 0.78±0.07 
PickPocket 1.1 
0.77 
5099 0.75 
0.69 
1655 0.82 
0.71 
5211 0.71 
0.79 
24218 0.67 
0.71 
5100 0.67±0.09 
(90.91) 0.71 (76.92) 0.53 (66.67) 0.55 (62.50) 0.91 (67.69) 0.67±0.07 
IEDB 
SMMPMBEC 0.18 
1123 0.75 
0.72 
2183 0.71 
0.74 
1674 0.83 
0.75 
9957 0.67 
0.64 
1674 0.84±0.07 
(50.00) 0.07 (70.59) 0.63 (75.00) 0.77 (62.50) 0.91 (70.59) 0.37±0.07 
IEDB SMM 
0.18 
59 1.00 
0.71 
1724 0.82 
0.76 
3355 0.71 
0.75 
8671 0.78 
0.64 
3025 0.75±0.07 
(100.00) 0.07 (75.00) 0.47 (70.83) 0.73 (66.67) 0.73 (66.67) 0.49±0.08 
MHCflurry 1.2 
0.71 
3941 0.75 
0.77 
2322 0.71 
0.75 
4369 0.67 
0.82 
10190 0.67 
0.76 
3942 0.71±0.08 
(90.00) 0.64 (73.68) 0.74 (66.67) 0.73 (60.00) 0.82 (70.49) 0.63±0.07 
MHCnuggets 2.0 
0.73 
1382 1.00 
0.80 
3169 0.71 
0.81 
5506 0.71 
0.81 
14997 0.67 
0.80 
5050 0.70±0.09 
(100.00) 0.50 (73.68) 0.74 (69.57) 0.82 (62.50) 0.91 (70.77) 0.71±0.08 
IEDB 
recommended 0.36 
6.20 1.00 
0.74 
3.15 0.71 
0.78 
5.35 0.75 
0.85 
19.90 0.89 
0.70 
6.40 0.77±0.07 
(100.00) 0.14 (72.22) 0.68 (75.00) 0.82 (81.82) 0.82 (71.70) 0.58±0.09 
IEDB consensus 
0.34 
3.85 1.00 
0.73 
2.80 0.71 
0.77 
5.00 0.75 
0.84 
21.95 0.78 
0.69 
6.53 0.74±0.08 
(100.00) 0.07 (72.22) 0.68 (75.00) 0.73 (69.23) 0.82 (67.92) 0.55±0.09 
MixMHCpred 
2.0.2 0.55 
22.00 0.75 
0.79 
2.00 0.71 
0.75 
6.00 0.75 
0.76 
9.00 0.78 
0.68 
4.00 0.77±0.07 
(88.89) 0.57 (76.19) 0.84 (72.73) 0.77 (63.64) 0.64 (72.22) 0.59±0.09 
HLA B7 8-mers (n=11) 9-mers (n=13) 10-mers (n=16) 11-mers (n=15) Pooled lengths (n=55) 
NetMHC 4.0 
0.97 
21900 0.80 
0.90 
6673 1.00 
0.79 
3061 0.92 
0.70 
16556 0.67 
0.77 
12895 0.70±0.12 
(85.71) 1.00 (100.00) 0.86 (75.00) 0.75 (75.00) 0.67 (66.67) 0.69±0.13 
NetMHC 3.4 
0.97 
16001 0.80 
0.93 
5180 1.00 
0.75 
5373 0.83 
0.87 
14182 0.67 
0.87 
7396 0.87±0.10 
(85.71) 1.00 (100.00) 0.86 (60.00) 0.75 (80.00) 0.89 (84.00) 0.81±0.11 
NetMHCpan 4.0 
0.90 
5515 1.00 
0.93 
14910 0.67 
0.79 
5644 0.83 
0.81 
20480 0.83 
0.81 
10711 0.86±0.09 
(100.00) 0.83 (77.78) 1.00 (60.00) 0.75 (87.50) 0.78 (82.61) 0.73±0.12 
NetMHCpan 3.0 
0.90 
6604 1.00 
0.88 
6431 0.67 
0.75 
4632 0.83 
0.80 
19735 0.83 
0.79 
14473 0.72±0.11 
(100.00) 0.83 (75.00) 0.86 (60.00) 0.75 (87.50) 0.78 (72.41) 0.82±0.10 
NetMHcpan 2.8 
0.93 
1846 1.00 
0.90 
3666 1.00 
0.71 
3279 0.83 
0.83 
7505 0.67 
0.86 
7506 0.76±0.10 
(100.00) 0.83 (100.00) 0.86 (60.00) 0.75 (80.00) 0.89 (75.86) 0.84±0.11 
NetMHCcons 1.1 
0.93 
1091 1.00 
0.93 
4335 1.00 
0.71 
4174 0.83 
0.85 
7946 0.67 
0.87 
7946 0.76±0.10 
(100.00) 0.83 (100.00) 0.86 (60.00) 0.75 (80.00) 0.89 (75.86) 0.85±0.09 
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Predictora AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Val. 
Thresholdc 
(PPV [%]) 
Specificity 
Sensitivity 
PickPocket 1.1 
0.93 
2340 1.00 
0.79 
462 0.83 
0.73 
1585 0.92 
0.65 
1766 0.83 
0.79 
2874 0.77±0.11 
(100.00) 0.83 (83.33) 0.71 (75.00) 0.75 (83.33) 0.56 (74.07) 0.76±0.12 
IEDB 
SMMPMBEC 0.87 
3196 0.80 
0.90 
1133 1.00 
0.69 
1308 0.67 
0.35 
3528 0.67 
0.65 
1309 0.82±0.11 
(83.33) 0.83 (100.00) 0.86 (42.86) 0.75 (33.33) 0.11 (72.22) 0.50±0.15 
IEDB SMM 
0.90 
333 1.00 
0.93 
1256 1.00 
0.40 
687 0.50 
0.39 
88 1.00 
0.64 
923 0.72±0.11 
(100.00) 0.83 (100.00) 0.86 (33.33) 0.50 (100.00) 0.22 (65.22) 0.55±0.12 
MHCflurry 1.2 
0.93 
1815 1.00 
0.88 
4448 0.83 
0.75 
2064 0.83 
0.83 
3295 0.83 
0.85 
4448 0.81±0.13 
(100.00) 0.83 (85.71) 0.86 (50.00) 0.75 (87.50) 0.78 (76.92) 0.77±0.11 
MHCnuggets 2.0 
0.93 
4125 1.00 
0.81 
2408 0.83 
0.85 
2912 0.92 
0.91 
8533 0.83 
0.87 
9056 0.75±0.10 
(100.00) 0.83 (83.33) 0.71 (75.00) 0.50 (88.89) 0.89 (75.86) 0.84±0.10 
IEDB 
recommended 1.00 
17.90 1.00 
0.93 
3.80 1.00 
0.63 
1.75 0.92 
0.44 
1.10 1.00 
0.74 
4.65 0.77±0.13 
(100.00) 1.00 (100.00) 0.86 (66.67) 0.50 (100.00) 0.11 (69.57) 0.63±0.13 
IEDB consensus 
1.00 
17.85 1.00 
0.93 
3.80 1.00 
0.63 
1.45 1.00 
0.46 
1.30 1.00 
0.74 
4.20 0.82±0.10 
(100.00) 1.00 (100.00) 0.86 (100.00) 0.25 (100.00) 0.11 (76.19) 0.61±0.14 
MixMHCpred 
2.0.2 0.90 
14.00 0.80 
0.79 
2.00 0.83 
0.58 
0.50 1.00 
0.70 
12.00 0.67 
0.71 
0.60 0.85±0.10 
(83.33) 0.83 (85.71) 0.86 (100.00) 0.75 (75.00) 0.67 (87.50) 0.43±0.14 
HLA B15 8-mers (n=20) 9-mers (n=34) 10-mers (n=48) 11-mers (n=25) Pooled lengths (n=127) 
NetMHC 4.0 
0.93 
14125 0.75 
0.83 
4254 0.67 
0.89 
6140 0.70 
0.82 
6524 0.80 
0.83 
7638 0.68±0.09 
(72.73) 1.00 (75.00) 0.79 (64.00) 0.89 (93.33) 0.70 (72.60) 0.82±0.06 
NetMHC 3.4 
0.80 
2654 0.67 
0.82 
5652 0.67 
0.89 
4551 0.83 
0.60 
438 0.80 
0.82 
5050 0.69±0.08 
(63.64) 0.88 (75.00) 0.79 (76.19) 0.94 (90.91) 0.50 (73.61) 0.81±0.08 
NetMHCpan 4.0 
0.99 
7695 0.92 
0.94 
4781 0.73 
0.86 
7669 0.67 
0.85 
5189 0.80 
0.89 
7230 0.72±0.09 
(88.89) 1.00 (81.82) 0.95 (62.96) 0.94 (94.12) 0.80 (75.64) 0.91±0.05 
NetMHCpan 3.0 
1.00 
7374 1.00 
0.94 
4008 0.87 
0.87 
7102 0.67 
0.79 
3766 1.00 
0.88 
7596 0.72±0.08 
(100.00) 1.00 (90.00) 0.95 (62.96) 0.83 (100.00) 0.65 (76.62) 0.91±0.05 
NetMHcpan 2.8 
0.80 
2808 0.67 
0.90 
7508 0.67 
0.87 
10190 0.70 
0.62 
709 0.80 
0.85 
6047 0.70±0.07 
(66.67) 1.00 (78.26) 0.95 (62.50) 0.94 (90.91) 0.50 (74.32) 0.85±0.06 
NetMHCcons 1.1 
0.82 
3219 0.75 
0.87 
7406 0.67 
0.89 
10875 0.67 
0.61 
558 0.80 
0.84 
5183 0.72±0.08 
(72.73) 1.00 (76.19) 0.84 (62.96) 0.78 (90.91) 0.50 (74.65) 0.82±0.07 
PickPocket 1.1 
0.71 
3933 0.75 
0.94 
4831 0.73 
0.83 
10875 0.73 
0.53 
2443 0.80 
0.81 
6756 0.70±0.08 
(62.50) 0.63 (81.82) 0.95 (63.64) 0.78 (90.00) 0.45 (72.86) 0.78±0.07 
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Predictora AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Thresholdb 
(PPV [%]) 
Specificity 
Sensitivity 
AROC 
Val. 
Thresholdc 
(PPV [%]) 
Specificity 
Sensitivity 
IEDB 
SMMPMBEC  -  
 -   -  
0.82 
3380 0.67 
0.79 
354 0.73 
 -  
 -   -  
0.72 
478 0.80±0.10 
( - )  -  (75.00) 0.79 (63.64) 0.78 ( - )  -  (68.97) 0.54±0.11 
IEDB SMM 
 -  
 -   -  
0.84 
2296 0.67 
0.82 
182 0.77 
 -  
 -   -  
0.71 
184 0.83±0.08 
( - )  -  (73.68) 0.74 (66.67) 0.78 ( - )  -  (73.08) 0.52±0.12 
MHCflurry 1.2 
0.67 
813 0.75 
0.88 
3836 0.67 
0.86 
2586 0.87 
0.55 
596 0.80 
0.80 
2586 0.73±0.08 
(57.14) 0.50 (78.26) 0.95 (77.78) 0.72 (90.91) 0.50 (74.60) 0.73±0.08 
MHCnuggets 2.0 
0.65 
686 0.92 
0.74 
494 1.00 
0.78 
6154 0.67 
0.42 
12 1.00 
0.76 
1934 0.71±0.08 
(75.00) 0.38 (100.00) 0.53 (56.52) 0.94 (100.00) 0.20 (69.49) 0.65±0.08 
IEDB 
recommended 0.91 
3.60 0.75 
0.81 
12.00 0.67 
0.89 
14.75 0.67 
0.81 
0.90 0.80 
0.85 
5.80 0.82±0.08 
(72.73) 1.00 (73.68) 0.74 (62.96) 0.78 (93.33) 0.70 (81.25) 0.80±0.07 
IEDB consensus 
0.91 
2.80 0.75 
0.81 
12.00 0.67 
0.87 
4.55 0.87 
0.81 
0.10 0.60 
0.84 
5.80 0.78±0.07 
(72.73) 1.00 (73.68) 0.74 (77.78) 0.83 (87.50) 0.70 (78.79) 0.80±0.07 
MixMHCpred 
2.0.2 0.81 
29.00 0.67 
0.88 
10.00 0.67 
0.80 
19.00 0.67 
0.83 
7.00 0.80 
0.84 
14.00 0.71±0.09 
(63.64) 0.88 (77.27) 0.89 (60.00) 0.00 (93.75) 0.75 (74.65) 0.81±0.07 
a: Units of thresholds depend on predictor output. IEDB recommended, IEDB consensus and MixMHCpred 2.0.2 express results as percentile rank, all others as IC50 in nM. 
b: Single length analysis was performed applying criteria-based thresholds. 
c: Pooled peptide length analysis was performed  applying bootstrapping-validated thresholds. Specificity and sensitivity are expressed mean ± SD of 100 runs. 
AROC: area under receiver operating characteristic curve, maximum = 1 
PPV [%]: positive predictive value expressed in % 
Grey cell: No possible threshold met the criteria for optimal thresholds. Analysis was performed for the threshold resulting in lowest FPR and highest TPR. 
- : Prediction was not available. 
Italic font: Numbers of peptides differ. 
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Supplementary Figure S1. Agarose gel electrophoresis of E6- and E7-specific PCR products amplified 
from genomic DNA of HPV16-positive cell lines. Amplification of E6 and E7 genes by PCR was verified by 
electrophoresis of a 1% agarose gel. From left to right first lanes show the marker (GeneRuler ladder mix with a 
range of 100-10000bp) followed by (A) a negative control with water, the UM-SCC104 PCR products of E6 and 
E7 or (B) the MRI-H-186 PCR products for E7 and E6. Expected amplicon sizes are 524bp for E6 and 505pb for 
E7. 
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Supplementary Figure S2. Threshold-dependent accuracy of predictors for different HLA types and 
peptide lengths. Accuracy of predictors is shown in line graphs for HLA types and pooled and single 8-, 9-, 10-, 
and 11-mer peptides. Symbols in different tones of grey represent the accuracy of a predictor by applying 
different decision thresholds: high (IC50 ≤50nM or percentile rank ≤0.5), intermediate (inter, IC50 ≤500nM or 
percentile rank ≤2) or low (IC50 ≤5000nM) binding likelihood. 
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Supplementary Figure S3. Illustration of criteria defined in this study for optimal decision thresholds. 
Optimal decision threshold were defined by resulting in a maximal FPR of 0.33 and a TPR which is minimal 
twice as high as the FPR, depicted by red lines in the ROC graph. Within the pink area resulting from these two 
criteria, the threshold resulting in the highest possible TPR and lowest possible FPR was selected for 
recommendation (blue arrow). For comparison, high (dark grey, IC50 ≤50nM or percentile rank ≤0.5), 
intermediate (medium grey, IC50 ≤500nM or percentile rank ≤2) and low (light grey, IC50 ≤5000nM) binding 
affinity thresholds are also indicated by arrows.  
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Supplementary Figure S4. Bootstrapping-based comparison of sensitivity, specificity and accuracy of 
predictors by applying individually recommended or general thresholds. 
(Figure continues, see Figure legend on page 174) 
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Supplementary Figure S4. Bootstrapping-based comparison of sensitivity, specificity and accuracy of 
predictors by applying individually recommended or general thresholds. 
(Figure continues, see Figure legend on page 174) 
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Supplementary Figure S4. Bootstrapping-based comparison of sensitivity, specificity and accuracy of 
predictors by applying individually recommended or general thresholds. 
(Figure continues, see Figure legend on page 174) 
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Supplementary Figure S4. Bootstrapping-based comparison of sensitivity, specificity and accuracy of 
predictors by applying individually recommended or general thresholds. 
(Figure continues, see Figure legend on page 174) 
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Supplementary Figure S4. Bootstrapping-based comparison of sensitivity, specificity and accuracy of 
predictors by applying individually recommended or general thresholds. Results are shown for (A) HLA 
A1, (B) HLA A3, (C) HLA A11, (D) HLA B7 and (E) HLA B15. Recommended thresholds were calculated and 
validated by bootstrapping as described. In a second bootstrapping sensitivity, specificity and accuracy of 
predictors applying recommended thresholds were compared to general thresholds for predicting high (IC50 
≤50nM or percentile rank (%) ≤0.5), intermediate (inter, IC50 ≤500nM or percentile rank (%) ≤2) or low (IC50 
≤5000nM) binding likelihood. Box plots and whiskers show bootstrapping quartiles and the 95% interval of data, 
respectively. Significant differences of means were determined by one-way ANOVA followed by Dunnett 
multiple comparisons test (significance, p<0.05). (***) p<0.001, (**) p<0.01, (*) p<0.05, (ns) not significant 
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Supplementary Figure S5. Comparison of predictor performance applying criteria-based thresholds and 
recommended thresholds. 
(Figure continues, see Figure legend on page 177) 
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Supplementary Figure S5. Comparison of predictor performance applying criteria-based thresholds and 
recommended thresholds. 
(Figure continues, see Figure legend on page 177) 
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Supplementary Figure S5. Comparison of predictor performance applying criteria-based thresholds and 
recommended thresholds. Results are shown for HLA (A) A1, (B) A3, (C) A11, (D) A24, (E) B7 and (F) B15. 
Recommended thresholds (left) were calculated by bootstrapping whereas criteria-based thresholds (right) were 
calculated by applying the defined optimal threshold criteria to the respective peptide set as described. In a 
second bootstrapping the two thresholds were applied and the confidence intervals of sensitivity, specificity and 
accuracy were calculated for 100 samplings. Box plots and whiskers show bootstrapping quartiles and the 95% 
interval of data, respectively. Significant differences of means were determined using Student’s t test 
(significance, p<0.05). (***) p<0.001, (**) p<0.01, (*) p<0.05, (ns) not significant.  
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Supplementary Figure S6. Classification of HLA binding prediction of HPV16 E6/E7 peptides to HLA A1, 
A3, A11, B7 and B15 according to application of different thresholds. 
(Figure continues, see Figure legend on page 180) 
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Supplementary Figure S6. Classification of HLA binding prediction of HPV16 E6/E7 peptides to HLA A1, 
A3, A11, B7 and B15 according to application of different thresholds. 
(Figure continues, see Figure legend on page 180) 
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Supplementary Figure S6. Classification of HLA binding prediction of HPV16 E6/E7 peptides to HLA A1, 
A3, A11, B7 and B15 according to application of different thresholds. HLA-ligands derived from HPV16 
E6/E7 were validated by experimental assessment (first column) and categorized into binders (blue) and 
nonbinders (red). Following columns indicate the predicted binding likelihood of peptides classified by different 
thresholds: predicted within (blue) or beyond (red) individual criteria-based (single peptide lengths) or 
recommended threshold (pooled lengths) or predicted within general threshold of IC50 ≤500nM or percentile 
rank ≤2 (dark shade of blue, red or grey). Grey fields indicate if calculation of a recommended threshold was not 
possible. In this case the binding likelihood of a binder resulting in lowest FPR and highest TPR was applied as 
threshold. If a prediction was not available, the field was left blank. 
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Supplementary Table S4. Table of HPV16
+
 cell lines with amino acid changes compared to the reference sequence. 
Cell line ID aa changes in E6 aa changes in E7  Nucleotide changes within E6 ORF Nucleotide changes within E7 ORF 
UM-SCC-104 L90V   T350G (L90V)    
CaSki R17T; L90V   A131G (R17T), T350G (L90V)    
SCC090 R17T; L90V   A131G (R17T), T350G (L90V)    
SCC152 R17T; L90V   A131G (R17T), T350G (L90V)    
866 R17I; Q21D; H85Y N29S 
T109C, G132T (R170I), C143G (Q21D in combi), G145T (Q21D in 
combi), T256A, T286A, A289G, C335T (H85Y), A403G  
A647G (N29S), C765T, T789C, 
T795G 
UM-SCC-47 
R17I; Q21D; E36Q; 
A68G; H85Y 
  
T109C, G132T (R17I), C143G (Q21D in combi), G145T (Q21D in combi), 
G188C ( E36Q), C285G ( A68G), T286A, A289G, C335T (H85Y), A403G  
A647G (N29S), T789C, T795G 
SCC154 Q21D; H85Y; L90V   G145T (Q21D), T286A, A288G, C335T (H85Y), T350G (L90V), A532G  T732C, T789C, T795G 
SNU-1299 Q21D; H85Y; L90V   G145T (Q21D), T286A, A289G, C335T (H85Y), T350G (L90V), A532G  T732C, T789C, T795G 
SiHa L90V; E120D L28F T350G (L90V), A442C (E120D)  A645C (L28F) 
C66#3 L90V   C256T, T350G (L90V)   
C66#7 L90V   C265T, T350G (L90V)   
MRI-H-196 L90V   T350G (L90V)    
W12 20861 L90V   C256T, T350G (L90V)   
W12 20863 L90V   C256T, T350G (L90V)   
SNU-1000 D32E; I34R N29S T178G (D32E), T183G (I34R) A647G (N29S), T846C 
SNU-1005 D32E N29S T178G (D32E)  A647G (N29S), T846C 
SNU-17 D32E N29S T178G (D32E)  A647G (N29S), T828C, T846C 
SNU-703 D32E N29S T178G (D32E)  A647G (N29S), T846C 
SNU-902 D32E N29S; S63F T178G (D32E) 
A647G (N29S), C749T (S63F), 
T846C 
UD-SCC2    H51N   C712A (H51N) 
E6 and E7 sequences of HPV16
+
 cell lines in our cell bank were compared to the reference sequence to determine presence of amino acid (aa) changes. Nucleotide changes, 
which did not result in silent mutation, were amended with the respective aa change. The E6 and E7 sequences of the cell lines MRI-H-186, 879, 915, 93VU147T, FK16A, 
Goerke, HPK 1A and Marqu are identical to the reference sequence and thus not listed in the table.  
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Supplementary Table S5. Sequence alignment of amplified HPV16 E6 and E7 sequences with reference 
sequences. 
MRI-H-186 E6 sequence vs. E6 reference sequence 
Query 1   TTTTATGCACCAAAAGAGAACTGCAATGTTTCAGGACCCACAGGAGCGACCCAGAAAGTT 60 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Ref   79  TTTTATGCACCAAAAGAGAACTGCAATGTTTCAGGACCCACAGGAGCGACCCAGAAAGTT 138 
Query 61  ACCACAGTTATGCACAGAGCTGCAAACAACTATACATGATATAATATTAGAATGTGTGTA 120 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Ref   139 ACCACAGTTATGCACAGAGCTGCAAACAACTATACATGATATAATATTAGAATGTGTGTA 198 
Query 121 CTGCAAGCAACAGTTACTGCGACGTGAGGTATATGACTTTGCTTTTCGGGATTTATGCAT 180 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Ref   199 CTGCAAGCAACAGTTACTGCGACGTGAGGTATATGACTTTGCTTTTCGGGATTTATGCAT 258 
Query 181 AGTATATAGAGATGGGAATCCATATGCTGTATGTGATAAATGTTTAAAGTTTTATTCTAA 240 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Ref   259 AGTATATAGAGATGGGAATCCATATGCTGTATGTGATAAATGTTTAAAGTTTTATTCTAA 318 
Query 241 AATTAGTGAGTATAGACATTATTGTTATAGTTTGTATGGAACAACATTAGAACAGCAATA 300 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Ref   319 AATTAGTGAGTATAGACATTATTGTTATAGTTTGTATGGAACAACATTAGAACAGCAATA 378 
Query 301 CAACAAACCGTTGTGTGATTTGTTAATTAGGTGTATTAACTGTCAAAAGCCACTGTGTCC 360 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Ref   379 CAACAAACCGTTGTGTGATTTGTTAATTAGGTGTATTAACTGTCAAAAGCCACTGTGTCC 438 
Query 361 TGAAGAAAAGCAAAGACATCTGGACAAAAAGCAAAGATTCCATAATATAAGGGGTCGGTG 420 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Ref   439 TGAAGAAAAGCAAAGACATCTGGACAAAAAGCAAAGATTCCATAATATAAGGGGTCGGTG 498 
Query 421 GACCGGTCGATGTATGTC 438 
          |||||||||||||||||| 
Ref   499 GACCGGTCGATGTATGTC 516 
Query 439 TTGTTGCAGATCATCAAGAACACGTAGAGAAACCCAGCTGTAATCATGCATGGAGATAC 497 
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Ref   517 TTGTTGCAGATCATCAAGAACACGTAGAGAAACCCAGCTGTAATCATGCATGGAGATAC 575 
MRI-H-186 E7 sequence vs. E7 reference sequence 
Query 4   AGAAACCCAGCTGTAATCATGCATGGAGATACACCTACATTGCATGAATATATGTTAGAT 63 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Ref   544 AGAAACCCAGCTGTAATCATGCATGGAGATACACCTACATTGCATGAATATATGTTAGAT 603 
Query 64  TTGCAACCAGAGACAACTGATCTCTACTGTTATGAGCAATTAAATGACAGCTCAGAGGAG 123 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Ref   604 TTGCAACCAGAGACAACTGATCTCTACTGTTATGAGCAATTAAATGACAGCTCAGAGGAG 663 
Query 124 GAGGATGAAATAGATGGTCCAGCTGGACAAGCAGAACCGGACAGAGCCCATTACAATATT 183 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Ref   664 GAGGATGAAATAGATGGTCCAGCTGGACAAGCAGAACCGGACAGAGCCCATTACAATATT 723 
Query 184 GTAACCTTTTGTTGCAAGTGTGACTCTACGCTTCGGTTGTGCGTACAAAGCACACACGTA 243 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Ref   724 GTAACCTTTTGTTGCAAGTGTGACTCTACGCTTCGGTTGTGCGTACAAAGCACACACGTA 783 
Query 244 GACATTCGTACTTTGGAAGACCTGTTAATGGGCACACTAGGAATTGTGTGCCCCATCTGT 303 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Ref   784 GACATTCGTACTTTGGAAGACCTGTTAATGGGCACACTAGGAATTGTGTGCCCCATCTGT 843 
Query 304 TCTCAGAAACCATAATCTACCATGGCTGATCCTGCAGGTACCAATGGGGAAGAGGGTACG 363 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Ref   844 TCTCAGAAACCATAATCTACCATGGCTGATCCTGCAGGTACCAATGGGGAAGAGGGTACG 903 
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UM-SCC104 E6 sequence vs. E6 reference sequence 
Query   8 ATGCACCAAAAGAGAACTGCAATGTTTCAGGACCCACAGGAGCGACCCAGAAAGTTACC   67 
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Ref    83 ATGCACCAAAAGAGAACTGCAATGTTTCAGGACCCACAGGAGCGACCCAGAAAGTTACC  141 
Query  68 ACAGTTATGCACAGAGCTGCAAACAACTATACATGATATAATATTAGAATGTGTGTACTG 127 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Ref   142 ACAGTTATGCACAGAGCTGCAAACAACTATACATGATATAATATTAGAATGTGTGTACTG 203 
Query 128 CAAGCAACAGTTACTGCGACGTGAGGTATATGACTTTGCTTTTCGGGATTTATGCATAGT 187 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Ref   202 CAAGCAACAGTTACTGCGACGTGAGGTATATGACTTTGCTTTTCGGGATTTATGCATAGT 261 
Query 188 ATATAGAGATGGGAATCCATATGCTGTATGTGATAAATGTTTAAAGTTTTATTCTAAAAT 247 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Ref   262 ATATAGAGATGGGAATCCATATGCTGTATGTGATAAATGTTTAAAGTTTTATTCTAAAAT 321 
Query 248 TAGTGAGTATAGACATTATTGTTATAGTGTGTATGGAACAACATTAGAACAGCAATACAA 307 
          |||||||||||||||||||||||||||| ||||||||||||||||||||||||||||||| 
Ref   322 TAGTGAGTATAGACATTATTGTTATAGTTTGTATGGAACAACATTAGAACAGCAATACAA 381 
Query 308 CAAACCGTTGTGTGATTTGTTAATTAGGTGTATTAACTGTCAAAAGCCACTGTGTCCTGA 367 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Ref   382 CAAACCGTTGTGTGATTTGTTAATTAGGTGTATTAACTGTCAAAAGCCACTGTGTCCTGA 441 
Query 368 AGAAAAGCAAAGACATCTGGACAAAAAGCAAAGATTCCATAATATAAGGGGTCGGTGGAC 427 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Ref   442 AGAAAAGCAAAGACATCTGGACAAAAAGCAAAGATTCCATAATATAAGGGGTCGGTGGAC 501 
Query 428 CGGTCGATGTATGTCTTGTTGCAGATCATCAAGAACACGTAGAGAAACCCAGCTGTAATC 487 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Ref   502 CGGTCGATGTATGTCTTGTTGCAGATCATCAAGAACACGTAGAGAAACCCAGCTGTAATC 561 
UM-SCC104 E7 sequence vs. E7 reference sequence 
Query   8 GATGTATGTCTTGTTGCAGATCATCAAGAACACGTAGAGAAACCCAGCTGTAATCATGCA  67 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Ref   507 GATGTATGTCTTGTTGCAGATCATCAAGAACACGTAGAGAAACCCAGCTGTAATCATGCA 566 
Query  68 TGGAGATACACCTACATTGCATGAATATATGTTAGATTTGCAACCAGAGACAACTGATCT 127 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Ref   567 TGGAGATACACCTACATTGCATGAATATATGTTAGATTTGCAACCAGAGACAACTGATCT 626 
Query 128 CTACTGTTATGAGCAATTAAATGACAGCTCAGAGGAGGAGGATGAAATAGATGGTCCAGC 187 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Ref   627 CTACTGTTATGAGCAATTAAATGACAGCTCAGAGGAGGAGGATGAAATAGATGGTCCAGC 686 
Query 188 TGGACAAGCAGAACCGGACAGAGCCCATTACAATATTGTAACCTTTTGTTGCAAGTGTGA 247 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Ref   687 TGGACAAGCAGAACCGGACAGAGCCCATTACAATATTGTAACCTTTTGTTGCAAGTGTGA 746 
Query 248 CTCTACGCTTCGGTTGTGCGTACAAAGCACACACGTAGACATTCGTACTTTGGAAGACCT 307 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Ref   747 CTCTACGCTTCGGTTGTGCGTACAAAGCACACACGTAGACATTCGTACTTTGGAAGACCT 806 
Query 308 GTTAATGGGCACACTAGGAATTGTGTGCCCCATCTGTTCTCAGAAACCATAATCTACCAT 367 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Ref   807 GTTAATGGGCACACTAGGAATTGTGTGCCCCATCTGTTCTCAGAAACCATAATCTACCAT 866 
grey: sequence beyond ORF 
underlined: overlap between E6 and E7 ORFs 
bold red: sequence mismatch 
NCBI reference sequence NC_001526.4 
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Supplementary Table S6. List of donors with positive IFNγ-responses in ELISpots assays 
Donor Epitope SI SFU/1x10
6
 cells A1 A2 A3 A11 A24 B7 B15 
BC4 
E6/37-46 3.56 201.67     x x       
E6/67-75 3.56 202.00       x       
E6/59-67 3.60 204.00     x x     x 
E7/77-86 3.88 220.00   x           
E6/48-55 4.32 245.00       x       
E7/78-86 4.35 246.67   x           
E6/68-75 4.44 251.67     x x       
E7/89-97 4.88 276.67     x x       
E6/52-60 5.21 295.00   x           
E6/34-44 5.44 308.33   x           
E7/88-97 5.91 335.00     x x       
E6/34-41 11.18 633.33       x       
E6/68-77 11.44 648.33 x   x x     x 
E7/87-97 14.62 828.33       x       
E6/93-101 14.65 830.00     x x       
E7/50-60 18.79 1065.00       x       
E6/106-115 23.32 1321.67     x x       
E7/53-60 27.35 1550.00       x       
E6/52-62 27.59 1563.33       x       
E7/52-60 34.12 1933.33       x       
BC7 
E7/67-76 16.63 221.67         x   x 
E6/107-115 19.25 256.67     x x       
BC9 
E6/134-144 6.75 225.00           x x 
E6/85-95 6.77 225.56         x     
E6/98-107 7.47 248.89         x     
E6/87-95 18.40 613.33         x     
E6/49-57 19.43 647.78         x     
BC14 
E6/53-61 2.01 315.71             x 
E6/97-106 2.06 323.57             x 
E7/66-74 2.35 370.00   x           
E7/81-91 2.35 370.00   x           
E7/82-91 2.37 373.57   x         x 
E6/32-41 2.40 378.00       x       
E6/94-101 2.46 386.67       x       
E7/80-90 2.51 395.33   x           
E6/69-79 2.73 429.00       x       
E7/12-19 2.77 435.38   x           
E6/68-77 2.78 436.67 x   x x     x 
E6/73-83 2.81 442.86             x 
E6/41-50 2.82 443.33             x 
E6/68-76 2.83 446.00       x     x 
E6/44-54 2.85 448.00         x x x 
E6/139-148 3.00 472.00       x       
E7/89-97 3.26 512.86     x x       
E7/88-97 3.63 570.67     x x       
E7/12-20 3.65 574.00   x           
E6/57-67 4.04 635.00             x 
E6/89-99 4.15 653.00     x x     x 
E7/87-97 4.62 726.67       x       
E7/82-89 7.67 1206.00           x x 
D01 E7/11-21 13.29 349.62   x           
D05 E7/11-20 3.34 529.69   x           
D06 
E7/81-90 2.25 833.33   x           
E7/80-90 10.28 548.33   x           
E7/12-19 183.00 1830.00   x           
E7/11-19 1348.38 17978.33   x           
D12 
E7/11-19 58.92 1963.81   x           
E7/12-19 64.50 716.64   x           
D18 E7/88-97 3.02 372.37     x x       
D21 E7/11-19 1003.65 7232.97   x           
D24 
E6/75-83 2.03 333.35     x   x   x 
E6/106-115 2.35 230.01     x x       
E6/129-138 2.54 960.05     x         
E6/107-115 2.59 553.36     x x       
E6/68-77 6.20 385.57 x   x x     x 
D25 
E7/11-18 6.55 218.33   x           
E6/25-33 12.00 240.00   x           
E6 H85Y, L90V/81-90 12.42 248.33   x           
E6 Q21D/18-26 15.17 303.33   x           
D30 E6/109-119 1.99 243.85     x         
D32 E7/77-87 7.88 315.00   x           
D33 E6 D32E/29-38 2.30 242.95   x           
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Donor Epitope SI SFU/1x10
6
 cells A1 A2 A3 A11 A24 B7 B15 
E7/11-20 11.86 312.63   x           
D35 
E6/68-77 2.56 269.22 x   x x     x 
E6/72-80 2.63 565.36     x   x     
D37 
E6/8-18 2.10 699.98     x         
E6/68-77 2.34 352.62 x   x x     x 
E6/93-101 2.54 373.67     x x       
E6 L90V/84-94 2.88 242.10     x         
D43 
E6/107-115 2.11 364.72     x x       
E6/106-115 2.17 382.36     x x       
E6/68-77 2.20 741.20 x   x x     x 
D44 
E6/107-115 1.98 216.67     x x       
E6/93-101 2.13 233.34     x x       
E6/106-115 2.40 297.63     x x       
E6/72-80 5.41 1159.55     x   x     
D45 
E7/85-93 2.13 971.72   x           
E7/77-87 2.51 514.44   x           
E7/11-21 2.74 221.50   x           
E6/37-46 2.84 1150.35     x x       
E6/18-28 3.13 1388.51   x           
E7/80-90 3.53 554.93   x           
E7/7-17 4.04 807.39   x           
E7/11-19 4.11 352.49   x           
E6/29-38 4.20 200.06   x           
E6 D32E/29-38 4.38 583.51   x           
E6/68-75 19.25 366.78     x x       
D46 
E7/77-87 2.21 773.33   x           
E6 H85Y/81 90 2.40 208.33   x           
E6/29-38 3.34 813.33   x           
H85Y, L90V/81-90 4.09 831.67   x           
E7/86-93 6.97 395.00   x           
X: marks the HLA alleles that can bind the epitope 
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Supplementary Figure S7. Flow cytometry analysis of intracellular cytokine production of freshly and 
thawed isolated PBMCs from healthy donors. Production of cytokines was analyzed by intracellular staining 
and flow cytometry measurement. (A) Gating strategy for analyzed CD8
+
 T cells is shown. (B) Presence of 
intracellular IFNγ, TNFα and granzyme B was assessed for (left to right): freshly isolated PBMCs stimulated 
with PMI/Ionomycin, thawed PBMCs of HLA-A2
+
 donor D25 stimulated with PMI/Ionomycin, CEF peptide 
pool, or the E6/25-33 epitope (which showed induction of IFNγ-response in this donor in a previous ELISpot 
assay). Of note: granzyme B is stored intracellularly and present in all conditions. 
 
  
  
  
  
  
 
